{"PMC7335943": [["BackgroundCOVID-19 was defined as a cluster of respiratory illnesses induced by the infectionof the 2019 novel coronavirus (2019-nCoV).1 Since the outbreak of COVID-19in Wuhan in December 2019, it has spread around the world rapidly.", [["respiratory", "ANATOMY", 47, 58], ["respiratory illnesses", "DISEASE", 47, 68], ["COVID-19in Wuhan", "CHEMICAL", 159, 175], ["coronavirus", "ORGANISM", 111, 122], ["coronavirus", "SPECIES", 111, 122], ["BackgroundCOVID", "TEST", 0, 15], ["respiratory illnesses", "PROBLEM", 47, 68], ["novel coronavirus", "PROBLEM", 105, 122], ["respiratory illnesses", "OBSERVATION", 47, 68]]], ["As an acuterespiratory infectious disease, the disease has been included in type B infectiousdiseases and managed according to the standard of type A infectious disease, thehighest level of infectious disease in China.", [["infectious disease", "DISEASE", 23, 41], ["type B infectiousdiseases", "DISEASE", 76, 101], ["infectious disease", "DISEASE", 150, 168], ["infectious disease", "DISEASE", 190, 208], ["an acuterespiratory infectious disease", "PROBLEM", 3, 41], ["the disease", "PROBLEM", 43, 54], ["type B infectiousdiseases", "PROBLEM", 76, 101], ["type A infectious disease", "PROBLEM", 143, 168], ["infectious disease in China", "PROBLEM", 190, 217], ["acuterespiratory", "OBSERVATION_MODIFIER", 6, 22], ["infectious", "OBSERVATION", 23, 33], ["infectious", "OBSERVATION", 150, 160], ["infectious", "OBSERVATION", 190, 200]]], ["The main transmission route of2019-nCoV is respiratory droplets and close contact, and it is possible to beinfected with 2019-nCoV for people exposed to an occlusive environment with highconcentration aerosols for a long time; moreover, feces might also lead to 2019-nCoVinfection via aerosols or close contact.2 Therefore, endoscopy wasconsidered as a risky medical operation which might lead to 2019-nCoV infection.Since the initial stage of the outbreak of COVID-19 in China, the Chinese Society ofDigestive Endoscopy (CSDE) has issued a series of recommendation documents to guidethe endoscopy works, and achieved satisfactory results.", [["respiratory droplets", "ANATOMY", 43, 63], ["of2019-nCoV", "CHEMICAL", 28, 39], ["infection", "DISEASE", 407, 416], ["COVID-19", "CHEMICAL", 460, 468], ["of2019-nCoV", "SIMPLE_CHEMICAL", 28, 39], ["people", "ORGANISM", 135, 141], ["feces", "ORGANISM_SUBSTANCE", 237, 242], ["people", "SPECIES", 135, 141], ["respiratory droplets", "PROBLEM", 43, 63], ["an occlusive environment", "TREATMENT", 153, 177], ["highconcentration aerosols", "TREATMENT", 183, 209], ["endoscopy", "TEST", 324, 333], ["a risky medical operation", "TREATMENT", 351, 376], ["nCoV infection", "PROBLEM", 402, 416], ["COVID", "TEST", 460, 465], ["endoscopy", "TEST", 588, 597], ["main", "OBSERVATION_MODIFIER", 4, 8], ["respiratory droplets", "OBSERVATION", 43, 63], ["occlusive", "OBSERVATION", 156, 165], ["infection", "OBSERVATION", 407, 416]]], ["To the best of ourknowledge, no new infectious case of COVID-19 resulting from endoscopic procedureshas been reported in China to date.", [["COVID-19", "CELL", 55, 63], ["COVID", "TEST", 55, 60], ["endoscopic procedureshas", "TREATMENT", 79, 103], ["no", "UNCERTAINTY", 29, 31], ["new", "OBSERVATION_MODIFIER", 32, 35], ["infectious", "OBSERVATION", 36, 46]]], ["Hence, we provide our experience to endoscopistsall over the world under such challenging situations of the prevention and controlof COVID-19.General principlesSelective endoscopic procedures are suggested for outpatients that do not have toreceive endoscopic procedures immediately.General principlesFor patients that need to undergo endoscopic procedures as soon as possible, COVID-19infection should be excluded initially by chest computed tomography (CT) results,polymerase chain reaction (PCR) results and personal history.General principlesFor patients infected with COVID-19, pneumonia should be treated at special medicalinstitutions first; and if patients have to receive endoscopic proceduresimmediately on account of medical conditions, endoscopic procedures should beconducted in particular wards that have the ability to prevent COVID-19infection.Preventive measuresFirst, doctors can provide education for patients via online and offline approaches,and tell them the potential risks of COVID-19 infection during endoscopicprocedures.", [["pneumonia", "DISEASE", 583, 592], ["infection", "DISEASE", 1009, 1018], ["patients", "ORGANISM", 305, 313], ["patients", "ORGANISM", 550, 558], ["patients", "ORGANISM", 656, 664], ["COVID-19infection", "GENE_OR_GENE_PRODUCT", 842, 859], ["patients", "ORGANISM", 920, 928], ["patients", "SPECIES", 305, 313], ["patients", "SPECIES", 550, 558], ["patients", "SPECIES", 656, 664], ["patients", "SPECIES", 920, 928], ["controlof COVID", "TREATMENT", 123, 138], ["Selective endoscopic procedures", "TREATMENT", 160, 191], ["endoscopic procedures", "TREATMENT", 249, 270], ["endoscopic procedures", "TEST", 335, 356], ["chest computed tomography", "TEST", 428, 453], ["CT)", "TEST", 455, 458], ["polymerase chain reaction", "PROBLEM", 467, 492], ["PCR", "TEST", 494, 497], ["COVID", "TREATMENT", 573, 578], ["pneumonia", "PROBLEM", 583, 592], ["endoscopic proceduresimmediately", "TREATMENT", 681, 713], ["medical conditions", "TREATMENT", 728, 746], ["endoscopic procedures", "TREATMENT", 748, 769], ["COVID-19infection", "PROBLEM", 842, 859], ["Preventive measures", "TREATMENT", 860, 879], ["COVID-19 infection", "PROBLEM", 1000, 1018], ["endoscopicprocedures", "TREATMENT", 1026, 1046], ["chest", "ANATOMY", 428, 433], ["infected", "OBSERVATION", 559, 567], ["pneumonia", "OBSERVATION", 583, 592], ["infection", "OBSERVATION", 1009, 1018]]], ["Selective endoscopic procedures are suggested for outpatients withouturgent/emergent situations and malignant tumours, and we have provided educationalmaterial for patients from the CSDE in Supplement 1, namely The CSDEProposal for the Patients in the Pandemic Area of COVID-19 (seeSupplementary material).Preventive measuresSecond, endoscopic centres can undertake training activities for outpatient andconsultant doctors, and help them master the protective knowledge.", [["malignant tumours", "ANATOMY", 100, 117], ["malignant tumours", "DISEASE", 100, 117], ["malignant tumours", "CANCER", 100, 117], ["patients", "ORGANISM", 164, 172], ["Patients", "ORGANISM", 236, 244], ["outpatients", "SPECIES", 50, 61], ["patients", "SPECIES", 164, 172], ["Patients", "SPECIES", 236, 244], ["Selective endoscopic procedures", "TEST", 0, 31], ["malignant tumours", "PROBLEM", 100, 117], ["COVID", "TEST", 269, 274], ["Preventive measuresSecond", "TREATMENT", 306, 331], ["malignant", "OBSERVATION_MODIFIER", 100, 109], ["tumours", "OBSERVATION", 110, 117]]], ["2019-nCoVinfection should be excluded initially by chest CT results, PCR results and personalhistory for patients that need to receive endoscopic procedures as soon as possible,such as a foreign body in the digestive tract, oesophageal and gastric varicesbleeding, severe peptic ulcer bleeding, biliary tract obstruction, malignant tumoursand so on.", [["chest", "ANATOMY", 51, 56], ["body", "ANATOMY", 195, 199], ["digestive tract", "ANATOMY", 207, 222], ["oesophageal", "ANATOMY", 224, 235], ["gastric", "ANATOMY", 240, 247], ["peptic ulcer", "ANATOMY", 272, 284], ["biliary tract", "ANATOMY", 295, 308], ["malignant tumoursand", "ANATOMY", 322, 342], ["oesophageal and gastric varicesbleeding", "DISEASE", 224, 263], ["peptic ulcer bleeding", "DISEASE", 272, 293], ["biliary tract obstruction", "DISEASE", 295, 320], ["patients", "ORGANISM", 105, 113], ["digestive tract", "ORGANISM_SUBDIVISION", 207, 222], ["oesophageal", "ORGAN", 224, 235], ["gastric", "ORGAN", 240, 247], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 272, 284], ["biliary tract", "PATHOLOGICAL_FORMATION", 295, 308], ["patients", "SPECIES", 105, 113], ["chest CT", "TEST", 51, 59], ["PCR", "TEST", 69, 72], ["endoscopic procedures", "TREATMENT", 135, 156], ["a foreign body in the digestive tract", "PROBLEM", 185, 222], ["oesophageal and gastric varicesbleeding", "PROBLEM", 224, 263], ["severe peptic ulcer bleeding", "PROBLEM", 265, 293], ["biliary tract obstruction", "PROBLEM", 295, 320], ["malignant tumoursand", "PROBLEM", 322, 342], ["chest", "ANATOMY", 51, 56], ["digestive tract", "ANATOMY", 207, 222], ["oesophageal", "ANATOMY", 224, 235], ["gastric", "ANATOMY", 240, 247], ["severe", "OBSERVATION_MODIFIER", 265, 271], ["peptic", "OBSERVATION_MODIFIER", 272, 278], ["ulcer bleeding", "OBSERVATION", 279, 293], ["biliary tract", "ANATOMY", 295, 308], ["obstruction", "OBSERVATION", 309, 320], ["malignant", "OBSERVATION", 322, 331]]], ["Of note, endoscopists can make a decision according to specificcircumstances, if patients with urgent/emergent situations are not able to providetimely CT and PCR results; and endoscopic centres should pay close attention to allmedical staff performing endoscopic procedures for patients without exact CT and PCRresults.", [["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 279, 287], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 279, 287], ["endoscopists", "TREATMENT", 9, 21], ["urgent/emergent situations", "PROBLEM", 95, 121], ["CT", "TEST", 152, 154], ["PCR", "TEST", 159, 162], ["endoscopic procedures", "TEST", 253, 274], ["exact CT", "TEST", 296, 304], ["PCRresults", "TEST", 309, 319]]], ["We recommend that the chest CT examinations and PCR tests should beperformed in the last 3 days, and intraday results are optimal.", [["chest", "ANATOMY", 22, 27], ["the chest CT examinations", "TEST", 18, 43], ["PCR tests", "TEST", 48, 57], ["chest", "ANATOMY", 22, 27]]], ["We provide thematerial for recording information of patients from the CSDE in Supplement 2, namelyThe CSDE Recommendation of Preliminary Screening Questionnaire for theAdmission of Patients in COVID-19 Pandemic Area (see Supplementarymaterial).", [["patients", "ORGANISM", 52, 60], ["Patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 52, 60], ["Patients", "SPECIES", 181, 189], ["COVID", "TEST", 193, 198]]], ["If endoscopic procedures have to be performed for patients infected with2019-nCoV immediately on account of medical conditions, endoscopic doctors shouldfully communicate with respiratory or intensive care unit doctors; and endoscopicprocedures should be conducted in particular wards that have the ability to prevent2019-nCoV infection.", [["respiratory", "ANATOMY", 176, 187], ["infection", "DISEASE", 327, 336], ["patients", "ORGANISM", 50, 58], ["with2019-nCoV", "ORGANISM", 68, 81], ["patients", "SPECIES", 50, 58], ["endoscopic procedures", "TEST", 3, 24], ["endoscopicprocedures", "TREATMENT", 224, 244], ["nCoV infection", "PROBLEM", 322, 336], ["infection", "OBSERVATION", 327, 336]]], ["Besides, for patients recovering from 2019-nCoV infection,endoscopic procedures could be conducted for them if necessary in a short time, andrelated proof material should be provided.Preventive measuresThird, endoscopic centres can set aside some special rooms for endoscopic proceduresduring the COVID-19 pandemic, and should conduct cleaning and disinfection workimmediately after every procedure.Preventive measuresFourth, endoscopic centres can make emergency plans.", [["infection", "DISEASE", 48, 57], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["nCoV infection", "PROBLEM", 43, 57], ["endoscopic procedures", "TREATMENT", 58, 79], ["Preventive measures", "TREATMENT", 183, 202], ["endoscopic proceduresduring the COVID", "TEST", 265, 302], ["disinfection", "TREATMENT", 348, 360], ["infection", "OBSERVATION", 48, 57]]], ["If patients with suspectedinfection with COVID-19 are found by outpatient and consultant doctors, endoscopiccentres should submit the case report to the related medical institutionsimmediately, and the doctors who received the patients with suspected infectionshould be isolated and observed closely in proper ways.", [["suspectedinfection", "DISEASE", 17, 35], ["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 227, 235]]], ["On the other hand,endoscopic centres can make intermittent follow-ups within 2 weeks after endoscopicoperations for all patients receiving endoscopic procedures during the COVID-19pandemic; and if patients with confirmed or suspected infection with COVID-19 arefound, all related personnel that have had contact with these patients should beisolated and observed closely in proper ways.Preventive measuresFifth, endoscopic centres can strengthen management for patients and family members,and take detailed measures as follows: set a one-way route in endoscopic centres,contain the number of waiting patients, enlarge spacing distance to at least 100 cmamong waiting patients, and insist that patients and family members wash their handsbefore entering the waiting room and wear medical masks in the waiting process.Preventive measuresOf note, magnetic guide capsule examinations could separate the patients andoperators in different rooms, and thus this technique might be an excellentalternative to endoscopic procedures for diagnosis gastroscopy and non-hematemesishaemorrhage.Personal protection for medical staff ::: The workflow of endoscopic centres during the COVID-19 pandemicFirst, medical staff of an endoscopic centre should have their temperature takenbefore going to work and leaving for work, and they should pay attention to thepresence of some related symptoms including dry cough, fatigue and so on.", [["capsule", "ANATOMY", 859, 866], ["infection", "DISEASE", 234, 243], ["non-hematemesishaemorrhage", "DISEASE", 1053, 1079], ["dry cough", "DISEASE", 1388, 1397], ["fatigue", "DISEASE", 1399, 1406], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 197, 205], ["patients", "ORGANISM", 323, 331], ["patients", "ORGANISM", 461, 469], ["patients", "ORGANISM", 600, 608], ["patients", "ORGANISM", 667, 675], ["patients", "ORGANISM", 693, 701], ["patients", "ORGANISM", 899, 907], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 197, 205], ["patients", "SPECIES", 323, 331], ["patients", "SPECIES", 461, 469], ["patients", "SPECIES", 600, 608], ["patients", "SPECIES", 667, 675], ["patients", "SPECIES", 693, 701], ["patients", "SPECIES", 899, 907], ["endoscopicoperations", "TREATMENT", 91, 111], ["endoscopic procedures", "TEST", 139, 160], ["the COVID", "TEST", 168, 177], ["infection", "PROBLEM", 234, 243], ["COVID", "TEST", 249, 254], ["Preventive measuresFifth", "TREATMENT", 386, 410], ["enlarge spacing distance", "PROBLEM", 610, 634], ["medical masks", "TREATMENT", 779, 792], ["magnetic guide capsule examinations", "TEST", 844, 879], ["endoscopic procedures", "TEST", 1001, 1022], ["gastroscopy", "TEST", 1037, 1048], ["non-hematemesishaemorrhage", "PROBLEM", 1053, 1079], ["some related symptoms", "PROBLEM", 1356, 1377], ["dry cough", "PROBLEM", 1388, 1397], ["fatigue", "PROBLEM", 1399, 1406], ["infection", "OBSERVATION", 234, 243], ["cough", "OBSERVATION", 1392, 1397]]], ["Ifsuspected symptoms of 2019-nCoV infection are found, medical staff should stopworking immediately and be tested or evaluated further; and isolation measuresought to be taken if necessary.Personal protection for medical staff ::: The workflow of endoscopic centres during the COVID-19 pandemicSecond, medical staff should wash their hands carefully according to relatedmedical rules for at least 2 minutes every time, and alcohol-based hand rub isalso recommended for more frequent hand disinfection.Personal protection for medical staff ::: The workflow of endoscopic centres during the COVID-19 pandemicThird, medical staff must wear medical masks in an endoscopic centre, and if themasks become contaminated, wet or are used for more than 4 hours, they should bereplaced.", [["hand", "ANATOMY", 437, 441], ["hand", "ANATOMY", 483, 487], ["infection", "DISEASE", 34, 43], ["alcohol", "CHEMICAL", 423, 430], ["alcohol", "CHEMICAL", 423, 430], ["alcohol", "SIMPLE_CHEMICAL", 423, 430], ["hand", "ORGANISM_SUBDIVISION", 437, 441], ["hand", "ORGANISM_SUBDIVISION", 483, 487], ["Ifsuspected symptoms", "PROBLEM", 0, 20], ["nCoV infection", "PROBLEM", 29, 43], ["isolation measuresought", "TREATMENT", 140, 163], ["the COVID", "TREATMENT", 273, 282], ["hand rub isalso", "TREATMENT", 437, 452], ["more frequent hand disinfection", "PROBLEM", 469, 500], ["the COVID", "TREATMENT", 585, 594], ["medical masks", "TREATMENT", 637, 650], ["infection", "OBSERVATION", 34, 43], ["disinfection", "OBSERVATION", 488, 500]]], ["Moreover, the number of medical staff including doctors, nurses andtechnicians in the operating room should be reduced to the minimum.Personal protection for medical staff ::: The workflow of endoscopic centres during the COVID-19 pandemicFourth, medical staff should wear corresponding protective equipment according todifferent danger levels.", [["the COVID", "TREATMENT", 218, 227], ["corresponding protective equipment", "TREATMENT", 273, 307]]], ["For medical staff at the booking table, they shouldwear medical work clothes, isolation gowns (if conditions allow), N95 masks andmedical work caps.", [["isolation gowns", "TREATMENT", 78, 93]]], ["For operating doctors, anaesthetists, nurses and technicians,they must wear medical work clothes, single-use medical protective clothing,anti-osmosis isolation gowns, medical protective caps, N95 masks, goggles orface shields, double medical gloves and shoe covers.", [["medical protective clothing", "TREATMENT", 109, 136], ["anti-osmosis isolation gowns", "TREATMENT", 137, 165], ["medical protective caps", "TREATMENT", 167, 190], ["N95 masks", "TREATMENT", 192, 201], ["goggles orface shields", "TREATMENT", 203, 225], ["double medical gloves", "TREATMENT", 227, 248]]], ["Moreover, respirator masksshould be provided for medical staff that perform tracheal intubation and sputumsuction.", [["tracheal", "ANATOMY", 76, 84], ["tracheal", "MULTI-TISSUE_STRUCTURE", 76, 84], ["tracheal intubation", "TREATMENT", 76, 95], ["sputumsuction", "TREATMENT", 100, 113], ["tracheal", "ANATOMY", 76, 84], ["intubation", "OBSERVATION", 85, 95]]], ["For cleaning and disinfection workers, they should wear medical workclothes, single-use medical protective clothing, medical protective caps, N95 orhigher level medical masks, goggles or face shields, medical gloves andlong-sleeved rubber gloves; moreover, water-resistance isolation gowns and shoecovers should be provided if necessary.", [["medical workclothes", "TREATMENT", 56, 75], ["medical protective clothing", "TREATMENT", 88, 115], ["medical protective caps", "TREATMENT", 117, 140], ["N95 orhigher level medical masks", "TREATMENT", 142, 174], ["face shields", "TREATMENT", 187, 199], ["medical gloves", "TREATMENT", 201, 215], ["sleeved rubber gloves", "TREATMENT", 224, 245], ["water-resistance isolation gowns", "TREATMENT", 257, 289], ["shoecovers", "TREATMENT", 294, 304]]], ["For medical staff delivering samples,they should wear medical work clothes, medical protective caps, rubber gloves,N95 or surgical masks; and a medical specimen box should be used during thedelivery (Table1).Personal protection for medical staff ::: The workflow of endoscopic centres during the COVID-19 pandemicFifth, medical staff should take off the protective equipment according to thestandard procedures.Personal protection for medical staff ::: The workflow of endoscopic centres during the COVID-19 pandemicOf note, endoscopic centres should provide surgical or N95 masks for patientsreceiving lower endoscopy procedures in order to protect both patients andmedical staff from infection with 2019-nCoV.", [["infection", "DISEASE", 686, 695], ["patients", "ORGANISM", 655, 663], ["patients", "SPECIES", 655, 663], ["medical work clothes", "TREATMENT", 54, 74], ["medical protective caps", "TREATMENT", 76, 99], ["rubber gloves", "TREATMENT", 101, 114], ["surgical masks", "TREATMENT", 122, 136], ["a medical specimen box", "TREATMENT", 142, 164], ["the COVID", "TREATMENT", 292, 301], ["the protective equipment", "TREATMENT", 350, 374], ["thestandard procedures", "TREATMENT", 388, 410], ["endoscopic centres", "TREATMENT", 525, 543], ["surgical or N95 masks", "TREATMENT", 559, 580], ["patientsreceiving lower endoscopy procedures", "TREATMENT", 585, 629], ["infection", "PROBLEM", 686, 695], ["rubber gloves", "OBSERVATION", 101, 114], ["infection", "OBSERVATION", 686, 695]]], ["Moreover, given the high risk of2019-nCoV infection during endoscopic procedures via an airborne route,including aspiration of oral and fecal material via endoscopes, we recommend thesame medical protection level for upper and lower endoscopy.Disinfection of operating rooms ::: The cleaning and disinfection of endoscopic centresEach hospital should choose a suitable place for endoscopic procedures incompliance with the laws, guidelines and regulations for the prevention andcontrol of COVID-19.2\u20136 We think that a negative-pressure room is theoptimal solution, if conditions permit; and this point is in agreement with thesuggestion of the American Society of Gastrointestinal Endoscopy(ASGE).7 Disinfection of the operating rooms is requiredimmediately after every endoscopic procedure.", [["oral", "ANATOMY", 127, 131], ["infection", "DISEASE", 42, 51], ["COVID-19.2\u20136", "CHEMICAL", 489, 501], ["COVID-19.2\u20136", "CHEMICAL", 489, 501], ["of2019-nCoV", "GENE_OR_GENE_PRODUCT", 30, 41], ["oral", "ORGANISM_SUBDIVISION", 127, 131], ["fecal material", "MULTI-TISSUE_STRUCTURE", 136, 150], ["upper", "ORGANISM_SUBDIVISION", 217, 222], ["nCoV infection", "PROBLEM", 37, 51], ["endoscopic procedures", "TREATMENT", 59, 80], ["an airborne route", "TREATMENT", 85, 102], ["aspiration", "TREATMENT", 113, 123], ["oral and fecal material via endoscopes", "TREATMENT", 127, 165], ["thesame medical protection level", "TREATMENT", 180, 212], ["upper and lower endoscopy", "TREATMENT", 217, 242], ["The cleaning", "TREATMENT", 279, 291], ["disinfection of endoscopic centres", "TREATMENT", 296, 330], ["endoscopic procedures", "TREATMENT", 379, 400], ["COVID", "TEST", 489, 494], ["theoptimal solution", "TREATMENT", 544, 563], ["Gastrointestinal Endoscopy", "TEST", 664, 690], ["every endoscopic procedure", "TREATMENT", 764, 790], ["infection", "OBSERVATION", 42, 51], ["fecal", "ANATOMY", 136, 141], ["Gastrointestinal", "ANATOMY", 664, 680]]], ["It is recommended to use medicaldynamic air disinfection equipment for continuous air disinfection in theendoscopy unit during the procedure.", [["medicaldynamic air disinfection equipment", "TREATMENT", 25, 66], ["continuous air disinfection", "TREATMENT", 71, 98], ["the procedure", "TREATMENT", 127, 140], ["air disinfection", "OBSERVATION", 82, 98]]], ["Terminal disinfection should be performedin accordance with the relevant standards.6,8,9 (a) Disinfectionwipes, 75% alcohol and chlorine disinfectant can be used in the disinfection forthe surface of the endoscopic equipment.", [["alcohol", "CHEMICAL", 116, 123], ["chlorine", "CHEMICAL", 128, 136], ["alcohol", "CHEMICAL", 116, 123], ["chlorine", "CHEMICAL", 128, 136], ["alcohol", "SIMPLE_CHEMICAL", 116, 123], ["chlorine", "SIMPLE_CHEMICAL", 128, 136], ["Terminal disinfection", "TREATMENT", 0, 21], ["Disinfectionwipes", "TEST", 93, 110], ["chlorine disinfectant", "TREATMENT", 128, 149], ["the endoscopic equipment", "TREATMENT", 200, 224], ["disinfection", "OBSERVATION", 9, 21], ["endoscopic", "OBSERVATION", 204, 214]]], ["The chlorine disinfectant should bewiped off with water after 30 minutes. (b) Chlorine disinfectant and chlorinedioxide disinfectant should be used for the disinfection of the ground and wipedoff 30 minutes later. (c) Medical dynamic air disinfection equipment can be usedfor the disinfection of air in the endoscopy unit.", [["chlorine", "CHEMICAL", 4, 12], ["Chlorine", "CHEMICAL", 78, 86], ["chlorinedioxide", "CHEMICAL", 104, 119], ["chlorine", "CHEMICAL", 4, 12], ["Chlorine", "CHEMICAL", 78, 86], ["chlorinedioxide", "CHEMICAL", 104, 119], ["chlorine", "SIMPLE_CHEMICAL", 4, 12], ["chlorinedioxide", "SIMPLE_CHEMICAL", 104, 119], ["The chlorine disinfectant", "TREATMENT", 0, 25], ["Chlorine disinfectant", "TREATMENT", 78, 99], ["chlorinedioxide disinfectant", "TREATMENT", 104, 132], ["Medical dynamic air disinfection equipment", "TREATMENT", 218, 260], ["chlorine disinfectant", "OBSERVATION", 4, 25], ["air disinfection", "OBSERVATION", 234, 250], ["air", "OBSERVATION", 296, 299]]], ["Other disinfection methods include themanual spray of 3% hydrogen peroxide, 5000 mg/L peroxyacetic acid, 500 mg/Lchlorine dioxide, the use of atomisation or vaporisation hydrogen oxidesteriliser and ultraviolet disinfection. (d) Open the window for sufficientventilation after disinfection.Cleaning and disinfection of the endoscope ::: The cleaning and disinfection of endoscopic centresThe endoscope should be cleaned and disinfected strictly according to theRegulation for cleaning and disinfection technique of flexibleendoscopes.10 It is not recommended to perform bedsidepretreatment for the endoscope.Cleaning and disinfection of the endoscope ::: The cleaning and disinfection of endoscopic centresThe endoscope and reusable accessories should be put into a double-layered yellowmedical waste bag and the related staff should seal the bag immediately afterthe operation.", [["hydrogen peroxide", "CHEMICAL", 57, 74], ["peroxyacetic acid", "CHEMICAL", 86, 103], ["Lchlorine dioxide", "CHEMICAL", 112, 129], ["hydrogen oxidesteriliser", "CHEMICAL", 170, 194], ["hydrogen peroxide", "CHEMICAL", 57, 74], ["peroxyacetic acid", "CHEMICAL", 86, 103], ["Lchlorine dioxide", "CHEMICAL", 112, 129], ["hydrogen", "CHEMICAL", 170, 178], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 57, 74], ["peroxyacetic acid", "SIMPLE_CHEMICAL", 86, 103], ["Lchlorine dioxide", "SIMPLE_CHEMICAL", 112, 129], ["vaporisation hydrogen oxidesteriliser", "SIMPLE_CHEMICAL", 157, 194], ["Other disinfection methods", "TREATMENT", 0, 26], ["themanual spray", "TREATMENT", 35, 50], ["3% hydrogen peroxide", "TREATMENT", 54, 74], ["L peroxyacetic acid", "TREATMENT", 84, 103], ["Lchlorine dioxide", "TREATMENT", 112, 129], ["atomisation", "TREATMENT", 142, 153], ["vaporisation hydrogen oxidesteriliser", "TREATMENT", 157, 194], ["ultraviolet disinfection", "TREATMENT", 199, 223], ["Open the window", "TREATMENT", 229, 244], ["sufficientventilation", "TREATMENT", 249, 270], ["disinfection", "TREATMENT", 277, 289], ["The cleaning", "TREATMENT", 337, 349], ["disinfection of endoscopic centres", "TREATMENT", 354, 388], ["The endoscope", "TREATMENT", 388, 401], ["cleaning", "TREATMENT", 476, 484], ["disinfection technique of flexibleendoscopes", "TREATMENT", 489, 533], ["the endoscope", "TEST", 594, 607], ["The cleaning", "TREATMENT", 655, 667], ["disinfection of endoscopic centres", "TREATMENT", 672, 706], ["The endoscope", "TREATMENT", 706, 719], ["reusable accessories", "TREATMENT", 724, 744], ["a double-layered yellowmedical waste bag", "TREATMENT", 764, 804], ["the bag", "TREATMENT", 839, 846], ["afterthe operation", "TREATMENT", 859, 877], ["waste bag", "OBSERVATION", 795, 804]]], ["The 2019-nCoV logo must be put on the bag and then the relatedstaff should transfer it to the endoscopy washroom.Cleaning and disinfection of the endoscope ::: The cleaning and disinfection of endoscopic centresImmerse all the endoscopes and reusable accessories immediately in 0.2\u20130.35%peroxyacetic acid or effective chlorine concentration 60 \u00b1 10 mg/L acidifiedwater for 5 minutes.", [["peroxyacetic acid", "CHEMICAL", 287, 304], ["chlorine", "CHEMICAL", 318, 326], ["peroxyacetic acid", "CHEMICAL", 287, 304], ["chlorine", "CHEMICAL", 318, 326], ["peroxyacetic acid", "SIMPLE_CHEMICAL", 287, 304], ["chlorine", "SIMPLE_CHEMICAL", 318, 326], ["the bag", "TREATMENT", 34, 41], ["The cleaning", "TREATMENT", 160, 172], ["disinfection", "TREATMENT", 177, 189], ["endoscopic centresImmerse", "TREATMENT", 193, 218], ["the endoscopes", "TREATMENT", 223, 237], ["reusable accessories", "TREATMENT", 242, 262], ["peroxyacetic acid", "TREATMENT", 287, 304], ["effective chlorine concentration", "TREATMENT", 308, 340]]], ["It is recommended to use a syringe to fill the channelswith detergent to ensure all the channels of the endoscope are fully soaked.Then clean and sterilise the endoscope according to specifications.Cleaning and disinfection of the endoscope ::: The cleaning and disinfection of endoscopic centresIt is recommended to choose peracetic acid and chlorine-containing preparationsas sterilant, other sterilants that meet the requirements can also beselected.Cleaning and disinfection of the endoscope ::: The cleaning and disinfection of endoscopic centresThe related staff should clean and disinfect the cleaning tank, rinsing tank,perfusion device and cleaning brush thoroughly with chlorine-containingdisinfectant, peroxyacetic acid or other disinfectants after the daily work inaccordance with relevant national regulations, and the disinfectant should bewiped off after 30 minutes.Cleaning and disinfection of the endoscope ::: The cleaning and disinfection of endoscopic centresAccording to the related medical waste management regulations,11 hospitalsmust disinfect the sewage discharged from washing tanks, rinsing tanks or fullyautomatic washer-disinfectors with medical wastewater disinfection equipmentbefore discharging them into the hospital sewage treatment system.Cleaning and disinfection of the endoscope ::: The cleaning and disinfection of endoscopic centresMedical waste should be packaged with double yellow medical waste bags markedwith the logo of 2019-nCoV and disposed in accordance with the relevantregulations.12,13ConclusionsCurrently, many countries are facing a very severe COVID-19 pandemic, and thereexists a very high risk of 2019-nCoV infection during endoscopic procedures.Therefore, endoscopists must take appropriate measures immediately to prevent thepotential spread of COVID-19 in endoscopic centres.", [["peracetic acid", "CHEMICAL", 324, 338], ["chlorine", "CHEMICAL", 343, 351], ["chlorine-containingdisinfectant", "CHEMICAL", 680, 711], ["peroxyacetic acid", "CHEMICAL", 713, 730], ["infection", "DISEASE", 1664, 1673], ["peracetic acid", "CHEMICAL", 324, 338], ["chlorine", "CHEMICAL", 343, 351], ["chlorine", "CHEMICAL", 680, 688], ["peroxyacetic acid", "CHEMICAL", 713, 730], ["peracetic acid", "SIMPLE_CHEMICAL", 324, 338], ["chlorine", "SIMPLE_CHEMICAL", 343, 351], ["sterilants", "SIMPLE_CHEMICAL", 395, 405], ["chlorine-containingdisinfectant", "SIMPLE_CHEMICAL", 680, 711], ["peroxyacetic acid", "SIMPLE_CHEMICAL", 713, 730], ["a syringe", "TREATMENT", 25, 34], ["the channelswith detergent", "TREATMENT", 43, 69], ["the endoscope", "TREATMENT", 100, 113], ["sterilise the endoscope", "TREATMENT", 146, 169], ["The cleaning", "TREATMENT", 245, 257], ["disinfection of endoscopic centres", "TREATMENT", 262, 296], ["peracetic acid", "TREATMENT", 324, 338], ["chlorine", "TREATMENT", 343, 351], ["preparationsas sterilant", "TREATMENT", 363, 387], ["The cleaning", "TREATMENT", 500, 512], ["disinfection of endoscopic centres", "TREATMENT", 517, 551], ["the cleaning tank", "TREATMENT", 596, 613], ["rinsing tank", "TREATMENT", 615, 627], ["perfusion device", "TREATMENT", 628, 644], ["cleaning brush", "TREATMENT", 649, 663], ["chlorine", "TREATMENT", 680, 688], ["peroxyacetic acid", "TREATMENT", 713, 730], ["other disinfectants", "TREATMENT", 734, 753], ["the disinfectant", "TREATMENT", 828, 844], ["The cleaning", "TREATMENT", 928, 940], ["disinfection", "TREATMENT", 945, 957], ["endoscopic centresAccording", "TREATMENT", 961, 988], ["medical waste management regulations", "TREATMENT", 1004, 1040], ["washing tanks", "TREATMENT", 1095, 1108], ["rinsing tanks", "TREATMENT", 1110, 1123], ["fullyautomatic washer", "TREATMENT", 1127, 1148], ["medical wastewater disinfection", "TREATMENT", 1167, 1198], ["The cleaning", "TREATMENT", 1321, 1333], ["disinfection", "TREATMENT", 1338, 1350], ["endoscopic centresMedical waste", "TREATMENT", 1354, 1385], ["double yellow medical waste bags", "TREATMENT", 1410, 1442], ["a very severe COVID", "PROBLEM", 1585, 1604], ["pandemic", "PROBLEM", 1608, 1616], ["nCoV infection", "PROBLEM", 1659, 1673], ["endoscopic procedures", "TREATMENT", 1681, 1702], ["endoscopists", "TREATMENT", 1714, 1726], ["COVID", "TEST", 1804, 1809], ["clean", "OBSERVATION", 136, 141], ["infection", "OBSERVATION", 1664, 1673]]], ["The preventive works of COVID-19in endoscopic centres has achieved preliminarily satisfactory results in China, andwe hope this paper could provide a reference for endoscopists in the pandemic areaof COVID-19 around the world.", [["COVID-19in", "CHEMICAL", 24, 34], ["endoscopists", "TEST", 164, 176]]]], "PMC7133335": [["Virulence and microbe-based biological weaponsBiological weapons might constitute live microbes or microbial components or products (e.g. toxins).", [["Virulence", "PROBLEM", 0, 9]]], ["Microbial component or product weapons are preformed compounds that are intended to incapacitate or kill as a result of deleterious effects on host homeostasis.", [["Microbial component", "PROBLEM", 0, 19], ["deleterious effects on host homeostasis", "PROBLEM", 120, 159], ["weapons", "OBSERVATION_MODIFIER", 31, 38]]], ["By contrast, live microbe-based biological weapons incapacitate or kill the host by inducing sufficient damage to produce disease.", [["disease", "PROBLEM", 122, 129]]], ["Microbial component or product weapons might differ in toxicity, but the concept of virulence is applicable only to microbe-based weapons.Virulence and microbe-based biological weaponsVirulence has been variously defined over the years and even today there is no universally used definition for this term [3].", [["toxicity", "DISEASE", 55, 63], ["Microbial component", "PROBLEM", 0, 19], ["virulence", "PROBLEM", 84, 93], ["Virulence", "PROBLEM", 138, 147]]], ["We recently defined virulence as the relative capacity of a microbe to cause damage in a susceptible host [3].", [["damage", "PROBLEM", 77, 83]]], ["Therefore, rather than being a singular microbial property, virulence is dependent on microbial and host variables, and as such is a readout of the amount of damage a susceptible host sustains from a host\u2013microbe relationship [4].", [["virulence", "PROBLEM", 60, 69], ["host variables", "OBSERVATION_MODIFIER", 100, 114]]], ["Virulence is defined as a relative term because we have no absolute measures of damage and consequently virulence is generally measured relative to another organism or to the historical experience with the disease [5].Virulence and microbe-based biological weaponsWhen assessing the relationship between virulence and the suitability of a microbe to serve as a biological weapon, it is important to consider the goal and the intent of the user.", [["Virulence", "PROBLEM", 0, 9], ["damage", "PROBLEM", 80, 86], ["consequently virulence", "PROBLEM", 91, 113], ["the disease", "PROBLEM", 202, 213], ["Virulence", "PROBLEM", 218, 227], ["virulence", "PROBLEM", 304, 313], ["weapons", "OBSERVATION_MODIFIER", 257, 264]]], ["For example, if the goal is to injure or kill individuals or groups of individuals, or to rapidly spread terror, the aggressor might select a microbe that causes disease and death soon after infection with a low inoculum.", [["death", "DISEASE", 174, 179], ["infection", "DISEASE", 191, 200], ["disease", "PROBLEM", 162, 169], ["death", "PROBLEM", 174, 179], ["infection", "PROBLEM", 191, 200], ["a low inoculum", "PROBLEM", 206, 220], ["low inoculum", "OBSERVATION_MODIFIER", 208, 220]]], ["Such a weapon would have a high degree of virulence on the basis of its capacity to induce damage and/or disease in a short time and because only a few organisms would be needed for this outcome.", [["virulence", "PROBLEM", 42, 51], ["its capacity", "PROBLEM", 68, 80], ["damage", "PROBLEM", 91, 97], ["disease", "PROBLEM", 105, 112], ["a few organisms", "PROBLEM", 146, 161], ["high degree", "OBSERVATION_MODIFIER", 27, 38], ["virulence", "OBSERVATION", 42, 51]]], ["By contrast, if the goal of a weapon is to undermine a society, civilization or species, the element of time and the inoculum that is needed to cause damage might be less important.", [["the inoculum", "TREATMENT", 113, 125], ["damage", "PROBLEM", 150, 156]]], ["For example, the inadvertent introduction of measles, smallpox and influenza into America by Europeans played havoc among indigenous societies and greatly facilitated their conquest, which in some cases occurred years after the initial contact 6, 7.", [["measles", "DISEASE", 45, 52], ["smallpox", "DISEASE", 54, 62], ["influenza", "DISEASE", 67, 76], ["measles", "TREATMENT", 45, 52], ["smallpox", "TREATMENT", 54, 62], ["influenza", "PROBLEM", 67, 76]]], ["Similarly, the Black Death epidemic might have originated from an act of biological warfare during a Black Sea siege, however, it took years to ravage Europe [8].", [["Death", "DISEASE", 21, 26], ["the Black Death epidemic", "PROBLEM", 11, 35], ["Black", "OBSERVATION_MODIFIER", 15, 20], ["Death", "OBSERVATION", 21, 26]]], ["Both the smallpox and Black Death epidemics were caused by organisms currently grouped as class A select agents.", [["smallpox", "DISEASE", 9, 17], ["Death", "DISEASE", 28, 33], ["Black Death epidemics", "PROBLEM", 22, 43], ["organisms", "PROBLEM", 59, 68], ["smallpox", "OBSERVATION_MODIFIER", 9, 17], ["Black", "OBSERVATION_MODIFIER", 22, 27], ["Death", "OBSERVATION_MODIFIER", 28, 33], ["epidemics", "OBSERVATION", 34, 43]]], ["This can be exemplified by human immunodeficiency virus (HIV), which has not been ranked high among biological warfare agents, presumably because of the difficulty in delivering this virus to a susceptible host and because the disease occurs many years after the initial infection.", [["human immunodeficiency virus (HIV)", "DISEASE", 27, 61], ["infection", "DISEASE", 271, 280], ["human immunodeficiency virus", "ORGANISM", 27, 55], ["HIV", "ORGANISM", 57, 60], ["human immunodeficiency virus (HIV", "SPECIES", 27, 60], ["human immunodeficiency virus", "SPECIES", 27, 55], ["HIV", "SPECIES", 57, 60], ["human immunodeficiency virus", "PROBLEM", 27, 55], ["HIV", "PROBLEM", 57, 60], ["biological warfare agents", "TREATMENT", 100, 125], ["this virus", "PROBLEM", 178, 188], ["the disease", "PROBLEM", 223, 234], ["the initial infection", "PROBLEM", 259, 280], ["disease", "OBSERVATION", 227, 234], ["infection", "OBSERVATION", 271, 280]]], ["Nevertheless, there have been documented cases of deliberate HIV infection, indicating it has potential as a biological weapon [9].", [["HIV infection", "DISEASE", 61, 74], ["HIV", "ORGANISM", 61, 64], ["HIV", "SPECIES", 61, 64], ["HIV", "SPECIES", 61, 64], ["deliberate HIV infection", "PROBLEM", 50, 74], ["infection", "OBSERVATION", 65, 74]]], ["Interestingly, the experience with HIV in certain countries bears similarities to those that have suffered from smallpox and bubonic plague epidemics, which has led some scientists to characterize HIV as a \u2018plague\u2019.", [["smallpox", "DISEASE", 112, 120], ["bubonic plague epidemics", "DISEASE", 125, 149], ["HIV", "ORGANISM", 197, 200], ["HIV", "SPECIES", 197, 200], ["HIV", "SPECIES", 35, 38], ["HIV", "SPECIES", 197, 200], ["HIV", "PROBLEM", 35, 38], ["smallpox and bubonic plague epidemics", "PROBLEM", 112, 149], ["bubonic", "OBSERVATION_MODIFIER", 125, 132], ["plague epidemics", "OBSERVATION", 133, 149]]], ["If the goal of an attack is to destabilize a society, then HIV has great weapon potential, as evidenced by the scourge and devastation that has visited numerous African societies.", [["HIV", "ORGANISM", 59, 62], ["HIV", "SPECIES", 59, 62]]], ["Such societal devastation poses a risk to the security and future of other nations around the globe, which cannot go forth without their youth.", [["globe", "ANATOMY", 94, 99]]], ["Given that the outcome of epidemics of bubonic plague, smallpox and HIV in susceptible populations is similar, then the assignment of plague and smallpox to class A status and not HIV must reflect considerations other than virulence.", [["bubonic plague", "DISEASE", 39, 53], ["smallpox", "DISEASE", 55, 63], ["HIV", "DISEASE", 68, 71], ["plague", "DISEASE", 134, 140], ["smallpox", "DISEASE", 145, 153], ["HIV", "ORGANISM", 180, 183], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 180, 183], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 180, 183], ["bubonic plague", "PROBLEM", 39, 53], ["smallpox", "PROBLEM", 55, 63], ["HIV in susceptible populations", "PROBLEM", 68, 98], ["plague", "PROBLEM", 134, 140], ["HIV", "PROBLEM", 180, 183], ["virulence", "PROBLEM", 223, 232]]], ["In the case of HIV, the outcome of infection is probably less relevant when assigning certain microbes to the select class than the process by which the outcome is achieved, the timing between infection and disease, and the preventative and therapeutic options that are available.", [["infection", "DISEASE", 35, 44], ["infection", "DISEASE", 193, 202], ["HIV", "ORGANISM", 15, 18], ["HIV", "SPECIES", 15, 18], ["HIV", "SPECIES", 15, 18], ["HIV", "PROBLEM", 15, 18], ["infection", "PROBLEM", 35, 44], ["infection", "PROBLEM", 193, 202], ["disease", "PROBLEM", 207, 214], ["therapeutic options", "TREATMENT", 241, 260], ["infection", "OBSERVATION", 35, 44], ["infection", "OBSERVATION", 193, 202]]], ["In addition, other factors such as the deliverability of the agent to targeted populations will also probably influence the level of threat that is assigned to a particular microbe.Virulence and microbe-based biological weaponsAlthough all successful microbe-based biological weapons are virulent in susceptible hosts, not all virulent microbes are considered candidates for use as biological weapons.", [["Virulence", "PROBLEM", 181, 190]]], ["Notably, some microbes notorious for causing epidemics of fulminant disease, such as Neisseria meningitidis and Streptococcus pyogenes, are not included in the select agents list.", [["fulminant disease", "DISEASE", 58, 75], ["Neisseria meningitidis", "DISEASE", 85, 107], ["Streptococcus pyogenes", "DISEASE", 112, 134], ["Neisseria meningitidis", "ORGANISM", 85, 107], ["Streptococcus pyogenes", "ORGANISM", 112, 134], ["Neisseria meningitidis", "SPECIES", 85, 107], ["Streptococcus pyogenes", "SPECIES", 112, 134], ["Neisseria meningitidis", "SPECIES", 85, 107], ["Streptococcus pyogenes", "SPECIES", 112, 134], ["fulminant disease", "PROBLEM", 58, 75], ["Neisseria meningitidis", "PROBLEM", 85, 107], ["Streptococcus pyogenes", "PROBLEM", 112, 134], ["fulminant", "OBSERVATION_MODIFIER", 58, 67], ["disease", "OBSERVATION", 68, 75], ["Streptococcus pyogenes", "OBSERVATION", 112, 134]]], ["By contrast, other microbes that cause only sporadic cases of human illness, such as Bacillus anthracis and Francisella tularensis, are considered highly dangerous category A biological agents.", [["human illness", "DISEASE", 62, 75], ["human", "ORGANISM", 62, 67], ["Bacillus anthracis", "ORGANISM", 85, 103], ["Francisella tularensis", "ORGANISM", 108, 130], ["human", "SPECIES", 62, 67], ["Bacillus anthracis", "SPECIES", 85, 103], ["Francisella tularensis", "SPECIES", 108, 130], ["human", "SPECIES", 62, 67], ["Bacillus anthracis", "SPECIES", 85, 103], ["Francisella tularensis", "SPECIES", 108, 130], ["human illness", "PROBLEM", 62, 75], ["Bacillus anthracis", "PROBLEM", 85, 103], ["Francisella tularensis", "PROBLEM", 108, 130]]], ["These examples suggest a complex relationship between the virulence of a microbe and its potential use in warfare and terrorism, and imply the importance of additional variables in determining the suitability of a microbe as a weapon.Virulence and microbe-based biological weaponsOne reason that the weapon potential of a microbe is not directly related to virulence is that none of the proposed definitions of virulence includes the parameter of time in their formulation.", [["Virulence", "PROBLEM", 234, 243], ["virulence", "PROBLEM", 411, 420], ["complex", "OBSERVATION_MODIFIER", 25, 32], ["weapons", "OBSERVATION_MODIFIER", 273, 280]]], ["Time is an important variable in the \u2018damage-response framework\u2019 because it is used to define the outcomes or states of microbial pathogenesis that follow infection [10].", [["infection", "DISEASE", 155, 164], ["microbial pathogenesis", "PROBLEM", 120, 142]]], ["The damage-response framework defines the outcomes of microbial infection (colonization, commensalism, latency and disease) as functions of host damage over time [10].", [["infection", "DISEASE", 64, 73], ["The damage", "PROBLEM", 0, 10], ["microbial infection", "PROBLEM", 54, 73], ["commensalism", "PROBLEM", 89, 101], ["latency and disease)", "PROBLEM", 103, 123], ["host damage", "PROBLEM", 140, 151], ["response framework", "OBSERVATION", 11, 29], ["microbial", "OBSERVATION_MODIFIER", 54, 63], ["infection", "OBSERVATION", 64, 73]]], ["The weaponization of B. anthracis can be envisioned as a modification of anthrax pathogenesis, whereby the relative proportion of individuals progressing to disease is increased and the route of infection is changed from gastrointestinal to pulmonary.", [["gastrointestinal", "ANATOMY", 221, 237], ["pulmonary", "ANATOMY", 241, 250], ["anthrax", "DISEASE", 73, 80], ["infection", "DISEASE", 195, 204], ["B. anthracis", "ORGANISM", 21, 33], ["anthrax", "ORGANISM", 73, 80], ["gastrointestinal", "ORGAN", 221, 237], ["pulmonary", "ORGAN", 241, 250], ["B. anthracis", "SPECIES", 21, 33], ["B. anthracis", "SPECIES", 21, 33], ["The weaponization of B. anthracis", "TREATMENT", 0, 33], ["anthrax pathogenesis", "PROBLEM", 73, 93], ["disease", "PROBLEM", 157, 164], ["infection", "PROBLEM", 195, 204], ["increased", "OBSERVATION_MODIFIER", 168, 177], ["infection", "OBSERVATION", 195, 204], ["pulmonary", "ANATOMY", 241, 250]]], ["Time is a significant variable because the effectiveness of biological agents as weapons is often a function of the rapidity with which they cause disease in a susceptible host.The weapon potential of a microbeWe begin with the assertion that each microbe has some weapon potential, which can range from high to nil.", [["biological agents", "TREATMENT", 60, 77], ["disease", "PROBLEM", 147, 154]]], ["Looking over the select list for common denominators we are struck by the paucity of commonalities that would allow classification within the generally accepted parameters of microbial virulence and pathogenicity.", [["microbial virulence", "PROBLEM", 175, 194], ["pathogenicity", "PROBLEM", 199, 212], ["microbial virulence", "OBSERVATION", 175, 194]]], ["Because virulence is a necessary but not sufficient condition for classification of a microbe as a select agent, there must be other considerations that are involved in making such choices.", [["virulence", "PROBLEM", 8, 17]]], ["The WP of a microbe is a function that includes such variables as its virulence, time to disease and susceptibility of possible target populations.", [["target populations", "PROBLEM", 128, 146], ["microbe", "OBSERVATION", 12, 19]]], ["For a microbe, the WP can be thought of as WP \u221d virulence/time to disease.The weapon potential of a microbeThe definition of virulence as the relative capacity of a microbe to cause damage in a host [3] is suitable as an operational concept in microbial pathogenesis, but computation of the WP of a microbe requires a more definable and/or quantifiable parameter.", [["disease", "PROBLEM", 66, 73], ["virulence", "PROBLEM", 125, 134], ["damage", "PROBLEM", 182, 188]]], ["For biological weapons, a more suitable relevant parameter might be the ratio of symptomatic to asymptomatic infections.", [["infections", "DISEASE", 109, 119], ["asymptomatic infections", "PROBLEM", 96, 119], ["asymptomatic", "OBSERVATION_MODIFIER", 96, 108], ["infections", "OBSERVATION", 109, 119]]], ["This narrower and more specialized definition of virulence includes the principle of host damage because a symptomatic infection is by definition one whereby the host suffers sufficient damage to manifest symptoms.", [["host damage", "DISEASE", 85, 96], ["infection", "DISEASE", 119, 128], ["virulence", "PROBLEM", 49, 58], ["host damage", "PROBLEM", 85, 96], ["a symptomatic infection", "PROBLEM", 105, 128], ["manifest symptoms", "PROBLEM", 196, 213], ["narrower", "OBSERVATION_MODIFIER", 5, 13], ["host damage", "OBSERVATION", 85, 96], ["symptomatic", "OBSERVATION_MODIFIER", 107, 118], ["infection", "OBSERVATION", 119, 128]]], ["In this regard, the WP incorporates the degree of host susceptibility, because damage that translates into disease can only occur in a susceptible host.The weapon potential of a microbeTo determine the virulence of a biological weapon (VBW) the following could be used: VBW=FSI/I, where FSI is the fraction of symptomatic infections for a given inoculum (I).", [["infections", "DISEASE", 322, 332], ["host susceptibility", "PROBLEM", 50, 69], ["damage", "PROBLEM", 79, 85], ["disease", "PROBLEM", 107, 114], ["symptomatic infections", "PROBLEM", 310, 332], ["host susceptibility", "OBSERVATION", 50, 69], ["symptomatic", "OBSERVATION_MODIFIER", 310, 321], ["infections", "OBSERVATION", 322, 332]]], ["VBW is not a fixed characteristic and is based on the degree of immunity in an individual or population.", [["fixed characteristic", "OBSERVATION_MODIFIER", 13, 33]]], ["Hence, a vaccination program would reduce VBW by reducing the fraction of symptomatic infections.", [["VBW", "DISEASE", 42, 45], ["infections", "DISEASE", 86, 96], ["VBW", "SIMPLE_CHEMICAL", 42, 45], ["VBW", "SPECIES", 42, 45], ["a vaccination program", "TREATMENT", 7, 28], ["symptomatic infections", "PROBLEM", 74, 96], ["symptomatic", "OBSERVATION_MODIFIER", 74, 85], ["infections", "OBSERVATION", 86, 96]]], ["For example, in a study of intrafamilial transmission of smallpox there were 73 cases of smallpox among 96 unvaccinated contacts (FSI=0.760) that presumably led to the infection, whereas among vaccinated individuals there were only 16 cases of smallpox among 331 contacts (FSI=0.048) [6].", [["smallpox", "DISEASE", 57, 65], ["smallpox", "DISEASE", 89, 97], ["infection", "DISEASE", 168, 177], ["smallpox", "DISEASE", 244, 252], ["a study", "TEST", 16, 23], ["smallpox", "PROBLEM", 89, 97], ["FSI", "TEST", 130, 133], ["the infection", "PROBLEM", 164, 177], ["FSI", "TEST", 273, 276], ["infection", "OBSERVATION", 168, 177]]], ["Furthermore, a higher state of immunity would require a significantly higher inoculum, further diminishing VBW.The weapon potential of a microbeThe WP of a microbe is also a function of other characteristics that include communicability and stability.", [["a significantly higher inoculum", "PROBLEM", 54, 85], ["further diminishing VBW", "PROBLEM", 87, 110], ["communicability", "PROBLEM", 221, 236], ["microbe", "OBSERVATION", 156, 163], ["stability", "OBSERVATION_MODIFIER", 241, 250]]], ["Communicability is a measure of transmissibility and contagiousness.", [["contagiousness", "DISEASE", 53, 67], ["contagiousness", "PROBLEM", 53, 67]]], ["Host-to-host communicability (C) is not a required quality of a biological weapon, as evidenced by the example of B. anthracis spores, but the potential for communicability can significantly influence the selection of an agent and its impact on the targeted population.", [["B. anthracis spores", "ORGANISM", 114, 133], ["B. anthracis", "SPECIES", 114, 126], ["B. anthracis", "SPECIES", 114, 126], ["B. anthracis spores", "PROBLEM", 114, 133], ["communicability", "PROBLEM", 157, 172], ["an agent", "TREATMENT", 218, 226]]], ["Although communicability functions as a threat amplifier, it is not always a desirable quality in a biological weapon because the aggressor cannot control the agent once it is released and there is always the potential that person-to-person communicability would affect friendly, non-targeted populations.", [["person", "SPECIES", 224, 230], ["person", "SPECIES", 234, 240]]], ["For a particular pathogen, the parameter C is \u22651.0.", [["a particular pathogen", "PROBLEM", 4, 25], ["the parameter C", "TEST", 27, 42]]], ["Microbes that are not transmissible have a C value of 1.0, such that this parameter does not influence the WP.", [["a C value", "TEST", 41, 50]]], ["Stability (S) is a required parameter for biological weapons because one can anticipate that some baseline stability is needed for a microbe to be developed into a biological weapon.", [["some baseline stability", "PROBLEM", 93, 116]]], ["First, the shorter the time between use of a microbe and its effect reduces the likelihood that a targeted population can adapt to the threat, and as a consequence the potential effect of the microbe increases.", [["a microbe", "TREATMENT", 43, 52]]], ["Second, microbes that act rapidly are more likely to cause terror.", [["terror", "PROBLEM", 59, 65], ["more likely", "UNCERTAINTY", 38, 49]]], ["Therefore, it is no surprise that the time between infection and disease is relatively short for all the microbes that are currently listed in the select agents list (Table 1).", [["infection", "DISEASE", 51, 60], ["infection", "PROBLEM", 51, 60], ["disease", "PROBLEM", 65, 72], ["no surprise", "UNCERTAINTY", 17, 28], ["infection", "OBSERVATION", 51, 60], ["disease", "OBSERVATION", 65, 72]]], ["However, the relationship between the time to disease and the weapon potential of a microbe is more complex.", [["disease", "PROBLEM", 46, 53], ["more complex", "OBSERVATION_MODIFIER", 95, 107]]], ["If the devastation brought to Africa by the HIV epidemic is considered, it is clear that even microbes that take a long time to cause disease can cause tremendous havoc.", [["HIV", "SPECIES", 44, 47], ["the devastation", "PROBLEM", 3, 18], ["disease", "PROBLEM", 134, 141], ["tremendous havoc", "PROBLEM", 152, 168]]], ["Consequently, they have tremendous weapon potential and it might be appropriate to consider them separately by disregarding the parameter of time (e.g. assign T=1.0).The weapon potential of a microbeThis formulation can then be used to compare the WP of various agents in the select agents list for which there is sufficient information available in the literature to estimate the various parameters (Box 1).", [["This formulation", "TREATMENT", 199, 215]]], ["The formula yields significantly larger values for the WP of B. anthracis and variola virus than for C. albicans, a fungal commensal that is not considered a potential biological weapon.", [["B. anthracis", "ORGANISM", 61, 73], ["variola virus", "ORGANISM", 78, 91], ["C. albicans", "ORGANISM", 101, 112], ["B. anthracis", "SPECIES", 61, 73], ["variola virus", "SPECIES", 78, 91], ["C. albicans", "SPECIES", 101, 112], ["B. anthracis", "SPECIES", 61, 73], ["variola virus", "SPECIES", 78, 91], ["C. albicans", "SPECIES", 101, 112], ["variola virus", "PROBLEM", 78, 91], ["C. albicans", "PROBLEM", 101, 112], ["a fungal commensal", "PROBLEM", 114, 132], ["variola virus", "OBSERVATION", 78, 91]]], ["Our calculation suggests that the WP for variola virus is several orders of magnitude greater than B. anthracis because the infective inoculum is believed to be smaller, and its high communicability provides a strong multiplier effect.", [["variola", "DISEASE", 41, 48], ["variola virus", "ORGANISM", 41, 54], ["B. anthracis", "ORGANISM", 99, 111], ["B. anthracis", "SPECIES", 99, 111], ["variola virus", "SPECIES", 41, 54], ["B. anthracis", "SPECIES", 99, 111], ["Our calculation", "TEST", 0, 15], ["the WP", "TREATMENT", 30, 36], ["variola virus", "PROBLEM", 41, 54], ["the infective inoculum", "PROBLEM", 120, 142], ["its high communicability", "PROBLEM", 174, 198], ["infective", "OBSERVATION_MODIFIER", 124, 133], ["inoculum", "OBSERVATION", 134, 142], ["believed to be", "UNCERTAINTY", 146, 160], ["smaller", "OBSERVATION_MODIFIER", 161, 168], ["high", "OBSERVATION_MODIFIER", 178, 182], ["strong", "OBSERVATION_MODIFIER", 210, 216], ["multiplier effect", "OBSERVATION", 217, 234]]], ["Interestingly, HIV yields a higher weapon potential than B. anthracis when certain assumptions are made (Box 1).", [["HIV", "ORGANISM", 15, 18], ["B. anthracis", "ORGANISM", 57, 69], ["HIV", "SPECIES", 15, 18], ["B. anthracis", "SPECIES", 57, 69], ["HIV", "SPECIES", 15, 18], ["B. anthracis", "SPECIES", 57, 69]]], ["However, if one disregards the parameter of time by assigning T=1.0 then the formula estimates a WP for HIV that is comparable to variola in a susceptible population (Box 1).Box 1Box 1.", [["variola", "DISEASE", 130, 137], ["HIV", "ORGANISM", 104, 107], ["Box 1Box 1", "GENE_OR_GENE_PRODUCT", 174, 184], ["Box 1Box 1", "DNA", 174, 184], ["HIV", "SPECIES", 104, 107], ["HIV", "PROBLEM", 104, 107], ["variola", "PROBLEM", 130, 137]]], ["Calculation of the weapon potential for Bacillus anthracis, variola virus, human immunodeficiency virus (HIV) and Candida albicansFor Bacillus anthracis (Table I) the fraction of symptomatic infections (FSI) of 0.008 was estimated from the Sverdlovsk anthrax outbreak where there were several hundred cases (we assumed 500) from a population of 59 000 that was selected for vaccination by the Soviet authorities following the accident [13].", [["human immunodeficiency virus (HIV) and Candida albicans", "DISEASE", 75, 130], ["infections", "DISEASE", 191, 201], ["anthrax", "DISEASE", 251, 258], ["Bacillus anthracis", "ORGANISM", 40, 58], ["variola virus", "ORGANISM", 60, 73], ["human immunodeficiency virus", "ORGANISM", 75, 103], ["HIV", "ORGANISM", 105, 108], ["Candida albicans", "ORGANISM", 114, 130], ["Bacillus anthracis", "ORGANISM", 134, 152], ["Bacillus anthracis", "SPECIES", 40, 58], ["variola virus", "SPECIES", 60, 73], ["human immunodeficiency virus", "SPECIES", 75, 103], ["HIV", "SPECIES", 105, 108], ["Candida albicans", "SPECIES", 114, 130], ["Bacillus anthracis", "SPECIES", 134, 152], ["Bacillus anthracis", "SPECIES", 40, 58], ["variola virus", "SPECIES", 60, 73], ["human immunodeficiency virus", "SPECIES", 75, 103], ["HIV", "SPECIES", 105, 108], ["Candida albicans", "SPECIES", 114, 130], ["Bacillus anthracis", "SPECIES", 134, 152], ["Bacillus anthracis", "PROBLEM", 40, 58], ["variola virus", "PROBLEM", 60, 73], ["human immunodeficiency virus", "PROBLEM", 75, 103], ["Candida albicans", "PROBLEM", 114, 130], ["Bacillus anthracis", "PROBLEM", 134, 152], ["symptomatic infections", "PROBLEM", 179, 201], ["FSI", "TEST", 203, 206], ["vaccination", "TREATMENT", 374, 385], ["variola virus", "OBSERVATION", 60, 73], ["symptomatic", "OBSERVATION_MODIFIER", 179, 190], ["infections", "OBSERVATION", 191, 201]]], ["Similarly, the time to disease was the mean incubation period for fatal cases in the Sverdlovsk incident [14].", [["Sverdlovsk", "DISEASE", 85, 95], ["fatal cases", "PROBLEM", 66, 77]]], ["In the second calculation the FSI of 0.0008 was estimated from the B. anthracis mail attacks where two cases of inhalational anthrax occurred among the 2446 persons that were potentially exposed in the Brentwood Mail Processing and Distribution Center in the District of Columbia [14].", [["anthrax", "DISEASE", 125, 132], ["B. anthracis", "ORGANISM", 67, 79], ["persons", "ORGANISM", 157, 164], ["B. anthracis", "SPECIES", 67, 79], ["persons", "SPECIES", 157, 164], ["B. anthracis", "SPECIES", 67, 79], ["inhalational anthrax", "PROBLEM", 112, 132], ["Distribution", "OBSERVATION_MODIFIER", 232, 244]]], ["The inoculum values of 8000, 50 and 1 spores correspond to LD50, LD10 and LD1, respectively, in monkeys 2, 11, and are used here with the caveat that we do not know the number of spores in the above incidents or the applicability of monkey susceptibility data to humans.", [["LD1", "GENE_OR_GENE_PRODUCT", 74, 77], ["monkey", "ORGANISM", 233, 239], ["humans", "ORGANISM", 263, 269], ["humans", "SPECIES", 263, 269], ["humans", "SPECIES", 263, 269], ["The inoculum values", "TEST", 0, 19], ["LD50", "TEST", 59, 63], ["LD10", "TEST", 65, 69], ["LD1", "TEST", 74, 77], ["inoculum", "OBSERVATION_MODIFIER", 4, 12]]], ["The values for LD10 and LD1 were taken from Ref.", [["LD10", "GENE_OR_GENE_PRODUCT", 15, 19], ["LD1", "GENE_OR_GENE_PRODUCT", 24, 27], ["LD10", "PROTEIN", 15, 19], ["LD1", "PROTEIN", 24, 27], ["The values", "TEST", 0, 10], ["LD10", "TEST", 15, 19], ["LD1", "TEST", 24, 27]]], ["Communicability was arbitrarily assigned a value of 1.0 (not communicable) because person-to-person spread of anthrax does not occur.", [["anthrax", "DISEASE", 110, 117], ["anthrax", "ORGANISM", 110, 117], ["person", "SPECIES", 83, 89]]], ["Stability was assigned a value of 1.0 because spores can remain viable for decades.For variola virus (Table I) we have used the value of 0.76 for the FSI based on a study where there were 73 cases of secondary smallpox among 95 unvaccinated contacts of individuals with smallpox in a study of intrafamilial transmission [6].", [["spores", "ANATOMY", 46, 52], ["smallpox", "DISEASE", 210, 218], ["smallpox", "DISEASE", 270, 278], ["variola virus", "ORGANISM", 87, 100], ["variola virus", "SPECIES", 87, 100], ["variola virus", "SPECIES", 87, 100], ["variola virus", "PROBLEM", 87, 100], ["a study", "TEST", 163, 170], ["secondary smallpox", "PROBLEM", 200, 218], ["smallpox", "TREATMENT", 270, 278]]], ["The inoculum used was taken from studies by Franz et al. [2].", [["The inoculum", "TREATMENT", 0, 12], ["inoculum", "OBSERVATION", 4, 12]]], ["The communicability value was arbitrarily set at 90 as there is widespread consensus that smallpox is a highly contagious disease [2].", [["smallpox", "DISEASE", 90, 98], ["The communicability value", "TEST", 0, 25], ["a highly contagious disease", "PROBLEM", 102, 129], ["highly", "OBSERVATION_MODIFIER", 104, 110], ["contagious", "OBSERVATION_MODIFIER", 111, 121]]], ["The time to disease varies between 7\u201317 days [2], therefore we used the value of 10.", [["the value", "TEST", 68, 77]]], ["Relative stability is unknown and we arbitrarily used 0.25 because it is a virus transmitted in aerosols.For HIV (Table I) the inoculum for 50% infectivity was estimated to be 1000 from blood transfusion and needle stick studies [15].", [["blood", "ANATOMY", 186, 191], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["HIV", "SPECIES", 109, 112], ["HIV", "SPECIES", 109, 112], ["a virus", "PROBLEM", 73, 80], ["HIV", "PROBLEM", 109, 112], ["the inoculum", "TREATMENT", 123, 135], ["blood transfusion", "TEST", 186, 203], ["needle stick studies", "TEST", 208, 228], ["stability", "OBSERVATION", 9, 18], ["virus", "OBSERVATION", 75, 80]]], ["The FSI was set at 0.99 because the overwhelming majority of infected individuals progress to AIDS given sufficient time.", [["AIDS", "DISEASE", 94, 98], ["individuals", "ORGANISM", 70, 81], ["The FSI", "TEST", 0, 7], ["infected individuals", "PROBLEM", 61, 81], ["AIDS", "PROBLEM", 94, 98], ["infected", "OBSERVATION", 61, 69]]], ["Communicability was arbitrarily set relatively low, at 5, because it requires exchange of fluids.", [["exchange of fluids", "TREATMENT", 78, 96]]], ["Stability was arbitrarily set a 0.25 and the time to disease was based on eight years between infection and development of AIDS.", [["infection", "DISEASE", 94, 103], ["AIDS", "DISEASE", 123, 127], ["infection", "PROBLEM", 94, 103], ["AIDS", "PROBLEM", 123, 127], ["infection", "OBSERVATION", 94, 103]]], ["In the second calculation the parameter of time was disregarded by setting it at 1.0.For Candida albicans (Table I) the values used are based on rough estimates from data on human vaginal candidiasis.", [["vaginal candidiasis", "ANATOMY", 180, 199], ["vaginal candidiasis", "DISEASE", 180, 199], ["Candida albicans", "ORGANISM", 89, 105], ["human", "ORGANISM", 174, 179], ["vaginal candidiasis", "PATHOLOGICAL_FORMATION", 180, 199], ["Candida albicans", "SPECIES", 89, 105], ["human", "SPECIES", 174, 179], ["Candida albicans", "SPECIES", 89, 105], ["human", "SPECIES", 174, 179], ["Candida albicans", "PROBLEM", 89, 105], ["human vaginal candidiasis", "PROBLEM", 174, 199], ["vaginal", "ANATOMY", 180, 187], ["candidiasis", "OBSERVATION", 188, 199]]], ["The FSI was calculated from the study of Levison et al. [16] based on estimates from vaginal candidiases, where 5 out of a total 17 women with Candida in vaginal fluids had symptoms.", [["vaginal", "ANATOMY", 85, 92], ["vaginal fluids", "ANATOMY", 154, 168], ["vaginal", "ORGANISM_SUBDIVISION", 85, 92], ["women", "ORGANISM", 132, 137], ["women", "SPECIES", 132, 137], ["The FSI", "TEST", 0, 7], ["the study", "TEST", 28, 37], ["vaginal candidiases", "PROBLEM", 85, 104], ["Candida in vaginal fluids", "TREATMENT", 143, 168], ["symptoms", "PROBLEM", 173, 181], ["vaginal candidiases", "ANATOMY", 85, 104], ["vaginal", "ANATOMY", 154, 161]]], ["The infective dose for Candida spp. is unknown; a value of 106 organisms is used based on the observation that women with candidal vaginitis had fungal burden in the range of Log10 7.9\u201311 colony forming units per milliliter [16].", [["Candida spp.", "DISEASE", 23, 35], ["candidal vaginitis", "DISEASE", 122, 140], ["Candida spp.", "ORGANISM", 23, 35], ["women", "ORGANISM", 111, 116], ["Candida spp.", "SPECIES", 23, 35], ["women", "SPECIES", 111, 116], ["Candida spp.", "SPECIES", 23, 35], ["The infective dose", "TREATMENT", 0, 18], ["Candida spp.", "PROBLEM", 23, 35], ["a value", "TEST", 48, 55], ["candidal vaginitis", "PROBLEM", 122, 140], ["fungal burden", "PROBLEM", 145, 158], ["Log10", "TEST", 175, 180], ["infective", "OBSERVATION_MODIFIER", 4, 13]]], ["The communicability of Candida spp. is unknown but it must be contagious because it is acquired shortly after birth and there is some evidence that it can be transmitted between sexual partners [17].", [["Candida spp.", "DISEASE", 23, 35], ["Candida spp.", "ORGANISM", 23, 35], ["Candida spp.", "SPECIES", 23, 35], ["Candida spp.", "SPECIES", 23, 35], ["Candida spp.", "PROBLEM", 23, 35], ["Candida spp.", "OBSERVATION", 23, 35]]], ["Because Candida spp. are free-living organisms that can survive in the environment we have arbitrarily set the stability value at 0.75.", [["Candida spp.", "ORGANISM", 8, 20], ["Candida spp.", "SPECIES", 8, 20], ["Candida spp.", "SPECIES", 8, 20], ["Candida spp.", "PROBLEM", 8, 20], ["free", "OBSERVATION_MODIFIER", 25, 29]]], ["The time to disease in humans is unknown and we have arbitrarily used five days.The weapon potential of a microbeClearly, the WP formalism proposed here is the first approximation for a very complex relationship and we do not claim to have found the optimal formulation.", [["humans", "ORGANISM", 23, 29], ["humans", "SPECIES", 23, 29], ["humans", "SPECIES", 23, 29], ["disease", "OBSERVATION", 12, 19]]], ["In fact, the basic formula can be modified further to consider other variables.", [["the basic formula", "TREATMENT", 9, 26]]], ["For example, one can add a terror modifier (X) based on the judgment that the agent would cause panic and social disruption: WP=[VBWSC/T]X.The weapon potential of a microbeThe X parameter can be large for conditions where there is high mortality, contagion and no prophylactic or therapeutic measures.", [["panic", "DISEASE", 96, 101], ["a terror modifier", "TREATMENT", 25, 42], ["panic", "PROBLEM", 96, 101], ["The X parameter", "TREATMENT", 172, 187], ["high mortality", "PROBLEM", 231, 245], ["prophylactic", "TREATMENT", 264, 276], ["therapeutic measures", "TREATMENT", 280, 300], ["large", "OBSERVATION", 195, 200]]], ["An example of such an agent could be Ebola virus, where the X parameter would enhance the WP values calculated.", [["Ebola virus", "DISEASE", 37, 48], ["Ebola virus", "ORGANISM", 37, 48], ["Ebola virus", "SPECIES", 37, 48], ["an agent", "TREATMENT", 19, 27], ["Ebola virus", "PROBLEM", 37, 48], ["the X parameter", "TEST", 56, 71], ["the WP values", "TEST", 86, 99]]], ["Conversely, for organisms that have low mortality and for which prophylactic and therapeutic measures are available, the X parameter would reduce the value of the calculated WP.", [["organisms", "PROBLEM", 16, 25], ["low mortality", "PROBLEM", 36, 49], ["prophylactic and therapeutic measures", "TREATMENT", 64, 101]]], ["Another variable that influences the weapon potential of a microbe is the deliverability (D) of the agent, which is a function of the technical capabilities of the user and the biological characteristics of the microbe.", [["the agent", "TREATMENT", 96, 105]]], ["Although this parameter is not fully independent of stability and communicability we have treated it differently, because deliverability is a major consideration in assessing the threat potential of microbes.", [["stability", "OBSERVATION", 52, 61], ["microbes", "OBSERVATION", 199, 207]]], ["We have arbitrarily set the value 0\u2264D\u22641, such that 0 denotes a situation where the microbe cannot be delivered and 1 describes a condition where microbial delivery is highly efficient and technological hurdles do not exist.", [["microbial delivery", "TREATMENT", 145, 163]]], ["Therefore, the WP formula can be modified to be WP=[VBWSC/T]XD.The weapon potential of a microbe", [["[VBWSC/T]XD", "CHEMICAL", 51, 62], ["the WP formula", "TREATMENT", 11, 25]]]], "c669926f49f9822a0a6ac27e7a319adeef24a589": [["The certainty of this statement is probably more disheartening than the statement itself.", [["probably", "UNCERTAINTY", 35, 43], ["more disheartening", "OBSERVATION_MODIFIER", 44, 62]]], ["Elective surgery has been deferred along with the non-urgent cancer cases.", [["cancer", "ANATOMY", 61, 67], ["cancer", "DISEASE", 61, 67], ["cancer", "CANCER", 61, 67], ["Elective surgery", "TREATMENT", 0, 16], ["cancer", "OBSERVATION", 61, 67]]], ["Even the cancer operations face a grim prognosis, firstly with the procedural-related mortality itself but more importantly, the added morbidity and mortality from the risk of contracting coronavirus.", [["cancer", "ANATOMY", 9, 15], ["cancer", "DISEASE", 9, 15], ["coronavirus", "DISEASE", 188, 199], ["cancer", "CANCER", 9, 15], ["coronavirus", "ORGANISM", 188, 199], ["contracting coronavirus", "PROBLEM", 176, 199], ["cancer", "OBSERVATION", 9, 15], ["contracting coronavirus", "OBSERVATION", 176, 199]]]], "ee2028f18c19056e6742d111157d17bb1019e0b7": [["Melanomas (MAAs) are neoplasms that arise from pigmented melanocytes differentiated from the neural crest.", [["Melanomas", "ANATOMY", 0, 9], ["MAAs", "ANATOMY", 11, 15], ["neoplasms", "ANATOMY", 21, 30], ["pigmented melanocytes", "ANATOMY", 47, 68], ["neural crest", "ANATOMY", 93, 105], ["Melanomas", "DISEASE", 0, 9], ["MAAs", "DISEASE", 11, 15], ["neoplasms", "DISEASE", 21, 30], ["Melanomas", "CANCER", 0, 9], ["MAAs", "CANCER", 11, 15], ["neoplasms", "CANCER", 21, 30], ["pigmented melanocytes", "CELL", 47, 68], ["neural crest", "MULTI-TISSUE_STRUCTURE", 93, 105], ["pigmented melanocytes", "CELL_TYPE", 47, 68], ["Melanomas (MAAs)", "PROBLEM", 0, 16], ["neoplasms", "PROBLEM", 21, 30], ["pigmented melanocytes", "PROBLEM", 47, 68], ["neoplasms", "OBSERVATION", 21, 30], ["pigmented", "OBSERVATION_MODIFIER", 47, 56], ["melanocytes", "OBSERVATION", 57, 68], ["neural", "ANATOMY_MODIFIER", 93, 99], ["crest", "ANATOMY", 100, 105]]], ["Cutaneous MAA represents only 4% of all skin cancers but accounts for almost all of the deaths associated with the disease.", [["skin cancers", "ANATOMY", 40, 52], ["MAA", "CHEMICAL", 10, 13], ["skin cancers", "DISEASE", 40, 52], ["deaths", "DISEASE", 88, 94], ["skin cancers", "CANCER", 40, 52], ["Cutaneous MAA", "PROBLEM", 0, 13], ["all skin cancers", "PROBLEM", 36, 52], ["the disease", "PROBLEM", 111, 122], ["4%", "OBSERVATION_MODIFIER", 30, 32], ["all", "OBSERVATION_MODIFIER", 36, 39], ["skin", "ANATOMY", 40, 44], ["cancers", "OBSERVATION", 45, 52], ["deaths", "OBSERVATION", 88, 94], ["disease", "OBSERVATION", 115, 122]]], ["The incidence of MAA over the last 30 years has more than doubled in the United States with 54,000 new cases and 7,600 deaths in 2003.", [["MAA", "CHEMICAL", 17, 20], ["deaths", "DISEASE", 119, 125], ["MAA", "OBSERVATION_MODIFIER", 17, 20]]], ["Intermittent acute sun exposure and lifetime sun exposure, age, skin pigment type, immune suppression, atypical nevi and family history are risk factors for MAA.", [["skin", "ANATOMY", 64, 68], ["nevi", "ANATOMY", 112, 116], ["immune suppression", "DISEASE", 83, 101], ["atypical nevi", "DISEASE", 103, 116], ["MAA", "CHEMICAL", 157, 160], ["MAA", "SIMPLE_CHEMICAL", 157, 160], ["Intermittent acute sun exposure", "PROBLEM", 0, 31], ["skin pigment type", "PROBLEM", 64, 81], ["immune suppression", "PROBLEM", 83, 101], ["atypical nevi", "PROBLEM", 103, 116], ["MAA", "PROBLEM", 157, 160], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["sun exposure", "OBSERVATION_MODIFIER", 19, 31], ["skin", "ANATOMY", 64, 68], ["pigment type", "OBSERVATION", 69, 81]]], ["The early stage disease is curable but reoccurrence is common for later stage disease and the prognosis is poor if the disease has spread to the lymph nodes and other tissues.", [["lymph nodes", "ANATOMY", 145, 156], ["tissues", "ANATOMY", 167, 174], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 145, 156], ["tissues", "TISSUE", 167, 174], ["The early stage disease", "PROBLEM", 0, 23], ["later stage disease", "PROBLEM", 66, 85], ["the disease", "PROBLEM", 115, 126], ["early", "OBSERVATION_MODIFIER", 4, 9], ["stage", "OBSERVATION_MODIFIER", 10, 15], ["disease", "OBSERVATION", 16, 23], ["curable", "OBSERVATION_MODIFIER", 27, 34], ["disease", "OBSERVATION", 119, 126], ["lymph nodes", "OBSERVATION", 145, 156]]], ["Standard treatment is biopsy and 2-cm wide excision after histological determination that the lesion is malignant.", [["lesion", "ANATOMY", 94, 100], ["lesion", "CANCER", 94, 100], ["biopsy", "TEST", 22, 28], ["2-cm wide excision", "TREATMENT", 33, 51], ["histological determination", "TEST", 58, 84], ["the lesion", "PROBLEM", 90, 100], ["malignant", "PROBLEM", 104, 113], ["lesion", "OBSERVATION", 94, 100], ["malignant", "OBSERVATION", 104, 113]]], ["In some cases, regional and sentinel lymph nodes are also removed and, if positive, adjuvant therapy consisting of interferon-a or IL-2 may be administered but response rates low and long term benefit are not significant.", [["lymph nodes", "ANATOMY", 37, 48], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 37, 48], ["interferon-a", "GENE_OR_GENE_PRODUCT", 115, 127], ["IL-2", "GENE_OR_GENE_PRODUCT", 131, 135], ["interferon", "PROTEIN", 115, 125], ["IL", "PROTEIN", 131, 133], ["regional and sentinel lymph nodes", "PROBLEM", 15, 48], ["adjuvant therapy", "TREATMENT", 84, 100], ["interferon", "TREATMENT", 115, 125], ["a or IL-2", "TREATMENT", 126, 135], ["response rates low and long term benefit", "PROBLEM", 160, 200], ["regional", "OBSERVATION_MODIFIER", 15, 23], ["sentinel", "OBSERVATION", 28, 36], ["lymph nodes", "OBSERVATION", 37, 48]]], ["[1] [2] [3] However, cases of spontaneous remission and reoccurrence of the disease many years after remission or resection, and correlation of remission with immune cell infiltrates all suggest that there is an immune surveillance process that could be leveraged to develop treatments for late stage disease.", [["immune cell", "ANATOMY", 159, 170], ["immune cell", "CELL", 159, 170], ["spontaneous remission", "PROBLEM", 30, 51], ["the disease", "PROBLEM", 72, 83], ["resection", "TREATMENT", 114, 123], ["immune cell infiltrates", "PROBLEM", 159, 182], ["an immune surveillance process", "PROBLEM", 209, 239], ["treatments", "TREATMENT", 275, 285], ["late stage disease", "PROBLEM", 290, 308], ["spontaneous remission", "OBSERVATION", 30, 51], ["resection", "OBSERVATION", 114, 123], ["immune cell infiltrates", "OBSERVATION", 159, 182], ["late stage", "OBSERVATION_MODIFIER", 290, 300], ["disease", "OBSERVATION", 301, 308]]], ["[4] [5] [6] [7] [8] The discovery of tumor antigens associated with MAA 9 has led to research and development of therapeutic vaccines designed to gener-ate antitumor responses with the aim of controlling metastasis.", [["tumor", "ANATOMY", 37, 42], ["antitumor", "ANATOMY", 156, 165], ["tumor", "DISEASE", 37, 42], ["MAA 9", "CHEMICAL", 68, 73], ["MAA 9", "CHEMICAL", 68, 73], ["[4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 19], ["tumor", "CANCER", 37, 42], ["MAA 9", "GENE_OR_GENE_PRODUCT", 68, 73], ["antitumor", "CANCER", 156, 165], ["tumor antigens", "PROTEIN", 37, 51], ["MAA 9", "PROTEIN", 68, 73], ["tumor antigens", "PROBLEM", 37, 51], ["therapeutic vaccines", "TREATMENT", 113, 133], ["controlling metastasis", "PROBLEM", 192, 214], ["tumor", "OBSERVATION", 37, 42], ["metastasis", "OBSERVATION", 204, 214]]], ["A wide variety of vaccination approaches and protocols are currently being tested.", [["vaccination approaches", "TREATMENT", 18, 40], ["protocols", "TREATMENT", 45, 54], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["variety", "OBSERVATION_MODIFIER", 7, 14]]], ["10 The results show that even though specific cellular immune responses are generated against the antigens, the response of the disease to the treatment is low.", [["cellular", "ANATOMY", 46, 54], ["cellular", "CELL", 46, 54], ["antigens", "PROTEIN", 98, 106], ["the disease", "PROBLEM", 124, 135], ["the treatment", "TREATMENT", 139, 152], ["disease", "OBSERVATION", 128, 135], ["low", "OBSERVATION_MODIFIER", 156, 159]]], ["The reasons for the low response rates are thought to be low immunogenicity of the antigens, which are usually self-antigens, and the natural selection of tumor variants that have immune-suppressive phenotypes arising through a process called immuno-editing.", [["tumor", "ANATOMY", 155, 160], ["tumor", "DISEASE", 155, 160], ["tumor", "CANCER", 155, 160], ["antigens", "PROTEIN", 83, 91], ["the low response rates", "PROBLEM", 16, 38], ["low immunogenicity of the antigens", "PROBLEM", 57, 91], ["tumor variants", "PROBLEM", 155, 169], ["suppressive phenotypes", "PROBLEM", 187, 209], ["immuno-editing", "PROBLEM", 243, 257], ["thought to be", "UNCERTAINTY", 43, 56], ["low", "OBSERVATION_MODIFIER", 57, 60], ["immunogenicity", "OBSERVATION", 61, 75], ["tumor", "OBSERVATION", 155, 160]]], ["11 The nature of the immune suppression may include secretion of immunosuppressive cytokines, 12 the expression of ligands (FAS-L) that initiate apoptosis in cytotoxic T-cells 13 and tumor variants that are deficient in antigen processing and presentation.", [["cytotoxic T-cells", "ANATOMY", 158, 175], ["tumor", "ANATOMY", 183, 188], ["tumor", "DISEASE", 183, 188], ["FAS-L", "GENE_OR_GENE_PRODUCT", 124, 129], ["cytotoxic T-cells 13", "CELL", 158, 178], ["tumor", "CANCER", 183, 188], ["antigen", "GENE_OR_GENE_PRODUCT", 220, 227], ["immunosuppressive cytokines", "PROTEIN", 65, 92], ["FAS", "PROTEIN", 124, 127], ["cytotoxic T-cells 13", "CELL_LINE", 158, 178], ["the immune suppression", "TREATMENT", 17, 39], ["immunosuppressive cytokines", "TREATMENT", 65, 92], ["FAS", "TEST", 124, 127], ["apoptosis", "PROBLEM", 145, 154], ["cytotoxic T-cells", "TEST", 158, 175], ["tumor variants", "PROBLEM", 183, 197], ["immune suppression", "OBSERVATION", 21, 39], ["tumor variants", "OBSERVATION", 183, 197]]], ["14 Variants that are deficient in the MHC Class I antigen processing pathway do not express MHC Class I antigens on the cell surface.", [["cell surface", "ANATOMY", 120, 132], ["Class I antigen", "GENE_OR_GENE_PRODUCT", 42, 57], ["MHC Class I antigens", "GENE_OR_GENE_PRODUCT", 92, 112], ["cell surface", "CELLULAR_COMPONENT", 120, 132], ["MHC Class I antigen", "PROTEIN", 38, 57], ["MHC Class I antigens", "PROTEIN", 92, 112]]], ["As a consequence, specific cytotoxic T-cells generated by the vaccine protocol are unable to recognize and kill these tumor variants due to defective presentation of tumor associated antigen-derived peptides recognized by the CTLs.", [["T-cells", "ANATOMY", 37, 44], ["tumor", "ANATOMY", 118, 123], ["tumor", "ANATOMY", 166, 171], ["CTLs", "ANATOMY", 226, 230], ["tumor", "DISEASE", 118, 123], ["tumor", "DISEASE", 166, 171], ["T-cells", "CELL", 37, 44], ["tumor", "CANCER", 118, 123], ["tumor", "CANCER", 166, 171], ["CTLs", "CELL", 226, 230], ["cytotoxic T-cells", "CELL_TYPE", 27, 44], ["tumor associated antigen", "PROTEIN", 166, 190], ["CTLs", "CELL_TYPE", 226, 230], ["the vaccine protocol", "TREATMENT", 58, 78], ["these tumor variants", "PROBLEM", 112, 132], ["defective presentation", "PROBLEM", 140, 162], ["tumor associated antigen", "PROBLEM", 166, 190], ["tumor", "OBSERVATION", 118, 123], ["tumor", "OBSERVATION", 166, 171]]]], "491f105e09b0af3c1e2f516a3893fe38598430c6": [["IntroductionThe hepatitis B virus (HBV) is one of the most successful human pathogens and remains a major health threat for the human population worldwide.", [["hepatitis B", "DISEASE", 16, 27], ["hepatitis B virus", "ORGANISM", 16, 33], ["HBV", "ORGANISM", 35, 38], ["human", "ORGANISM", 70, 75], ["human", "ORGANISM", 128, 133], ["hepatitis B virus", "SPECIES", 16, 33], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 128, 133], ["hepatitis B virus", "SPECIES", 16, 33], ["HBV", "SPECIES", 35, 38], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 128, 133], ["The hepatitis B virus", "PROBLEM", 12, 33], ["hepatitis", "OBSERVATION", 16, 25]]], ["About 257 million people are persistently infected, facing a high risk to develop liver cirrhosis and hepatocellular carcinoma [1] .", [["liver cirrhosis", "ANATOMY", 82, 97], ["hepatocellular carcinoma", "ANATOMY", 102, 126], ["liver cirrhosis", "DISEASE", 82, 97], ["hepatocellular carcinoma", "DISEASE", 102, 126], ["people", "ORGANISM", 18, 24], ["liver", "ORGAN", 82, 87], ["hepatocellular carcinoma", "CANCER", 102, 126], ["people", "SPECIES", 18, 24], ["persistently infected", "PROBLEM", 29, 50], ["liver cirrhosis", "PROBLEM", 82, 97], ["hepatocellular carcinoma", "PROBLEM", 102, 126], ["persistently", "OBSERVATION_MODIFIER", 29, 41], ["infected", "OBSERVATION", 42, 50], ["liver", "ANATOMY", 82, 87], ["cirrhosis", "OBSERVATION", 88, 97], ["hepatocellular", "ANATOMY", 102, 116], ["carcinoma", "OBSERVATION", 117, 126]]], ["Current treatments can control HBV replication without eliminating HBV infection.", [["HBV infection", "DISEASE", 67, 80], ["HBV", "ORGANISM", 31, 34], ["HBV", "ORGANISM", 67, 70], ["HBV", "SPECIES", 31, 34], ["HBV", "SPECIES", 67, 70], ["Current treatments", "TREATMENT", 0, 18], ["HBV replication", "TREATMENT", 31, 46], ["HBV infection", "PROBLEM", 67, 80], ["infection", "OBSERVATION", 71, 80]]], ["To develop new, curative therapies for chronic HBV carriers, an improved understanding of the viral life cycle is essential.", [["HBV", "ORGANISM", 47, 50], ["HBV", "SPECIES", 47, 50], ["curative therapies", "TREATMENT", 16, 34], ["chronic HBV carriers", "PROBLEM", 39, 59], ["new", "OBSERVATION_MODIFIER", 11, 14], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["HBV", "OBSERVATION", 47, 50]]], ["Like all viruses, HBV needs to exploit the molecular machinery of a cell to multiply [2, 3] .", [["cell", "ANATOMY", 68, 72], ["HBV", "ORGANISM", 18, 21], ["cell", "CELL", 68, 72], ["HBV", "SPECIES", 18, 21], ["all viruses", "PROBLEM", 5, 16], ["HBV", "PROBLEM", 18, 21], ["viruses", "OBSERVATION", 9, 16]]], ["Hijacking host cell processes applies in particular to HBV, as its DNA genome with about 3 kb in size is one of the smallest viral genomes known [4, 5] .IntroductionHBV is a hepatotropic, enveloped virus that replicates by protein-primed reverse transcription.", [["cell", "ANATOMY", 15, 19], ["host cell", "CELL", 10, 19], ["HBV", "ORGANISM", 55, 58], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["DNA genome", "DNA", 67, 77], ["viral genomes", "DNA", 125, 138], ["HBV", "SPECIES", 55, 58], ["Hijacking host cell processes", "TREATMENT", 0, 29], ["HBV", "PROBLEM", 55, 58], ["a hepatotropic, enveloped virus", "PROBLEM", 172, 203], ["host cell processes", "OBSERVATION", 10, 29], ["size", "OBSERVATION_MODIFIER", 97, 101], ["smallest", "OBSERVATION_MODIFIER", 116, 124], ["viral genomes", "OBSERVATION", 125, 138]]], ["Its genome merely encompasses four overlapping open reading frames (ORF) encoding the polymerase/reverse transcriptase (Pol), the capsid-forming core protein and its cognate secretory precore protein, as well as the regulatory X protein and three related envelope proteins [4] [5] [6] .", [["polymerase/reverse transcriptase", "GENE_OR_GENE_PRODUCT", 86, 118], ["Pol", "GENE_OR_GENE_PRODUCT", 120, 123], ["open reading frames", "DNA", 47, 66], ["ORF", "DNA", 68, 71], ["polymerase/reverse transcriptase", "PROTEIN", 86, 118], ["Pol", "PROTEIN", 120, 123], ["capsid-forming core protein", "PROTEIN", 130, 157], ["cognate secretory precore protein", "PROTEIN", 166, 199], ["regulatory X protein", "PROTEIN", 216, 236], ["envelope proteins", "PROTEIN", 255, 272], ["the polymerase/reverse transcriptase (Pol", "TREATMENT", 82, 123], ["envelope proteins", "TEST", 255, 272]]], ["The envelope proteins accomplish virion attachment to hepatocytes via binding to the liver cell-specific sodium taurocholate cotransporting polypeptide (NTCP) [7] .", [["virion", "ANATOMY", 33, 39], ["hepatocytes", "ANATOMY", 54, 65], ["liver cell", "ANATOMY", 85, 95], ["sodium taurocholate", "CHEMICAL", 105, 124], ["sodium taurocholate", "CHEMICAL", 105, 124], ["hepatocytes", "CELL", 54, 65], ["liver cell", "CELL", 85, 95], ["sodium taurocholate cotransporting polypeptide", "GENE_OR_GENE_PRODUCT", 105, 151], ["envelope proteins", "PROTEIN", 4, 21], ["hepatocytes", "CELL_TYPE", 54, 65], ["sodium taurocholate cotransporting polypeptide", "PROTEIN", 105, 151], ["The envelope proteins", "TREATMENT", 0, 21], ["virion attachment", "TREATMENT", 33, 50], ["specific sodium taurocholate cotransporting polypeptide", "TREATMENT", 96, 151], ["liver", "ANATOMY", 85, 90]]], ["After HBV uptake and disassembly, the viral nucleocapsid (NC) is delivered to the nucleus where the partially double-stranded viral genome is complemented into a covalently closed circular DNA.", [["nucleus", "ANATOMY", 82, 89], ["HBV", "ORGANISM", 6, 9], ["nucleus", "CELLULAR_COMPONENT", 82, 89], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["viral nucleocapsid", "PROTEIN", 38, 56], ["partially double-stranded viral genome", "DNA", 100, 138], ["covalently closed circular DNA", "DNA", 162, 192], ["HBV", "SPECIES", 6, 9], ["HBV uptake", "PROBLEM", 6, 16], ["the viral nucleocapsid (NC)", "PROBLEM", 34, 61], ["the partially double-stranded viral genome", "PROBLEM", 96, 138], ["a covalently closed circular DNA", "PROBLEM", 160, 192], ["viral nucleocapsid", "OBSERVATION", 38, 56], ["nucleus", "ANATOMY", 82, 89], ["viral genome", "OBSERVATION", 126, 138], ["circular DNA", "OBSERVATION", 180, 192]]], ["This replication intermediate serves as aExpression ConstructsThe plasmid pHBV carries a 1.1 mer of the HBV genome (nt 2922 to 84, derived from genotype D, GenBank\u2122 accession number V01460) under the transcriptional control of the human metallothionein (hMT) IIA promoter in a pUC19 backbone [32] .", [["pHBV", "GENE_OR_GENE_PRODUCT", 74, 78], ["HBV", "ORGANISM", 104, 107], ["human", "ORGANISM", 231, 236], ["metallothionein (hMT) IIA", "GENE_OR_GENE_PRODUCT", 237, 262], ["aExpression Constructs", "DNA", 40, 62], ["pHBV", "DNA", 74, 78], ["HBV genome", "DNA", 104, 114], ["nt 2922 to 84", "DNA", 116, 129], ["genotype D", "DNA", 144, 154], ["GenBank\u2122 accession number V01460", "DNA", 156, 188], ["human metallothionein (hMT) IIA promoter", "DNA", 231, 271], ["human", "SPECIES", 231, 236], ["HBV", "SPECIES", 104, 107], ["human", "SPECIES", 231, 236], ["The plasmid pHBV", "TREATMENT", 62, 78], ["the HBV genome", "TEST", 100, 114], ["the human metallothionein (hMT) IIA promoter", "TREATMENT", 227, 271], ["a pUC19 backbone", "TREATMENT", 275, 291]]], ["To prevent expression of the L, M and S envelope proteins (HBV.Env minus ), their translational start codons were inactivated by mutagenesis, as described [33] .", [["S envelope proteins", "GENE_OR_GENE_PRODUCT", 38, 57], ["Env", "GENE_OR_GENE_PRODUCT", 63, 66], ["L, M and S envelope proteins", "PROTEIN", 29, 57], ["translational start codons", "DNA", 82, 108], ["HBV", "SPECIES", 59, 62], ["the L, M and S envelope proteins", "PROBLEM", 25, 57], ["HBV", "PROBLEM", 59, 62]]], ["In the HBV.L minus construct, only the L-specific start codon was substituted by a threonine residue [33] .", [["threonine", "CHEMICAL", 83, 92], ["threonine", "CHEMICAL", 83, 92], ["HBV.L minus construct", "DNA", 7, 28], ["L-specific start codon", "DNA", 39, 61], ["the L-specific start codon", "TREATMENT", 35, 61], ["a threonine residue", "TREATMENT", 81, 100]]], ["To ablate the core expression from the HBV replicon (HBV.C minus ), a stop codon at triplet 38 of the core gene was created [34] .", [["HBV replicon", "ORGANISM", 39, 51], ["HBV", "ORGANISM", 53, 56], ["stop codon", "DNA", 70, 80], ["triplet 38", "DNA", 84, 94], ["core gene", "DNA", 102, 111], ["HBV", "SPECIES", 39, 42], ["HBV", "SPECIES", 53, 56], ["the HBV replicon", "TREATMENT", 35, 51], ["HBV", "PROBLEM", 53, 56], ["a stop codon", "TREATMENT", 68, 80]]], ["The mutant HBV.Pol minus replicon carries an aspartic acid-to-histidine substitution at amino acid (aa) position 540 of the HBV polymerase and has been shown to be defective in reverse transcriptase activity [32] .", [["aspartic acid", "CHEMICAL", 45, 58], ["histidine", "CHEMICAL", 62, 71], ["amino acid", "CHEMICAL", 88, 98], ["aspartic acid", "CHEMICAL", 45, 58], ["histidine", "CHEMICAL", 62, 71], ["amino acid", "CHEMICAL", 88, 98], ["mutant HBV", "ORGANISM", 4, 14], ["Pol", "GENE_OR_GENE_PRODUCT", 15, 18], ["aspartic acid", "AMINO_ACID", 45, 58], ["amino acid", "AMINO_ACID", 88, 98], ["aa) position 540", "AMINO_ACID", 100, 116], ["amino acid (aa) position 540", "PROTEIN", 88, 116], ["HBV polymerase", "PROTEIN", 124, 138], ["reverse transcriptase", "PROTEIN", 177, 198], ["HBV", "SPECIES", 11, 14], ["HBV", "SPECIES", 124, 127], ["The mutant HBV", "PROBLEM", 0, 14], ["Pol minus replicon", "TREATMENT", 15, 33], ["an aspartic acid", "TREATMENT", 42, 58], ["histidine substitution at amino acid (aa) position", "TREATMENT", 62, 112], ["the HBV polymerase", "TEST", 120, 138], ["HBV", "OBSERVATION", 11, 14]]], ["For trans-complementation studies of the HBV.C minus replicon, the vector pNI2.C containing the HBV core gene preceded by the hMT IIa promoter was used [35] .", [["HBV", "ORGANISM", 41, 44], ["C", "GENE_OR_GENE_PRODUCT", 79, 80], ["HBV", "ORGANISM", 96, 99], ["hMT IIa", "GENE_OR_GENE_PRODUCT", 126, 133], ["pNI2", "DNA", 74, 78], ["HBV core gene", "DNA", 96, 109], ["hMT IIa promoter", "DNA", 126, 142], ["HBV", "SPECIES", 41, 44], ["HBV", "SPECIES", 96, 99], ["trans-complementation studies", "TEST", 4, 33], ["the HBV", "PROBLEM", 37, 44], ["C minus replicon", "TREATMENT", 45, 61], ["the vector pNI2", "TREATMENT", 63, 78], ["the HBV core gene", "TREATMENT", 92, 109], ["the hMT IIa promoter", "TREATMENT", 122, 142], ["HBV", "ANATOMY", 41, 44], ["minus replicon", "OBSERVATION", 47, 61], ["HBV", "OBSERVATION", 96, 99]]], ["The core mutant C.K96A, defective in capsid envelopment, has been described [34] .", [["C.K96A", "GENE_OR_GENE_PRODUCT", 16, 22], ["core mutant C.K96A", "PROTEIN", 4, 22], ["defective in capsid envelopment", "PROBLEM", 24, 55], ["defective", "OBSERVATION_MODIFIER", 24, 33], ["capsid envelopment", "OBSERVATION", 37, 55]]], ["The plasmid pT7HB2.7, which directs the synthesis of all three HBV envelope proteins under their authentic promoters, was kindly provided by C. Sureau (INTS, Paris, France) [13] and used for trans-complementation of the HBV.Env minus replicon.", [["pT7HB2", "GENE_OR_GENE_PRODUCT", 12, 18], ["HBV", "ORGANISM", 220, 223], ["Env", "GENE_OR_GENE_PRODUCT", 224, 227], ["plasmid pT7HB2.7", "DNA", 4, 20], ["HBV envelope proteins", "PROTEIN", 63, 84], ["HBV", "SPECIES", 63, 66], ["HBV", "SPECIES", 220, 223], ["The plasmid pT7HB2", "TEST", 0, 18], ["the HBV", "PROBLEM", 216, 223], ["Env minus replicon", "TREATMENT", 224, 242], ["HBV", "OBSERVATION", 220, 223], ["minus replicon", "OBSERVATION", 228, 242]]], ["To inactivate the N-glycan acceptor site within the S domain of the three envelope proteins, the asparagine residue at aa position 146 (N146) was replaced by a glutamic acid residue (Env.N146D), as described [36] .", [["asparagine", "CHEMICAL", 97, 107], ["glutamic acid", "CHEMICAL", 160, 173], ["N", "CHEMICAL", 18, 19], ["asparagine", "CHEMICAL", 97, 107], ["glutamic acid", "CHEMICAL", 160, 173], ["Env.N146D", "CHEMICAL", 183, 192], ["asparagine", "AMINO_ACID", 97, 107], ["aa position 146", "AMINO_ACID", 119, 134], ["N146", "AMINO_ACID", 136, 140], ["glutamic acid", "AMINO_ACID", 160, 173], ["N-glycan acceptor site", "PROTEIN", 18, 40], ["S domain", "PROTEIN", 52, 60], ["envelope proteins", "PROTEIN", 74, 91], ["the N-glycan acceptor", "TREATMENT", 14, 35], ["the asparagine residue", "PROBLEM", 93, 115], ["a glutamic acid residue", "TEST", 158, 181]]], ["For the sole expression of the S protein under the control of the hMT IIa promoter, plasmid pNI2.S.HA carrying the S gene with a C-terminal-fused haemagglutinin (HA) tag was used [10] .", [["plasmid", "ANATOMY", 84, 91], ["C", "CHEMICAL", 129, 130], ["hMT IIa", "GENE_OR_GENE_PRODUCT", 66, 73], ["HA", "GENE_OR_GENE_PRODUCT", 99, 101], ["S protein", "PROTEIN", 31, 40], ["hMT IIa promoter", "DNA", 66, 82], ["plasmid pNI2", "DNA", 84, 96], ["S gene", "DNA", 115, 121], ["C-terminal-fused haemagglutinin (HA) tag", "DNA", 129, 169], ["S.", "SPECIES", 97, 99], ["S.", "SPECIES", 97, 99], ["the S protein", "TREATMENT", 27, 40], ["the hMT IIa promoter", "TREATMENT", 62, 82], ["plasmid pNI2", "TREATMENT", 84, 96], ["a C-terminal-fused haemagglutinin (HA) tag", "TREATMENT", 127, 169]]], ["Where indicated, HBV replication was studied in cells transfected with pCEP4\u2206CMV\u2206SV40/1.1 \u00d7 HBV (termed pHBV* herein), which carries the 1.1 mer of the HBV genome in a modified pCEP4 plasmid backbone [22] .", [["cells", "ANATOMY", 48, 53], ["HBV", "ORGANISM", 17, 20], ["cells", "CELL", 48, 53], ["pCEP4", "GENE_OR_GENE_PRODUCT", 71, 76], ["CMV", "ORGANISM", 77, 80], ["SV40", "ORGANISM", 81, 85], ["1.1 \u00d7 HBV", "ORGANISM", 86, 95], ["HBV", "ORGANISM", 152, 155], ["pCEP4", "PROTEIN", 71, 76], ["HBV genome", "DNA", 152, 162], ["pCEP4 plasmid", "DNA", 177, 190], ["HBV", "SPECIES", 17, 20], ["HBV", "SPECIES", 92, 95], ["HBV", "SPECIES", 152, 155], ["HBV replication", "PROBLEM", 17, 32], ["pCEP4", "TEST", 71, 76], ["CMV", "TEST", 77, 80], ["SV40", "TEST", 81, 85], ["HBV", "PROBLEM", 92, 95], ["the HBV genome", "TREATMENT", 148, 162], ["a modified pCEP4 plasmid backbone", "TREATMENT", 166, 199], ["HBV genome", "OBSERVATION", 152, 162]]], ["The plasmid pEYFP-ER encodes an enhanced yellow fluorescent protein (EYFP) with an N-terminal-fused ER-targeting sequence of calreticulin plus a C-terminal-fused ER retrieval sequence and was purchased from Clontech (Clontech, Mountain View, CA, USA).", [["plasmid", "ANATOMY", 4, 11], ["N", "CHEMICAL", 83, 84], ["C", "CHEMICAL", 145, 146], ["pEYFP-ER", "GENE_OR_GENE_PRODUCT", 12, 20], ["yellow fluorescent protein", "GENE_OR_GENE_PRODUCT", 41, 67], ["EYFP", "GENE_OR_GENE_PRODUCT", 69, 73], ["ER", "GENE_OR_GENE_PRODUCT", 100, 102], ["calreticulin", "GENE_OR_GENE_PRODUCT", 125, 137], ["ER", "GENE_OR_GENE_PRODUCT", 162, 164], ["pEYFP", "PROTEIN", 12, 17], ["ER", "PROTEIN", 18, 20], ["yellow fluorescent protein", "PROTEIN", 41, 67], ["EYFP", "PROTEIN", 69, 73], ["N-terminal-fused ER-targeting sequence", "PROTEIN", 83, 121], ["calreticulin", "PROTEIN", 125, 137], ["C-terminal-fused ER retrieval sequence", "DNA", 145, 183], ["The plasmid pEYFP", "TEST", 0, 17], ["an N", "TEST", 80, 84], ["calreticulin", "TEST", 125, 137]]], ["The vector pGRASP65-GFP (green fluorescent protein) was kindly provided by E. Hildt (PEI, Langen, Germany) and encodes a fusion protein of GRASP65, a peripheral membrane protein that is localized to the cis-Golgi, and of the green fluorescent protein (GFP).", [["peripheral membrane", "ANATOMY", 150, 169], ["Golgi", "ANATOMY", 207, 212], ["pGRASP65-GFP", "GENE_OR_GENE_PRODUCT", 11, 23], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 25, 50], ["GRASP65", "GENE_OR_GENE_PRODUCT", 139, 146], ["peripheral membrane", "CELLULAR_COMPONENT", 150, 169], ["Golgi", "CELLULAR_COMPONENT", 207, 212], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 225, 250], ["GFP", "GENE_OR_GENE_PRODUCT", 252, 255], ["pGRASP65", "DNA", 11, 19], ["GFP", "PROTEIN", 20, 23], ["green fluorescent protein", "PROTEIN", 25, 50], ["fusion protein", "PROTEIN", 121, 135], ["GRASP65", "PROTEIN", 139, 146], ["peripheral membrane protein", "PROTEIN", 150, 177], ["cis-Golgi", "PROTEIN", 203, 212], ["green fluorescent protein", "PROTEIN", 225, 250], ["GFP", "PROTEIN", 252, 255], ["The vector", "TEST", 0, 10], ["a fusion protein", "TEST", 119, 135], ["a peripheral membrane protein", "TEST", 148, 177], ["the green fluorescent protein", "TEST", 221, 250]]], ["The plasmid pDsRed-Golgi carries the DsRed-coding sequence fused to the N-terminal 81 aa of human \u03b2 1,4-galactosyltransferase, which targets the fusion protein to the trans-medial region of the Golgi (Clontech, Mountain View, CA, USA).", [["pDsRed-Golgi", "ANATOMY", 12, 24], ["medial region", "ANATOMY", 173, 186], ["Golgi", "ANATOMY", 194, 199], ["Golgi", "CELLULAR_COMPONENT", 19, 24], ["DsRed", "GENE_OR_GENE_PRODUCT", 37, 42], ["human", "ORGANISM", 92, 97], ["\u03b2 1,4-galactosyltransferase", "GENE_OR_GENE_PRODUCT", 98, 125], ["Golgi", "CELLULAR_COMPONENT", 194, 199], ["plasmid pDsRed", "DNA", 4, 18], ["Golgi", "DNA", 19, 24], ["DsRed-coding sequence", "DNA", 37, 58], ["N-terminal 81 aa", "PROTEIN", 72, 88], ["human \u03b2 1,4-galactosyltransferase", "PROTEIN", 92, 125], ["fusion protein", "PROTEIN", 145, 159], ["trans-medial region", "PROTEIN", 167, 186], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["the fusion protein", "TEST", 141, 159], ["medial", "ANATOMY_MODIFIER", 173, 179], ["region", "ANATOMY_MODIFIER", 180, 186], ["Golgi", "ANATOMY_MODIFIER", 194, 199]]], ["The expression vector encoding human Vps4A with a C-terminal EGFP tag was generously provided by W. Sundquist (University of Utah, Salt Lake Cit, UT, USA).", [["C", "CHEMICAL", 50, 51], ["human", "ORGANISM", 31, 36], ["Vps4A", "GENE_OR_GENE_PRODUCT", 37, 42], ["expression vector", "DNA", 4, 21], ["human Vps4A", "PROTEIN", 31, 42], ["C-terminal EGFP tag", "DNA", 50, 69], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["a C-terminal EGFP tag", "TREATMENT", 48, 69]]], ["The vector pcDNA3.1(+)-ERGIC-53 carrying the human ERGIC-53 gene (NM_005570.", [["pcDNA3", "GENE_OR_GENE_PRODUCT", 11, 17], ["human", "ORGANISM", 45, 50], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 51, 59], ["vector pcDNA3.1(+)-ERGIC-53", "DNA", 4, 31], ["human ERGIC-53 gene", "DNA", 45, 64], ["NM_005570", "DNA", 66, 75], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["The vector pcDNA3", "TEST", 0, 17], ["ERGIC", "TEST", 23, 28], ["the human ERGIC", "TEST", 41, 56]]], ["3) under the control of the CMV promoter was purchased from GenScript (GenScript Biotech, Leiden, Netherlands).", [["CMV", "ORGANISM", 28, 31], ["CMV promoter", "DNA", 28, 40], ["CMV", "SPECIES", 28, 31], ["the CMV promoter", "TREATMENT", 24, 40], ["CMV promoter", "OBSERVATION", 28, 40]]], ["For tagging with the Myc epitope, the aa sequence 28-37 of ERGIC-53 was mutated to EQKLISEEDL by Q5 \u00ae Site-Directed Mutagenesis (New England Biolabs, Ipswich, Cells 2020, 9, 1889 4 of 25 MA, USA) with the oligonucleotides 5 -CCGAGGAGGACCTCCTGGTGCAGAGCGACGG-3 and 5 -AGATTAATTTTTGCTCGAAACGGCGATGTGGC-3 .SiRNAs, Cell Culture and TransfectionFor transient expression analyses, the human hepatocellular carcinoma cell line HuH-7 was used that was obtained by the European Collection of Authenticated Cell Cultures (http://cellbank. nibiohn.go.jp/english/).", [["Cell", "ANATOMY", 310, 314], ["hepatocellular carcinoma cell line HuH-7", "ANATOMY", 384, 424], ["Cell", "ANATOMY", 496, 500], ["hepatocellular carcinoma", "DISEASE", 384, 408], ["nibiohn", "CHEMICAL", 528, 535], ["Myc", "GENE_OR_GENE_PRODUCT", 21, 24], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 59, 67], ["Cell Culture", "CELL", 310, 322], ["human", "ORGANISM", 378, 383], ["hepatocellular carcinoma cell line HuH-7", "CELL", 384, 424], ["Cell Cultures", "CELL", 496, 509], ["http", "CELL", 511, 515], ["Myc epitope", "PROTEIN", 21, 32], ["ERGIC-53", "DNA", 59, 67], ["EQKLISEEDL", "DNA", 83, 93], ["human hepatocellular carcinoma cell line", "CELL_LINE", 378, 418], ["HuH-7", "CELL_LINE", 419, 424], ["Authenticated Cell Cultures", "CELL_LINE", 482, 509], ["human", "SPECIES", 378, 383], ["human", "SPECIES", 378, 383], ["the Myc epitope", "TEST", 17, 32], ["the aa sequence", "TEST", 34, 49], ["ERGIC", "TEST", 59, 64], ["New England Biolabs", "TEST", 129, 148], ["Cells", "TEST", 159, 164], ["the oligonucleotides", "TEST", 201, 221], ["CCGAGGAGGACCTCCTGGTGCAGAGCGACGG", "TEST", 225, 256], ["AGATTAATTTTTGCTCGAAACGGCGATGTGGC", "TEST", 266, 298], ["SiRNAs", "TREATMENT", 302, 308], ["Cell Culture", "TEST", 310, 322], ["Transfection", "TEST", 327, 339], ["transient expression analyses", "PROBLEM", 343, 372], ["the human hepatocellular carcinoma cell line", "TREATMENT", 374, 418], ["HuH", "TEST", 419, 422], ["Authenticated Cell Cultures", "TEST", 482, 509], ["SiRNAs", "ANATOMY", 302, 308], ["hepatocellular", "ANATOMY", 384, 398], ["carcinoma", "OBSERVATION", 399, 408]]], ["This cell line is not susceptible to HBV infection, because it expresses very low levels of the NTCP receptor and is therefore a useful model to study the production and release of the virus rather than infection [7] .", [["cell line", "ANATOMY", 5, 14], ["HBV infection", "DISEASE", 37, 50], ["infection", "DISEASE", 203, 212], ["cell line", "CELL", 5, 14], ["HBV", "ORGANISM", 37, 40], ["NTCP receptor", "GENE_OR_GENE_PRODUCT", 96, 109], ["cell line", "CELL_LINE", 5, 14], ["NTCP receptor", "PROTEIN", 96, 109], ["HBV", "SPECIES", 37, 40], ["This cell line", "TREATMENT", 0, 14], ["HBV infection", "PROBLEM", 37, 50], ["the NTCP receptor", "TREATMENT", 92, 109], ["the virus", "PROBLEM", 181, 190], ["infection", "PROBLEM", 203, 212], ["cell line", "OBSERVATION", 5, 14], ["not susceptible to", "UNCERTAINTY", 18, 36], ["HBV", "OBSERVATION_MODIFIER", 37, 40], ["infection", "OBSERVATION", 41, 50], ["very", "OBSERVATION_MODIFIER", 73, 77], ["low levels", "OBSERVATION_MODIFIER", 78, 88]]], ["Cells were cultured in Dulbecco's modified Eagle's medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum and 5-\u00b5g/mL ciprofloxacin (Fresenius Kabi, Bad Homburg, Germany).", [["Cells", "ANATOMY", 0, 5], ["fetal bovine serum", "ANATOMY", 125, 143], ["ciprofloxacin", "CHEMICAL", 156, 169], ["ciprofloxacin", "CHEMICAL", 156, 169], ["Cells", "CELL", 0, 5], ["bovine", "ORGANISM", 131, 137], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["ciprofloxacin", "SIMPLE_CHEMICAL", 156, 169], ["bovine", "SPECIES", 131, 137], ["bovine", "SPECIES", 131, 137], ["Cells", "TEST", 0, 5], ["Dulbecco", "TEST", 23, 31], ["10% fetal bovine serum", "TREATMENT", 121, 143], ["ciprofloxacin", "TREATMENT", 156, 169]]], ["Transfections of cells with plasmid DNAs were performed with Lipofectamine \u2122 Plus (Thermo Fisher Scientific, Waltham, MA, USA).", [["cells", "ANATOMY", 17, 22], ["plasmid", "ANATOMY", 28, 35], ["cells", "CELL", 17, 22], ["plasmid DNAs", "DNA", 28, 40], ["plasmid DNAs", "TREATMENT", 28, 40], ["Lipofectamine", "TREATMENT", 61, 74]]], ["For depletion of EAP20 (NM_032353.3), Sar1A (NM_01142648), Sar1B (NM_016103.3), Sec23A (NM_006364.4), Sec23B (NM_006363), Sec24A (NM_021982) or Sec24B (NM_006323), single siRNA duplexes or siGENOME SMARTpool RNAs (Dharmacon, Lafayette, CO, USA) were used as described [22, 29] .", [["EAP20", "GENE_OR_GENE_PRODUCT", 17, 22], ["Sar1A", "GENE_OR_GENE_PRODUCT", 38, 43], ["NM_021982", "GENE_OR_GENE_PRODUCT", 130, 139], ["EAP20", "PROTEIN", 17, 22], ["Sar1A", "PROTEIN", 38, 43], ["Sar1B", "PROTEIN", 59, 64], ["Sec23A", "PROTEIN", 80, 86], ["NM_006364.4", "PROTEIN", 88, 99], ["Sec23B", "PROTEIN", 102, 108], ["Sec24A", "PROTEIN", 122, 128], ["siGENOME SMARTpool RNAs", "DNA", 189, 212], ["EAP20", "TEST", 17, 22], ["NM_", "TEST", 24, 27], ["Sar1A", "TEST", 38, 43], ["Sar1B", "TEST", 59, 64], ["Sec23A", "TEST", 80, 86], ["NM_", "TEST", 88, 91], ["Sec23B", "TEST", 102, 108], ["Sec24A", "TEST", 122, 128], ["Sec24B", "TEST", 144, 150], ["single siRNA duplexes", "TREATMENT", 164, 185], ["siGENOME SMARTpool RNAs", "TREATMENT", 189, 212]]], ["To silence the expression of ERGIC-53 (NM_005570), a siRNA (5 -GGACAGAAUCGUAUUCAUC-3 ) targeting nucleotide positions 1009-1027 was obtained from Dharmacon (Dharmacon, Lafayette, CO, USA).", [["nucleotide positions 1009-1027", "CHEMICAL", 97, 127], ["nucleotide", "CHEMICAL", 97, 107], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 29, 37], ["NM_005570", "GENE_OR_GENE_PRODUCT", 39, 48], ["ERGIC-53", "DNA", 29, 37], ["siRNA (5 -GGACAGAAUCGUAUUCAUC-3", "DNA", 53, 84], ["nucleotide positions 1009-1027", "DNA", 97, 127], ["ERGIC", "TEST", 29, 34], ["a siRNA", "TEST", 51, 58], ["GGACAGAAUCGUAUUCAUC", "TEST", 63, 82], ["nucleotide positions", "TEST", 97, 117], ["siRNA", "ANATOMY", 53, 58]]], ["The specificity and efficacy of this siRNA has been approved in independent studies [37] [38] [39] .", [["this siRNA", "TREATMENT", 32, 42]]], ["A control siRNA with no known homology to mammalian genes was purchased from Qiagen (Qiagen, Hilden, Germany).", [["mammalian genes", "DNA", 42, 57], ["A control siRNA", "TREATMENT", 0, 15]]], ["For combined transfection, HuH-7 cells were first transfected with siRNAs by using the Lipofectamine \u2122 RNAiMAX transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA).", [["HuH-7 cells", "ANATOMY", 27, 38], ["HuH-7 cells", "CELL", 27, 38], ["HuH-7 cells", "CELL_LINE", 27, 38], ["combined transfection", "PROBLEM", 4, 25], ["HuH", "TEST", 27, 30], ["siRNAs", "TREATMENT", 67, 73], ["the Lipofectamine", "TREATMENT", 83, 100], ["RNAiMAX transfection reagent", "TREATMENT", 103, 131], ["transfection", "OBSERVATION", 13, 25]]], ["In a typical experiment, 3 \u00d7 10 5 cells per well of a 12-well plate were transfected with a final concentration of 20-nM siRNA, according to the protocol of the supplier.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["a 12-well plate", "TREATMENT", 52, 67], ["20-nM siRNA", "TREATMENT", 115, 126]]], ["After 48 to 72 h, cells were retransfected with 2-\u00b5g plasmid DNA, and transfected cells were harvested after an additional 48 to 72 h, as indicated in the text.", [["cells", "ANATOMY", 18, 23], ["plasmid", "ANATOMY", 53, 60], ["cells", "ANATOMY", 82, 87], ["cells", "CELL", 18, 23], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["cells", "CELL", 82, 87], ["plasmid DNA", "DNA", 53, 64], ["transfected cells", "CELL_LINE", 70, 87], ["cells", "TEST", 18, 23], ["2-\u00b5g plasmid DNA", "TREATMENT", 48, 64], ["transfected cells", "PROBLEM", 70, 87], ["transfected cells", "OBSERVATION", 70, 87]]], ["For drug treatment, cells were incubated with 1-\u00b5M brefeldin A (BFA; Sigma-Aldrich, St. Louis, MO, USA) for 2 h at 37 \u2022 C.AntibodiesPolyclonal antisera against recombinant native (K45) or denatured (K46) HBV core particles were raised in rabbits, as described [35] .", [["cells", "ANATOMY", 20, 25], ["brefeldin A", "CHEMICAL", 51, 62], ["BFA", "CHEMICAL", 64, 67], ["brefeldin A", "CHEMICAL", 51, 62], ["BFA", "CHEMICAL", 64, 67], ["cells", "CELL", 20, 25], ["brefeldin A", "SIMPLE_CHEMICAL", 51, 62], ["BFA", "SIMPLE_CHEMICAL", 64, 67], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 69, 82], ["St. Louis", "ORGANISM", 84, 93], ["HBV", "ORGANISM", 204, 207], ["rabbits", "ORGANISM", 238, 245], ["K45", "PROTEIN", 180, 183], ["rabbits", "SPECIES", 238, 245], ["HBV", "SPECIES", 204, 207], ["rabbits", "SPECIES", 238, 245], ["drug treatment", "TREATMENT", 4, 18], ["Polyclonal antisera", "TREATMENT", 132, 151], ["denatured (K46) HBV core particles", "PROBLEM", 188, 222]]], ["In addition, commercially available polyclonal rabbit (B0586; Dako, Carpinteria, CA, USA) or monoclonal mouse (3HB17; HyTest, Turku, Finland) antisera against the core antigen or capsid particle, respectively, were used.", [["rabbit", "ORGANISM", 47, 53], ["Dako", "GENE_OR_GENE_PRODUCT", 62, 66], ["Carpinteria", "GENE_OR_GENE_PRODUCT", 68, 79], ["CA", "GENE_OR_GENE_PRODUCT", 81, 83], ["USA", "GENE_OR_GENE_PRODUCT", 85, 88], ["mouse", "ORGANISM", 104, 109], ["antisera against the core antigen", "GENE_OR_GENE_PRODUCT", 142, 175], ["core antigen", "PROTEIN", 163, 175], ["rabbit", "SPECIES", 47, 53], ["mouse", "SPECIES", 104, 109], ["rabbit", "SPECIES", 47, 53], ["mouse", "SPECIES", 104, 109], ["polyclonal rabbit", "TEST", 36, 53], ["Dako", "TEST", 62, 66], ["Carpinteria", "TEST", 68, 79], ["CA", "TEST", 81, 83], ["antisera", "TREATMENT", 142, 150]]], ["For immunodetection of the HBV L protein, a rabbit antibody raised against a recombinant peptide encoding aa 1-42 of L fused to glutathione S-transferase (K1350; Eurogentec, Li\u00e8ge, Belgium) or the mouse antibodies HepB preS1 (sc-57761; Santa Cruz, CA, USA) and MA18/7 (D. Glebe, University of Giessen, Giessen, Germany), recognizing L-specific epitopes, were employed.", [["glutathione", "CHEMICAL", 128, 139], ["sc-57761", "CHEMICAL", 226, 234], ["glutathione", "CHEMICAL", 128, 139], ["S", "CHEMICAL", 140, 141], ["HBV L", "ORGANISM", 27, 32], ["rabbit", "ORGANISM", 44, 50], ["glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 128, 153], ["mouse", "ORGANISM", 197, 202], ["HBV L protein", "PROTEIN", 27, 40], ["rabbit antibody", "PROTEIN", 44, 59], ["glutathione S-transferase", "PROTEIN", 128, 153], ["mouse antibodies", "PROTEIN", 197, 213], ["HepB preS1", "PROTEIN", 214, 224], ["L-specific epitopes", "PROTEIN", 333, 352], ["rabbit", "SPECIES", 44, 50], ["mouse", "SPECIES", 197, 202], ["HBV", "SPECIES", 27, 30], ["rabbit", "SPECIES", 44, 50], ["mouse", "SPECIES", 197, 202], ["immunodetection", "TEST", 4, 19], ["the HBV L protein", "TEST", 23, 40], ["a rabbit antibody", "TEST", 42, 59], ["glutathione S", "TEST", 128, 141], ["transferase", "TEST", 142, 153], ["K1350", "TEST", 155, 160], ["Eurogentec", "TEST", 162, 172], ["Li\u00e8ge", "TEST", 174, 179], ["the mouse antibodies", "TEST", 193, 213], ["HepB preS1", "TEST", 214, 224]]], ["For immunoprecipitation (IP) of all three HBV envelope proteins, a rabbit polyclonal antiserum (K38) against the S domain was used [33] .", [["HBV", "ORGANISM", 42, 45], ["rabbit", "ORGANISM", 67, 73], ["HBV envelope proteins", "PROTEIN", 42, 63], ["rabbit polyclonal antiserum", "PROTEIN", 67, 94], ["K38", "PROTEIN", 96, 99], ["S domain", "PROTEIN", 113, 121], ["rabbit", "SPECIES", 67, 73], ["HBV", "SPECIES", 42, 45], ["rabbit", "SPECIES", 67, 73], ["immunoprecipitation (IP", "TREATMENT", 4, 27], ["all three HBV envelope proteins", "PROBLEM", 32, 63], ["a rabbit polyclonal antiserum", "TREATMENT", 65, 94], ["the S domain", "TEST", 109, 121]]], ["Antibodies obtained from Covance (Covance, HISS Diagnostics, Freiburg im Breisgau, Germany) were mouse anti-HA (16B12) and anti-Myc (9E10).", [["mouse", "ORGANISM", 97, 102], ["anti-HA", "GENE_OR_GENE_PRODUCT", 103, 110], ["anti-Myc", "GENE_OR_GENE_PRODUCT", 123, 131], ["9E10", "GENE_OR_GENE_PRODUCT", 133, 137], ["mouse anti-HA", "PROTEIN", 97, 110], ["16B12", "PROTEIN", 112, 117], ["Myc", "PROTEIN", 128, 131], ["9E10", "PROTEIN", 133, 137], ["mouse", "SPECIES", 97, 102], ["mouse", "SPECIES", 97, 102], ["Antibodies", "TEST", 0, 10], ["mouse anti-HA", "TREATMENT", 97, 110], ["anti-Myc", "TREATMENT", 123, 131]]], ["The mouse anti-EAP20 (VPS25: sc-271648) antibody was purchased from Santa Cruz (Santa Cruz, CA, USA), while the mouse anti-ERGIC-53 (OTI1A8) antibody was from Enzo (Enzo Life Sciences, Farmingdale, NY, USA).", [["VPS25: sc-271648", "CHEMICAL", 22, 38], ["mouse", "ORGANISM", 4, 9], ["anti-EAP20", "GENE_OR_GENE_PRODUCT", 10, 20], ["sc-271648", "GENE_OR_GENE_PRODUCT", 29, 38], ["mouse", "ORGANISM", 112, 117], ["anti-ERGIC-53", "GENE_OR_GENE_PRODUCT", 118, 131], ["OTI1A8", "ORGANISM", 133, 139], ["Enzo", "ORGANISM", 159, 163], ["mouse anti-EAP20 (VPS25: sc-271648) antibody", "PROTEIN", 4, 48], ["Santa Cruz", "PROTEIN", 68, 78], ["mouse anti-ERGIC-53 (OTI1A8) antibody", "PROTEIN", 112, 149], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 112, 117], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 112, 117], ["the mouse anti-ERGIC", "TEST", 108, 128]]], ["Antibodies obtained from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA) were rabbit anti-ERGIC-53 (E1031), rabbit anti-Sec24A (HPA056825), anti-\u03b2-actin (AC15) and anti-\u03b1-tubulin (B-5-1-2).", [["anti-ERGIC-53", "CHEMICAL", 87, 100], ["anti-Sec24A", "CHEMICAL", 117, 128], ["HPA056825", "CHEMICAL", 130, 139], ["anti-\u03b2-actin", "CHEMICAL", 142, 154], ["B-5-1-2", "CHEMICAL", 182, 189], ["Sigma-Aldrich", "ORGANISM", 25, 38], ["Sigma-Aldrich", "ORGANISM", 40, 53], ["St. Louis", "ORGANISM", 55, 64], ["MO", "ORGANISM", 66, 68], ["rabbit", "ORGANISM", 80, 86], ["anti-ERGIC-53", "SIMPLE_CHEMICAL", 87, 100], ["E1031", "ORGANISM", 102, 107], ["rabbit", "ORGANISM", 110, 116], ["anti-Sec24A", "GENE_OR_GENE_PRODUCT", 117, 128], ["HPA056825", "SIMPLE_CHEMICAL", 130, 139], ["anti-\u03b2-actin", "SIMPLE_CHEMICAL", 142, 154], ["AC15", "SIMPLE_CHEMICAL", 156, 160], ["anti-\u03b1-tubulin", "SIMPLE_CHEMICAL", 166, 180], ["B-5-1-2", "ORGANISM", 182, 189], ["rabbit anti-Sec24A", "PROTEIN", 110, 128], ["anti-\u03b2-actin", "PROTEIN", 142, 154], ["AC15", "PROTEIN", 156, 160], ["anti-\u03b1-tubulin", "PROTEIN", 166, 180], ["B", "PROTEIN", 182, 183], ["rabbit", "SPECIES", 80, 86], ["rabbit", "SPECIES", 110, 116], ["rabbit anti-ERGIC-53", "SPECIES", 80, 100], ["rabbit", "SPECIES", 110, 116], ["Antibodies", "TEST", 0, 10], ["rabbit anti-ERGIC", "TEST", 80, 97], ["anti-\u03b2-actin (AC15)", "TREATMENT", 142, 161], ["anti-\u03b1-tubulin", "TREATMENT", 166, 180]]], ["Peroxidase-labeled secondary antibodies were obtained from Dianova (Hamburg, Germany), and fluorophore-labeled antibodies were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, MA, USA).Quantitative Reverse Transcription PCR (qRT-PCR) AnalysisTotal mRNAs were isolated from cells using the peqGold TriFast (Peqlab Biotechnologie, Darmstadt, Germany) and the Direct-zol \u2122 RNA MiniPrep kit (Zymo Research, Irvine, CA, USA).", [["cells", "ANATOMY", 300, 305], ["Peroxidase", "GENE_OR_GENE_PRODUCT", 0, 10], ["fluorophore", "SIMPLE_CHEMICAL", 91, 102], ["cells", "CELL", 300, 305], ["secondary antibodies", "PROTEIN", 19, 39], ["fluorophore-labeled antibodies", "PROTEIN", 91, 121], ["AnalysisTotal mRNAs", "RNA", 261, 280], ["Peroxidase", "TEST", 0, 10], ["secondary antibodies", "PROBLEM", 19, 39], ["Quantitative Reverse Transcription PCR", "TEST", 212, 250], ["qRT", "TEST", 252, 255], ["PCR", "TEST", 256, 259], ["AnalysisTotal mRNAs", "TEST", 261, 280], ["the peqGold TriFast (Peqlab Biotechnologie", "TREATMENT", 312, 354], ["Darmstadt", "TREATMENT", 356, 365], ["the Direct-zol", "TREATMENT", 380, 394]]], ["The mRNA was digested with 5 U RNase-free, recombinant DNase I (Roche Diagnostics, Rotkreuz, Switzerland), and cDNA synthesis was performed by using the qScript cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA, USA). qRT-PCR reactions were conducted as described [40] .", [["RNase", "GENE_OR_GENE_PRODUCT", 31, 36], ["DNase I", "GENE_OR_GENE_PRODUCT", 55, 62], ["mRNA", "RNA", 4, 8], ["RNase", "PROTEIN", 31, 36], ["DNase I", "PROTEIN", 55, 62], ["5 U RNase", "TREATMENT", 27, 36], ["cDNA synthesis", "TREATMENT", 111, 125], ["PCR reactions", "PROBLEM", 224, 237]]], ["For data analysis, the comparative cycle threshold method (C T ) was used, and data were reported as the fold change normalized to an endogenous reference gene (\u03b2-actin).", [["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 161, 168], ["endogenous reference gene", "DNA", 134, 159], ["\u03b2-actin", "DNA", 161, 168], ["data analysis", "TEST", 4, 17], ["the comparative cycle threshold method (C T )", "TEST", 19, 64]]], ["To quantify the ERGIC-53 transcript levels, the primers 5 -CAGATCAAATTCGAGTAGCACCA-3 and 5 -AATATTCCAACACCATTCCACAGA-3 were used.", [["AATATTCCAACACCATTCCACAGA-3", "GENE_OR_GENE_PRODUCT", 92, 118], ["ERGIC", "DNA", 16, 21], ["primers 5 -CAGATCAAATTCGAGTAGCACCA-3 and 5 -AATATTCCAACACCATTCCACAGA-3", "DNA", 48, 118], ["transcript levels", "TEST", 25, 42], ["the primers", "TEST", 44, 55], ["CAGATCAAATTCGAGTAGCACCA", "TEST", 59, 82], ["5 -AATATTCCAACACCATTCCACAGA-3", "TREATMENT", 89, 118]]], ["All other primer pairs have been described previously [29] .Subviral Particle AnalysisTo probe for subviral particle production, an SVP release assay was used, as described [29] .", [["SVP", "GENE_OR_GENE_PRODUCT", 132, 135], ["primer pairs", "DNA", 10, 22], ["SVP", "PROTEIN", 132, 135], ["All other primer pairs", "PROBLEM", 0, 22], ["Subviral Particle AnalysisTo probe", "TREATMENT", 60, 94], ["subviral particle production", "TREATMENT", 99, 127], ["an SVP release assay", "TEST", 129, 149], ["subviral particle", "OBSERVATION", 99, 116]]], ["Briefly, cells were lysed for 20 min on ice, and lysates were centrifuged for 5 min at 15,000\u00d7 g and 4 \u2022 C.Subviral Particle AnalysisTo analyze the secretion of SVPs from transfected cells, clarified culture medium was concentrated by ultracentrifugation through a 20% (w/v) sucrose cushion (4 h at 100,000\u00d7 g and 4 \u2022 C), and samples were subjected to Western blot (WB) analysis.Viral Particle AnalysisThe production and release of HBV particles were determined by a TaqMan \u00ae chemistry-based real-time PCR, as described [22] .", [["cells", "ANATOMY", 9, 14], ["lysates", "ANATOMY", 49, 56], ["cells", "ANATOMY", 183, 188], ["samples", "ANATOMY", 326, 333], ["sucrose", "CHEMICAL", 275, 282], ["sucrose", "CHEMICAL", 275, 282], ["cells", "CELL", 9, 14], ["lysates", "ORGANISM_SUBSTANCE", 49, 56], ["SVPs", "GENE_OR_GENE_PRODUCT", 161, 165], ["cells", "CELL", 183, 188], ["HBV", "ORGANISM", 432, 435], ["SVPs", "PROTEIN", 161, 165], ["transfected cells", "CELL_LINE", 171, 188], ["HBV", "SPECIES", 432, 435], ["ice", "TREATMENT", 40, 43], ["lysates", "TEST", 49, 56], ["transfected cells", "PROBLEM", 171, 188], ["culture medium", "TEST", 200, 214], ["w/v) sucrose cushion", "TREATMENT", 270, 290], ["Viral Particle Analysis", "TEST", 379, 402], ["HBV particles", "PROBLEM", 432, 445], ["a TaqMan", "TEST", 465, 473], ["transfected cells", "OBSERVATION", 171, 188]]], ["Briefly, cell lysates and supernatants were harvested, and intracellular nucleocapsids and extracellular virions were isolated by immunomagnetic separation using PureProteome \u2122 Protein G Magnetic Beads (Millipore, Billerica, MA, USA) coated with capsid (K45)-and envelope-specific (K38 and K1350) antibodies, respectively.", [["cell lysates", "ANATOMY", 9, 21], ["supernatants", "ANATOMY", 26, 38], ["intracellular nucleocapsids", "ANATOMY", 59, 86], ["extracellular virions", "ANATOMY", 91, 112], ["cell lysates", "CELL", 9, 21], ["intracellular nucleocapsids", "CELLULAR_COMPONENT", 59, 86], ["extracellular virions", "CELLULAR_COMPONENT", 91, 112], ["K45", "GENE_OR_GENE_PRODUCT", 254, 257], ["K45", "PROTEIN", 254, 257], ["envelope-specific (K38 and K1350) antibodies", "PROTEIN", 263, 307], ["cell lysates", "TREATMENT", 9, 21], ["supernatants", "TREATMENT", 26, 38], ["intracellular nucleocapsids", "PROBLEM", 59, 86], ["extracellular virions", "TREATMENT", 91, 112], ["immunomagnetic separation", "TREATMENT", 130, 155], ["PureProteome \u2122 Protein G Magnetic Beads", "TREATMENT", 162, 201], ["capsid (K45)", "TREATMENT", 246, 258], ["antibodies", "TEST", 297, 307], ["cell lysates", "OBSERVATION", 9, 21], ["extracellular virions", "OBSERVATION", 91, 112]]], ["After isolation of the viral DNA, PCR analyses were performed with a 7500 Real-Time PCR System and Sequence Detection Software 4.0 (Applied Biosystems, Foster, CA, USA).", [["DNA", "CELLULAR_COMPONENT", 29, 32], ["viral DNA", "DNA", 23, 32], ["the viral DNA", "TEST", 19, 32], ["PCR analyses", "TEST", 34, 46], ["Sequence Detection Software", "TEST", 99, 126], ["viral DNA", "OBSERVATION", 23, 32]]], ["Dependent on the transfected HBV replicon constructs, simplex or multiplex PCR analysis were conducted, with the latter using two primer/probe sets targeting either the HBV genome or the hygromycin resistance gene of the pCEP plasmid backbone, as described [22] .", [["plasmid", "ANATOMY", 226, 233], ["hygromycin", "CHEMICAL", 187, 197], ["hygromycin", "CHEMICAL", 187, 197], ["HBV", "ORGANISM", 29, 32], ["simplex", "ORGANISM", 54, 61], ["HBV", "ORGANISM", 169, 172], ["hygromycin", "GENE_OR_GENE_PRODUCT", 187, 197], ["transfected HBV replicon constructs", "DNA", 17, 52], ["HBV genome", "DNA", 169, 179], ["hygromycin resistance gene", "DNA", 187, 213], ["pCEP plasmid backbone", "DNA", 221, 242], ["HBV", "SPECIES", 29, 32], ["HBV", "SPECIES", 169, 172], ["the transfected HBV replicon constructs", "TREATMENT", 13, 52], ["simplex", "PROBLEM", 54, 61], ["multiplex PCR analysis", "TEST", 65, 87], ["two primer/probe sets", "TREATMENT", 126, 147], ["the HBV genome", "TREATMENT", 165, 179], ["the hygromycin resistance gene", "TREATMENT", 183, 213], ["the pCEP plasmid backbone", "TREATMENT", 217, 242], ["hygromycin resistance", "OBSERVATION", 187, 208]]], ["Where indicated, cells were lysed by osmotic shock in a hypotonic lysis buffer (10-mM Tris-HCl, pH 7.5, 10-mM NaCl and 1.5-mM MgCl 2 ) for 15 min on ice and three subsequent freeze-thaw cycles (using liquid nitrogen to freeze and a 37 \u2022 C water bath to thaw).", [["cells", "ANATOMY", 17, 22], ["shock", "DISEASE", 45, 50], ["Tris-HCl", "CHEMICAL", 86, 94], ["NaCl", "CHEMICAL", 110, 114], ["Tris-HCl", "CHEMICAL", 86, 94], ["NaCl", "CHEMICAL", 110, 114], ["MgCl 2", "CHEMICAL", 126, 132], ["nitrogen", "CHEMICAL", 207, 215], ["cells", "CELL", 17, 22], ["Tris-HCl", "SIMPLE_CHEMICAL", 86, 94], ["osmotic shock", "PROBLEM", 37, 50], ["a hypotonic lysis buffer", "TREATMENT", 54, 78], ["Tris", "TEST", 86, 90], ["pH", "TEST", 96, 98], ["NaCl", "TEST", 110, 114], ["1.5-mM MgCl", "TREATMENT", 119, 130], ["ice", "TREATMENT", 149, 152], ["three subsequent freeze-thaw cycles", "TREATMENT", 157, 192], ["liquid nitrogen", "TREATMENT", 200, 215], ["a 37 \u2022 C water bath", "TREATMENT", 230, 249], ["osmotic shock", "OBSERVATION", 37, 50], ["hypotonic lysis", "OBSERVATION", 56, 71]]], ["Lysates were supplemented with NaCl to a final concentration of 150 mM and centrifuged for 30 min at 15,000\u00d7 g and 4 \u2022 C. Intracellular enveloped viral particles were immunoisolated by an envelope-specific IP in the absence of detergents and assayed by PCR.Endoglycosidase H (EndoH) TreatmentFor EndoH digestion, cell supernatants were concentrated by ultracentrifugation through a 20% (w/v) sucrose cushion (4 h at 100,000\u00d7 g and 4 \u2022 C), and pellets were suspended in Tris-buffered saline TBS buffer (TBS; 50-mM Tris-HCl, pH 7.5, and 150-mM NaCl).", [["Lysates", "ANATOMY", 0, 7], ["Intracellular", "ANATOMY", 122, 135], ["cell supernatants", "ANATOMY", 313, 330], ["NaCl", "CHEMICAL", 31, 35], ["Endoglycosidase H", "CHEMICAL", 257, 274], ["EndoH", "CHEMICAL", 276, 281], ["sucrose", "CHEMICAL", 392, 399], ["Tris-HCl", "CHEMICAL", 513, 521], ["NaCl", "CHEMICAL", 542, 546], ["NaCl", "CHEMICAL", 31, 35], ["H", "CHEMICAL", 273, 274], ["EndoH", "CHEMICAL", 276, 281], ["sucrose", "CHEMICAL", 392, 399], ["Tris", "CHEMICAL", 469, 473], ["Tris-HCl", "CHEMICAL", 513, 521], ["NaCl", "CHEMICAL", 542, 546], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["Endoglycosidase H", "SIMPLE_CHEMICAL", 257, 274], ["EndoH", "SIMPLE_CHEMICAL", 276, 281], ["EndoH", "SIMPLE_CHEMICAL", 296, 301], ["cell", "CELL", 313, 317], ["Tris-buffered saline TBS", "SIMPLE_CHEMICAL", 469, 493], ["Tris-HCl", "SIMPLE_CHEMICAL", 513, 521], ["NaCl", "TREATMENT", 31, 35], ["Intracellular enveloped viral particles", "PROBLEM", 122, 161], ["Endoglycosidase H (EndoH) Treatment", "TREATMENT", 257, 292], ["EndoH digestion", "TREATMENT", 296, 311], ["cell supernatants", "TREATMENT", 313, 330], ["w/v) sucrose cushion", "TREATMENT", 387, 407], ["pellets", "TREATMENT", 443, 450], ["buffered saline TBS buffer", "TREATMENT", 474, 500], ["TBS", "TEST", 502, 505], ["pH", "TEST", 523, 525], ["viral particles", "OBSERVATION", 146, 161]]], ["Cells were lysed in TBS supplemented with 0.5% Nonidet P-40 (NP-40), and lysates were centrifuged for 5 min at 15,000\u00d7 g and 4 \u2022 C. After the addition of 10 \u00d7 glycoprotein denaturing buffer (New England Biolabs, Ipswich, MA, USA), samples were heated at 100 \u2022 C for 10 min.", [["Cells", "ANATOMY", 0, 5], ["lysates", "ANATOMY", 73, 80], ["samples", "ANATOMY", 231, 238], ["Nonidet P-40 (NP-40", "CHEMICAL", 47, 66], ["Nonidet P-40", "CHEMICAL", 47, 59], ["Cells", "CELL", 0, 5], ["Nonidet P-40", "SIMPLE_CHEMICAL", 47, 59], ["NP-40", "SIMPLE_CHEMICAL", 61, 66], ["lysates", "ORGANISM_SUBSTANCE", 73, 80], ["TBS", "TEST", 20, 23], ["NP", "TEST", 61, 63], ["lysates", "TEST", 73, 80], ["10 \u00d7 glycoprotein denaturing buffer", "TREATMENT", 154, 189]]], ["Next, samples were adjusted to 10 \u00d7 GlycoBuffer 3 (New England Biolabs, Ipswich, MA, USA), divided in two portions and incubated for 1 h at 37 \u2022 C with or without 2-\u00b5L EndoH (New England Biolabs, Ipswich, MA, USA).Coimmunoprecipitation (CO-IP) AssayTo probe for intracellular protein interactions, cells were either lysed with a 2% CHAPS solution dissolved in HBS (50-mM Hepes-KCl, pH 7.5, 200-mM NaCl and 20-mM N-ethylmaleimide) or with Triton buffer (50-mM Tris-HCl, pH 7.5, 150-mM NaCl, 1-mM CaCl 2 and 1% Triton X-100) in the presence of 1 \u00d7 protease inhibitor mixture for 20 min on ice.", [["samples", "ANATOMY", 6, 13], ["intracellular", "ANATOMY", 262, 275], ["cells", "ANATOMY", 298, 303], ["KCl", "CHEMICAL", 377, 380], ["NaCl", "CHEMICAL", 397, 401], ["N-ethylmaleimide", "CHEMICAL", 412, 428], ["Triton buffer", "CHEMICAL", 438, 451], ["Tris-HCl", "CHEMICAL", 459, 467], ["NaCl", "CHEMICAL", 484, 488], ["CaCl", "CHEMICAL", 495, 499], ["Triton X-100", "CHEMICAL", 509, 521], ["CHAPS", "CHEMICAL", 332, 337], ["KCl", "CHEMICAL", 377, 380], ["NaCl", "CHEMICAL", 397, 401], ["N-ethylmaleimide", "CHEMICAL", 412, 428], ["Tris-HCl", "CHEMICAL", 459, 467], ["NaCl", "CHEMICAL", 484, 488], ["CaCl 2", "CHEMICAL", 495, 501], ["Triton X-100", "CHEMICAL", 509, 521], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 262, 275], ["cells", "CELL", 298, 303], ["CHAPS", "SIMPLE_CHEMICAL", 332, 337], ["HBS", "SIMPLE_CHEMICAL", 360, 363], ["N-ethylmaleimide", "SIMPLE_CHEMICAL", 412, 428], ["Triton buffer", "SIMPLE_CHEMICAL", 438, 451], ["Tris-HCl", "SIMPLE_CHEMICAL", 459, 467], ["Triton X-100", "SIMPLE_CHEMICAL", 509, 521], ["samples", "TEST", 6, 13], ["Coimmunoprecipitation (CO-IP) AssayTo probe", "TREATMENT", 214, 257], ["intracellular protein interactions", "PROBLEM", 262, 296], ["a 2% CHAPS solution", "TREATMENT", 327, 346], ["HBS", "TEST", 360, 363], ["Hepes", "TEST", 371, 376], ["KCl", "TREATMENT", 377, 380], ["pH", "TEST", 382, 384], ["NaCl", "TEST", 397, 401], ["mM N-ethylmaleimide", "TREATMENT", 409, 428], ["Triton buffer", "TREATMENT", 438, 451], ["Tris", "TEST", 459, 463], ["pH", "TEST", 469, 471], ["NaCl", "TEST", 484, 488], ["CaCl", "TEST", 495, 499], ["1 \u00d7 protease inhibitor mixture", "TREATMENT", 542, 572]]], ["After centrifugation for 20 min at 15,000\u00d7 g and 4 \u2022 C, lysates were immediately subjected to immunoprecipitation using tosyl-activated, superparamagnetic polystyrene beads (Dynabeads Sheep anti-rabbit or Dynabeads Sheep anti-mouse IgGs; Thermo Fisher Scientific, Waltham, MA, USA) that had been precoated with the anti-core (K45) or anti-L (57761) antibodies, as described [41] .", [["lysates", "ANATOMY", 56, 63], ["tosyl", "CHEMICAL", 120, 125], ["polystyrene", "CHEMICAL", 155, 166], ["lysates", "ORGANISM_SUBSTANCE", 56, 63], ["tosyl", "SIMPLE_CHEMICAL", 120, 125], ["superparamagnetic polystyrene beads", "SIMPLE_CHEMICAL", 137, 172], ["anti-core", "GENE_OR_GENE_PRODUCT", 315, 324], ["Dynabeads Sheep anti-rabbit", "PROTEIN", 174, 201], ["Dynabeads Sheep anti-mouse IgGs", "PROTEIN", 205, 236], ["anti-core", "PROTEIN", 315, 324], ["K45", "PROTEIN", 326, 329], ["anti-L (57761) antibodies", "PROTEIN", 334, 359], ["anti-rabbit", "SPECIES", 190, 201], ["anti-mouse", "SPECIES", 221, 231], ["anti-rabbit", "SPECIES", 190, 201], ["Sheep", "SPECIES", 215, 220], ["centrifugation", "TREATMENT", 6, 20], ["lysates", "TREATMENT", 56, 63], ["immunoprecipitation", "TEST", 94, 113], ["tosyl-activated, superparamagnetic polystyrene beads", "TREATMENT", 120, 172], ["Dynabeads Sheep anti-rabbit", "TREATMENT", 174, 201], ["Sheep anti-mouse IgGs", "TREATMENT", 215, 236], ["the anti-core (K45)", "TREATMENT", 311, 330]]], ["After incubation for 3 h at 4 \u2022 C with agitation, the immune complexes were washed three times with either 0.5% CHAPS/HBS (CHAPS-lysed cells) or with 50-mM Tris-HCl, pH 7.5, 150-mM NaCl, 1-mM CaCl 2 and 0.1% Triton X-100 (Triton-lysed cells).Fluorescence MicroscopyFor immunofluorescence (IF), cells grown on coverslips were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature and permeabilized with 0.2% Triton X-100 for 10 min.", [["cells", "ANATOMY", 135, 140], ["cells", "ANATOMY", 235, 240], ["cells", "ANATOMY", 294, 299], ["agitation", "DISEASE", 39, 48], ["Tris-HCl", "CHEMICAL", 156, 164], ["NaCl", "CHEMICAL", 181, 185], ["CaCl", "CHEMICAL", 192, 196], ["Triton X-100", "CHEMICAL", 208, 220], ["Triton X-100", "CHEMICAL", 421, 433], ["CHAPS", "CHEMICAL", 112, 117], ["CHAPS", "CHEMICAL", 123, 128], ["Tris-HCl", "CHEMICAL", 156, 164], ["NaCl", "CHEMICAL", 181, 185], ["CaCl 2", "CHEMICAL", 192, 198], ["Triton X-100", "CHEMICAL", 208, 220], ["paraformaldehyde", "CHEMICAL", 339, 355], ["PFA", "CHEMICAL", 357, 360], ["CHAPS", "SIMPLE_CHEMICAL", 112, 117], ["HBS", "SIMPLE_CHEMICAL", 118, 121], ["CHAPS", "SIMPLE_CHEMICAL", 123, 128], ["cells", "CELL", 135, 140], ["Tris-HCl", "SIMPLE_CHEMICAL", 156, 164], ["CaCl 2", "SIMPLE_CHEMICAL", 192, 198], ["Triton X-100", "SIMPLE_CHEMICAL", 208, 220], ["Triton", "SIMPLE_CHEMICAL", 222, 228], ["cells", "CELL", 235, 240], ["cells", "CELL", 294, 299], ["paraformaldehyde", "SIMPLE_CHEMICAL", 339, 355], ["PFA", "SIMPLE_CHEMICAL", 357, 360], ["Triton X-100", "SIMPLE_CHEMICAL", 421, 433], ["agitation", "PROBLEM", 39, 48], ["the immune complexes", "TREATMENT", 50, 70], ["HBS (CHAPS-lysed cells", "TREATMENT", 118, 140], ["pH", "TEST", 166, 168], ["NaCl", "TEST", 181, 185], ["CaCl", "TEST", 192, 196], ["Triton-lysed cells", "TREATMENT", 222, 240], ["Fluorescence MicroscopyFor immunofluorescence", "TEST", 242, 287], ["coverslips", "TEST", 309, 319], ["4% paraformaldehyde (PFA", "TREATMENT", 336, 360]]], ["Cells were blocked in phosphate-buffered saline (PBS) containing 1% BSA, incubated with the indicated primary antibodies for 1 h at 37 \u2022 C, rinsed with PBS and then incubated with Alexa Fluor-tagged secondary antibodies for 1 h at 37 \u2022 C. Cell nuclei (DNA) were stained with Hoechst 33,342 (Sigma-Aldrich, St. Louis, MO, USA).", [["Cells", "ANATOMY", 0, 5], ["Cell nuclei", "ANATOMY", 239, 250], ["phosphate", "CHEMICAL", 22, 31], ["Hoechst 33,342", "CHEMICAL", 275, 289], ["phosphate", "CHEMICAL", 22, 31], ["Hoechst 33,342", "CHEMICAL", 275, 289], ["Cells", "CELL", 0, 5], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 22, 47], ["BSA", "SIMPLE_CHEMICAL", 68, 71], ["Alexa Fluor", "SIMPLE_CHEMICAL", 180, 191], ["Cell nuclei", "CELL", 239, 250], ["DNA", "CELLULAR_COMPONENT", 252, 255], ["Hoechst 33,342", "SIMPLE_CHEMICAL", 275, 289], ["St. Louis", "ORGANISM", 306, 315], ["primary antibodies", "PROTEIN", 102, 120], ["Alexa Fluor-tagged secondary antibodies", "PROTEIN", 180, 219], ["Cells", "TEST", 0, 5], ["phosphate-buffered saline (PBS)", "TREATMENT", 22, 53], ["1% BSA", "TREATMENT", 65, 71], ["PBS", "TREATMENT", 152, 155], ["Alexa Fluor", "TREATMENT", 180, 191], ["Hoechst", "TEST", 275, 282], ["Cell nuclei", "OBSERVATION", 239, 250]]], ["Images were acquired separately for each channel using a Zeiss Axiovert 200 M microscope equipped with a Plan-Apochromat 100\u00d7 (1.4 NA) and a Zeiss Axiocam digital camera (Zeiss, Oberkochen, Germany).", [["Zeiss Axiocam digital camera", "DNA", 141, 169], ["Images", "TEST", 0, 6], ["a Zeiss Axiovert", "TREATMENT", 55, 71], ["Apochromat", "TREATMENT", 110, 120]]], ["AxioVision software 4.7.1 (Zeiss, Oberkochen, Germany) was used for merging pictures, and Tiffs were assembled into figures using Adobe Photoshop CS6.", [["AxioVision software", "TEST", 0, 19], ["Tiffs", "TEST", 90, 95]]], ["For quantitative colocalization analysis (QCA), digital photographs were quantitated using the AxioVision colocalization software (4.7.1; Zeiss, Oberkochen, Germany) by calculating the pixel intensity-based Pearson's correlation coefficients (PCC) of randomly selected cells (25 cells per coverslip).StatisticsStatistical differences between groups and statistical graphs were assessed with a two-tailed, unpaired t-test using Microsoft Office Excel 2016.", [["cells", "ANATOMY", 269, 274], ["cells", "ANATOMY", 279, 284], ["cells", "CELL", 269, 274], ["cells", "CELL", 279, 284], ["quantitative colocalization analysis", "TEST", 4, 40], ["digital photographs", "TEST", 48, 67], ["the AxioVision colocalization software", "TEST", 91, 129], ["Zeiss", "TEST", 138, 143], ["the pixel intensity", "TEST", 181, 200], ["statistical graphs", "TEST", 353, 371]]], ["Differences between groups were considered significant when the p-value was * p < 0.05 or ** p < 0.01.HBV L Resides within Markedly Crescent-Shaped ER-Associated CompartmentsUnlike those of HBV subviral envelope particles (SVPs), intracellular trafficking pathways of the viral envelope are poorly understood.", [["intracellular", "ANATOMY", 230, 243], ["ER", "GENE_OR_GENE_PRODUCT", 148, 150], ["HBV", "ORGANISM", 190, 193], ["subviral envelope particles", "GENE_OR_GENE_PRODUCT", 194, 221], ["SVPs", "GENE_OR_GENE_PRODUCT", 223, 227], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 230, 243], ["ER", "PROTEIN", 148, 150], ["HBV", "SPECIES", 102, 105], ["HBV", "SPECIES", 190, 193], ["the p-value", "TEST", 60, 71], ["HBV", "PROBLEM", 102, 105], ["HBV subviral envelope particles", "PROBLEM", 190, 221], ["the viral envelope", "PROBLEM", 268, 286], ["Markedly", "OBSERVATION_MODIFIER", 123, 131], ["Crescent", "OBSERVATION_MODIFIER", 132, 140], ["Shaped", "OBSERVATION_MODIFIER", 141, 147], ["HBV", "OBSERVATION", 190, 193], ["envelope particles", "OBSERVATION", 203, 221], ["viral envelope", "OBSERVATION", 272, 286]]], ["Unlike those of HBV spherical subviral envelope particles (SVPs) formed by S alone, intracellular trafficking pathways of the L are poorly understood.", [["intracellular", "ANATOMY", 84, 97], ["HBV", "ORGANISM", 16, 19], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["HBV", "SPECIES", 16, 19], ["HBV spherical subviral envelope particles", "PROBLEM", 16, 57], ["subviral envelope particles", "OBSERVATION", 30, 57]]], ["To study HBV envelope transport through the cell secretory system, we used a transient replication system by transfecting HuH-7 cells with a replication-competent HBV replicon plasmid and performed IF analysis.", [["cell secretory system", "ANATOMY", 44, 65], ["HuH-7 cells", "ANATOMY", 122, 133], ["plasmid", "ANATOMY", 176, 183], ["HBV", "ORGANISM", 9, 12], ["cell", "CELL", 44, 48], ["HuH-7 cells", "CELL", 122, 133], ["HBV", "ORGANISM", 163, 166], ["HuH-7 cells", "CELL_LINE", 122, 133], ["replication-competent HBV replicon plasmid", "DNA", 141, 183], ["IF", "PROTEIN", 198, 200], ["HBV", "SPECIES", 9, 12], ["HBV", "SPECIES", 163, 166], ["a transient replication system", "TREATMENT", 75, 105], ["a replication", "TREATMENT", 139, 152], ["competent HBV replicon plasmid", "TREATMENT", 153, 183], ["analysis", "TEST", 201, 209]]], ["For organelle-specific reporters, cells were cotransfected with either pYFP.ER, pYFP.GRASP65 or pDsRed.Golgi that encode autofluorescent marker proteins specific for the ER, cis Golgi or medial/trans Golgi, respectively.", [["organelle", "ANATOMY", 4, 13], ["cells", "ANATOMY", 34, 39], ["Golgi", "ANATOMY", 103, 108], ["ER", "ANATOMY", 170, 172], ["Golgi", "ANATOMY", 178, 183], ["medial/trans Golgi", "ANATOMY", 187, 205], ["organelle", "CELLULAR_COMPONENT", 4, 13], ["cells", "CELL", 34, 39], ["pYFP", "GENE_OR_GENE_PRODUCT", 71, 75], ["ER", "GENE_OR_GENE_PRODUCT", 76, 78], ["pYFP", "GENE_OR_GENE_PRODUCT", 80, 84], ["GRASP65", "GENE_OR_GENE_PRODUCT", 85, 92], ["pDsRed", "GENE_OR_GENE_PRODUCT", 96, 102], ["Golgi", "CELLULAR_COMPONENT", 103, 108], ["ER", "GENE_OR_GENE_PRODUCT", 170, 172], ["cis Golgi", "GENE_OR_GENE_PRODUCT", 174, 183], ["Golgi", "CELLULAR_COMPONENT", 200, 205], ["pYFP", "PROTEIN", 71, 75], ["ER", "PROTEIN", 76, 78], ["pYFP", "PROTEIN", 80, 84], ["GRASP65", "PROTEIN", 85, 92], ["pDsRed", "PROTEIN", 96, 102], ["autofluorescent marker proteins", "PROTEIN", 121, 152], ["ER", "PROTEIN", 170, 172], ["cis Golgi", "PROTEIN", 174, 183], ["medial/trans Golgi", "PROTEIN", 187, 205], ["pDsRed", "PROBLEM", 96, 102], ["autofluorescent marker proteins", "TEST", 121, 152], ["medial", "ANATOMY_MODIFIER", 187, 193]]], ["Three days post-transfection, cells were fixed with PFA, permeabilized and stained with antibodies against the L envelope protein.", [["cells", "ANATOMY", 30, 35], ["PFA", "CHEMICAL", 52, 55], ["cells", "CELL", 30, 35], ["PFA", "SIMPLE_CHEMICAL", 52, 55], ["antibodies against the L envelope", "GENE_OR_GENE_PRODUCT", 88, 121], ["antibodies", "PROTEIN", 88, 98], ["L envelope protein", "PROTEIN", 111, 129], ["PFA", "TEST", 52, 55], ["antibodies", "TREATMENT", 88, 98], ["the L envelope protein", "PROBLEM", 107, 129]]], ["To locate the ER/Golgi intermediate compartment (ERGIC), cells were co-stained with antibodies against ERGIC-53, an approved marker of this organelle [42] .", [["ER/Golgi intermediate compartment", "ANATOMY", 14, 47], ["ERGIC", "ANATOMY", 49, 54], ["cells", "ANATOMY", 57, 62], ["organelle", "ANATOMY", 140, 149], ["ER", "GENE_OR_GENE_PRODUCT", 14, 16], ["Golgi", "CELLULAR_COMPONENT", 17, 22], ["cells", "CELL", 57, 62], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 103, 111], ["ER", "PROTEIN", 14, 16], ["ERGIC", "PROTEIN", 49, 54], ["antibodies", "PROTEIN", 84, 94], ["ERGIC", "PROTEIN", 103, 108], ["antibodies", "TEST", 84, 94], ["ERGIC", "TEST", 103, 108]]], ["As shown in Figure 1A , L reproducibly appeared in a confined, crescent-shaped structure in the perinuclear region, partly emerging with dissections.", [["perinuclear region", "ANATOMY", 96, 114], ["perinuclear region", "CELLULAR_COMPONENT", 96, 114], ["a confined, crescent-shaped structure in the perinuclear region", "PROBLEM", 51, 114], ["dissections", "PROBLEM", 137, 148], ["L reproducibly", "OBSERVATION_MODIFIER", 24, 38], ["confined", "OBSERVATION_MODIFIER", 53, 61], ["crescent", "OBSERVATION_MODIFIER", 63, 71], ["shaped", "OBSERVATION_MODIFIER", 72, 78], ["structure", "OBSERVATION", 79, 88], ["perinuclear", "ANATOMY_MODIFIER", 96, 107], ["region", "ANATOMY_MODIFIER", 108, 114], ["dissections", "OBSERVATION", 137, 148]]], ["Worth mentioning, a similar pattern emerged when S domain-specific antibodies were used for staining (data not shown), indicating that the CS structure is specific for the viral envelope rather than for L. As would be expected, a similar pattern emerged when S domain-specific antibodies were used for staining ( Figure 1A ).", [["S domain", "PROTEIN", 49, 57], ["antibodies", "PROTEIN", 67, 77], ["S domain", "PROTEIN", 259, 267], ["specific antibodies", "PROTEIN", 268, 287], ["S domain", "TEST", 49, 57], ["specific antibodies", "TEST", 58, 77], ["staining (data", "TEST", 92, 106], ["the CS structure", "PROBLEM", 135, 151], ["the viral envelope", "PROBLEM", 168, 186], ["S domain", "TEST", 259, 267], ["specific antibodies", "TEST", 268, 287]]], ["To assess the impact of the L protein on the formation of the CS structure, comparative studies were performed with a mutant HBV.L minus replicon construct that is defective in L protein synthesis [33] .", [["L protein", "PROTEIN", 28, 37], ["L minus replicon construct", "DNA", 129, 155], ["L protein", "PROTEIN", 177, 186], ["comparative studies", "TEST", 76, 95], ["L minus replicon construct", "TREATMENT", 129, 155], ["defective in L protein synthesis", "PROBLEM", 164, 196], ["minus", "OBSERVATION", 131, 136], ["replicon construct", "OBSERVATION", 137, 155], ["defective", "OBSERVATION_MODIFIER", 164, 173]]], ["In the absence of L, the S domain-specific antibody rendered a diffuse granular staining pattern of the M and S envelope proteins ( Figure 1A) , indicating that the CS structure is specific for L. As would be expected for a viral transmembrane envelope protein, the L-specific staining pattern clearly colocalized with the reticular structures labeled by the ER marker YFP.ER ( Figure 1B) .", [["reticular structures", "ANATOMY", 323, 343], ["ER", "ANATOMY", 359, 361], ["Figure 1A", "GENE_OR_GENE_PRODUCT", 132, 141], ["reticular structures", "TISSUE", 323, 343], ["ER", "GENE_OR_GENE_PRODUCT", 359, 361], ["YFP", "GENE_OR_GENE_PRODUCT", 369, 372], ["ER", "GENE_OR_GENE_PRODUCT", 373, 375], ["S domain-specific antibody", "PROTEIN", 25, 51], ["M and S envelope proteins", "PROTEIN", 104, 129], ["Figure 1A", "PROTEIN", 132, 141], ["viral transmembrane envelope protein", "PROTEIN", 224, 260], ["ER", "PROTEIN", 359, 361], ["YFP", "PROTEIN", 369, 372], ["ER", "PROTEIN", 373, 375], ["Figure 1B", "PROTEIN", 378, 387], ["the S domain", "TEST", 21, 33], ["specific antibody", "TEST", 34, 51], ["a diffuse granular staining pattern", "PROBLEM", 61, 96], ["the M and S envelope proteins", "TEST", 100, 129], ["the CS structure", "PROBLEM", 161, 177], ["a viral transmembrane envelope protein", "PROBLEM", 222, 260], ["the L-specific staining pattern", "TEST", 262, 293], ["L", "ANATOMY_MODIFIER", 18, 19], ["diffuse", "OBSERVATION_MODIFIER", 63, 70], ["granular staining", "OBSERVATION", 71, 88], ["reticular", "ANATOMY_MODIFIER", 323, 332]]], ["However, unlike many other viral envelope proteins synthesized within and transported through the secretory system, the L-specific CS structure neither colocalized with ERGICnor Golgi-specific areas ( Figure 1B ).", [["secretory system", "ANATOMY", 98, 114], ["viral envelope proteins", "PROTEIN", 27, 50], ["L-specific CS structure", "PROTEIN", 120, 143], ["many other viral envelope proteins", "PROBLEM", 16, 50]]], ["To investigate whether HBV might traverse post-ER compartments or not, we analyzed the nature of the N-glycans that are added to the asparagine acceptor site N146 of about half of the L molecules during their integration into the ER membrane.", [["ER compartments", "ANATOMY", 47, 62], ["ER membrane", "ANATOMY", 230, 241], ["asparagine", "CHEMICAL", 133, 143], ["asparagine", "CHEMICAL", 133, 143], ["HBV", "ORGANISM", 23, 26], ["ER", "GENE_OR_GENE_PRODUCT", 47, 49], ["ER", "GENE_OR_GENE_PRODUCT", 230, 232], ["membrane", "CELLULAR_COMPONENT", 233, 241], ["ER", "PROTEIN", 47, 49], ["asparagine acceptor site", "PROTEIN", 133, 157], ["L molecules", "PROTEIN", 184, 195], ["ER", "PROTEIN", 230, 232], ["HBV", "SPECIES", 23, 26], ["HBV", "PROBLEM", 23, 26], ["the N-glycans", "TREATMENT", 97, 110], ["the asparagine acceptor site", "TREATMENT", 129, 157]]], ["During glycoprotein transport through the secretory pathway, Golgi-residing enzymes process glycoproteins and modify N-linked mannose-rich oligosaccharides into complex glycans that are resistant to treatment with Endoglycosidase H (EndoH).", [["Endoglycosidase H", "CHEMICAL", 214, 231], ["EndoH", "CHEMICAL", 233, 238], ["N", "CHEMICAL", 117, 118], ["mannose", "CHEMICAL", 126, 133], ["Endoglycosidase H", "CHEMICAL", 214, 231], ["EndoH", "CHEMICAL", 233, 238], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 7, 19], ["Endoglycosidase H", "SIMPLE_CHEMICAL", 214, 231], ["EndoH", "SIMPLE_CHEMICAL", 233, 238], ["Golgi-residing enzymes", "PROTEIN", 61, 83], ["glycoproteins", "PROTEIN", 92, 105], ["Endoglycosidase H", "PROTEIN", 214, 231], ["EndoH", "PROTEIN", 233, 238], ["Golgi-residing enzymes process glycoproteins", "PROBLEM", 61, 105], ["N-linked mannose-rich oligosaccharides", "TREATMENT", 117, 155], ["complex glycans", "PROBLEM", 161, 176]]], ["By implication, an EndoH sensitivity of glycoproteins indicates the presence of high-mannose glycans and the absence of glycoprotein modification by Golgi-residing enzymes and vice versa.", [["mannose", "CHEMICAL", 85, 92], ["EndoH", "SIMPLE_CHEMICAL", 19, 24], ["Golgi-residing enzymes", "GENE_OR_GENE_PRODUCT", 149, 171], ["EndoH", "PROTEIN", 19, 24], ["Golgi-residing enzymes", "PROTEIN", 149, 171], ["an EndoH sensitivity of glycoproteins", "TEST", 16, 53], ["high-mannose glycans", "PROBLEM", 80, 100], ["glycoprotein modification", "TREATMENT", 120, 145], ["mannose glycans", "OBSERVATION", 85, 100]]], ["We therefore conducted EndoH digestions of intra-and extracellular HBV particles.", [["extracellular", "ANATOMY", 53, 66], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 66], ["HBV", "ORGANISM", 67, 70], ["HBV", "SPECIES", 67, 70], ["intra-and extracellular HBV particles", "PROBLEM", 43, 80], ["HBV particles", "OBSERVATION", 67, 80]]], ["As shown in Figure 1C , L is naturally synthesized in nonglycosylated p39 and single-glycosylated gp42 forms due to its partial N-glycosylation.", [["N", "CHEMICAL", 128, 129], ["p39", "GENE_OR_GENE_PRODUCT", 70, 73], ["gp42", "GENE_OR_GENE_PRODUCT", 98, 102], ["nonglycosylated p39", "PROTEIN", 54, 73], ["gp42", "PROTEIN", 98, 102], ["its partial N-glycosylation", "TREATMENT", 116, 143]]], ["Cell-associated L was entirely sensitive to EndoH, which converted the gp42 form to the p39 form.", [["Cell", "ANATOMY", 0, 4], ["EndoH", "CHEMICAL", 44, 49], ["EndoH", "CHEMICAL", 44, 49], ["Cell", "CELL", 0, 4], ["EndoH", "SIMPLE_CHEMICAL", 44, 49], ["gp42", "GENE_OR_GENE_PRODUCT", 71, 75], ["p39", "GENE_OR_GENE_PRODUCT", 88, 91], ["EndoH", "PROTEIN", 44, 49], ["gp42 form", "PROTEIN", 71, 80], ["p39 form", "PROTEIN", 88, 96], ["sensitive", "OBSERVATION", 31, 40]]], ["By contrast, extracellular L resisted EndoH digestion concomitant with an increased molecular weight of its gp42 form by about one kDa as a consequence of N-glycan processing.", [["extracellular", "ANATOMY", 13, 26], ["N", "CHEMICAL", 155, 156], ["extracellular L", "SIMPLE_CHEMICAL", 13, 28], ["EndoH", "GENE_OR_GENE_PRODUCT", 38, 43], ["gp42", "GENE_OR_GENE_PRODUCT", 108, 112], ["EndoH", "PROTEIN", 38, 43], ["gp42 form", "PROTEIN", 108, 117], ["extracellular L resisted EndoH digestion", "TREATMENT", 13, 53], ["N-glycan processing", "TREATMENT", 155, 174], ["increased", "OBSERVATION_MODIFIER", 74, 83]]], ["Accordingly, the viral envelope must have traversed the Golgi apparatus en route to the exterior.", [["Golgi apparatus", "ANATOMY", 56, 71], ["Golgi", "CELLULAR_COMPONENT", 56, 61], ["the viral envelope", "PROBLEM", 13, 31], ["viral envelope", "OBSERVATION", 17, 31]]], ["To account for the intracellular EndoH sensitivity of L together with its missing colocalization with ERGIC-and Golgi-specific markers, L might be blocked in a pre-ERGIC compartment for much of its time in the cell to match the rate-limiting step in viral particle assembly.", [["intracellular", "ANATOMY", 19, 32], ["cell", "ANATOMY", 210, 214], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 32], ["EndoH", "SIMPLE_CHEMICAL", 33, 38], ["ERGIC", "GENE_OR_GENE_PRODUCT", 102, 107], ["cell", "CELL", 210, 214], ["EndoH", "PROTEIN", 33, 38], ["ERGIC", "PROTEIN", 102, 107], ["Golgi-specific markers", "PROTEIN", 112, 134], ["the intracellular EndoH sensitivity", "TEST", 15, 50], ["ERGIC", "TEST", 102, 107], ["a pre-ERGIC compartment", "TREATMENT", 158, 181], ["the rate", "TEST", 224, 232], ["viral particle", "OBSERVATION", 250, 264]]], ["Once budded, the viral particles appeared to be rapidly released out of the cell.HBV L Recruits Core/Capsid to the Crescent-Shaped ER-Associated CompartmentsTo gain insights into HBV assembly/budding sites, we comparatively inspected the intracellular distribution of wt and mutant HBV replicon constructs on a single cell level.", [["cell", "ANATOMY", 76, 80], ["intracellular", "ANATOMY", 238, 251], ["cell", "ANATOMY", 318, 322], ["cell", "CELL", 76, 80], ["HBV", "ORGANISM", 81, 84], ["ER", "GENE_OR_GENE_PRODUCT", 131, 133], ["HBV", "ORGANISM", 179, 182], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 238, 251], ["mutant HBV", "ORGANISM", 275, 285], ["cell", "CELL", 318, 322], ["ER", "PROTEIN", 131, 133], ["wt and mutant HBV replicon constructs", "DNA", 268, 305], ["HBV", "SPECIES", 81, 84], ["HBV", "SPECIES", 179, 182], ["HBV", "SPECIES", 282, 285], ["the viral particles", "PROBLEM", 13, 32], ["HBV assembly/budding sites", "PROBLEM", 179, 205], ["mutant HBV replicon constructs", "TREATMENT", 275, 305], ["viral particles", "OBSERVATION", 17, 32], ["cell", "ANATOMY", 76, 80], ["Crescent", "OBSERVATION_MODIFIER", 115, 123], ["Shaped", "OBSERVATION_MODIFIER", 124, 130], ["HBV replicon", "OBSERVATION", 282, 294]]], ["The mutant replicons were either defective in core synthesis (HBV.C minus ), envelope synthesis (HBV.Env minus ), L protein expression (HBV.L minus ), reverse transcription (HBV.Pol minus ) or in nucleocapsid envelopment (HBV.C.K96A).HBV L Recruits Core/Capsid to the Crescent-Shaped ER-Associated CompartmentsIn HBV.C minus -expressing HuH-7 cells, L appeared in its typical CS structure, implicating that this feature is an intrinsic capacity of L, irrespective of an ongoing replication ( Figure 2A ).", [["HuH-7 cells", "ANATOMY", 337, 348], ["Env minus ), L protein", "GENE_OR_GENE_PRODUCT", 101, 123], ["Pol", "GENE_OR_GENE_PRODUCT", 178, 181], ["C.K96A", "GENE_OR_GENE_PRODUCT", 226, 232], ["HBV", "ORGANISM", 234, 237], ["ER", "GENE_OR_GENE_PRODUCT", 284, 286], ["HuH-7 cells", "CELL", 337, 348], ["L", "CELL", 350, 351], ["mutant replicons", "DNA", 4, 20], ["Env minus", "PROTEIN", 101, 110], ["L protein", "PROTEIN", 114, 123], ["C.K96A", "PROTEIN", 226, 232], ["ER", "PROTEIN", 284, 286], ["C minus -expressing HuH-7 cells", "CELL_LINE", 317, 348], ["HBV", "SPECIES", 62, 65], ["HBV", "SPECIES", 97, 100], ["HBV", "SPECIES", 136, 139], ["HBV", "SPECIES", 174, 177], ["HBV", "SPECIES", 222, 225], ["HBV", "SPECIES", 234, 237], ["HBV", "SPECIES", 313, 316], ["The mutant replicons", "TREATMENT", 0, 20], ["defective in core synthesis (HBV", "PROBLEM", 33, 65], ["envelope synthesis (HBV", "PROBLEM", 77, 100], ["HBV", "PROBLEM", 136, 139], ["HBV", "PROBLEM", 174, 177], ["C minus", "TEST", 317, 324], ["HuH", "TEST", 337, 340], ["HBV", "OBSERVATION", 136, 139], ["Crescent", "OBSERVATION_MODIFIER", 268, 276], ["Shaped", "OBSERVATION_MODIFIER", 277, 283], ["HBV", "OBSERVATION", 313, 316]]], ["Upon ablation of the synthesis of all three envelope proteins, core yielded a diffuse staining dispersed throughout the cytoplasm with some nuclear labeling ( Figure 2B ).", [["cytoplasm", "ANATOMY", 120, 129], ["nuclear", "ANATOMY", 140, 147], ["cytoplasm", "ORGANISM_SUBSTANCE", 120, 129], ["nuclear", "CELLULAR_COMPONENT", 140, 147], ["envelope proteins", "PROTEIN", 44, 61], ["a diffuse staining", "PROBLEM", 76, 94], ["diffuse", "OBSERVATION_MODIFIER", 78, 85], ["staining", "OBSERVATION", 86, 94]]], ["An almost identical distribution of core was observed, when only the expression of the L envelope protein was prevented ( Figure 2C ).", [["L envelope protein", "PROTEIN", 87, 105], ["the L envelope protein", "TREATMENT", 83, 105], ["almost", "OBSERVATION_MODIFIER", 3, 9], ["identical", "OBSERVATION_MODIFIER", 10, 19], ["distribution", "OBSERVATION_MODIFIER", 20, 32], ["core", "OBSERVATION_MODIFIER", 36, 40]]], ["In the presence of the viral envelope, the core staining pattern thoroughly changed, as it now accumulated in the L-specific CS structure ( Figure 2D ).", [["the viral envelope", "PROBLEM", 19, 37], ["the core staining pattern", "PROBLEM", 39, 64], ["viral envelope", "OBSERVATION", 23, 37], ["core", "OBSERVATION_MODIFIER", 43, 47], ["staining", "OBSERVATION_MODIFIER", 48, 56], ["pattern", "OBSERVATION_MODIFIER", 57, 64]]], ["A similar overlap and recruitment of core by L was observed when capsid-rather than core-specific antibodies were used for staining ( Figure 2E ).", [["core-specific antibodies", "PROTEIN", 84, 108], ["capsid", "TEST", 65, 71], ["core-specific antibodies", "TEST", 84, 108], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["overlap", "OBSERVATION", 10, 17], ["recruitment", "OBSERVATION_MODIFIER", 22, 33]]], ["Even core/capsids defective in reverse transcription, but competent for pgRNA genome packaging [43] , were found to extensively colocalize with the characteristic CS structure of L ( Figure 2F ).", [["pgRNA", "GENE_OR_GENE_PRODUCT", 72, 77], ["pgRNA genome", "DNA", 72, 84], ["Even core/capsids defective", "PROBLEM", 0, 27], ["pgRNA genome packaging", "TREATMENT", 72, 94], ["capsids defective", "OBSERVATION", 10, 27], ["L", "ANATOMY_MODIFIER", 179, 180]]], ["Conversely, when the HBV.C minus replicon was trans-complemented with a core mutant that had been shown to be competent in nucleocapsid formation but defective in envelopment (HBV.C.K96A) [44] , no recruitment of core could be detected ( Figure 2G ).", [["HBV", "ORGANISM", 21, 24], ["C", "GENE_OR_GENE_PRODUCT", 25, 26], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 123, 135], ["HBV", "SPECIES", 21, 24], ["HBV", "SPECIES", 176, 179], ["the HBV", "PROBLEM", 17, 24], ["C minus replicon", "TREATMENT", 25, 41], ["a core mutant", "PROBLEM", 70, 83], ["defective in envelopment (HBV", "PROBLEM", 150, 179], ["nucleocapsid formation", "OBSERVATION", 123, 145]]], ["To corroborate whether the spatial overlaps of the core and L-staining pattern relied on true protein interactions, coimmunoprecipitation (CO-IP) studies were performed.", [["true protein interactions", "PROBLEM", 89, 114], ["coimmunoprecipitation (CO-IP) studies", "TEST", 116, 153], ["L", "ANATOMY_MODIFIER", 60, 61]]], ["To this aim, cell lysates of transfected cells were subjected to a core-specific IP followed by L-specific WB.", [["cell lysates", "ANATOMY", 13, 25], ["cells", "ANATOMY", 41, 46], ["WB", "ANATOMY", 107, 109], ["cell lysates", "CELL", 13, 25], ["cells", "CELL", 41, 46], ["transfected cells", "CELL_LINE", 29, 46], ["L-specific WB", "PROTEIN", 96, 109], ["cell lysates", "TREATMENT", 13, 25], ["transfected cells", "PROBLEM", 29, 46], ["transfected cells", "OBSERVATION", 29, 46]]], ["Thereby, wt core but not the envelopment-defective core.K96A mutant reproducibly brought down L ( Figure 2H ).", [["K96A mutant", "PROTEIN", 56, 67], ["defective core", "PROBLEM", 41, 55], ["defective", "OBSERVATION", 41, 50]]], ["Together, the cell imaging and biochemical data indicate that L on its own accumulated in the confined CS structure towards core/capsid particles were actively recruited, likely via a direct interaction between L and core.", [["cell", "ANATOMY", 14, 18], ["cell", "CELL", 14, 18], ["the cell imaging", "TEST", 10, 26], ["biochemical data", "TEST", 31, 47], ["capsid particles", "OBSERVATION", 129, 145]]], ["Since the interaction-defective core.K96A mutant failed to be attracted by L, the CS structure likely mirrors HBV interaction sites. .", [["K96A", "GENE_OR_GENE_PRODUCT", 37, 41], ["HBV", "ORGANISM", 110, 113], ["K96A mutant", "PROTEIN", 37, 48], ["HBV interaction sites", "PROTEIN", 110, 131], ["HBV", "SPECIES", 110, 113], ["mirrors HBV interaction sites", "PROBLEM", 102, 131], ["defective", "OBSERVATION_MODIFIER", 22, 31], ["core", "OBSERVATION_MODIFIER", 32, 36], ["likely", "UNCERTAINTY", 95, 101], ["mirrors HBV", "OBSERVATION", 102, 113]]], ["Cells shown in panel F were cotransfected with the core-defective replicon and a plasmid encoding the core mutant C.K96A.", [["Cells", "ANATOMY", 0, 5], ["plasmid", "ANATOMY", 81, 88], ["Cells", "CELL", 0, 5], ["panel F", "CELL", 15, 22], ["C.K96A", "GENE_OR_GENE_PRODUCT", 114, 120], ["core-defective replicon", "DNA", 51, 74], ["plasmid", "DNA", 81, 88], ["core mutant C.K96A", "PROTEIN", 102, 120], ["the core-defective replicon", "TREATMENT", 47, 74], ["a plasmid", "TREATMENT", 79, 88], ["defective replicon", "OBSERVATION", 56, 74]]], ["PFA-fixed cells were double-stained with mouse antibodies against L (57761, L, green) and rabbit antibodies against core (B0586, C, red), followed by staining with Alexa Fluor 488-conjugated anti-mouse and Alexa Fluor 546-conjugated anti-rabbit antibodies (A-G).", [["cells", "ANATOMY", 10, 15], ["PFA", "CHEMICAL", 0, 3], ["Alexa Fluor 488", "CHEMICAL", 164, 179], ["Alexa Fluor 546", "CHEMICAL", 206, 221], ["PFA", "SIMPLE_CHEMICAL", 0, 3], ["cells", "CELL", 10, 15], ["mouse", "ORGANISM", 41, 46], ["rabbit", "ORGANISM", 90, 96], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 164, 179], ["Alexa Fluor 546", "SIMPLE_CHEMICAL", 206, 221], ["A-G", "SIMPLE_CHEMICAL", 257, 260], ["PFA-fixed cells", "CELL_LINE", 0, 15], ["mouse antibodies", "PROTEIN", 41, 57], ["L (57761, L, green", "PROTEIN", 66, 84], ["rabbit antibodies", "PROTEIN", 90, 107], ["Alexa Fluor 488-conjugated anti-mouse", "PROTEIN", 164, 201], ["Alexa Fluor 546-conjugated anti-rabbit antibodies", "PROTEIN", 206, 255], ["A-G", "PROTEIN", 257, 260], ["mouse", "SPECIES", 41, 46], ["rabbit", "SPECIES", 90, 96], ["anti-mouse", "SPECIES", 191, 201], ["anti-rabbit", "SPECIES", 233, 244], ["mouse", "SPECIES", 41, 46], ["rabbit", "SPECIES", 90, 96], ["Alexa Fluor 546", "SPECIES", 206, 221], ["PFA", "TEST", 0, 3], ["fixed cells", "PROBLEM", 4, 15], ["mouse antibodies", "TEST", 41, 57], ["rabbit antibodies", "TEST", 90, 107], ["C", "TEST", 129, 130], ["Alexa Fluor", "TEST", 164, 175], ["conjugated anti-mouse", "TEST", 180, 201], ["Alexa Fluor", "TEST", 206, 217], ["conjugated anti-rabbit antibodies", "TEST", 222, 255], ["fixed cells", "OBSERVATION", 4, 15]]], ["In the panels shown in E, cells were reacted with rabbit anti-L antibodies (K1350, L, green) and mouse antibodies recognizing the viral capsid rather than the core protein (3HB17, Capsid, red).", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["rabbit", "ORGANISM", 50, 56], ["anti-L", "GENE_OR_GENE_PRODUCT", 57, 63], ["mouse", "ORGANISM", 97, 102], ["Capsid", "GENE_OR_GENE_PRODUCT", 180, 186], ["rabbit anti-L antibodies", "PROTEIN", 50, 74], ["K1350, L, green", "PROTEIN", 76, 91], ["mouse antibodies", "PROTEIN", 97, 113], ["viral capsid", "PROTEIN", 130, 142], ["core protein", "PROTEIN", 159, 171], ["3HB17", "PROTEIN", 173, 178], ["Capsid", "PROTEIN", 180, 186], ["red", "PROTEIN", 188, 191], ["rabbit", "SPECIES", 50, 56], ["mouse", "SPECIES", 97, 102], ["rabbit", "SPECIES", 50, 56], ["mouse", "SPECIES", 97, 102], ["the panels", "TEST", 3, 13], ["rabbit anti-L antibodies", "TEST", 50, 74], ["K1350", "TEST", 76, 81], ["mouse antibodies", "TEST", 97, 113], ["the viral capsid", "PROBLEM", 126, 142], ["the core protein", "TEST", 155, 171], ["viral capsid", "OBSERVATION", 130, 142]]], ["Overlaid images are displayed in the Merge panels, and nuclei staining is shown in blue.", [["nuclei", "ANATOMY", 55, 61], ["nuclei", "CELLULAR_COMPONENT", 55, 61], ["Overlaid images", "TEST", 0, 15], ["the Merge panels", "TEST", 33, 49], ["nuclei staining", "TEST", 55, 70], ["nuclei staining", "OBSERVATION", 55, 70]]], ["Outlined areas are shown at larger magnifications.", [["larger", "OBSERVATION_MODIFIER", 28, 34]]], ["For quantitative colocalization analysis (QCA), Pearson\u00b4s correlation coefficient (PCC) values were calculated and represent the mean \u00b1 SD.", [["quantitative colocalization analysis", "TEST", 4, 40]]], ["(H) HuH-7 cells were transfected with HBV.C minus together with control plasmids (Con), the wt core (C) or mutant C.K96A genes.", [["H) HuH-7 cells", "ANATOMY", 1, 15], ["H) HuH-7 cells", "CELL", 1, 15], ["HBV", "ORGANISM", 38, 41], ["Con", "GENE_OR_GENE_PRODUCT", 82, 85], ["wt core (C)", "GENE_OR_GENE_PRODUCT", 92, 103], ["C.K96A", "GENE_OR_GENE_PRODUCT", 114, 120], ["(H) HuH-7 cells", "CELL_LINE", 0, 15], ["control plasmids", "DNA", 64, 80], ["Con", "DNA", 82, 85], ["wt core (C)", "DNA", 92, 103], ["mutant C.K96A genes", "DNA", 107, 126], ["HBV", "SPECIES", 38, 41], ["HuH", "TEST", 4, 7], ["HBV", "PROBLEM", 38, 41], ["control plasmids", "TREATMENT", 64, 80], ["the wt core (C)", "TREATMENT", 88, 103]]], ["Cell extracts were prepared by CHAPS-lysis and assayed by L-and core-specific WB to monitor protein expression (Input).", [["Cell extracts", "ANATOMY", 0, 13], ["CHAPS", "CHEMICAL", 31, 36], ["Cell extracts", "ORGANISM_SUBSTANCE", 0, 13], ["CHAPS", "SIMPLE_CHEMICAL", 31, 36], ["core-specific WB", "PROTEIN", 64, 80], ["Cell extracts", "TREATMENT", 0, 13]]], ["For immunoprecipitation (IP), lysates were incubated with anti-core antibodies (K45), followed by immunoblotting with the L-specific MA18/7 antibody.", [["lysates", "ANATOMY", 30, 37], ["lysates", "ORGANISM_SUBSTANCE", 30, 37], ["K45", "SIMPLE_CHEMICAL", 80, 83], ["MA18/7", "GENE_OR_GENE_PRODUCT", 133, 139], ["anti-core antibodies", "PROTEIN", 58, 78], ["K45", "PROTEIN", 80, 83], ["L-specific MA18/7 antibody", "PROTEIN", 122, 148], ["lysates", "TEST", 30, 37], ["anti-core antibodies", "TEST", 58, 78], ["immunoblotting", "TEST", 98, 112]]], ["IgG.HC denotes IgG heavy chains.", [["IgG heavy chains", "GENE_OR_GENE_PRODUCT", 15, 31], ["IgG.HC", "PROTEIN", 0, 6], ["IgG heavy chains", "PROTEIN", 15, 31], ["IgG.HC", "TEST", 0, 6], ["IgG heavy chains", "OBSERVATION", 15, 31]]], ["Coimmunoprecipitation (CO-IP) analyses were done in triplicate, and a representative blot is shown.HBV Particle Egress Requires the COPII components Sec24A, Sec23B and Sar1We previously showed that HBV spherical SVPs use the cellular COPII machinery for ER export and secretion [29] .", [["cellular", "ANATOMY", 225, 233], ["ER", "ANATOMY", 254, 256], ["HBV", "ORGANISM", 99, 102], ["COPII", "GENE_OR_GENE_PRODUCT", 132, 137], ["Sec24A", "GENE_OR_GENE_PRODUCT", 149, 155], ["Sec23B", "GENE_OR_GENE_PRODUCT", 157, 163], ["Sar1We", "GENE_OR_GENE_PRODUCT", 168, 174], ["SVPs", "GENE_OR_GENE_PRODUCT", 212, 216], ["cellular", "CELL", 225, 233], ["COPII", "GENE_OR_GENE_PRODUCT", 234, 239], ["ER", "GENE_OR_GENE_PRODUCT", 254, 256], ["COPII components", "PROTEIN", 132, 148], ["Sec24A", "PROTEIN", 149, 155], ["Sec23B", "PROTEIN", 157, 163], ["Sar1We", "PROTEIN", 168, 174], ["COPII", "PROTEIN", 234, 239], ["ER", "PROTEIN", 254, 256], ["HBV", "SPECIES", 99, 102], ["HBV", "SPECIES", 198, 201], ["Coimmunoprecipitation (CO-IP) analyses", "TEST", 0, 38], ["a representative blot", "TEST", 68, 89], ["HBV spherical SVPs", "PROBLEM", 198, 216], ["Particle Egress", "OBSERVATION", 103, 118]]], ["Since intracellular trafficking pathways of HBV subviral and viral particles are supposed to differ [2, 21, 45] , a common exploitation of COPII transport carriers is ambiguous.", [["intracellular", "ANATOMY", 6, 19], ["COPII", "ANATOMY", 139, 144], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 19], ["HBV subviral", "ORGANISM", 44, 56], ["COPII", "GENE_OR_GENE_PRODUCT", 139, 144], ["COPII", "PROTEIN", 139, 144], ["HBV", "SPECIES", 44, 47], ["HBV subviral and viral particles", "PROBLEM", 44, 76], ["viral particles", "OBSERVATION", 61, 76]]], ["Therefore, we reasoned to investigate the role of COPII factors in the production and release of infectious HBV particles.", [["COPII", "GENE_OR_GENE_PRODUCT", 50, 55], ["HBV", "ORGANISM", 108, 111], ["COPII factors", "PROTEIN", 50, 63], ["HBV", "SPECIES", 108, 111], ["COPII factors", "PROBLEM", 50, 63], ["infectious HBV particles", "PROBLEM", 97, 121], ["infectious", "OBSERVATION", 97, 107]]], ["For RNA interference (RNAi), HuH-7 cells were treated with siRNA duplexes for 48 h prior to transfection with the pHBV* replicon construct.", [["HuH-7 cells", "ANATOMY", 29, 40], ["HuH-7 cells", "CELL", 29, 40], ["pHBV", "GENE_OR_GENE_PRODUCT", 114, 118], ["HuH-7 cells", "CELL_LINE", 29, 40], ["pHBV* replicon construct", "DNA", 114, 138], ["RNA interference", "PROBLEM", 4, 20], ["RNAi", "TEST", 22, 26], ["HuH", "TEST", 29, 32], ["siRNA duplexes", "TREATMENT", 59, 73], ["the pHBV* replicon construct", "TREATMENT", 110, 138]]], ["After an additional 72 h, cell lysates and supernatants were harvested.", [["cell lysates", "ANATOMY", 26, 38], ["supernatants", "ANATOMY", 43, 55], ["cell lysates", "ORGANISM_SUBSTANCE", 26, 38], ["cell lysates", "TREATMENT", 26, 38], ["supernatants", "TREATMENT", 43, 55], ["harvested", "OBSERVATION", 61, 70]]], ["The used siRNAs comprised control duplexes (siCon) and single or siRNA pools targeting Sec24A, Sec24B, Sec23A, Sec23B, Sar1A or Sar1B.", [["Sec24A", "GENE_OR_GENE_PRODUCT", 87, 93], ["Sec24B", "GENE_OR_GENE_PRODUCT", 95, 101], ["Sec23A", "GENE_OR_GENE_PRODUCT", 103, 109], ["Sec23B", "GENE_OR_GENE_PRODUCT", 111, 117], ["Sar1A", "GENE_OR_GENE_PRODUCT", 119, 124], ["Sar1B", "GENE_OR_GENE_PRODUCT", 128, 133], ["Sec24A", "PROTEIN", 87, 93], ["Sec24B", "PROTEIN", 95, 101], ["Sec23A", "PROTEIN", 103, 109], ["Sec23B", "PROTEIN", 111, 117], ["Sar1A", "PROTEIN", 119, 124], ["Sar1B", "PROTEIN", 128, 133], ["The used siRNAs comprised control duplexes (siCon)", "TREATMENT", 0, 50], ["single or siRNA pools", "PROBLEM", 55, 76], ["Sec24A", "TEST", 87, 93]]], ["Sec24 is the cargo adaptor protein of COPII and associates with Sec23 to form the inner coat layer, while the Sar1 GTPase recruits the Sec23/Sec24 dimer to the ER membrane.", [["inner coat layer", "ANATOMY", 82, 98], ["ER membrane", "ANATOMY", 160, 171], ["Sec24", "GENE_OR_GENE_PRODUCT", 0, 5], ["COPII", "GENE_OR_GENE_PRODUCT", 38, 43], ["Sec23", "GENE_OR_GENE_PRODUCT", 64, 69], ["inner coat layer", "CELLULAR_COMPONENT", 82, 98], ["Sar1", "GENE_OR_GENE_PRODUCT", 110, 114], ["Sec23", "GENE_OR_GENE_PRODUCT", 135, 140], ["Sec24", "GENE_OR_GENE_PRODUCT", 141, 146], ["ER membrane", "CELLULAR_COMPONENT", 160, 171], ["Sec24", "PROTEIN", 0, 5], ["cargo adaptor protein", "PROTEIN", 13, 34], ["COPII", "PROTEIN", 38, 43], ["Sec23", "PROTEIN", 64, 69], ["Sar1 GTPase", "PROTEIN", 110, 121], ["Sec23", "PROTEIN", 135, 140], ["Sec24 dimer", "PROTEIN", 141, 152], ["ER", "PROTEIN", 160, 162], ["Sec23", "TREATMENT", 64, 69], ["the Sar1 GTPase", "TEST", 106, 121], ["inner", "ANATOMY_MODIFIER", 82, 87], ["coat layer", "ANATOMY", 88, 98], ["ER membrane", "ANATOMY", 160, 171]]], ["To monitor depletion, COPII-specific transcripts were measured by qRT-PCR, which revealed an almost complete knockdown (KD) of each targeted COPII component ( Figure 3 ).", [["COPII", "ANATOMY", 141, 146], ["COPII", "GENE_OR_GENE_PRODUCT", 22, 27], ["COPII", "GENE_OR_GENE_PRODUCT", 141, 146], ["COPII", "PROTEIN", 22, 27], ["COPII component", "PROTEIN", 141, 156], ["PCR", "TEST", 70, 73], ["knockdown", "OBSERVATION", 109, 118]]], ["Cell lysates were probed for the expression and stability profiles of the viral L envelope and core proteins by specific WBs.", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "CELL", 0, 12], ["viral L envelope and core proteins", "PROTEIN", 74, 108], ["WBs", "PROTEIN", 121, 124], ["Cell lysates", "TEST", 0, 12], ["the viral L envelope", "PROBLEM", 70, 90], ["core proteins", "TEST", 95, 108]]], ["As shown in Figure 3 , neither knockdown (KD) affected the intracellular steady-state levels of either of the two viral proteins.", [["intracellular", "ANATOMY", 59, 72], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 72], ["viral proteins", "PROTEIN", 114, 128], ["the intracellular steady", "TEST", 55, 79], ["the two viral proteins", "PROBLEM", 106, 128]]], ["The formation and release of HBV particles were analyzed by a virion production (VP) assay.", [["HBV", "ORGANISM", 29, 32], ["HBV", "SPECIES", 29, 32], ["HBV particles", "PROBLEM", 29, 42]]], ["For this, intracellular NCs and extracellular virions were immunoprecipitated with capsid-or envelope-specific antibodies, respectively, followed by particle disruption and real-time, multiplex PCR quantification of the number of HBV progeny genomes.", [["intracellular NCs", "ANATOMY", 10, 27], ["extracellular virions", "ANATOMY", 32, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 23], ["NCs", "SIMPLE_CHEMICAL", 24, 27], ["extracellular virions", "CELLULAR_COMPONENT", 32, 53], ["HBV", "ORGANISM", 230, 233], ["capsid-or envelope-specific antibodies", "PROTEIN", 83, 121], ["HBV progeny genomes", "DNA", 230, 249], ["HBV", "SPECIES", 230, 233], ["extracellular virions", "TREATMENT", 32, 53], ["capsid", "TEST", 83, 89], ["multiplex PCR", "TEST", 184, 197], ["HBV progeny genomes", "PROBLEM", 230, 249], ["HBV progeny genomes", "OBSERVATION", 230, 249]]], ["Neither RNAi had a substantial effect on the formation of intracellular, replication-competent NCs.", [["intracellular", "ANATOMY", 58, 71], ["NCs", "ANATOMY", 95, 98], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 71], ["NCs", "CELL", 95, 98], ["substantial", "OBSERVATION_MODIFIER", 19, 30], ["effect", "OBSERVATION_MODIFIER", 31, 37]]], ["However, upon the silencing of Sec24A and Sec23B, the amounts of extracellular virions decreased in a highly significant manner, as compared to siCon-treated cells ( Figure 3) .", [["extracellular virions", "ANATOMY", 65, 86], ["cells", "ANATOMY", 158, 163], ["Sec24A", "GENE_OR_GENE_PRODUCT", 31, 37], ["Sec23B", "GENE_OR_GENE_PRODUCT", 42, 48], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 78], ["cells", "CELL", 158, 163], ["Sec24A", "PROTEIN", 31, 37], ["Sec23B", "PROTEIN", 42, 48], ["siCon-treated cells", "CELL_LINE", 144, 163], ["extracellular virions", "PROBLEM", 65, 86], ["amounts", "OBSERVATION_MODIFIER", 54, 61], ["extracellular virions", "OBSERVATION", 65, 86], ["decreased", "OBSERVATION_MODIFIER", 87, 96], ["highly significant", "OBSERVATION_MODIFIER", 102, 120]]], ["Conversely, the loss of the two closely related Sec24B [46] or Sec23A [47] isoforms had no inhibitory effects on virus production and release.", [["Sec24B [46]", "GENE_OR_GENE_PRODUCT", 48, 59], ["Sec23A [47]", "GENE_OR_GENE_PRODUCT", 63, 74], ["Sec24B [46] or Sec23A [47] isoforms", "PROTEIN", 48, 83], ["Sec23A", "TEST", 63, 69], ["inhibitory effects", "PROBLEM", 91, 109], ["virus production", "TREATMENT", 113, 129]]], ["This indicates that HBV strictly depends on the specific functions provided by Sec24A and Sec23B in the same manner as HBV SVPs.", [["HBV", "ORGANISM", 20, 23], ["Sec24A", "GENE_OR_GENE_PRODUCT", 79, 85], ["Sec23B", "GENE_OR_GENE_PRODUCT", 90, 96], ["HBV", "ORGANISM", 119, 122], ["SVPs", "PATHOLOGICAL_FORMATION", 123, 127], ["Sec24A", "PROTEIN", 79, 85], ["Sec23B", "PROTEIN", 90, 96], ["HBV", "SPECIES", 20, 23], ["HBV", "SPECIES", 119, 122], ["HBV strictly", "PROBLEM", 20, 32], ["HBV SVPs", "PROBLEM", 119, 127], ["HBV", "OBSERVATION", 20, 23]]], ["In case of the KDs of the two Sar1 isoforms, the inhibition of the HBV release was obvious, albeit less pronounced (Figure 3 ).", [["KDs", "GENE_OR_GENE_PRODUCT", 15, 18], ["Sar1", "GENE_OR_GENE_PRODUCT", 30, 34], ["HBV", "ORGANISM", 67, 70], ["KDs", "PROTEIN", 15, 18], ["Sar1 isoforms", "PROTEIN", 30, 43], ["HBV", "SPECIES", 67, 70], ["the HBV release", "TEST", 63, 78], ["less pronounced", "OBSERVATION_MODIFIER", 99, 114]]], ["Since the Sar1A and Sar1B isoforms share 89% sequence identity concomitant with overlapping functions [48] , the individual loss of either isoform may be partly compensated by its paralog.", [["Sar1A", "GENE_OR_GENE_PRODUCT", 10, 15], ["Sar1B", "GENE_OR_GENE_PRODUCT", 20, 25], ["Sar1A and Sar1B isoforms", "PROTEIN", 10, 34], ["the Sar1A", "TEST", 6, 15]]], ["Together, these results demonstrate that HBV viral particles, similar to spherical subviral particles, require the COPII machinery for exiting the host cell, involving functions of Sec24A, Sec23B and Sar1.", [["cell", "ANATOMY", 152, 156], ["HBV viral particles", "ORGANISM", 41, 60], ["COPII", "GENE_OR_GENE_PRODUCT", 115, 120], ["host cell", "CELL", 147, 156], ["Sec24A", "GENE_OR_GENE_PRODUCT", 181, 187], ["Sec23B", "GENE_OR_GENE_PRODUCT", 189, 195], ["Sar1", "GENE_OR_GENE_PRODUCT", 200, 204], ["COPII", "PROTEIN", 115, 120], ["Sec24A", "PROTEIN", 181, 187], ["Sec23B", "PROTEIN", 189, 195], ["Sar1", "PROTEIN", 200, 204], ["HBV", "SPECIES", 41, 44], ["HBV viral particles", "PROBLEM", 41, 60], ["spherical subviral particles", "PROBLEM", 73, 101], ["the COPII machinery", "TREATMENT", 111, 130], ["subviral particles", "OBSERVATION", 83, 101], ["host cell", "OBSERVATION", 147, 156]]], ["Hence, a COPII-guided export out of the ER appears to be a mandatory step in HBV biology. .", [["ER", "ANATOMY", 40, 42], ["COPII", "CELLULAR_COMPONENT", 9, 14], ["ER", "GENE_OR_GENE_PRODUCT", 40, 42], ["HBV", "ORGANISM", 77, 80], ["COPII", "PROTEIN", 9, 14], ["ER", "PROTEIN", 40, 42], ["HBV", "SPECIES", 77, 80]]], ["HBV release requires COPII components.", [["HBV", "ORGANISM", 0, 3], ["COPII", "GENE_OR_GENE_PRODUCT", 21, 26], ["COPII components", "PROTEIN", 21, 37], ["HBV", "SPECIES", 0, 3], ["HBV release", "TREATMENT", 0, 11], ["COPII components", "TREATMENT", 21, 37], ["COPII components", "OBSERVATION", 21, 37]]], ["HuH-7 cells were treated with control siRNA (siCon) or siRNAs targeting Sec24A, Sec24B, Sec23A, Sec23B, Sar1A or Sar1B for 48 h and retransfected with the pHBV* replicon.", [["HuH-7 cells", "ANATOMY", 0, 11], ["HuH-7 cells", "CELL", 0, 11], ["Sec24A", "GENE_OR_GENE_PRODUCT", 72, 78], ["Sec24B", "GENE_OR_GENE_PRODUCT", 80, 86], ["Sec23A", "GENE_OR_GENE_PRODUCT", 88, 94], ["Sec23B", "GENE_OR_GENE_PRODUCT", 96, 102], ["Sar1A", "GENE_OR_GENE_PRODUCT", 104, 109], ["Sar1B", "GENE_OR_GENE_PRODUCT", 113, 118], ["HuH-7 cells", "CELL_LINE", 0, 11], ["Sec24A", "PROTEIN", 72, 78], ["Sec24B", "PROTEIN", 80, 86], ["Sec23A", "PROTEIN", 88, 94], ["Sec23B", "PROTEIN", 96, 102], ["Sar1A", "PROTEIN", 104, 109], ["Sar1B", "DNA", 113, 118], ["pHBV* replicon", "DNA", 155, 169], ["HuH", "TEST", 0, 3], ["control siRNA (siCon)", "TREATMENT", 30, 51], ["siRNAs", "TREATMENT", 55, 61], ["Sar1A", "TREATMENT", 104, 109], ["Sar1B", "TREATMENT", 113, 118], ["the pHBV", "TREATMENT", 151, 159], ["replicon", "TREATMENT", 161, 169], ["7 cells", "OBSERVATION_MODIFIER", 4, 11]]], ["After an additional 72 h, lysates and supernatants were harvested.", [["lysates", "ANATOMY", 26, 33], ["supernatants", "ANATOMY", 38, 50], ["lysates", "ORGANISM_SUBSTANCE", 26, 33], ["lysates and supernatants", "TREATMENT", 26, 50], ["harvested", "OBSERVATION", 56, 65]]], ["To check for depletion, transcript levels of the RNA interference (RNAi)-targeted genes were measured by qRT-PCR and demonstrated in percent amount relative to control cells (n = 4, \u00b1 SD).", [["cells", "ANATOMY", 168, 173], ["cells", "CELL", 168, 173], ["RNA interference (RNAi)-targeted genes", "DNA", 49, 87], ["control cells", "CELL_TYPE", 160, 173], ["depletion", "PROBLEM", 13, 22], ["transcript levels", "TEST", 24, 41], ["PCR", "TEST", 109, 112]]], ["To monitor protein synthesis, cell lysates were examined by WB using tubulin-, L-(K1350) and core-specific (K46) antibodies.", [["cell lysates", "ANATOMY", 30, 42], ["WB", "ANATOMY", 60, 62], ["cell lysates", "CELL", 30, 42], ["tubulin-", "GENE_OR_GENE_PRODUCT", 69, 77], ["WB", "PROTEIN", 60, 62], ["tubulin-, L-(K1350) and core-specific (K46) antibodies", "PROTEIN", 69, 123], ["protein synthesis", "TEST", 11, 28], ["cell lysates", "TEST", 30, 42], ["tubulin-", "TEST", 69, 77], ["core-specific (K46) antibodies", "TEST", 93, 123]]], ["The nonglycosylated (p39) and glycosylated (gp42) forms of L are indicated.", [["p39", "GENE_OR_GENE_PRODUCT", 21, 24], ["glycosylated (gp42) forms of L", "GENE_OR_GENE_PRODUCT", 30, 60], ["p39", "PROTEIN", 21, 24], ["gp42", "PROTEIN", 44, 48], ["The nonglycosylated (p39) and glycosylated (gp42)", "TEST", 0, 49]]], ["HBV release was measured by envelope-specific IP of supernatants using anti-L (K1350) and anti-S (K38) antibodies and real-time multiplex PCR measurements of the viral genomes (extracellular virions).", [["supernatants", "ANATOMY", 52, 64], ["extracellular virions", "ANATOMY", 177, 198], ["HBV", "ORGANISM", 0, 3], ["anti-L", "GENE_OR_GENE_PRODUCT", 71, 77], ["K1350", "SIMPLE_CHEMICAL", 79, 84], ["extracellular virions", "CELLULAR_COMPONENT", 177, 198], ["anti-L (K1350)", "PROTEIN", 71, 85], ["anti-S (K38) antibodies", "PROTEIN", 90, 113], ["viral genomes", "DNA", 162, 175], ["HBV", "SPECIES", 0, 3], ["HBV release", "PROBLEM", 0, 11], ["anti-L (K1350)", "TREATMENT", 71, 85], ["anti-S (K38) antibodies", "TREATMENT", 90, 113], ["multiplex PCR measurements", "TEST", 128, 154], ["the viral genomes (extracellular virions", "PROBLEM", 158, 198], ["viral genomes", "OBSERVATION", 162, 175], ["extracellular virions", "OBSERVATION", 177, 198]]], ["Nonenveloped intracellular nucleocapsids (intracellular NCs) were immunoprecipitated with anti-capsid (K45) antibodies and analyzed by PCR.", [["intracellular nucleocapsids", "ANATOMY", 13, 40], ["intracellular NCs", "ANATOMY", 42, 59], ["intracellular nucleocapsids", "CELLULAR_COMPONENT", 13, 40], ["intracellular NCs", "CELLULAR_COMPONENT", 42, 59], ["anti-capsid", "GENE_OR_GENE_PRODUCT", 90, 101], ["anti-capsid (K45) antibodies", "PROTEIN", 90, 118], ["Nonenveloped intracellular nucleocapsids (intracellular NCs", "PROBLEM", 0, 59], ["anti-capsid (K45) antibodies", "TREATMENT", 90, 118], ["PCR", "TEST", 135, 138], ["intracellular nucleocapsids", "OBSERVATION", 13, 40]]], ["PCR results were demonstrated in the percent amount relative to siCon-transfected cells.", [["cells", "ANATOMY", 82, 87], ["cells", "CELL", 82, 87], ["siCon-transfected cells", "CELL_LINE", 64, 87], ["PCR", "TEST", 0, 3], ["percent", "OBSERVATION_MODIFIER", 37, 44], ["amount", "OBSERVATION_MODIFIER", 45, 51], ["transfected cells", "OBSERVATION", 70, 87]]], ["Error bars indicate the standard deviations from the mean of three experiments measured in duplicates. ** p < 0.01 compared to control.HBV L Colocalizes with ERGIC-53 upon ER Export BlockGiven that the Sec24A isoform is the essential COPII component linked to the export of both the viral and subviral HBV envelope, we next investigated the fate of the ER-arrested envelopes due to Sec24A KD.", [["COPII", "ANATOMY", 234, 239], ["ER", "ANATOMY", 353, 355], ["HBV L", "ORGANISM", 135, 140], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 158, 166], ["ER", "GENE_OR_GENE_PRODUCT", 172, 174], ["Sec24A", "GENE_OR_GENE_PRODUCT", 202, 208], ["COPII", "GENE_OR_GENE_PRODUCT", 234, 239], ["subviral HBV", "ORGANISM", 293, 305], ["ER", "GENE_OR_GENE_PRODUCT", 353, 355], ["ERGIC", "PROTEIN", 158, 163], ["ER", "PROTEIN", 172, 174], ["Sec24A isoform", "PROTEIN", 202, 216], ["COPII component", "PROTEIN", 234, 249], ["ER", "PROTEIN", 353, 355], ["Sec24A", "PROTEIN", 382, 388], ["HBV", "SPECIES", 135, 138], ["HBV", "SPECIES", 302, 305], ["the standard deviations", "PROBLEM", 20, 43], ["ERGIC", "TEST", 158, 163], ["the viral and subviral HBV envelope", "PROBLEM", 279, 314], ["standard deviations", "OBSERVATION", 24, 43], ["COPII component", "OBSERVATION", 234, 249], ["viral", "OBSERVATION", 283, 288], ["subviral HBV", "OBSERVATION", 293, 305]]], ["To study spherical SVP trafficking, HuH-7 cells were transiently transfected with an expression construct encoding only the S envelope gene (HBV.S) ( Figure 4A ).", [["HuH-7 cells", "ANATOMY", 36, 47], ["SVP", "GENE_OR_GENE_PRODUCT", 19, 22], ["HuH-7 cells", "CELL", 36, 47], ["HuH-7 cells", "CELL_LINE", 36, 47], ["S envelope gene", "DNA", 124, 139], ["HBV.S", "DNA", 141, 146], ["HuH", "TEST", 36, 39], ["an expression construct", "PROBLEM", 82, 105], ["spherical SVP", "OBSERVATION", 9, 22]]], ["Notably, this is an established approach to study exclusively the fate of subviral HBV spheres [29] .", [["HBV", "SPECIES", 83, 86], ["subviral HBV spheres", "PROBLEM", 74, 94]]], ["Consistent with our previous IF analysis [29] and for recapitulation herein, HBV.S showed a diffuse granular staining pattern typical for viral surface proteins that are synthesized at the ER ( Figure 4B ).", [["surface", "ANATOMY", 144, 151], ["HBV", "ORGANISM", 77, 80], ["ER", "GENE_OR_GENE_PRODUCT", 189, 191], ["viral surface proteins", "PROTEIN", 138, 160], ["ER", "PROTEIN", 189, 191], ["Figure 4B", "PROTEIN", 194, 203], ["HBV", "SPECIES", 77, 80], ["our previous IF analysis", "TEST", 16, 40], ["recapitulation herein", "TREATMENT", 54, 75], ["HBV", "PROBLEM", 77, 80], ["a diffuse granular staining pattern", "PROBLEM", 90, 125], ["viral surface proteins", "PROBLEM", 138, 160], ["diffuse", "OBSERVATION_MODIFIER", 92, 99], ["granular staining", "OBSERVATION", 100, 117]]], ["Moreover, itHBV L Colocalizes with ERGIC-53 upon ER Export BlockGiven that the Sec24A isoform is the essential COPII component linked to the export of both the viral and subviral HBV envelope, we next investigated the fate of the ER-arrested envelopes due to Sec24A KD.", [["COPII", "ANATOMY", 111, 116], ["ER", "ANATOMY", 230, 232], ["itHBV L", "GENE_OR_GENE_PRODUCT", 10, 17], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 35, 43], ["ER", "GENE_OR_GENE_PRODUCT", 49, 51], ["Sec24A", "GENE_OR_GENE_PRODUCT", 79, 85], ["COPII", "GENE_OR_GENE_PRODUCT", 111, 116], ["subviral HBV", "ORGANISM", 170, 182], ["ER", "GENE_OR_GENE_PRODUCT", 230, 232], ["itHBV L", "PROTEIN", 10, 17], ["ERGIC", "PROTEIN", 35, 40], ["ER", "PROTEIN", 49, 51], ["Sec24A isoform", "PROTEIN", 79, 93], ["COPII component", "PROTEIN", 111, 126], ["ER", "PROTEIN", 230, 232], ["Sec24A", "PROTEIN", 259, 265], ["itHBV", "SPECIES", 10, 15], ["HBV", "SPECIES", 179, 182], ["ERGIC", "TEST", 35, 40], ["the viral and subviral HBV envelope", "PROBLEM", 156, 191], ["COPII component", "OBSERVATION", 111, 126], ["viral", "OBSERVATION", 160, 165], ["subviral HBV", "OBSERVATION", 170, 182]]], ["To study spherical SVP trafficking, HuH-7 cells were transiently transfected with an expression construct encoding only the S envelope gene (HBV.S) ( Figure 4A ).", [["HuH-7 cells", "ANATOMY", 36, 47], ["SVP", "GENE_OR_GENE_PRODUCT", 19, 22], ["HuH-7 cells", "CELL", 36, 47], ["HuH-7 cells", "CELL_LINE", 36, 47], ["S envelope gene", "DNA", 124, 139], ["HBV.S", "DNA", 141, 146], ["HuH", "TEST", 36, 39], ["an expression construct", "PROBLEM", 82, 105], ["spherical SVP", "OBSERVATION", 9, 22]]], ["Notably, this is an established approach to study exclusively the fate of subviral HBV spheres [29] .", [["HBV", "SPECIES", 83, 86], ["subviral HBV spheres", "PROBLEM", 74, 94]]], ["Consistent with our previous IF analysis [29] and for recapitulation herein, HBV.S showed a diffuse granular staining pattern typical for viral surface proteins that are synthesized at the ER ( Figure 4B ).", [["surface", "ANATOMY", 144, 151], ["HBV", "ORGANISM", 77, 80], ["ER", "GENE_OR_GENE_PRODUCT", 189, 191], ["viral surface proteins", "PROTEIN", 138, 160], ["ER", "PROTEIN", 189, 191], ["Figure 4B", "PROTEIN", 194, 203], ["HBV", "SPECIES", 77, 80], ["our previous IF analysis", "TEST", 16, 40], ["recapitulation herein", "TREATMENT", 54, 75], ["HBV", "PROBLEM", 77, 80], ["a diffuse granular staining pattern", "PROBLEM", 90, 125], ["viral surface proteins", "PROBLEM", 138, 160], ["diffuse", "OBSERVATION_MODIFIER", 92, 99], ["granular staining", "OBSERVATION", 100, 117]]], ["Moreover, it largely colocalized with ERGIC-53-stained structures, implicating that HBV.S is transported out of the ER to the ERGIC in control cells ( Figure 4B ).", [["ER", "ANATOMY", 116, 118], ["cells", "ANATOMY", 143, 148], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 38, 46], ["HBV", "ORGANISM", 84, 87], ["ER", "GENE_OR_GENE_PRODUCT", 116, 118], ["cells", "CELL", 143, 148], ["ERGIC", "PROTEIN", 38, 43], ["ER", "PROTEIN", 116, 118], ["ERGIC", "DNA", 126, 131], ["control cells", "CELL_TYPE", 135, 148], ["HBV", "SPECIES", 84, 87], ["ERGIC", "TEST", 38, 43], ["HBV", "PROBLEM", 84, 87], ["HBV", "OBSERVATION", 84, 87]]], ["Upon Sec24A inactivation, the staining pattern of HBV.S strongly changed, as it now appeared in dot-like structures, reminiscent of ER-arrested aggregates, that no longer coincided with ERGIC-53 signals ( Figure 4B) .", [["dot-like structures", "ANATOMY", 96, 115], ["ER", "ANATOMY", 132, 134], ["Sec24A", "GENE_OR_GENE_PRODUCT", 5, 11], ["HBV", "ORGANISM", 50, 53], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 186, 194], ["Sec24A", "PROTEIN", 5, 11], ["ER", "PROTEIN", 132, 134], ["ERGIC", "PROTEIN", 186, 191], ["HBV", "SPECIES", 50, 53], ["HBV", "PROBLEM", 50, 53], ["arrested aggregates", "PROBLEM", 135, 154], ["ERGIC", "TEST", 186, 191], ["HBV", "OBSERVATION", 50, 53], ["arrested aggregates", "OBSERVATION", 135, 154], ["no longer", "UNCERTAINTY", 161, 170]]], ["Notably, under these conditions, the distribution of ERGIC-53 also altered.", [["ERGIC-53", "CHEMICAL", 53, 61], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 53, 61], ["ERGIC", "PROTEIN", 53, 58], ["ERGIC", "TEST", 53, 58], ["altered", "OBSERVATION_MODIFIER", 67, 74]]], ["In normal cells, this protein predominantly localizes to the ERGIC compartment, as displayed by the given name ERGIC-53.", [["cells", "ANATOMY", 10, 15], ["ERGIC compartment", "ANATOMY", 61, 78], ["cells", "CELL", 10, 15], ["ERGIC", "GENE_OR_GENE_PRODUCT", 61, 66], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 111, 119], ["normal cells", "CELL_TYPE", 3, 15], ["ERGIC", "PROTEIN", 111, 116], ["this protein", "TEST", 17, 29], ["normal cells", "OBSERVATION", 3, 15], ["ERGIC compartment", "OBSERVATION", 61, 78]]], ["It is a high mannose-specific lectin that cycles cargoes between the ER and the cis-Golgi through COPII and COPI-dependent pathways (see also Figure 5A ) [49, 50] .", [["ER", "ANATOMY", 69, 71], ["cis-Golgi", "ANATOMY", 80, 89], ["mannose", "CHEMICAL", 13, 20], ["mannose", "SIMPLE_CHEMICAL", 13, 20], ["lectin", "GENE_OR_GENE_PRODUCT", 30, 36], ["ER", "GENE_OR_GENE_PRODUCT", 69, 71], ["cis-Golgi", "CELLULAR_COMPONENT", 80, 89], ["COPII", "GENE_OR_GENE_PRODUCT", 98, 103], ["COPI", "GENE_OR_GENE_PRODUCT", 108, 112], ["lectin", "PROTEIN", 30, 36], ["ER", "PROTEIN", 69, 71], ["cis-Golgi", "PROTEIN", 80, 89], ["COPII", "PROTEIN", 98, 103], ["COPI", "PROTEIN", 108, 112], ["a high mannose", "PROBLEM", 6, 20]]], ["Upon immunostaining, it appeared in juxtanuclear, tubulovesicular clusters in control cells, which shifted to a perinuclear, ER-like structure in Sec24A KD cells ( Figure 4B) .", [["juxtanuclear", "ANATOMY", 36, 48], ["tubulovesicular clusters", "ANATOMY", 50, 74], ["cells", "ANATOMY", 86, 91], ["perinuclear", "ANATOMY", 112, 123], ["ER-like structure", "ANATOMY", 125, 142], ["Sec24A KD cells", "ANATOMY", 146, 161], ["juxtanuclear", "CELLULAR_COMPONENT", 36, 48], ["cells", "CELL", 86, 91], ["perinuclear", "CELLULAR_COMPONENT", 112, 123], ["ER", "GENE_OR_GENE_PRODUCT", 125, 127], ["control cells", "CELL_TYPE", 78, 91], ["ER", "PROTEIN", 125, 127], ["Sec24A KD cells", "CELL_LINE", 146, 161], ["immunostaining", "TEST", 5, 19], ["juxtanuclear, tubulovesicular clusters in control cells", "PROBLEM", 36, 91], ["juxtanuclear", "ANATOMY_MODIFIER", 36, 48], ["tubulovesicular clusters", "OBSERVATION", 50, 74], ["control cells", "OBSERVATION", 78, 91], ["perinuclear", "OBSERVATION_MODIFIER", 112, 123], ["Sec24A", "OBSERVATION_MODIFIER", 146, 152], ["KD cells", "OBSERVATION", 153, 161]]], ["Hence, the ER export of both HBV.S and ERGIC-53 is apparently impaired in Sec24A-silenced cells.", [["cells", "ANATOMY", 90, 95], ["ER", "GENE_OR_GENE_PRODUCT", 11, 13], ["HBV", "ORGANISM", 29, 32], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 39, 47], ["Sec24A", "GENE_OR_GENE_PRODUCT", 74, 80], ["cells", "CELL", 90, 95], ["ER", "PROTEIN", 11, 13], ["Sec24A-silenced cells", "CELL_LINE", 74, 95], ["HBV", "SPECIES", 29, 32], ["both HBV.S", "TEST", 24, 34], ["ERGIC", "TEST", 39, 44], ["impaired", "OBSERVATION", 62, 70]]], ["Upon Sec24A inactivation, the staining pattern of HBV.S strongly changed, as it now appeared in dot-like structures, reminiscent of ER-arrested aggregates, that no longer coincided with ERGIC-53 signals ( Figure 4B) .", [["dot-like structures", "ANATOMY", 96, 115], ["ER", "ANATOMY", 132, 134], ["Sec24A", "GENE_OR_GENE_PRODUCT", 5, 11], ["HBV", "ORGANISM", 50, 53], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 186, 194], ["Sec24A", "PROTEIN", 5, 11], ["ER", "PROTEIN", 132, 134], ["ERGIC", "PROTEIN", 186, 191], ["HBV", "SPECIES", 50, 53], ["HBV", "PROBLEM", 50, 53], ["arrested aggregates", "PROBLEM", 135, 154], ["ERGIC", "TEST", 186, 191], ["HBV", "OBSERVATION", 50, 53], ["arrested aggregates", "OBSERVATION", 135, 154], ["no longer", "UNCERTAINTY", 161, 170]]], ["Notably, under these conditions, the distribution of ERGIC-53 also altered.", [["ERGIC-53", "CHEMICAL", 53, 61], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 53, 61], ["ERGIC", "PROTEIN", 53, 58], ["ERGIC", "TEST", 53, 58], ["altered", "OBSERVATION_MODIFIER", 67, 74]]], ["In normal cells, this protein predominantly localizes to the ERGIC compartment, as displayed by the given name ERGIC-53.", [["cells", "ANATOMY", 10, 15], ["ERGIC compartment", "ANATOMY", 61, 78], ["cells", "CELL", 10, 15], ["ERGIC", "GENE_OR_GENE_PRODUCT", 61, 66], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 111, 119], ["normal cells", "CELL_TYPE", 3, 15], ["ERGIC", "PROTEIN", 111, 116], ["this protein", "TEST", 17, 29], ["normal cells", "OBSERVATION", 3, 15], ["ERGIC compartment", "OBSERVATION", 61, 78]]], ["It is a high mannosespecific lectin that cycles cargoes between the ER and the cis-Golgi through COPII and COPIdependent pathways (see also Figure 5A ) [49, 50] .", [["ER", "ANATOMY", 68, 70], ["cis-Golgi", "ANATOMY", 79, 88], ["lectin", "GENE_OR_GENE_PRODUCT", 29, 35], ["ER", "GENE_OR_GENE_PRODUCT", 68, 70], ["cis-Golgi", "CELLULAR_COMPONENT", 79, 88], ["COPII", "GENE_OR_GENE_PRODUCT", 97, 102], ["mannosespecific lectin", "PROTEIN", 13, 35], ["ER", "PROTEIN", 68, 70], ["cis-Golgi", "PROTEIN", 79, 88], ["COPII", "PROTEIN", 97, 102], ["a high mannosespecific lectin", "PROBLEM", 6, 35]]], ["Upon immunostaining, it appeared in juxtanuclear, tubulovesicular clusters in control cells, which shifted to a perinuclear, ER-like structure in Sec24A KD cells ( Figure 4B) .", [["juxtanuclear", "ANATOMY", 36, 48], ["tubulovesicular clusters", "ANATOMY", 50, 74], ["cells", "ANATOMY", 86, 91], ["perinuclear", "ANATOMY", 112, 123], ["ER-like structure", "ANATOMY", 125, 142], ["Sec24A KD cells", "ANATOMY", 146, 161], ["juxtanuclear", "CELLULAR_COMPONENT", 36, 48], ["cells", "CELL", 86, 91], ["perinuclear", "CELLULAR_COMPONENT", 112, 123], ["ER", "GENE_OR_GENE_PRODUCT", 125, 127], ["control cells", "CELL_TYPE", 78, 91], ["ER", "PROTEIN", 125, 127], ["Sec24A KD cells", "CELL_LINE", 146, 161], ["immunostaining", "TEST", 5, 19], ["juxtanuclear, tubulovesicular clusters in control cells", "PROBLEM", 36, 91], ["juxtanuclear", "ANATOMY_MODIFIER", 36, 48], ["tubulovesicular clusters", "OBSERVATION", 50, 74], ["control cells", "OBSERVATION", 78, 91], ["perinuclear", "OBSERVATION_MODIFIER", 112, 123], ["Sec24A", "OBSERVATION_MODIFIER", 146, 152], ["KD cells", "OBSERVATION", 153, 161]]], ["Hence, the ER export of both HBV.S and ERGIC-53 is apparently impaired in Sec24A-silenced cells.Blocking N146-linked Glycosylation Inhibits HBV Egress without Affecting Envelope/Core InteractionsSince ERGIC-53 acts as a high mannose-specific lectin, we next focused on the HBV-specific Nglycans.", [["cells", "ANATOMY", 90, 95], ["mannose", "CHEMICAL", 225, 232], ["ER", "GENE_OR_GENE_PRODUCT", 11, 13], ["HBV", "ORGANISM", 29, 32], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 39, 47], ["Sec24A", "GENE_OR_GENE_PRODUCT", 74, 80], ["cells", "CELL", 90, 95], ["N146", "SIMPLE_CHEMICAL", 105, 109], ["HBV", "ORGANISM", 140, 143], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 201, 209], ["mannose", "SIMPLE_CHEMICAL", 225, 232], ["lectin", "GENE_OR_GENE_PRODUCT", 242, 248], ["HBV", "ORGANISM", 273, 276], ["Nglycans", "GENE_OR_GENE_PRODUCT", 286, 294], ["ER", "PROTEIN", 11, 13], ["Sec24A-silenced cells", "CELL_LINE", 74, 95], ["N146", "PROTEIN", 105, 109], ["lectin", "PROTEIN", 242, 248], ["HBV-specific Nglycans", "PROTEIN", 273, 294], ["HBV", "SPECIES", 29, 32], ["HBV", "SPECIES", 140, 143], ["HBV", "SPECIES", 273, 276], ["both HBV.S", "TEST", 24, 34], ["ERGIC", "TEST", 39, 44], ["Blocking", "TREATMENT", 96, 104], ["HBV Egress", "PROBLEM", 140, 150], ["ERGIC", "TEST", 201, 206], ["the HBV", "TEST", 269, 276], ["impaired", "OBSERVATION", 62, 70]]], ["A number of studies have shown that HBV release requires sugar moieties linked to the Nglycan acceptor N146 of the envelope proteins [11] [12] [13] [14] [15] [16] .", [["sugar", "CHEMICAL", 57, 62], ["Nglycan", "CHEMICAL", 86, 93], ["HBV", "ORGANISM", 36, 39], ["sugar moieties", "SIMPLE_CHEMICAL", 57, 71], ["[11] [12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 133, 162], ["Nglycan acceptor N146", "PROTEIN", 86, 107], ["envelope proteins", "PROTEIN", 115, 132], ["HBV", "SPECIES", 36, 39], ["studies", "TEST", 12, 19], ["HBV release", "PROBLEM", 36, 47], ["sugar moieties", "TREATMENT", 57, 71], ["the envelope proteins", "TEST", 111, 132]]], ["To ascertain the importance of the N146- ERGIC-53 is a type I integral membrane protein with a C-terminal transmembrane domain (TM) and a luminal cargo recognition domain (CRD) interacting with N-linked high-mannose glycans of cargo proteins (CP) within the ER.", [["membrane", "ANATOMY", 71, 79], ["luminal", "ANATOMY", 138, 145], ["ER", "ANATOMY", 258, 260], ["luminal", "CHEMICAL", 138, 145], ["C", "CHEMICAL", 95, 96], ["N", "CHEMICAL", 194, 195], ["mannose", "CHEMICAL", 208, 215], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 41, 49], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["ER", "GENE_OR_GENE_PRODUCT", 258, 260], ["N146", "DNA", 35, 39], ["ERGIC-53", "DNA", 41, 49], ["type I integral membrane protein", "PROTEIN", 55, 87], ["C-terminal transmembrane domain", "PROTEIN", 95, 126], ["TM", "PROTEIN", 128, 130], ["luminal cargo recognition domain", "PROTEIN", 138, 170], ["CRD", "PROTEIN", 172, 175], ["N-linked high-mannose glycans", "PROTEIN", 194, 223], ["cargo proteins", "PROTEIN", 227, 241], ["CP", "PROTEIN", 243, 245], ["ER", "PROTEIN", 258, 260], ["a C-terminal transmembrane domain", "TREATMENT", 93, 126]]], ["Its cytoplasmic ER exit motif (C) binds to Sec24, the cargo adaptor of COPII.", [["cytoplasmic", "ANATOMY", 4, 15], ["cytoplasmic", "ORGANISM_SUBSTANCE", 4, 15], ["ER", "GENE_OR_GENE_PRODUCT", 16, 18], ["Sec24", "GENE_OR_GENE_PRODUCT", 43, 48], ["COPII", "GENE_OR_GENE_PRODUCT", 71, 76], ["cytoplasmic ER exit motif", "PROTEIN", 4, 29], ["Sec24", "PROTEIN", 43, 48], ["cargo adaptor", "PROTEIN", 54, 67], ["COPII", "PROTEIN", 71, 76], ["cytoplasmic", "OBSERVATION_MODIFIER", 4, 15]]], ["GTP activation of Sar1 leads to the formation of the Sec23/24 heterodimer, cargo capture and coat polymerization by the Sec13/31 complex.", [["GTP", "CHEMICAL", 0, 3], ["GTP", "CHEMICAL", 0, 3], ["GTP", "SIMPLE_CHEMICAL", 0, 3], ["Sar1", "GENE_OR_GENE_PRODUCT", 18, 22], ["Sec23/24", "GENE_OR_GENE_PRODUCT", 53, 61], ["Sec13/31", "GENE_OR_GENE_PRODUCT", 120, 128], ["Sar1", "PROTEIN", 18, 22], ["Sec23/24 heterodimer", "PROTEIN", 53, 73], ["Sec13/31 complex", "PROTEIN", 120, 136], ["the Sec23/24 heterodimer", "TREATMENT", 49, 73], ["coat polymerization", "TREATMENT", 93, 112], ["Sar1 leads", "OBSERVATION", 18, 28], ["coat polymerization", "OBSERVATION", 93, 112]]], ["(B) The treatment of HuH-7 cells with the control (siCon) or ERGIC-53-specific siRNAs for 2 days and retransfection with the HBV* replicon construct for an additional 3 days.", [["HuH-7 cells", "ANATOMY", 21, 32], ["HuH-7 cells", "CELL", 21, 32], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 61, 69], ["HBV", "ORGANISM", 125, 128], ["HuH-7 cells", "CELL_LINE", 21, 32], ["HBV* replicon construct", "DNA", 125, 148], ["HBV", "SPECIES", 125, 128], ["The treatment of HuH-7 cells", "TREATMENT", 4, 32], ["ERGIC", "TEST", 61, 66], ["retransfection", "TREATMENT", 101, 115], ["the HBV* replicon construct", "TREATMENT", 121, 148]]], ["The degree of ERGIC-53 depletion was measured by qRT-PCR of the transcript levels and WB analysis.", [["ERGIC-53", "CHEMICAL", 14, 22], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 14, 22], ["ERGIC", "PROTEIN", 14, 19], ["ERGIC-53 depletion", "PROBLEM", 14, 32], ["the transcript levels", "TEST", 60, 81], ["WB analysis", "TEST", 86, 97], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["ERGIC", "OBSERVATION_MODIFIER", 14, 19], ["53 depletion", "OBSERVATION", 20, 32]]], ["Cellular lysates and supernatants were subjected to tubulin-, L-and core-specific WB and to the virion production assay (n = 3, \u00b1 SD).", [["Cellular lysates", "ANATOMY", 0, 16], ["supernatants", "ANATOMY", 21, 33], ["WB", "ANATOMY", 82, 84], ["Cellular lysates", "ORGANISM_SUBSTANCE", 0, 16], ["tubulin", "GENE_OR_GENE_PRODUCT", 52, 59], ["tubulin", "PROTEIN", 52, 59], ["core-specific WB", "PROTEIN", 68, 84], ["Cellular lysates", "TEST", 0, 16], ["supernatants", "TEST", 21, 33], ["tubulin", "TEST", 52, 59], ["the virion production assay", "TEST", 92, 119]]], ["(C) Treatment of HuH-7 cells with control (siCon), Sec24A-or ERGIC-53-specific siRNA duplexes for 3 days and retransfection with an haemagglutinin (HA)-tagged S construct (HBV.S) for an additional 2 days.", [["HuH-7 cells", "ANATOMY", 17, 28], ["HuH-7 cells", "CELL", 17, 28], ["Sec24A", "SIMPLE_CHEMICAL", 51, 57], ["ERGIC-53", "SIMPLE_CHEMICAL", 61, 69], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 132, 146], ["HBV", "ORGANISM", 172, 175], ["HuH-7 cells", "CELL_LINE", 17, 28], ["haemagglutinin (HA)-tagged S construct", "DNA", 132, 170], ["HBV", "SPECIES", 172, 175], ["HuH", "TEST", 17, 20], ["Sec24A", "TEST", 51, 57], ["ERGIC", "TEST", 61, 66], ["specific siRNA duplexes", "TREATMENT", 70, 93], ["retransfection", "TREATMENT", 109, 123], ["an haemagglutinin (HA", "TREATMENT", 129, 150], ["HBV", "PROBLEM", 172, 175]]], ["The ERGIC-53-specific RNAi experiments were done in duplicate.", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 4, 12], ["ERGIC-53", "DNA", 4, 12], ["The ERGIC", "TEST", 0, 9], ["specific RNAi experiments", "TEST", 13, 38]]], ["To monitor depletion, cell lysates were examined by Sec24A-and ERGIC-53-specific WB.", [["cell lysates", "ANATOMY", 22, 34], ["WB", "ANATOMY", 81, 83], ["cell lysates", "ORGANISM_SUBSTANCE", 22, 34], ["Sec24A", "GENE_OR_GENE_PRODUCT", 52, 58], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 63, 71], ["WB", "CELL", 81, 83], ["Sec24A", "PROTEIN", 52, 58], ["WB", "PROTEIN", 81, 83], ["cell lysates", "TEST", 22, 34], ["Sec24A", "TEST", 52, 58], ["ERGIC", "TEST", 63, 68]]], ["Cell lysates (Cell) and concentrated cell supernatants (Medium) were probed by anti-HA immunoblotting.", [["Cell lysates", "ANATOMY", 0, 12], ["Cell", "ANATOMY", 14, 18], ["cell supernatants", "ANATOMY", 37, 54], ["Cell lysates", "CELL", 0, 12], ["Cell", "CELL", 14, 18], ["cell", "CELL", 37, 41], ["Cell lysates", "TEST", 0, 12], ["concentrated cell supernatants", "TREATMENT", 24, 54], ["anti-HA immunoblotting", "TREATMENT", 79, 101], ["concentrated cell", "OBSERVATION_MODIFIER", 24, 41]]], ["The nonglycosylated (p24) and glycosylated (gp27 and gp28) forms of HBV.S are depicted.Blocking N146-linked Glycosylation Inhibits HBV Egress without Affecting Envelope/Core InteractionsIn contrast, the HBV L protein, synthesized in HBV-replicating cells, could not be traced within the ERGIC, as no colocalization between L and ERGIC-53 was detectable in the control cells ( Figure 4C ).", [["cells", "ANATOMY", 249, 254], ["cells", "ANATOMY", 368, 373], ["p24", "GENE_OR_GENE_PRODUCT", 21, 24], ["gp27", "GENE_OR_GENE_PRODUCT", 44, 48], ["gp28", "GENE_OR_GENE_PRODUCT", 53, 57], ["HBV", "ORGANISM", 68, 71], ["N146", "SIMPLE_CHEMICAL", 96, 100], ["HBV", "ORGANISM", 131, 134], ["HBV L", "ORGANISM", 203, 208], ["HBV", "ORGANISM", 233, 236], ["cells", "CELL", 249, 254], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 329, 337], ["cells", "CELL", 368, 373], ["p24", "PROTEIN", 21, 24], ["glycosylated", "PROTEIN", 30, 42], ["gp27", "PROTEIN", 44, 48], ["gp28", "PROTEIN", 53, 57], ["N146", "PROTEIN", 96, 100], ["HBV L protein", "PROTEIN", 203, 216], ["HBV-replicating cells", "CELL_TYPE", 233, 254], ["ERGIC", "PROTEIN", 287, 292], ["ERGIC", "PROTEIN", 329, 334], ["control cells", "CELL_TYPE", 360, 373], ["HBV", "SPECIES", 68, 71], ["HBV", "SPECIES", 131, 134], ["HBV", "SPECIES", 203, 206], ["HBV", "SPECIES", 233, 236], ["The nonglycosylated (p24) and glycosylated (gp27 and gp28)", "TREATMENT", 0, 58], ["HBV", "PROBLEM", 68, 71], ["Blocking", "TREATMENT", 87, 95], ["Glycosylation", "TREATMENT", 108, 121], ["HBV Egress", "PROBLEM", 131, 141], ["the HBV L protein", "TEST", 199, 216], ["HBV", "PROBLEM", 233, 236], ["ERGIC", "TEST", 329, 334], ["HBV", "OBSERVATION", 68, 71], ["replicating cells", "OBSERVATION", 237, 254]]], ["In further difference to spherical SVPs, the naturally occurring structure of L was preserved in Sec24A KD cells without any signs of aggregation.", [["Sec24A KD cells", "ANATOMY", 97, 112], ["Sec24A KD cells", "CELL", 97, 112], ["Sec24A KD cells", "CELL_LINE", 97, 112], ["aggregation", "PROBLEM", 134, 145], ["difference", "OBSERVATION_MODIFIER", 11, 21], ["spherical SVPs", "OBSERVATION", 25, 39], ["L", "ANATOMY_MODIFIER", 78, 79], ["without any signs of", "UNCERTAINTY", 113, 133], ["aggregation", "OBSERVATION", 134, 145]]], ["Quite unexpectedly, in this setting, ERGIC-53 intensively colocalized with L, implicating that the lectin is seemingly entrapped by the L-specific CS structure if arrested in the ER.", [["ER", "ANATOMY", 179, 181], ["ERGIC-53", "CHEMICAL", 37, 45], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 37, 45], ["lectin", "GENE_OR_GENE_PRODUCT", 99, 105], ["ER", "GENE_OR_GENE_PRODUCT", 179, 181], ["lectin", "PROTEIN", 99, 105], ["ER", "PROTEIN", 179, 181], ["ERGIC", "TEST", 37, 42], ["entrapped", "OBSERVATION", 119, 128]]], ["Similar staining experiments were done in cells depleted for the related Sec24B isoform.", [["cells", "ANATOMY", 42, 47], ["cells", "CELL", 42, 47], ["Sec24B", "GENE_OR_GENE_PRODUCT", 73, 79], ["Sec24B isoform", "PROTEIN", 73, 87], ["Similar staining experiments", "PROBLEM", 0, 28], ["staining", "OBSERVATION", 8, 16]]], ["However, this intervention did not affect the typical juxtanuclear distribution of ERGIC-53 and, consequently, did not result in ERGIC-53/L colocalization ( Figure 4C ).", [["juxtanuclear", "ANATOMY", 54, 66], ["juxtanuclear", "CELLULAR_COMPONENT", 54, 66], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 83, 91], ["ERGIC", "PROTEIN", 83, 88], ["ERGIC", "PROTEIN", 129, 134], ["ERGIC", "TEST", 83, 88], ["ERGIC", "TEST", 129, 134]]], ["We infer from these results that ERGIC-53 may be a preferred cargo of Sec24A rather than of Sec24B.", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 33, 41], ["Sec24A", "GENE_OR_GENE_PRODUCT", 70, 76], ["Sec24B", "GENE_OR_GENE_PRODUCT", 92, 98], ["Sec24A", "PROTEIN", 70, 76], ["Sec24B", "PROTEIN", 92, 98], ["ERGIC", "TEST", 33, 38]]], ["If arrested in the ER, ERGIC-53 tightly associated with the HBV L envelope protein either by chance or for action.HBV Particle Egress Requires ERGIC-53, while HBV Spherical Subviral Particle Egress Does NotTo distinguish between these possibilities, we probed for a functional role of ERGIC-53 in HBV propagation.", [["ER", "ANATOMY", 19, 21], ["ER", "GENE_OR_GENE_PRODUCT", 19, 21], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 23, 31], ["HBV", "ORGANISM", 114, 117], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 285, 293], ["HBV", "ORGANISM", 297, 300], ["ER", "PROTEIN", 19, 21], ["ERGIC", "PROTEIN", 23, 28], ["HBV L envelope protein", "PROTEIN", 60, 82], ["ERGIC", "PROTEIN", 285, 290], ["HBV", "SPECIES", 60, 63], ["HBV", "SPECIES", 114, 117], ["HBV", "SPECIES", 159, 162], ["HBV", "SPECIES", 297, 300], ["ERGIC", "TEST", 23, 28], ["the HBV L envelope protein", "TREATMENT", 56, 82], ["HBV Particle Egress", "TREATMENT", 114, 133], ["ERGIC", "TEST", 143, 148], ["HBV Spherical Subviral Particle Egress", "TREATMENT", 159, 197], ["ERGIC", "TEST", 285, 290], ["HBV propagation", "TREATMENT", 297, 312], ["Subviral Particle", "OBSERVATION", 173, 190]]], ["HuH-7 cells were treated with control RNA duplexes or a single ERGIC-53-specific siRNA prior to transfection with the HBV replicon (pHBV replicon and subjected to the virion production assay (n = 3, \u00b1 SD) exactly as described above.", [["HuH-7 cells", "ANATOMY", 0, 11], ["HuH-7 cells", "CELL", 0, 11], ["HBV", "ORGANISM", 118, 121], ["pHBV replicon", "ORGANISM", 132, 145], ["HuH-7 cells", "CELL_LINE", 0, 11], ["HBV replicon", "DNA", 118, 130], ["pHBV replicon", "DNA", 132, 145], ["HBV", "SPECIES", 118, 121], ["pHBV", "SPECIES", 132, 136], ["HuH", "TEST", 0, 3], ["control RNA duplexes", "TREATMENT", 30, 50], ["a single ERGIC", "TEST", 54, 68], ["transfection", "TREATMENT", 96, 108], ["the HBV replicon (pHBV replicon", "TREATMENT", 114, 145], ["the virion production assay", "TEST", 163, 190], ["7 cells", "OBSERVATION_MODIFIER", 4, 11]]], ["For a reference, a siCon treatment of cells was included.", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["a siCon treatment of cells", "TREATMENT", 17, 43]]], ["Lysates were probed by anti-EAP20 and anti-core (K46) immunoblotting.", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["anti-EAP20", "GENE_OR_GENE_PRODUCT", 23, 33], ["anti-EAP20", "PROTEIN", 23, 33], ["Lysates", "TEST", 0, 7], ["anti-core (K46) immunoblotting", "TREATMENT", 38, 68]]], ["The same lysates were mock-treated or treated with EndoH prior to anti-L (K1350) WB.", [["lysates", "ANATOMY", 9, 16], ["EndoH", "CHEMICAL", 51, 56], ["EndoH", "CHEMICAL", 51, 56], ["lysates", "ORGANISM_SUBSTANCE", 9, 16], ["EndoH", "SIMPLE_CHEMICAL", 51, 56], ["EndoH", "TREATMENT", 51, 56], ["anti-L (K1350)", "TREATMENT", 66, 80]]], ["The L-specific p39 and gp42 forms are indicated. ** p < 0.01 compared to control.DiscussionOne important outcome of this work was the finding that HBV not only uses the ER membrane as a platform for protein synthesis but additionally subverts the ER export machinery for viral propagation.", [["ER membrane", "ANATOMY", 169, 180], ["ER", "ANATOMY", 247, 249], ["p39", "GENE_OR_GENE_PRODUCT", 15, 18], ["gp42", "GENE_OR_GENE_PRODUCT", 23, 27], ["HBV", "ORGANISM", 147, 150], ["ER", "GENE_OR_GENE_PRODUCT", 169, 171], ["membrane", "CELLULAR_COMPONENT", 172, 180], ["ER", "GENE_OR_GENE_PRODUCT", 247, 249], ["L-specific p39 and gp42 forms", "PROTEIN", 4, 33], ["ER", "PROTEIN", 169, 171], ["ER", "PROTEIN", 247, 249], ["HBV", "SPECIES", 147, 150], ["The L-specific p39 and gp42 forms", "TEST", 0, 33], ["HBV", "PROBLEM", 147, 150], ["protein synthesis", "TREATMENT", 199, 216], ["viral propagation", "PROBLEM", 271, 288], ["viral propagation", "OBSERVATION", 271, 288]]], ["We herein identified ERGIC-53, a lectin-like cargo receptor within the early exocytic pathway, along with distinct COPII components as critical host factors guiding the egress of HBV viral particles.DiscussionUpon the infection of liver cells, HBV does not only produce enveloped progeny virions but, also, empty envelope subviral particles (SVPs) that are secreted in large excess compared to virions and are thought to neutralize the host immune response against infectious HBV [26, 27, 45] .", [["exocytic", "ANATOMY", 77, 85], ["COPII", "ANATOMY", 115, 120], ["liver cells", "ANATOMY", 231, 242], ["virions", "ANATOMY", 288, 295], ["virions", "ANATOMY", 394, 401], ["infection", "DISEASE", 218, 227], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 21, 29], ["lectin", "GENE_OR_GENE_PRODUCT", 33, 39], ["COPII", "GENE_OR_GENE_PRODUCT", 115, 120], ["HBV", "ORGANISM", 179, 182], ["liver cells", "CELL", 231, 242], ["HBV", "ORGANISM", 244, 247], ["empty envelope subviral particles", "GENE_OR_GENE_PRODUCT", 307, 340], ["SVPs", "GENE_OR_GENE_PRODUCT", 342, 346], ["infectious HBV", "ORGANISM", 465, 479], ["ERGIC", "PROTEIN", 21, 26], ["lectin-like cargo receptor", "PROTEIN", 33, 59], ["COPII components", "PROTEIN", 115, 131], ["liver cells", "CELL_TYPE", 231, 242], ["SVPs", "PROTEIN", 342, 346], ["HBV", "SPECIES", 179, 182], ["HBV", "SPECIES", 244, 247], ["HBV", "SPECIES", 476, 479], ["ERGIC", "TEST", 21, 26], ["distinct COPII components", "PROBLEM", 106, 131], ["critical host factors", "PROBLEM", 135, 156], ["HBV viral particles", "PROBLEM", 179, 198], ["the infection of liver cells", "PROBLEM", 214, 242], ["HBV", "PROBLEM", 244, 247], ["empty envelope subviral particles", "PROBLEM", 307, 340], ["large excess", "PROBLEM", 369, 381], ["infectious HBV", "PROBLEM", 465, 479], ["exocytic pathway", "OBSERVATION", 77, 93], ["distinct", "OBSERVATION_MODIFIER", 106, 114], ["COPII components", "OBSERVATION", 115, 131], ["HBV viral particles", "OBSERVATION", 179, 198], ["infection", "OBSERVATION", 218, 227], ["liver", "ANATOMY", 231, 236], ["progeny virions", "OBSERVATION", 280, 295], ["subviral particles", "OBSERVATION", 322, 340], ["large", "OBSERVATION_MODIFIER", 369, 374], ["excess", "OBSERVATION", 375, 381]]], ["By analyzing spherical SVP trafficking through the cell secretory pathway, we previously found that the pathogen usurps distinct components of the COPII vesicle-forming machinery for spherical SVP host cell exit [29] .", [["cell", "ANATOMY", 51, 55], ["COPII vesicle", "ANATOMY", 147, 160], ["cell", "ANATOMY", 202, 206], ["SVP", "GENE_OR_GENE_PRODUCT", 23, 26], ["cell", "CELL", 51, 55], ["COPII", "GENE_OR_GENE_PRODUCT", 147, 152], ["vesicle", "CELLULAR_COMPONENT", 153, 160], ["SVP", "PROTEIN", 23, 26], ["COPII", "PROTEIN", 147, 152], ["spherical SVP", "OBSERVATION", 13, 26], ["COPII vesicle", "OBSERVATION", 147, 160], ["spherical SVP", "OBSERVATION", 183, 196], ["host cell exit", "OBSERVATION", 197, 211]]], ["As there is evidence suggesting that the trafficking and export routes of HBV spherical subviral and viral particles may differ [21, 23] , we recapitulated COPII interference experiments in HBV-replicating HuH-7 liver cell cultures.", [["HuH-7 liver cell cultures", "ANATOMY", 206, 231], ["HBV spherical subviral", "ORGANISM", 74, 96], ["COPII", "GENE_OR_GENE_PRODUCT", 156, 161], ["HBV", "ORGANISM", 190, 193], ["HuH-7 liver cell cultures", "CELL", 206, 231], ["COPII", "PROTEIN", 156, 161], ["HuH-7 liver cell cultures", "CELL_LINE", 206, 231], ["HBV", "SPECIES", 74, 77], ["HBV", "SPECIES", 190, 193], ["the trafficking", "PROBLEM", 37, 52], ["HBV spherical subviral and viral particles", "PROBLEM", 74, 116], ["HBV", "TEST", 190, 193], ["HuH", "TEST", 206, 209], ["liver cell cultures", "TEST", 212, 231], ["evidence suggesting", "UNCERTAINTY", 12, 31], ["viral particles", "OBSERVATION", 101, 116], ["COPII interference", "OBSERVATION", 156, 174], ["liver", "ANATOMY", 212, 217]]], ["Thereby, we observed that HBV virion release exhibited the same COPII selectivity as SVP secretion, as it required a functioning Sar1 GTPase, along with the Sec24A and Sec23B isoforms.", [["HBV", "ORGANISM", 26, 29], ["COPII", "GENE_OR_GENE_PRODUCT", 64, 69], ["SVP", "GENE_OR_GENE_PRODUCT", 85, 88], ["Sar1", "GENE_OR_GENE_PRODUCT", 129, 133], ["Sec24A", "GENE_OR_GENE_PRODUCT", 157, 163], ["Sec23B", "GENE_OR_GENE_PRODUCT", 168, 174], ["COPII", "PROTEIN", 64, 69], ["SVP", "PROTEIN", 85, 88], ["Sar1 GTPase", "PROTEIN", 129, 140], ["Sec24A", "PROTEIN", 157, 163], ["Sec23B isoforms", "PROTEIN", 168, 183], ["HBV", "SPECIES", 26, 29], ["HBV virion release", "PROBLEM", 26, 44], ["a functioning Sar1 GTPase", "TREATMENT", 115, 140], ["the Sec24A and Sec23B isoforms", "TREATMENT", 153, 183], ["COPII selectivity", "OBSERVATION", 64, 81]]], ["Despite the massive overproduction of SVPs, efficient HBV secretion was shown to be maintained upon the mutational ablation of the concomitant SVP formation [52] .", [["SVPs", "GENE_OR_GENE_PRODUCT", 38, 42], ["HBV", "ORGANISM", 54, 57], ["SVP", "GENE_OR_GENE_PRODUCT", 143, 146], ["SVPs", "PROTEIN", 38, 42], ["SVP", "PROTEIN", 143, 146], ["HBV", "SPECIES", 54, 57], ["the massive overproduction of SVPs", "PROBLEM", 8, 42], ["efficient HBV secretion", "PROBLEM", 44, 67], ["the mutational ablation", "TREATMENT", 100, 123], ["massive", "OBSERVATION_MODIFIER", 12, 19], ["overproduction", "OBSERVATION", 20, 34]]], ["We thus infer that the viral envelope per se requires COPII-guided export mechanisms out of the ER.DiscussionSurprisingly, however, we failed to detect the HBV envelope beyond the ER, as it colocalized neither with ERGIC-nor Golgi-specific structures.", [["ER", "ANATOMY", 96, 98], ["ER", "ANATOMY", 180, 182], ["COPII", "GENE_OR_GENE_PRODUCT", 54, 59], ["ER", "GENE_OR_GENE_PRODUCT", 96, 98], ["HBV", "ORGANISM", 156, 159], ["ER", "GENE_OR_GENE_PRODUCT", 180, 182], ["ERGIC", "GENE_OR_GENE_PRODUCT", 215, 220], ["COPII", "PROTEIN", 54, 59], ["ER", "PROTEIN", 96, 98], ["ER", "PROTEIN", 180, 182], ["ERGIC", "PROTEIN", 215, 220], ["HBV", "SPECIES", 156, 159], ["the viral envelope", "PROBLEM", 19, 37], ["the HBV envelope", "PROBLEM", 152, 168]]], ["Rather, the envelope accumulated in perinuclear ER regions in the form of a confined, crescent-shaped structure (CS).", [["perinuclear ER", "ANATOMY", 36, 50], ["perinuclear", "CELLULAR_COMPONENT", 36, 47], ["ER", "GENE_OR_GENE_PRODUCT", 48, 50], ["perinuclear ER regions", "PROTEIN", 36, 58], ["a confined, crescent-shaped structure", "PROBLEM", 74, 111], ["envelope", "OBSERVATION_MODIFIER", 12, 20], ["accumulated", "OBSERVATION", 21, 32], ["perinuclear", "OBSERVATION_MODIFIER", 36, 47], ["confined", "OBSERVATION_MODIFIER", 76, 84], ["crescent", "OBSERVATION_MODIFIER", 86, 94], ["shaped", "OBSERVATION_MODIFIER", 95, 101], ["structure", "OBSERVATION_MODIFIER", 102, 111]]], ["Since this structure was preserved even while interfering with the ER exit, provoked by Sec24A silencing or BFA treatment, the HBV envelope appears to be blocked in a pre-ERGIC compartment for much of its time in the cell.", [["cell", "ANATOMY", 217, 221], ["BFA", "CHEMICAL", 108, 111], ["BFA", "CHEMICAL", 108, 111], ["ER", "GENE_OR_GENE_PRODUCT", 67, 69], ["Sec24A", "GENE_OR_GENE_PRODUCT", 88, 94], ["BFA", "SIMPLE_CHEMICAL", 108, 111], ["HBV", "ORGANISM", 127, 130], ["cell", "CELL", 217, 221], ["ER", "PROTEIN", 67, 69], ["Sec24A", "PROTEIN", 88, 94], ["HBV", "SPECIES", 127, 130], ["Sec24A silencing", "TREATMENT", 88, 104], ["BFA treatment", "TREATMENT", 108, 121], ["the HBV envelope", "PROBLEM", 123, 139], ["preserved", "OBSERVATION", 25, 34]]], ["In contrast, the HBV subviral envelope has been shown to be transported out of the ER to the ERGIC where SVP assembly takes place.", [["ER", "ANATOMY", 83, 85], ["HBV", "ORGANISM", 17, 20], ["ER", "GENE_OR_GENE_PRODUCT", 83, 85], ["ERGIC", "GENE_OR_GENE_PRODUCT", 93, 98], ["SVP", "GENE_OR_GENE_PRODUCT", 105, 108], ["ER", "PROTEIN", 83, 85], ["ERGIC", "DNA", 93, 98], ["SVP", "PROTEIN", 105, 108], ["HBV", "SPECIES", 17, 20], ["the HBV subviral envelope", "PROBLEM", 13, 38]]], ["Hence, although both envelope types are dependent on COPII-guided transport events, the underlying mechanisms may not be thoroughly identical.DiscussionIn search for possible differences, we herein discovered the cellular ERGIC-53 lectin to be crucial for HBV viral particle release but dispensable for HBV spherical SVP secretion.", [["cellular", "ANATOMY", 213, 221], ["COPII", "GENE_OR_GENE_PRODUCT", 53, 58], ["cellular", "CELL", 213, 221], ["lectin", "GENE_OR_GENE_PRODUCT", 231, 237], ["HBV", "ORGANISM", 256, 259], ["HBV", "ORGANISM", 303, 306], ["SVP", "GENE_OR_GENE_PRODUCT", 317, 320], ["COPII", "PROTEIN", 53, 58], ["cellular ERGIC-53 lectin", "PROTEIN", 213, 237], ["HBV", "SPECIES", 256, 259], ["HBV", "SPECIES", 303, 306], ["the cellular ERGIC", "TEST", 209, 227], ["HBV viral particle release", "PROBLEM", 256, 282], ["HBV spherical SVP secretion", "PROBLEM", 303, 330], ["may not be", "UNCERTAINTY", 110, 120], ["SVP secretion", "OBSERVATION", 317, 330]]], ["ERGIC-53 is an ER export receptor for a limited number of glycoproteins and cycles between the ER, the ERGIC and the cis-Golgi through COPII and COPI-dependent pathways [42, 49, 50, 53] .", [["cis-Golgi", "ANATOMY", 117, 126], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 0, 8], ["ER", "GENE_OR_GENE_PRODUCT", 15, 17], ["ER", "GENE_OR_GENE_PRODUCT", 95, 97], ["ERGIC", "GENE_OR_GENE_PRODUCT", 103, 108], ["cis-Golgi", "CELLULAR_COMPONENT", 117, 126], ["COPII", "GENE_OR_GENE_PRODUCT", 135, 140], ["COPI", "GENE_OR_GENE_PRODUCT", 145, 149], ["ERGIC", "PROTEIN", 0, 5], ["ER", "PROTEIN", 15, 17], ["glycoproteins", "PROTEIN", 58, 71], ["ER", "PROTEIN", 95, 97], ["ERGIC", "PROTEIN", 103, 108], ["cis-Golgi", "PROTEIN", 117, 126], ["COPII", "PROTEIN", 135, 140], ["COPI", "PROTEIN", 145, 149]]], ["Its cytosolic tail contains an ER exit motif that binds to Sec24, the COPII cargo adaptor for anterograde transport, while an adjacent motif interacts with COPI to mediate the retrograde transport [50] .", [["cytosolic tail", "ANATOMY", 4, 18], ["COPI", "ANATOMY", 156, 160], ["cytosolic tail", "CELLULAR_COMPONENT", 4, 18], ["ER", "GENE_OR_GENE_PRODUCT", 31, 33], ["Sec24", "GENE_OR_GENE_PRODUCT", 59, 64], ["COPII", "GENE_OR_GENE_PRODUCT", 70, 75], ["COPI", "GENE_OR_GENE_PRODUCT", 156, 160], ["cytosolic tail", "PROTEIN", 4, 18], ["ER exit motif", "PROTEIN", 31, 44], ["Sec24", "PROTEIN", 59, 64], ["COPII cargo adaptor", "PROTEIN", 70, 89], ["COPI", "PROTEIN", 156, 160], ["anterograde transport", "TREATMENT", 94, 115], ["COPI", "TREATMENT", 156, 160], ["cytosolic tail", "OBSERVATION", 4, 18]]], ["In-line with this, our IF studies showed that the trafficking of ERGIC-53, i.e., its export out of the ER was impaired upon the silencing of Sec24A.", [["ER", "ANATOMY", 103, 105], ["ERGIC-53", "CHEMICAL", 65, 73], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 65, 73], ["ER", "GENE_OR_GENE_PRODUCT", 103, 105], ["Sec24A", "GENE_OR_GENE_PRODUCT", 141, 147], ["ERGIC", "PROTEIN", 65, 70], ["ER", "PROTEIN", 103, 105], ["Sec24A", "PROTEIN", 141, 147], ["our IF studies", "TEST", 19, 33], ["ERGIC", "TEST", 65, 70], ["line", "OBSERVATION", 3, 7]]], ["Mammalian cells contain four Sec24 isoforms that can be structurally and functionally divided into two subclasses, Sec24A/B and Sec24C/D. Interestingly, we found that the closely related Sec24B isoform failed to compensate for the loss of Sec24A and did not interfere with proper ERGIC-53 trafficking.", [["cells", "ANATOMY", 10, 15], ["Mammalian cells", "CELL", 0, 15], ["Sec24", "GENE_OR_GENE_PRODUCT", 29, 34], ["Sec24A", "GENE_OR_GENE_PRODUCT", 115, 121], ["B", "GENE_OR_GENE_PRODUCT", 122, 123], ["Sec24C/D", "GENE_OR_GENE_PRODUCT", 128, 136], ["Sec24B", "GENE_OR_GENE_PRODUCT", 187, 193], ["Sec24A", "GENE_OR_GENE_PRODUCT", 239, 245], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 280, 288], ["Mammalian cells", "CELL_TYPE", 0, 15], ["Sec24 isoforms", "PROTEIN", 29, 43], ["Sec24A", "PROTEIN", 115, 121], ["B", "PROTEIN", 122, 123], ["Sec24C", "PROTEIN", 128, 134], ["D", "PROTEIN", 135, 136], ["Sec24B isoform", "PROTEIN", 187, 201], ["Sec24A", "PROTEIN", 239, 245], ["ERGIC", "PROTEIN", 280, 285], ["Mammalian cells", "TREATMENT", 0, 15], ["the loss of Sec24A", "PROBLEM", 227, 245]]], ["Consistent with this, previous in vitro COPII budding assays and peptide-binding analyses revealed that all four Sec24 isoforms can, in principle, recognize ERGIC-53, though Sec24A turned out to be the most important isoform guiding the anterograde trafficking of the lectin [46, 54] .", [["COPII", "GENE_OR_GENE_PRODUCT", 40, 45], ["Sec24", "GENE_OR_GENE_PRODUCT", 113, 118], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 157, 165], ["Sec24A", "GENE_OR_GENE_PRODUCT", 174, 180], ["lectin", "GENE_OR_GENE_PRODUCT", 268, 274], ["COPII", "PROTEIN", 40, 45], ["Sec24 isoforms", "PROTEIN", 113, 127], ["ERGIC", "PROTEIN", 157, 162], ["Sec24A", "PROTEIN", 174, 180], ["lectin", "PROTEIN", 268, 274], ["vitro COPII budding assays", "TEST", 34, 60], ["peptide-binding analyses", "TEST", 65, 89], ["ERGIC", "TEST", 157, 162]]], ["Together, our results implicate that both the HBV envelope and cellular ERGIC-53 are selective clients of the Sec24A isoform.DiscussionOur observation that ER-trapped ERGIC-53 intensively colocalized with the HBV envelope provided a starting point for functional studies.", [["cellular", "ANATOMY", 63, 71], ["ERGIC-53", "CHEMICAL", 167, 175], ["HBV", "ORGANISM", 46, 49], ["cellular", "CELL", 63, 71], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 72, 80], ["Sec24A", "GENE_OR_GENE_PRODUCT", 110, 116], ["ER", "GENE_OR_GENE_PRODUCT", 156, 158], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 167, 175], ["HBV", "ORGANISM", 209, 212], ["ERGIC", "PROTEIN", 72, 77], ["Sec24A isoform", "PROTEIN", 110, 124], ["ER", "PROTEIN", 156, 158], ["ERGIC", "PROTEIN", 167, 172], ["HBV", "SPECIES", 46, 49], ["HBV", "SPECIES", 209, 212], ["the HBV envelope", "TEST", 42, 58], ["cellular ERGIC", "TEST", 63, 77], ["ERGIC", "TEST", 167, 172], ["the HBV envelope", "PROBLEM", 205, 221], ["functional studies", "TEST", 252, 270]]], ["The RNAi-mediated silencing of ERGIC-53 profoundly inhibited HBV egress without affecting the proper envelope protein synthesis, viral replication and nucleocapsid formation.", [["ERGIC-53", "CHEMICAL", 31, 39], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 31, 39], ["HBV", "ORGANISM", 61, 64], ["nucleocapsid", "CELLULAR_COMPONENT", 151, 163], ["ERGIC-53", "DNA", 31, 39], ["HBV", "SPECIES", 61, 64], ["The RNAi", "TEST", 0, 8], ["ERGIC", "TEST", 31, 36], ["HBV egress", "PROBLEM", 61, 71], ["the proper envelope protein synthesis", "TREATMENT", 90, 127], ["viral replication", "TREATMENT", 129, 146], ["nucleocapsid formation", "PROBLEM", 151, 173], ["HBV", "OBSERVATION", 61, 64], ["viral replication", "OBSERVATION", 129, 146], ["nucleocapsid formation", "OBSERVATION", 151, 173]]], ["Our finding that even the envelopment of viral nucleocapsids were not compromised in ERGIC-53-silenced cells strongly points to a role of the lectin in HBV trafficking rather than assembly.", [["cells", "ANATOMY", 103, 108], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 85, 93], ["cells", "CELL", 103, 108], ["lectin", "GENE_OR_GENE_PRODUCT", 142, 148], ["HBV", "ORGANISM", 152, 155], ["ERGIC-53-silenced cells", "CELL_LINE", 85, 108], ["lectin", "PROTEIN", 142, 148], ["HBV", "SPECIES", 152, 155], ["viral nucleocapsids", "PROBLEM", 41, 60], ["ERGIC", "TEST", 85, 90], ["viral nucleocapsids", "OBSERVATION", 41, 60], ["HBV", "OBSERVATION", 152, 155]]], ["To do so, ERGIC-53 associates with the viral L glycoprotein, as evidenced by CO-IF and CO-IP studies.", [["ERGIC-53", "CHEMICAL", 10, 18], ["CO", "CHEMICAL", 77, 79], ["CO", "CHEMICAL", 87, 89], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 10, 18], ["viral L glycoprotein", "GENE_OR_GENE_PRODUCT", 39, 59], ["CO-IF", "GENE_OR_GENE_PRODUCT", 77, 82], ["CO-IP", "SIMPLE_CHEMICAL", 87, 92], ["ERGIC", "PROTEIN", 10, 15], ["viral L glycoprotein", "PROTEIN", 39, 59], ["ERGIC", "TEST", 10, 15], ["the viral L glycoprotein", "PROBLEM", 35, 59], ["CO", "TEST", 77, 79], ["CO-IP studies", "TEST", 87, 100]]], ["Conversely, the trafficking and secretion of HBV spherical SVP release did not require ERGIC-53.", [["ERGIC-53", "CHEMICAL", 87, 95], ["HBV", "ORGANISM", 45, 48], ["SVP", "GENE_OR_GENE_PRODUCT", 59, 62], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 87, 95], ["ERGIC", "PROTEIN", 87, 92], ["HBV", "SPECIES", 45, 48], ["HBV spherical SVP release", "PROBLEM", 45, 70], ["ERGIC", "TEST", 87, 92]]], ["Amongst others, the HBV viral and subviral envelopes differ in their needs of N-glycans added to the N146 acceptor site.", [["N146", "CHEMICAL", 101, 105], ["HBV viral", "ORGANISM", 20, 29], ["N-glycans", "GENE_OR_GENE_PRODUCT", 78, 87], ["N146 acceptor site", "DNA", 101, 119], ["HBV", "SPECIES", 20, 23], ["the HBV viral", "PROBLEM", 16, 29], ["subviral envelopes", "TREATMENT", 34, 52], ["N-glycans", "TREATMENT", 78, 87], ["the N146 acceptor site", "TREATMENT", 97, 119]]], ["Several studies have shown that an inhibition of N-glycosylation evoked by either the mutational inactivation of N146 or pharmaceutical interventions blocked the virion release, which we confirmed herein.", [["N146", "CHEMICAL", 113, 117], ["N", "CHEMICAL", 49, 50], ["N146", "SIMPLE_CHEMICAL", 113, 117], ["Several studies", "TEST", 0, 15], ["N-glycosylation", "TREATMENT", 49, 64], ["pharmaceutical interventions", "TREATMENT", 121, 149], ["the virion release", "TREATMENT", 158, 176]]], ["Under the same conditions, the spherical SVP secretion preceded normally [11, 13, 14] .", [["SVP", "GENE_OR_GENE_PRODUCT", 41, 44], ["the spherical SVP secretion", "TEST", 27, 54], ["spherical", "OBSERVATION_MODIFIER", 31, 40], ["SVP", "OBSERVATION_MODIFIER", 41, 44], ["secretion", "OBSERVATION", 45, 54]]], ["The apparent correlation between N-glycan and ERGIC-53 requirements and vice versa implicate that the viral, but not the subviral, envelope is a client of the lectin.", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 46, 54], ["lectin", "GENE_OR_GENE_PRODUCT", 159, 165], ["ERGIC", "PROTEIN", 46, 51], ["lectin", "PROTEIN", 159, 165], ["N-glycan", "TREATMENT", 33, 41], ["ERGIC-53 requirements", "TREATMENT", 46, 67], ["the viral", "PROBLEM", 98, 107], ["viral", "OBSERVATION", 102, 107]]], ["ERGIC-53 may thus serve as a pivotal device to segregate the maturation pathways of the HBV viral and subviral particles.DiscussionAlthough mammalian cells contain vast amounts of glycoproteins, only a subset of polypeptides are trafficked in an ERGIC-53-dependent manner.", [["cells", "ANATOMY", 150, 155], ["ERGIC-53", "CHEMICAL", 0, 8], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 0, 8], ["HBV", "ORGANISM", 88, 91], ["mammalian cells", "CELL", 140, 155], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 246, 254], ["mammalian cells", "CELL_TYPE", 140, 155], ["glycoproteins", "PROTEIN", 180, 193], ["HBV", "SPECIES", 88, 91], ["ERGIC", "TEST", 0, 5], ["a pivotal device", "TREATMENT", 27, 43], ["the HBV viral and subviral particles", "PROBLEM", 84, 120], ["mammalian cells", "PROBLEM", 140, 155], ["vast amounts of glycoproteins", "PROBLEM", 164, 193], ["a subset of polypeptides", "TREATMENT", 200, 224], ["HBV", "ANATOMY", 88, 91], ["subviral particles", "OBSERVATION", 102, 120], ["mammalian cells", "OBSERVATION", 140, 155], ["vast", "OBSERVATION_MODIFIER", 164, 168], ["amounts", "OBSERVATION_MODIFIER", 169, 176]]], ["These include mostly soluble glycoproteins, like blood clotting factor V (FV) and factor VIII (FVIII), cathepsin C, cathepsin Z, \u03b11-antitrypsin and matrix metalloproteinase-9 [37, [55] [56] [57] .", [["blood", "ANATOMY", 49, 54], ["blood clotting factor V", "GENE_OR_GENE_PRODUCT", 49, 72], ["FV", "GENE_OR_GENE_PRODUCT", 74, 76], ["factor VIII", "GENE_OR_GENE_PRODUCT", 82, 93], ["FVIII", "GENE_OR_GENE_PRODUCT", 95, 100], ["cathepsin C", "GENE_OR_GENE_PRODUCT", 103, 114], ["cathepsin Z", "GENE_OR_GENE_PRODUCT", 116, 127], ["\u03b11-antitrypsin", "GENE_OR_GENE_PRODUCT", 129, 143], ["matrix metalloproteinase-9", "GENE_OR_GENE_PRODUCT", 148, 174], ["soluble glycoproteins", "PROTEIN", 21, 42], ["blood clotting factor V", "PROTEIN", 49, 72], ["FV", "PROTEIN", 74, 76], ["factor VIII", "PROTEIN", 82, 93], ["FVIII", "PROTEIN", 95, 100], ["cathepsin C", "PROTEIN", 103, 114], ["cathepsin Z", "PROTEIN", 116, 127], ["\u03b11", "PROTEIN", 129, 131], ["antitrypsin", "PROTEIN", 132, 143], ["matrix metalloproteinase-9", "PROTEIN", 148, 174], ["mostly soluble glycoproteins", "PROBLEM", 14, 42], ["blood clotting factor V", "TEST", 49, 72], ["factor VIII (FVIII", "TEST", 82, 100], ["cathepsin C", "TEST", 103, 114], ["cathepsin Z", "TEST", 116, 127], ["matrix metalloproteinase", "TEST", 148, 172]]], ["Its restricted clientele may explain why the loss of ERGIC-53 function is well-tolerated both in vitro and in vivo [55, 58, 59] .", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 53, 61], ["ERGIC", "PROTEIN", 53, 58], ["the loss of ERGIC", "PROBLEM", 41, 58]]], ["Merely, mutations in ERGIC-53 lead to the genetic bleeding disorder-combined deficiency of FV and FVIII, a rare autosomal recessive disease [58] .", [["bleeding disorder", "DISEASE", 50, 67], ["autosomal recessive disease", "DISEASE", 112, 139], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 21, 29], ["FV", "GENE_OR_GENE_PRODUCT", 91, 93], ["FVIII", "GENE_OR_GENE_PRODUCT", 98, 103], ["ERGIC-53", "DNA", 21, 29], ["FV", "PROTEIN", 91, 93], ["FVIII", "PROTEIN", 98, 103], ["ERGIC", "TEST", 21, 26], ["the genetic bleeding disorder", "PROBLEM", 38, 67], ["combined deficiency of FV and FVIII", "PROBLEM", 68, 103], ["a rare autosomal recessive disease", "PROBLEM", 105, 139], ["FVIII", "ANATOMY", 98, 103], ["autosomal", "OBSERVATION_MODIFIER", 112, 121], ["recessive disease", "OBSERVATION", 122, 139]]], ["To account for the amazing small number of cargoes, interaction analyses revealed that ERGIC-53 often recognizes a combined oligosaccharide/peptide structure that may limit its repertoire of cargoes [60] [61] [62] .", [["ERGIC-53", "CHEMICAL", 87, 95], ["ERGIC-53", "CHEMICAL", 87, 95], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 87, 95], ["ERGIC", "PROTEIN", 87, 92], ["interaction analyses", "TEST", 52, 72], ["ERGIC", "TEST", 87, 92], ["a combined oligosaccharide/peptide structure", "TREATMENT", 113, 157]]], ["For example, its interaction with cathepsin Z is mediated by a \u03b2-hairpin loop next to the N-linked carbohydrate [59] .", [["N", "CHEMICAL", 90, 91], ["carbohydrate", "CHEMICAL", 99, 111], ["cathepsin Z", "GENE_OR_GENE_PRODUCT", 34, 45], ["cathepsin Z", "PROTEIN", 34, 45], ["\u03b2-hairpin loop", "PROTEIN", 63, 77], ["cathepsin Z", "TREATMENT", 34, 45], ["a \u03b2-hairpin loop", "TREATMENT", 61, 77]]], ["A carbohydrate-plus conformation-dependent recognition by ERGIC-53 may likewise apply to the HBV envelope types.", [["ERGIC-53", "CHEMICAL", 58, 66], ["carbohydrate", "CHEMICAL", 2, 14], ["ERGIC-53", "SIMPLE_CHEMICAL", 58, 66], ["HBV", "ORGANISM", 93, 96], ["ERGIC", "PROTEIN", 58, 63], ["HBV", "SPECIES", 93, 96], ["A carbohydrate", "TREATMENT", 0, 14]]], ["Despite sharing the same primary sequences, the configuration of the L-specific S domain within the viral envelope may differ from the S protein within the subviral envelope.", [["L-specific S domain", "PROTEIN", 69, 88], ["S protein", "PROTEIN", 135, 144], ["the L-specific S domain", "PROBLEM", 65, 88], ["the viral envelope", "PROBLEM", 96, 114], ["the S protein", "TEST", 131, 144], ["viral envelope", "OBSERVATION", 100, 114], ["subviral envelope", "OBSERVATION", 156, 173]]], ["In favor of this view, L is known to exhibit a dual transmembrane topology [10, 63] that may affect the signature recognized by ERGIC-53.", [["transmembrane", "ANATOMY", 52, 65], ["ERGIC-53", "CHEMICAL", 128, 136], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 128, 136], ["ERGIC", "PROTEIN", 128, 133], ["this view", "TEST", 12, 21], ["a dual transmembrane topology", "TEST", 45, 74], ["ERGIC", "TEST", 128, 133]]], ["Even so, based on the results obtained with the N-glycosylation-defective HBV envelope mutant, the glycan code dominates the protein code.DiscussionThus far, there is one other report demonstrating a direct exploitation of ERGIC-53 by viruses [39] .", [["ERGIC-53", "CHEMICAL", 223, 231], ["N", "CHEMICAL", 48, 49], ["HBV", "ORGANISM", 74, 77], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 223, 231], ["HBV envelope mutant", "PROTEIN", 74, 93], ["protein code", "PROTEIN", 125, 137], ["HBV", "SPECIES", 74, 77], ["the N-glycosylation-defective HBV envelope mutant", "TREATMENT", 44, 93], ["ERGIC", "TEST", 223, 228]]], ["Several highly pathogenic RNA viruses, including arenavirus, coronavirus and filovirus, have been shown to take over ERGIC-53 for propagation.", [["arenavirus, coronavirus and filovirus", "DISEASE", 49, 86], ["coronavirus", "ORGANISM", 61, 72], ["arenavirus, coronavirus", "SPECIES", 49, 72], ["Several highly pathogenic RNA viruses", "PROBLEM", 0, 37], ["arenavirus", "PROBLEM", 49, 59], ["coronavirus", "PROBLEM", 61, 72], ["filovirus", "PROBLEM", 77, 86], ["ERGIC", "TEST", 117, 122], ["highly", "OBSERVATION_MODIFIER", 8, 14], ["pathogenic RNA viruses", "OBSERVATION", 15, 37]]], ["Similar to HBV, the envelope glycoproteins of these viruses associate with ERGIC-53 in a productive manner [39] .", [["ERGIC-53", "CHEMICAL", 75, 83], ["HBV", "ORGANISM", 11, 14], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 75, 83], ["envelope glycoproteins", "PROTEIN", 20, 42], ["ERGIC", "PROTEIN", 75, 80], ["HBV", "SPECIES", 11, 14], ["HBV", "PROBLEM", 11, 14], ["the envelope glycoproteins", "TREATMENT", 16, 42], ["these viruses", "PROBLEM", 46, 59], ["ERGIC", "TEST", 75, 80], ["HBV", "OBSERVATION", 11, 14]]], ["However, dissimilar to HBV, loss of the ERGIC-53 function did not compromise arenavirus glycoprotein trafficking or particle release but impaired viral infectiousness.", [["impaired viral infectiousness", "DISEASE", 137, 166], ["HBV", "ORGANISM", 23, 26], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 40, 48], ["arenavirus", "ORGANISM", 77, 87], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 88, 100], ["ERGIC", "PROTEIN", 40, 45], ["arenavirus glycoprotein", "PROTEIN", 77, 100], ["HBV", "SPECIES", 23, 26], ["HBV", "PROBLEM", 23, 26], ["the ERGIC", "TEST", 36, 45], ["arenavirus glycoprotein trafficking", "TREATMENT", 77, 112], ["impaired viral infectiousness", "PROBLEM", 137, 166], ["HBV", "OBSERVATION", 23, 26], ["impaired", "OBSERVATION_MODIFIER", 137, 145], ["viral infectiousness", "OBSERVATION", 146, 166]]], ["As an underlying mechanism, virus-induced changes in ERGIC-53 trafficking were identified, resulting in an ERGIC-53 appearance at the plasma membrane where the budding arenavirus incorporated the lectin for an improvement of infectivity [39] .DiscussionSuch alterations in ERGIC-53 trafficking could not be detected in HBV-replicating cells unless the ER export was blocked.", [["plasma membrane", "ANATOMY", 134, 149], ["cells", "ANATOMY", 335, 340], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 53, 61], ["plasma membrane", "CELLULAR_COMPONENT", 134, 149], ["lectin", "GENE_OR_GENE_PRODUCT", 196, 202], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 273, 281], ["HBV", "ORGANISM", 319, 322], ["cells", "CELL", 335, 340], ["ER", "GENE_OR_GENE_PRODUCT", 352, 354], ["ERGIC", "PROTEIN", 53, 58], ["lectin", "PROTEIN", 196, 202], ["ERGIC", "PROTEIN", 273, 278], ["HBV-replicating cells", "CELL_TYPE", 319, 340], ["ER", "PROTEIN", 352, 354], ["HBV", "SPECIES", 319, 322], ["virus", "PROBLEM", 28, 33], ["ERGIC", "TEST", 53, 58], ["an ERGIC", "TEST", 104, 112], ["the budding arenavirus", "PROBLEM", 156, 178], ["infectivity", "PROBLEM", 225, 236], ["HBV", "PROBLEM", 319, 322], ["plasma membrane", "OBSERVATION", 134, 149], ["budding arenavirus", "OBSERVATION", 160, 178], ["improvement", "OBSERVATION_MODIFIER", 210, 221]]], ["Moreover, we were unable to verify a colocalization between ERGIC-53 and the viral envelope under natural settings, which was unanticipated given its pro-viral role in HBV propagation.", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 60, 68], ["HBV", "ORGANISM", 168, 171], ["ERGIC", "PROTEIN", 60, 65], ["HBV", "SPECIES", 168, 171], ["ERGIC", "TEST", 60, 65], ["HBV propagation", "TREATMENT", 168, 183], ["HBV propagation", "OBSERVATION", 168, 183]]], ["ERGIC-53 is known to capture its cargoes in a pH-and Ca 2+ -dependent manner at the ER and releases them in the ERGIC, where the lower pH and Ca 2+ concentrations diminish its affinity for glycoproteins [50, 53] .", [["ERGIC-53", "CHEMICAL", 0, 8], ["Ca", "CHEMICAL", 53, 55], ["Ca", "CHEMICAL", 142, 144], ["ERGIC-53", "CHEMICAL", 0, 8], ["Ca 2+", "CHEMICAL", 53, 58], ["Ca 2+", "CHEMICAL", 142, 147], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 0, 8], ["Ca 2+", "SIMPLE_CHEMICAL", 53, 58], ["ER", "GENE_OR_GENE_PRODUCT", 84, 86], ["Ca 2+", "SIMPLE_CHEMICAL", 142, 147], ["ER", "PROTEIN", 84, 86], ["ERGIC", "TEST", 0, 5], ["a pH", "TEST", 44, 48], ["Ca", "TEST", 53, 55], ["the lower pH", "TEST", 125, 137], ["Ca", "TEST", 142, 144], ["glycoproteins", "TEST", 189, 202]]], ["Hence, within the ERGIC, the HBV envelope may rapidly dissociate from ERGIC-53, thereby rendering their colocalization below the limit of detection.", [["ERGIC-53", "CHEMICAL", 70, 78], ["HBV", "ORGANISM", 29, 32], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 70, 78], ["ERGIC", "DNA", 18, 23], ["ERGIC", "PROTEIN", 70, 75], ["HBV", "SPECIES", 29, 32], ["the HBV envelope", "PROBLEM", 25, 41], ["ERGIC", "TEST", 70, 75]]], ["Similarly, we failed to detect HBV envelope structures within Golgi stacks, although the N-glycan pattern of the extracellular virions implicate a transit through this compartment.", [["Golgi stacks", "ANATOMY", 62, 74], ["extracellular virions", "ANATOMY", 113, 134], ["N", "CHEMICAL", 89, 90], ["Golgi stacks", "CELLULAR_COMPONENT", 62, 74], ["extracellular virions", "CELLULAR_COMPONENT", 113, 134], ["HBV", "SPECIES", 31, 34], ["HBV envelope structures", "PROBLEM", 31, 54], ["Golgi stacks", "TEST", 62, 74], ["the extracellular virions", "TREATMENT", 109, 134], ["HBV", "OBSERVATION", 31, 34], ["Golgi stacks", "OBSERVATION", 62, 74], ["extracellular virions", "OBSERVATION", 113, 134]]], ["One likely interpretation may be that HBV assembly and budding are inextricably linked and rate-limiting processes.", [["HBV", "ORGANISM", 38, 41], ["HBV", "SPECIES", 38, 41], ["HBV", "PROBLEM", 38, 41], ["likely interpretation may be", "UNCERTAINTY", 4, 32], ["HBV", "OBSERVATION", 38, 41]]], ["Once disseminated from the host membrane, HBV viral particles may be rapidly exported out of the cell.DiscussionThere is concordant evidence that HBV budding takes place at intracellular membranes rather than at the plasma membrane.", [["membrane", "ANATOMY", 32, 40], ["cell", "ANATOMY", 97, 101], ["intracellular membranes", "ANATOMY", 173, 196], ["plasma membrane", "ANATOMY", 216, 231], ["host membrane", "CELLULAR_COMPONENT", 27, 40], ["HBV", "ORGANISM", 42, 45], ["cell", "CELL", 97, 101], ["HBV", "ORGANISM", 146, 149], ["intracellular membranes", "CELLULAR_COMPONENT", 173, 196], ["plasma membrane", "CELLULAR_COMPONENT", 216, 231], ["HBV", "SPECIES", 42, 45], ["HBV", "SPECIES", 146, 149], ["the host membrane", "TREATMENT", 23, 40], ["HBV viral particles", "PROBLEM", 42, 61], ["HBV budding", "PROBLEM", 146, 157], ["disseminated", "OBSERVATION", 5, 17], ["host membrane", "OBSERVATION", 27, 40], ["viral particles", "OBSERVATION", 46, 61], ["HBV", "OBSERVATION", 146, 149], ["plasma membrane", "ANATOMY", 216, 231]]], ["In regard to our microscopy studies, the viral envelope accumulated in crescent-shaped ER-associated structures where it actively recruited the viral core/capsid.", [["ER", "ANATOMY", 87, 89], ["structures", "ANATOMY", 101, 111], ["ER", "GENE_OR_GENE_PRODUCT", 87, 89], ["ER", "PROTEIN", 87, 89], ["our microscopy studies", "TEST", 13, 35], ["the viral envelope", "PROBLEM", 37, 55], ["the viral core/capsid", "PROBLEM", 140, 161], ["crescent", "OBSERVATION_MODIFIER", 71, 79], ["shaped", "OBSERVATION_MODIFIER", 80, 86], ["viral", "OBSERVATION", 144, 149]]], ["This CS structure shares hallmarks of viral interaction platforms, as an envelopment-defective core mutant (C.K96A) failed to be attracted.", [["envelopment-defective core mutant", "PROTEIN", 73, 106], ["C.K96A", "PROTEIN", 108, 114], ["viral interaction platforms", "PROBLEM", 38, 65], ["defective core mutant", "PROBLEM", 85, 106], ["viral interaction", "OBSERVATION", 38, 55]]], ["Our results are in accord with recent confocal microscopy and CO-IP studies that demonstrated a lack of interaction between the HBV L protein and the C.K96A mutant [64] .", [["HBV L", "GENE_OR_GENE_PRODUCT", 128, 133], ["C.K96A", "GENE_OR_GENE_PRODUCT", 150, 156], ["HBV L protein", "PROTEIN", 128, 141], ["C.K96A", "PROTEIN", 150, 156], ["HBV", "SPECIES", 128, 131], ["recent confocal microscopy", "TEST", 31, 57], ["CO-IP studies", "TEST", 62, 75], ["the HBV L protein", "TEST", 124, 141]]], ["Nonetheless, the C.K96A mutant has been shown to warrant the formation and secretion of genome-free empty virions, another HBV particle type with relatively unknown functions [65] .", [["virions", "ANATOMY", 106, 113], ["C.K96A", "GENE_OR_GENE_PRODUCT", 17, 23], ["C.K96A mutant", "PROTEIN", 17, 30], ["free empty virions", "PROBLEM", 95, 113]]], ["Unlike complete virions, empty virion assembly requires only the S envelope protein and may thus proceed via distinct mechanisms and pathways.", [["virions", "ANATOMY", 16, 23], ["S envelope protein", "PROTEIN", 65, 83], ["virions", "OBSERVATION", 16, 23], ["empty virion", "OBSERVATION", 25, 37]]], ["Our observation that the characteristic recruitment of the viral core to the L-specific CS structure and even the formation of enveloped HBV-replicating nucleocapsids preserved upon the ER exit block led us to infer that HBV assembly initiates at the ER.", [["nucleocapsids", "ANATOMY", 153, 166], ["ER", "ANATOMY", 186, 188], ["ER", "ANATOMY", 251, 253], ["HBV", "ORGANISM", 137, 140], ["nucleocapsids", "CELLULAR_COMPONENT", 153, 166], ["ER", "GENE_OR_GENE_PRODUCT", 186, 188], ["HBV", "ORGANISM", 221, 224], ["ER", "GENE_OR_GENE_PRODUCT", 251, 253], ["ER", "PROTEIN", 186, 188], ["ER", "PROTEIN", 251, 253], ["HBV", "SPECIES", 221, 224], ["Our observation", "TEST", 0, 15], ["enveloped HBV", "PROBLEM", 127, 140], ["HBV", "PROBLEM", 221, 224], ["recruitment", "OBSERVATION_MODIFIER", 40, 51], ["enveloped", "OBSERVATION_MODIFIER", 127, 136], ["HBV", "OBSERVATION", 137, 140]]], ["Therefore, ERGIC-53 and the COPII coat proteins presumably come into play.", [["ERGIC-53", "GENE_OR_GENE_PRODUCT", 11, 19], ["COPII", "GENE_OR_GENE_PRODUCT", 28, 33], ["ERGIC", "PROTEIN", 11, 16], ["COPII coat proteins", "PROTEIN", 28, 47], ["ERGIC", "TEST", 11, 16], ["the COPII coat proteins", "TREATMENT", 24, 47]]], ["However, their temporal and spatial modes of action are yet ambiguous.", [["temporal", "OBSERVATION_MODIFIER", 15, 23]]], ["In particular, we still do not know whether Sec24A may act as a direct COPII adaptor for the viral envelope or as an indirect adaptor recognizing the envelope-associated ERGIC-53 cargo receptor.", [["COPII", "ANATOMY", 71, 76], ["Sec24A", "GENE_OR_GENE_PRODUCT", 44, 50], ["COPII", "GENE_OR_GENE_PRODUCT", 71, 76], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 170, 178], ["Sec24A", "PROTEIN", 44, 50], ["COPII adaptor", "PROTEIN", 71, 84], ["envelope-associated ERGIC-53 cargo receptor", "PROTEIN", 150, 193], ["a direct COPII adaptor", "TREATMENT", 62, 84], ["the viral envelope", "PROBLEM", 89, 107]]], ["A bipartite use of adaptors and receptors has been suggested to amplify the cargo capture into vesicles [66] .DiscussionIn regard to its ESCRT dependency and cell-imaging studies, HBV has been viewed as a MVB-budding virus [20] [21] [22] [23] [24] 67] .", [["vesicles", "ANATOMY", 95, 103], ["cell", "ANATOMY", 158, 162], ["MVB", "ANATOMY", 205, 208], ["vesicles", "CELLULAR_COMPONENT", 95, 103], ["cell", "CELL", 158, 162], ["HBV", "ORGANISM", 180, 183], ["MVB", "CELLULAR_COMPONENT", 205, 208], ["20] [21] [22] [23] [24] 67", "SIMPLE_CHEMICAL", 224, 250], ["adaptors", "PROTEIN", 19, 27], ["HBV", "SPECIES", 180, 183], ["adaptors", "TREATMENT", 19, 27], ["receptors", "TREATMENT", 32, 41], ["its ESCRT dependency", "PROBLEM", 133, 153], ["cell-imaging studies", "TEST", 158, 178], ["HBV", "PROBLEM", 180, 183], ["a MVB", "TEST", 203, 208], ["budding virus", "PROBLEM", 209, 222]]], ["However, the tracing of viral proteins or particles within the MVB/endosomal system does not mandatorily ascertain their use as viral exit portals.", [["MVB", "ANATOMY", 63, 66], ["endosomal system", "ANATOMY", 67, 83], ["MVB", "CELLULAR_COMPONENT", 63, 66], ["endosomal", "CELLULAR_COMPONENT", 67, 76], ["viral proteins", "PROTEIN", 24, 38], ["the tracing", "TEST", 9, 20], ["viral proteins", "PROBLEM", 24, 38], ["viral exit portals", "PROBLEM", 128, 146], ["endosomal system", "OBSERVATION", 67, 83]]], ["Rather, HBV progeny particles and proteins have been shown to be destructed within the endo-lysosomal system [68] [69] [70] .", [["HBV", "ORGANISM", 8, 11], ["HBV", "SPECIES", 8, 11], ["HBV progeny particles", "PROBLEM", 8, 29]]], ["Many viruses have been shown to hijack and recruit the ESCRT machinery to wrap membranes around new virus particles at their particular budding sites [25] .", [["membranes", "ANATOMY", 79, 88], ["ESCRT", "GENE_OR_GENE_PRODUCT", 55, 60], ["membranes", "CELLULAR_COMPONENT", 79, 88], ["Many viruses", "PROBLEM", 0, 12], ["wrap membranes", "TREATMENT", 74, 88], ["new virus particles", "PROBLEM", 96, 115], ["viruses", "OBSERVATION", 5, 12], ["wrap membranes", "OBSERVATION_MODIFIER", 74, 88], ["virus", "OBSERVATION", 100, 105]]], ["Consistent with this, we found that Vps4A, the terminal ATPase of the ESCRT machinery, was specifically recruited by the HBV-specific ER-associated CS structure.", [["Vps4A", "GENE_OR_GENE_PRODUCT", 36, 41], ["ATPase", "GENE_OR_GENE_PRODUCT", 56, 62], ["ESCRT", "GENE_OR_GENE_PRODUCT", 70, 75], ["ER", "GENE_OR_GENE_PRODUCT", 134, 136], ["Vps4A", "PROTEIN", 36, 41], ["terminal ATPase", "PROTEIN", 47, 62], ["ESCRT", "PROTEIN", 70, 75], ["ER", "PROTEIN", 134, 136], ["associated CS structure", "PROTEIN", 137, 160], ["HBV", "SPECIES", 121, 124], ["Vps4A", "TEST", 36, 41], ["the HBV", "TEST", 117, 124], ["terminal", "OBSERVATION_MODIFIER", 47, 55], ["ESCRT machinery", "OBSERVATION", 70, 85], ["HBV", "OBSERVATION", 121, 124]]], ["In addition, the functional inactivation of the ESCRT-II complex inhibited the HBV release prior to N-glycan processing occurring within the Golgi complex.", [["Golgi complex", "ANATOMY", 141, 154], ["ESCRT-II", "GENE_OR_GENE_PRODUCT", 48, 56], ["HBV", "ORGANISM", 79, 82], ["Golgi", "CELLULAR_COMPONENT", 141, 146], ["ESCRT-II complex", "PROTEIN", 48, 64], ["Golgi complex", "PROTEIN", 141, 154], ["HBV", "SPECIES", 79, 82], ["the HBV release", "PROBLEM", 75, 90], ["N-glycan processing", "TREATMENT", 100, 119], ["HBV", "OBSERVATION", 79, 82]]], ["While the precise itinerary of HBV out of the cell remains to be decoded, our results altogether implicate that ESCRT-driven HBV assembly and budding may occur at the ER.DiscussionThis study is the first to document an essential role of the cellular ERGIC-53 lectin in HBV's pathogenic life cycle.", [["cell", "ANATOMY", 46, 50], ["ER", "ANATOMY", 167, 169], ["cellular", "ANATOMY", 241, 249], ["HBV", "ORGANISM", 31, 34], ["cell", "CELL", 46, 50], ["ESCRT", "GENE_OR_GENE_PRODUCT", 112, 117], ["HBV", "ORGANISM", 125, 128], ["ER", "GENE_OR_GENE_PRODUCT", 167, 169], ["cellular", "CELL", 241, 249], ["ERGIC-53 lectin", "GENE_OR_GENE_PRODUCT", 250, 265], ["HBV", "ORGANISM", 269, 272], ["ESCRT", "PROTEIN", 112, 117], ["ER", "PROTEIN", 167, 169], ["cellular ERGIC-53 lectin", "PROTEIN", 241, 265], ["HBV", "SPECIES", 31, 34], ["HBV", "SPECIES", 125, 128], ["HBV", "SPECIES", 269, 272], ["ESCRT", "TEST", 112, 117], ["HBV", "PROBLEM", 125, 128], ["This study", "TEST", 180, 190], ["the cellular ERGIC", "TEST", 237, 255], ["HBV", "OBSERVATION", 31, 34]]], ["ERGIC-53 acts in teamwork with selective components of the COPII machinery, encompassing Sec24A, Sec23B and Sar1, to drive HBV ER export.", [["COPII", "ANATOMY", 59, 64], ["ERGIC-53", "CHEMICAL", 0, 8], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 0, 8], ["COPII", "GENE_OR_GENE_PRODUCT", 59, 64], ["Sec24A", "GENE_OR_GENE_PRODUCT", 89, 95], ["Sec23B", "GENE_OR_GENE_PRODUCT", 97, 103], ["Sar1", "GENE_OR_GENE_PRODUCT", 108, 112], ["HBV", "ORGANISM", 123, 126], ["ER", "GENE_OR_GENE_PRODUCT", 127, 129], ["COPII", "PROTEIN", 59, 64], ["Sec24A", "PROTEIN", 89, 95], ["Sec23B", "PROTEIN", 97, 103], ["Sar1", "PROTEIN", 108, 112], ["ER", "PROTEIN", 127, 129], ["HBV", "SPECIES", 123, 126]]], ["Viral SVP secretion bypasses the need of this trafficking factor, implicating that ERGIC-53 resembles a checkpoint for the spatiotemporal export pathway segregation of HBV viral and spherical subviral particles.", [["Viral", "ORGANISM", 0, 5], ["SVP", "GENE_OR_GENE_PRODUCT", 6, 9], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 83, 91], ["HBV viral", "ORGANISM", 168, 177], ["SVP", "PROTEIN", 6, 9], ["trafficking factor", "PROTEIN", 46, 64], ["ERGIC-53", "PROTEIN", 83, 91], ["HBV", "SPECIES", 168, 171], ["Viral SVP secretion bypasses", "PROBLEM", 0, 28], ["this trafficking factor", "PROBLEM", 41, 64], ["a checkpoint", "TREATMENT", 102, 114], ["HBV viral and spherical subviral particles", "PROBLEM", 168, 210], ["SVP", "OBSERVATION_MODIFIER", 6, 9], ["secretion bypasses", "OBSERVATION", 10, 28], ["spherical subviral particles", "OBSERVATION", 182, 210]]], ["The characterization of the HBV-ERGIC-53 interaction identifies a pathogen-derived N-glycan as a crucial but not exclusive ligand of the lectin.", [["N", "CHEMICAL", 83, 84], ["HBV", "ORGANISM", 28, 31], ["ERGIC-53", "ORGANISM", 32, 40], ["lectin", "GENE_OR_GENE_PRODUCT", 137, 143], ["lectin", "PROTEIN", 137, 143], ["HBV-ERGIC-53", "SPECIES", 28, 40], ["the HBV", "TEST", 24, 31], ["a pathogen", "PROBLEM", 64, 74], ["HBV", "OBSERVATION", 28, 31]]], ["The fact that the loss of ERGIC-53 or its function is well-tolerated in humans renders this protein as an attractive cellular target for therapeutic antiviral intervention.", [["cellular", "ANATOMY", 117, 125], ["ERGIC-53", "GENE_OR_GENE_PRODUCT", 26, 34], ["humans", "ORGANISM", 72, 78], ["cellular", "CELL", 117, 125], ["ERGIC", "PROTEIN", 26, 31], ["humans", "SPECIES", 72, 78], ["humans", "SPECIES", 72, 78], ["the loss of ERGIC", "PROBLEM", 14, 31], ["this protein", "PROBLEM", 87, 99], ["therapeutic antiviral intervention", "TREATMENT", 137, 171]]]], "PMC7149347": [["Core Quantitative and Qualitative Approaches Used in Pharmacy Practice Research ::: Introduction to Research Methodologies Used in Pharmacy PracticeTraditionally, core quantitative approaches used in pharmacy practice research include nonexperiments, quasi-experimental designs, and true experimental designs such as prospective randomized controlled intervention trials.", [["Research Methodologies", "TREATMENT", 100, 122], ["prospective randomized controlled intervention trials", "TREATMENT", 317, 370]]], ["Nonexperiments also include observational study designs that are often described as pharmacoepidemiologic study designs such as case\u2013control study, cohort study, nested case\u2013control study, and cross-sectional study (Etminan, 2004, Etminan and Samii, 2004).", [["observational study", "TEST", 28, 47], ["case\u2013control study", "TEST", 128, 146], ["cohort study", "TEST", 148, 160], ["nested case\u2013control study", "TEST", 162, 187], ["cross-sectional study", "TEST", 193, 214]]], ["These include the five qualitative approaches to inquiry: narrative research, phenomenology, grounded theory, ethnography, and case study.", [["case study", "TEST", 127, 137]]], ["Furthermore, there is an increasing importance on the appropriate selection and use of mixed method approach (Hadi et al., 2013; Hadi and Closs, 2016a, Hadi and Closs, 2016b), which are often designed and applied wrongly.", [["mixed method approach", "TREATMENT", 87, 108], ["increasing", "OBSERVATION_MODIFIER", 25, 35]]], ["Finally, it is worthwhile to be familiar with novel research methodologies such as discrete choice experiments, Delphi techniques, simulated client technique, and nominal group techniques, which fall between quantitative and qualitative approaches, often with no clear differentiation on where they belong.", [["nominal group techniques", "TREATMENT", 163, 187]]], ["Although called \u201cnovel\u201d in the context of this chapter, these methods are not new in other relevant disciplines, but new and not commonly used in pharmacy practice research.Research Question and Selection of Study Design ::: Introduction to Research Methodologies Used in Pharmacy PracticePharmacy practice researchers begin by conception of a research idea or identifying a research question and defining a hypothesis based on the question.", [["Research Methodologies", "TREATMENT", 241, 263], ["a hypothesis", "PROBLEM", 406, 418]]], ["The researcher then selects a study design that will be suitable to answer the research question.", [["a study", "TEST", 28, 35]]], ["The study design should be appropriately selected prior to initiation of any research investigation.", [["The study", "TEST", 0, 9], ["any research investigation", "TEST", 73, 99]]], ["Selecting an inappropriate study design may potentially undermine the validity of a study in its entirety.", [["an inappropriate study", "TEST", 10, 32], ["a study", "TEST", 82, 89]]], ["These study designs have been variously classified and one common classification system is quantitative vs. qualitative study designs.", [["These study", "TEST", 0, 11], ["qualitative study designs", "TEST", 108, 133]]], ["Study designs play a major role in determining the scientific value of research studies.", [["research studies", "TEST", 71, 87]]], ["Inappropriate choice of a study design is impossible to correct after completion of the study.", [["a study", "TEST", 24, 31], ["the study", "TEST", 84, 93]]], ["Good understanding of basic study design concepts will aid researchers in conducting robust and rigorous practice-based research.", [["basic study", "TEST", 22, 33]]], ["This chapter introduces the structure and the fundamentals of common study designs used in pharmacy practice research and discusses the important considerations for conducting pharmacy practice research in terms of study design, data collection, data analyses, and ethical considerations.Classification of Research Methodologies Used in Pharmacy PracticeVarious classifications for research designs and methods used in pharmacy practice have been used in the literature.", [["data collection", "TEST", 229, 244], ["data analyses", "TEST", 246, 259], ["research designs", "TREATMENT", 382, 398], ["methods", "TREATMENT", 403, 410]]], ["The following are some of the approaches for the classification of research designs:1.Classification based on time orientation: Retrospective vs. prospective designsa.Retrospective design\u2014A retrospective study design observes what has happened in the past.", [["prospective designsa", "PROBLEM", 146, 166], ["A retrospective study", "TEST", 188, 209]]], ["It begins and ends in the present.", [["ends", "OBSERVATION_MODIFIER", 14, 18]]], ["An example of this design is retrospective case-control study.Case example: Investigators were looking for the association between acute myocardial infarction and smoking status, type of tobacco, amount of smoke, etc. (Teo et al., 2006).", [["myocardial", "ANATOMY", 137, 147], ["acute myocardial infarction", "DISEASE", 131, 158], ["smoking", "CHEMICAL", 163, 170], ["myocardial", "MULTI-TISSUE_STRUCTURE", 137, 147], ["tobacco", "ORGANISM", 187, 194], ["tobacco", "SPECIES", 187, 194], ["retrospective case", "TEST", 29, 47], ["control study", "TEST", 48, 61], ["acute myocardial infarction", "PROBLEM", 131, 158], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["myocardial", "ANATOMY", 137, 147], ["infarction", "OBSERVATION", 148, 158], ["smoke", "OBSERVATION", 206, 211]]], ["Another example of a case\u2013control study from published literature is the study investigating the association between the use of phenylpropanolamine and the risk of hemorrhagic stroke (Kernan et al., 2000).b.Prospective design\u2014A prospective study design begins in the present and progresses forward, collecting data from subjects whose outcomes lie in the future.", [["phenylpropanolamine", "CHEMICAL", 128, 147], ["hemorrhagic stroke", "DISEASE", 164, 182], ["phenylpropanolamine", "CHEMICAL", 128, 147], ["phenylpropanolamine", "SIMPLE_CHEMICAL", 128, 147], ["a case\u2013control study", "TEST", 19, 39], ["the study", "TEST", 69, 78], ["phenylpropanolamine", "TREATMENT", 128, 147], ["hemorrhagic stroke", "PROBLEM", 164, 182], ["A prospective study", "TEST", 226, 245], ["hemorrhagic", "OBSERVATION_MODIFIER", 164, 175], ["stroke", "OBSERVATION", 176, 182]]], ["An example of this design is prospective cohort study.Case example: Investigators were interested to determine the long-term effectiveness of influenza vaccines in elderly people; they recruited cohorts of vaccinated and unvaccinated community-dwelling elderly (Nichol et al., 2007).2.Classification based on study purpose: Descriptive vs. analytical designsa.Descriptive design\u2014A descriptive study describes a population/sample in terms of distribution of the variables, and frequency of outcomes of interest.", [["people", "ORGANISM", 172, 178], ["people", "SPECIES", 172, 178], ["prospective cohort study", "TEST", 29, 53], ["influenza vaccines", "TREATMENT", 142, 160], ["study purpose", "TEST", 309, 322], ["A descriptive study", "TEST", 379, 398]]], ["Unlike analytical studies that include control (comparison) group, descriptive studies do not include a comparison group.", [["analytical studies", "TEST", 7, 25], ["descriptive studies", "TEST", 67, 86]]], ["Descriptive studies include case reports, case series reports, cross-sectional studies, surveillance studies, and ecological studies.Case example: A case report was written by a physician who contracted Severe Acute Respiratory Syndrome (SARS) during an outbreak in Hong Kong (Wu and Sung, 2003).", [["Acute Respiratory Syndrome", "DISEASE", 210, 236], ["SARS", "DISEASE", 238, 242], ["cross-sectional studies", "TEST", 63, 86], ["surveillance studies", "TEST", 88, 108], ["ecological studies", "TEST", 114, 132], ["Severe Acute Respiratory Syndrome", "PROBLEM", 203, 236], ["Severe", "OBSERVATION_MODIFIER", 203, 209], ["Acute", "OBSERVATION_MODIFIER", 210, 215], ["Respiratory Syndrome", "OBSERVATION", 216, 236]]], ["Another example is an ecological study examining diet and sunlight as risks for prostate cancer mortality (Colli and Colli, 2006).", [["prostate cancer", "ANATOMY", 80, 95], ["prostate cancer", "DISEASE", 80, 95], ["prostate cancer", "CANCER", 80, 95], ["an ecological study", "TEST", 19, 38], ["prostate cancer mortality", "PROBLEM", 80, 105], ["prostate", "ANATOMY", 80, 88], ["cancer", "OBSERVATION", 89, 95]]], ["Chim et al. conducted a large population-based survey in Australia to determine what community members think about the factors that do and should influence government spending on prescribed medicines (Chim et al., 2017).b.Analytical design\u2014An analytical study identifies risk factors, associated factors, mediating factors, etc. Analytical studies are either experimental or observational.", [["risk factors", "PROTEIN", 271, 283], ["mediating factors", "PROTEIN", 305, 322], ["prescribed medicines", "TREATMENT", 179, 199], ["An analytical study", "TEST", 240, 259], ["risk factors", "PROBLEM", 271, 283], ["mediating factors", "PROBLEM", 305, 322], ["Analytical studies", "TEST", 329, 347], ["large", "OBSERVATION_MODIFIER", 24, 29], ["population", "OBSERVATION", 30, 40]]], ["Case\u2013control and cohort studies are types of observational studies.Case example: A group of investigators carried out a study to establish an association between the use of traditional eye medicines (TEM) and corneal ulcers.", [["eye", "ANATOMY", 185, 188], ["corneal", "ANATOMY", 209, 216], ["corneal ulcers", "DISEASE", 209, 223], ["eye", "ORGAN", 185, 188], ["corneal ulcers", "PATHOLOGICAL_FORMATION", 209, 223], ["cohort studies", "TEST", 17, 31], ["observational studies", "TEST", 45, 66], ["a study", "TEST", 118, 125], ["traditional eye medicines", "TREATMENT", 173, 198], ["corneal ulcers", "PROBLEM", 209, 223], ["eye", "ANATOMY", 185, 188], ["corneal", "ANATOMY", 209, 216], ["ulcers", "OBSERVATION", 217, 223]]], ["In this case, both case\u2013control and cohort study designs are applicable.", [["cohort study", "TEST", 36, 48]]], ["In an example of a case control study, Archibugi et al. aimed to investigate the association between aspirin and statin exclusive and combined and pancreatic ductal adenocarcinoma occurrence (Archibugi et al., 2017).", [["pancreatic ductal adenocarcinoma", "ANATOMY", 147, 179], ["aspirin", "CHEMICAL", 101, 108], ["statin", "CHEMICAL", 113, 119], ["pancreatic ductal adenocarcinoma", "DISEASE", 147, 179], ["aspirin", "CHEMICAL", 101, 108], ["statin", "CHEMICAL", 113, 119], ["aspirin", "SIMPLE_CHEMICAL", 101, 108], ["pancreatic ductal adenocarcinoma", "CANCER", 147, 179], ["a case control study", "TEST", 17, 37], ["aspirin", "TREATMENT", 101, 108], ["statin", "TREATMENT", 113, 119], ["pancreatic ductal adenocarcinoma occurrence", "PROBLEM", 147, 190], ["pancreatic ductal", "ANATOMY", 147, 164], ["adenocarcinoma", "OBSERVATION", 165, 179]]], ["Another example of a cohort study is a study carried out by Wei et al. in which they investigated whether or not acid-suppression medicines increased the risk of bacterial gastroenteritis (Wei et al., 2017).3.Classification based on investigator orientation: Experimental vs. quasi-experimental vs. observational designsa.Experimental design\u2014In experimental design (also known as interventional design), the investigator performs an intervention and evaluates cause and effect relationships.Case examples: Investigators conducted a study about the newer versus older antihypertensive agents in African hypertensive patients (NOAAH) trial (nct01030458) to compare the efficacy of single-pill combinations of newer versus older antihypertensive agents (i.e., a single-pill combination of newer drugs, not involving a diuretic, with a combination of older drugs including a diuretic) (Odili et al., 2012).", [["bacterial gastroenteritis", "DISEASE", 162, 187], ["hypertensive", "DISEASE", 602, 614], ["patients", "ORGANISM", 615, 623], ["patients", "SPECIES", 615, 623], ["a cohort study", "TEST", 19, 33], ["a study", "TEST", 37, 44], ["acid-suppression medicines", "TREATMENT", 113, 139], ["bacterial gastroenteritis", "PROBLEM", 162, 187], ["observational designsa", "PROBLEM", 299, 321], ["an intervention", "TREATMENT", 430, 445], ["a study", "TEST", 530, 537], ["older antihypertensive agents", "TREATMENT", 561, 590], ["African hypertensive patients (NOAAH) trial", "TREATMENT", 594, 637], ["single-pill combinations", "TREATMENT", 679, 703], ["newer versus older antihypertensive agents", "TREATMENT", 707, 749], ["newer drugs", "TREATMENT", 786, 797], ["a diuretic", "TREATMENT", 813, 823], ["older drugs", "TREATMENT", 847, 858], ["a diuretic", "TREATMENT", 869, 879], ["bacterial gastroenteritis", "OBSERVATION", 162, 187]]], ["In a crossover design, a group of investigators evaluated the effect of spironolactone on nonresolving central serous chorioretinopathy (Bousquet et al., 2015).b.Quasi-experimental design\u2014The quasi-experimental design is very similar to the true experimental design described above and it involves an intervention.", [["spironolactone", "CHEMICAL", 72, 86], ["central serous chorioretinopathy", "DISEASE", 103, 135], ["spironolactone", "CHEMICAL", 72, 86], ["spironolactone", "SIMPLE_CHEMICAL", 72, 86], ["serous", "ORGANISM_SUBSTANCE", 111, 117], ["spironolactone", "TREATMENT", 72, 86], ["nonresolving central serous chorioretinopathy", "PROBLEM", 90, 135], ["an intervention", "TREATMENT", 298, 313], ["central", "OBSERVATION_MODIFIER", 103, 110], ["serous chorioretinopathy", "OBSERVATION", 111, 135]]], ["The design has been employed when randomization is inappropriate or impossible, especially when implementing complex interventions.Case examples: Prashanth et al. aimed to understand if (and how) a package of interventions targeting primary health centers and community participation platforms affect utilization and access to generic medicines for people with noncommunicable diseases using quasi-experimental design approach (Prashanth et al., 2016).c.Observational design\u2014It involves only observation of natural phenomena and does not involve investigator intervention.", [["noncommunicable diseases", "DISEASE", 361, 385], ["people", "ORGANISM", 349, 355], ["c", "GENE_OR_GENE_PRODUCT", 452, 453], ["people", "SPECIES", 349, 355], ["complex interventions", "TREATMENT", 109, 130], ["generic medicines", "TREATMENT", 327, 344], ["noncommunicable diseases", "PROBLEM", 361, 385], ["quasi-experimental design approach", "TREATMENT", 392, 426], ["natural phenomena", "PROBLEM", 507, 524], ["investigator intervention", "TREATMENT", 546, 571], ["natural phenomena", "OBSERVATION", 507, 524]]], ["Typically, this study design investigates associations and not causation.", [["this study", "TEST", 11, 21]]], ["Examples include cohort study and case\u2013control study.", [["cohort study", "TEST", 17, 29], ["case\u2013control study", "TEST", 34, 52]]], ["These studies can explore an association between a pharmacologic agent and a disease of interest.", [["These studies", "TEST", 0, 13], ["a pharmacologic agent", "TREATMENT", 49, 70], ["a disease of interest", "PROBLEM", 75, 96]]], ["Case examples: Please see previous examples of these.4.Classification based on question orientation: Quantitative vs. qualitative vs. mixed method designsa.Quantitative design\u2014This is based on measurement of quantity and it is applicable to phenomenon that can be quantified (i.e., expressed in terms of numbers).Case examples: Please see experimental studies, and case\u2013control and cohort study designs.b.Qualitative design\u2014Qualitative research is concerned with qualitative phenomenon (i.e., a phenomenon relating to or involving quality).Case examples: Investigators in Canada explored the lived experiences of youth who are prescribed antipsychotics by conducting interpretative phenomenology study (Murphy et al., 2015).c.Mixed method designs\u2014Mixed method design brings together qualitative and quantitative methodologies within a single study to answer or understand a research problem (Hadi et al., 2013).Case examples: Shiyanbola et al. combined focus group discussion with a survey tool to investigate patients' perceived value and use of quality measures in evaluating and choosing community pharmacies (Shiyanbola and Mort, 2015).5.Classification of pharmacoepidemiologic study designsBelow is a brief description of traditional and novel pharmacoepidemiologic study designs.", [["youth", "ORGANISM", 613, 618], ["patients", "ORGANISM", 1010, 1018], ["patients", "SPECIES", 1010, 1018], ["mixed method designsa", "PROBLEM", 134, 155], ["qualitative phenomenon", "PROBLEM", 463, 485], ["a phenomenon", "PROBLEM", 493, 505], ["antipsychotics", "TREATMENT", 638, 652], ["a single study", "TEST", 833, 847], ["quality measures", "TREATMENT", 1047, 1063], ["pharmacoepidemiologic study", "TEST", 1160, 1187], ["traditional and novel pharmacoepidemiologic study designs", "TREATMENT", 1227, 1284], ["method designs", "OBSERVATION", 732, 746]]], ["Several examples of pharmacoepidemiologic study designs are provided above.", [["pharmacoepidemiologic study", "TEST", 20, 47]]], ["Some descriptive studies including case reports, case series, and ecological studies will not be described in this chapter.a.Case\u2013control studies\u2014In this design, patients (those who develop the disease or outcome of interest) are identified and control patients (those who do not develop the disease or outcome of interest) are sampled at random from the original cohort that gives rise to the cases (Etminan and Samii, 2004, Newman et al., 2013).", [["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 253, 261], ["case series", "TEST", 49, 60], ["ecological studies", "TEST", 66, 84], ["Case\u2013control studies", "TEST", 125, 145], ["the disease", "PROBLEM", 190, 201], ["the disease", "PROBLEM", 288, 299]]], ["The distribution of exposure to certain risk factors between the cases and the controls is then explored, and an odds ratio (OR) is calculated.b.Cohort studies\u2014This can be described as a study in which a group of exposed subjects and a group of unexposed subjects are followed over time and the incidence of the disease or outcome of interest in the exposed group is compared with that in the unexposed group (Etminan and Samii, 2004, Hulley et al., 2013).c.Case-crossover studies\u2014The case-crossover may be considered comparable to a crossover randomized controlled trial in which the patients act as their own control (Etminan and Samii, 2004).", [["subjects", "ORGANISM", 255, 263], ["patients", "ORGANISM", 585, 593], ["patients", "SPECIES", 585, 593], ["certain risk factors", "PROBLEM", 32, 52], ["Cohort studies", "TEST", 145, 159], ["a study", "TEST", 185, 192], ["the disease", "PROBLEM", 308, 319], ["a crossover randomized controlled trial", "TREATMENT", 532, 571], ["disease", "OBSERVATION", 312, 319]]], ["The between-patient confounding that occurs in a classic case-control study is circumvented in this design.", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19]]], ["Tubiana et al. evaluated the role of antibiotic prophylaxis and assessed the relation between invasive dental procedures and oral streptococcal infective endocarditis, using a nationwide population-based cohort and a case-crossover study design (Tubiana et al., 2017).d.Case\u2013time control studies\u2014This design is an extension of the case-crossover design, but includes a control group (Etminan and Samii, 2004).", [["oral", "ANATOMY", 125, 129], ["streptococcal infective endocarditis", "DISEASE", 130, 166], ["oral", "ORGANISM_SUBDIVISION", 125, 129], ["antibiotic prophylaxis", "TREATMENT", 37, 59], ["invasive dental procedures", "TREATMENT", 94, 120], ["oral streptococcal infective endocarditis", "PROBLEM", 125, 166], ["streptococcal", "OBSERVATION_MODIFIER", 130, 143], ["infective", "OBSERVATION_MODIFIER", 144, 153], ["endocarditis", "OBSERVATION", 154, 166]]], ["A group of researchers assessed medication-related hospitalization.", [["medication", "TREATMENT", 32, 42]]], ["They used the case\u2013time control study design to investigate the associations between 12 high risk medication categories (e.g., antidiabetic agents, diuretics, benzodiazepine hypnotics) and unplanned hospitalizations (Lin et al., 2017).e.Nested case\u2013control studies\u2014In this design, a cohort of individuals is followed during certain time periods until a certain outcome is reached and the analysis is conducted as a case\u2013control study in which cases are matched to only a sample of control subjects (Etminan, 2004). de Jong et al. examined the association between interferon-\u03b2 (IFN-\u03b2) and potential adverse events using population-based health administrative data in Canada (De Jong et al., 2017).f.Cross-sectional studies\u2014In this type of study, the investigator measures the outcome of interest and the exposures among the study participants at the same time (Hulley et al., 2013, Setia, 2016b).", [["benzodiazepine hypnotics", "CHEMICAL", 159, 183], ["benzodiazepine", "CHEMICAL", 159, 173], ["diuretics", "SIMPLE_CHEMICAL", 148, 157], ["benzodiazepine", "SIMPLE_CHEMICAL", 159, 173], ["individuals", "ORGANISM", 293, 304], ["interferon-\u03b2", "GENE_OR_GENE_PRODUCT", 563, 575], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 577, 582], ["interferon-\u03b2", "PROTEIN", 563, 575], ["IFN", "PROTEIN", 577, 580], ["participants", "SPECIES", 829, 841], ["the case\u2013time control study", "TREATMENT", 10, 37], ["antidiabetic agents", "TREATMENT", 127, 146], ["diuretics", "TREATMENT", 148, 157], ["benzodiazepine hypnotics", "TREATMENT", 159, 183], ["the analysis", "TEST", 384, 396], ["a case\u2013control study", "TEST", 413, 433], ["interferon", "TREATMENT", 563, 573], ["potential adverse events", "PROBLEM", 588, 612], ["Cross-sectional studies", "TEST", 698, 721], ["study", "TEST", 738, 743], ["the study", "TEST", 819, 828]]]], "PMC7432801": [], "PMC7405215": [["IMMUNOSUPPRESSION OF PTSDPTSD is defined as a stress\u2010related disorder with subsequent autoimmune disease that may arise after exposure to a serious traumatic event or injury.3It is suggested that PTSD conforms with a bi\u2010phasic stress response model: Acute stress may reflect an enhancement of the immune response while chronic stress may reflect a suppression of the immune response with increased susceptibility to infections.", [["stress\u2010related disorder", "DISEASE", 46, 69], ["autoimmune disease", "DISEASE", 86, 104], ["PTSD", "DISEASE", 196, 200], ["infections", "DISEASE", 416, 426], ["a stress\u2010related disorder", "PROBLEM", 44, 69], ["subsequent autoimmune disease", "PROBLEM", 75, 104], ["a serious traumatic event", "PROBLEM", 138, 163], ["injury", "PROBLEM", 167, 173], ["PTSD", "PROBLEM", 196, 200], ["Acute stress", "PROBLEM", 250, 262], ["the immune response", "PROBLEM", 293, 312], ["chronic stress", "PROBLEM", 319, 333], ["the immune response", "PROBLEM", 363, 382], ["increased susceptibility to infections", "PROBLEM", 388, 426], ["autoimmune disease", "OBSERVATION", 86, 104], ["injury", "OBSERVATION", 167, 173], ["stress", "OBSERVATION", 256, 262], ["may reflect", "UNCERTAINTY", 263, 274], ["enhancement", "OBSERVATION", 278, 289], ["immune response", "OBSERVATION", 297, 312], ["infections", "OBSERVATION", 416, 426]]], ["Therefore, these correlations pose a complex question regarding the conversion from T\u2010helper 1 cells (Th1) to T\u2010helper 2 cells (Th2).IMMUNOSUPPRESSION OF PTSDA study showed that chronic stress elicits the simultaneous suppression and enhancement of the immune response via alteration of the cytokine expression pattern.4In the chronic stress model, CD4+ Th1 subsets release Th1 cytokines that activate the inflammatory cellular immune response.", [["T\u2010helper 1 cells", "ANATOMY", 84, 100], ["T\u2010helper 2 cells", "ANATOMY", 110, 126], ["cellular", "ANATOMY", 419, 427], ["T\u2010helper 1 cells", "CELL", 84, 100], ["Th1", "CELL", 102, 105], ["T\u2010helper 2 cells", "CELL", 110, 126], ["Th2", "CELL", 128, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 349, 352], ["cellular", "CELL", 419, 427], ["T\u2010helper 1 cells", "CELL_LINE", 84, 100], ["Th1", "CELL_TYPE", 102, 105], ["T\u2010helper 2 cells", "CELL_TYPE", 110, 126], ["Th2", "CELL_LINE", 128, 131], ["cytokine", "PROTEIN", 291, 299], ["CD4", "PROTEIN", 349, 352], ["Th1 subsets", "CELL_TYPE", 354, 365], ["Th1 cytokines", "PROTEIN", 374, 387], ["the conversion from T\u2010helper 1 cells", "TREATMENT", 64, 100], ["IMMUNOSUPPRESSION OF PTSDA study", "TEST", 133, 165], ["chronic stress", "PROBLEM", 178, 192], ["the immune response", "PROBLEM", 249, 268], ["the cytokine expression pattern", "PROBLEM", 287, 318], ["the chronic stress model", "PROBLEM", 323, 347], ["CD4", "TEST", 349, 352], ["Th1 cytokines", "TEST", 374, 387], ["the inflammatory cellular immune response", "PROBLEM", 402, 443], ["chronic", "OBSERVATION_MODIFIER", 178, 185], ["stress", "OBSERVATION", 186, 192], ["immune response", "OBSERVATION", 253, 268], ["cytokine expression", "OBSERVATION", 291, 310], ["chronic", "OBSERVATION_MODIFIER", 327, 334], ["stress model", "OBSERVATION", 335, 347], ["inflammatory", "OBSERVATION_MODIFIER", 406, 418], ["cellular immune response", "OBSERVATION", 419, 443]]], ["The response involves IL12 and IFN\u2010G, which is strongly suppressed by IL10.", [["IL12", "GENE_OR_GENE_PRODUCT", 22, 26], ["IFN\u2010G", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL10", "GENE_OR_GENE_PRODUCT", 70, 74], ["IL12", "PROTEIN", 22, 26], ["IFN\u2010G", "PROTEIN", 31, 36], ["IL10", "PROTEIN", 70, 74], ["IL12 and IFN\u2010G", "TREATMENT", 22, 36]]], ["This action helps to shift the cellular immune response from anti\u2010inflammatory process of Th1 to Th2 via adrenergic agonists as a result of stress.", [["cellular", "ANATOMY", 31, 39], ["cellular", "CELL", 31, 39], ["Th1", "GENE_OR_GENE_PRODUCT", 90, 93], ["Th2", "GENE_OR_GENE_PRODUCT", 97, 100], ["adrenergic agonists", "GENE_OR_GENE_PRODUCT", 105, 124], ["Th2", "CELL_TYPE", 97, 100], ["anti\u2010inflammatory process", "TREATMENT", 61, 86], ["adrenergic agonists", "TREATMENT", 105, 124], ["stress", "PROBLEM", 140, 146], ["cellular immune response", "OBSERVATION", 31, 55]]], ["Moreover, the immunosuppressive effect is specific to the inflammatory cellular immune system.", [["cellular", "ANATOMY", 71, 79], ["cellular", "CELL", 71, 79], ["the immunosuppressive effect", "PROBLEM", 10, 38], ["the inflammatory cellular immune system", "PROBLEM", 54, 93], ["inflammatory cellular immune system", "OBSERVATION", 58, 93]]], ["A shift from Th1 to Th2 cellular is strongly enhanced through the suppression of IL12, which is a major Th1 agonist within humoral immunity.", [["Th2 cellular", "ANATOMY", 20, 32], ["Th1", "GENE_OR_GENE_PRODUCT", 13, 16], ["Th2 cellular", "CELL", 20, 32], ["IL12", "GENE_OR_GENE_PRODUCT", 81, 85], ["Th1", "GENE_OR_GENE_PRODUCT", 104, 107], ["IL12", "PROTEIN", 81, 85], ["shift", "OBSERVATION_MODIFIER", 2, 7], ["strongly", "OBSERVATION_MODIFIER", 36, 44], ["enhanced", "OBSERVATION_MODIFIER", 45, 53], ["humoral immunity", "OBSERVATION", 123, 139]]], ["These effects above are observed over both the short and long term in PTSD.", [["PTSD", "DISEASE", 70, 74], ["PTSD", "PROBLEM", 70, 74]]], ["This decreased reaction of the immune system is also observed due to senescence with the chronic down\u2010regulation of cortisol receptors sites.", [["cortisol", "CHEMICAL", 116, 124], ["cortisol", "CHEMICAL", 116, 124], ["cortisol receptors", "GENE_OR_GENE_PRODUCT", 116, 134], ["cortisol receptors sites", "DNA", 116, 140], ["This decreased reaction of the immune system", "PROBLEM", 0, 44], ["the chronic down\u2010regulation of cortisol receptors sites", "TREATMENT", 85, 140], ["decreased", "OBSERVATION_MODIFIER", 5, 14], ["reaction", "OBSERVATION", 15, 23], ["immune system", "OBSERVATION", 31, 44], ["chronic", "OBSERVATION_MODIFIER", 89, 96]]], ["The down\u2010regulation of cortisol receptors may reduce the capacity of lymphocytes to respond to anti\u2010inflammatory signals and allow other cytokine\u2010mediated processes to dominate in patients with PTSD.IMMUNOSUPPRESSION AND SUSCEPTIBILITY TO COVID\u201019Many clinical observations have shown that elderly patients, those with an underlying chronic disease and treated with immunosuppressants, or patients otherwise in an immunosuppressed state could suffer from a decreased immune response and greater susceptibility to life\u2010threatening virus infections.", [["lymphocytes", "ANATOMY", 69, 80], ["cortisol", "CHEMICAL", 23, 31], ["PTSD", "DISEASE", 194, 198], ["chronic disease", "DISEASE", 333, 348], ["infections", "DISEASE", 536, 546], ["cortisol", "CHEMICAL", 23, 31], ["cortisol receptors", "GENE_OR_GENE_PRODUCT", 23, 41], ["lymphocytes", "CELL", 69, 80], ["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 298, 306], ["patients", "ORGANISM", 389, 397], ["cortisol receptors", "PROTEIN", 23, 41], ["lymphocytes", "CELL_TYPE", 69, 80], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 298, 306], ["patients", "SPECIES", 389, 397], ["The down\u2010regulation of cortisol receptors", "TREATMENT", 0, 41], ["the capacity of lymphocytes", "PROBLEM", 53, 80], ["anti\u2010inflammatory signals", "TREATMENT", 95, 120], ["other cytokine\u2010mediated processes", "TREATMENT", 131, 164], ["PTSD", "PROBLEM", 194, 198], ["IMMUNOSUPPRESSION", "TREATMENT", 199, 216], ["an underlying chronic disease", "PROBLEM", 319, 348], ["immunosuppressants", "TREATMENT", 366, 384], ["a decreased immune response", "PROBLEM", 455, 482], ["greater susceptibility to life\u2010threatening virus infections", "PROBLEM", 487, 546], ["chronic", "OBSERVATION_MODIFIER", 333, 340], ["disease", "OBSERVATION", 341, 348], ["decreased immune response", "OBSERVATION", 457, 482]]], ["Such infections show rapid national and international spread, such as in the case of SARS\u2010CoV\u20102, which is currently posing a global health emergency.5,6The results of studies are particularly important for individuals who might be at a higher risk of developing complications that are associated with respiratory virus infections, such as the elderly, for whom the increased susceptibility to pathogens is a serious public health problem.", [["infections", "DISEASE", 5, 15], ["SARS", "DISEASE", 85, 89], ["5,6", "CHEMICAL", 149, 152], ["respiratory virus infections", "DISEASE", 301, 329], ["individuals", "ORGANISM", 206, 217], ["SARS\u2010CoV", "SPECIES", 85, 93], ["Such infections", "PROBLEM", 0, 15], ["rapid national and international spread", "PROBLEM", 21, 60], ["SARS", "PROBLEM", 85, 89], ["studies", "TEST", 167, 174], ["developing complications", "PROBLEM", 251, 275], ["respiratory virus infections", "PROBLEM", 301, 329], ["the increased susceptibility to pathogens", "PROBLEM", 361, 402], ["a serious public health problem", "PROBLEM", 406, 437], ["rapid", "OBSERVATION_MODIFIER", 21, 26], ["complications", "OBSERVATION", 262, 275], ["associated with", "UNCERTAINTY", 285, 300], ["respiratory virus", "OBSERVATION", 301, 318]]], ["Influenza and pneumonia are the fifth leading cause of mortality in individuals aged 50 or older who might have lower immunity.IMMUNOSUPPRESSION AND SUSCEPTIBILITY TO COVID\u201019Another clue has been showed that pregnancy is an independent risk factor to develop severe virus pneumonia under immune tolerance.", [["Influenza", "DISEASE", 0, 9], ["pneumonia", "DISEASE", 14, 23], ["pneumonia", "DISEASE", 273, 282], ["Influenza", "SPECIES", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["pneumonia", "PROBLEM", 14, 23], ["IMMUNOSUPPRESSION", "TREATMENT", 127, 144], ["an independent risk factor", "PROBLEM", 222, 248], ["severe virus pneumonia under immune tolerance", "PROBLEM", 260, 305], ["pneumonia", "OBSERVATION", 14, 23], ["severe", "OBSERVATION_MODIFIER", 260, 266], ["virus", "OBSERVATION_MODIFIER", 267, 272], ["pneumonia", "OBSERVATION", 273, 282], ["immune tolerance", "OBSERVATION", 289, 305]]], ["The pregnancy bias toward Th2 system dominance which left pregnant woman vulnerable to viral infections might bring a challenge for the prevention of SARS\u2010CoV\u20102 infection.7", [["viral infections", "DISEASE", 87, 103], ["SARS", "DISEASE", 150, 154], ["infection", "DISEASE", 161, 170], ["woman", "ORGANISM", 67, 72], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 155, 160], ["woman", "SPECIES", 67, 72], ["The pregnancy bias", "PROBLEM", 0, 18], ["viral infections", "PROBLEM", 87, 103], ["SARS", "PROBLEM", 150, 154], ["CoV\u20102 infection", "PROBLEM", 155, 170], ["infection", "OBSERVATION", 161, 170]]]], "PMC7334824": [["The mobile device data tracks each consumer\u2019s mobile device and provides raw device counts.", [["The mobile device", "TREATMENT", 0, 17], ["mobile device", "TREATMENT", 46, 59], ["raw device counts", "TEST", 73, 90]]], ["The population covered in the database, and in this study, includes thousands of anonymous mobile devices\u2019 customers from all across the U.S. states and territories.", [["this study", "TEST", 47, 57], ["anonymous mobile devices", "TREATMENT", 81, 105], ["population", "OBSERVATION_MODIFIER", 4, 14]]], ["The number of total devices residing in homes in the census block by 12-digit FIPS code defines the total number of devices.", [["total devices", "TREATMENT", 14, 27], ["the total number of devices", "TREATMENT", 96, 123], ["number", "OBSERVATION_MODIFIER", 4, 10], ["total", "OBSERVATION_MODIFIER", 14, 19], ["devices", "OBSERVATION", 20, 27]]], ["The total number of devices that did not leave their home location (geohash-7 measure) during the day defines the number of completely stay-at-home devices.Data ::: MATERIALS AND METHODSFull-time work location is specified if a device spent at least 6 hours a day between 8 a.m.-6 p.m., at a location other than their home location for at least 6 weeks.", [["The total number of devices", "TREATMENT", 0, 27], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Total number of devices at full-time work per day is provided by Safegraph.Data ::: MATERIALS AND METHODSNext, we obtained information on distance and time spent outside the home during the time.", [["devices", "TREATMENT", 16, 23]]], ["Median_home_timeit is presented in minutes for all devices included in the total number of devices during the time period.", [["all devices", "TREATMENT", 47, 58], ["the total number of devices", "TREATMENT", 71, 98]]], ["Then the database calculates the median of all these devices.Data ::: MATERIALS AND METHODSWe obtained county level non-pharmaceutical intervention (NPIs) data from New York Times \u201cSee Which States and Cities Have Told Residents to Stay at Home\u201d and Keystone \u201cCounty level COVID-19 Non-pharmaceutical Database\u201d [9].", [["non-pharmaceutical intervention", "TREATMENT", 116, 147], ["COVID", "TEST", 273, 278]]], ["The NPIs include local government imposed social distancing regulations, including social distancing regulations for vulnerable persons, social distancing of the general population, gathering size limitations, closure of public venues, closure of schools and universities, non-essential services closure and lock down between January 21, 2020 and March 31, 2020.", [["persons", "SPECIES", 128, 135], ["non-essential services closure", "TREATMENT", 273, 303], ["size", "OBSERVATION_MODIFIER", 192, 196]]], ["The NPIs data is also defined by county.Data ::: MATERIALS AND METHODSCounty level COVID-19 infections data was obtained from the Centers for Disease Control and Prevention Coronavirus updates [10, 11].", [["infections", "DISEASE", 92, 102], ["The NPIs data", "TEST", 0, 13], ["METHODSCounty level COVID", "TEST", 63, 88], ["infections data", "TEST", 92, 107], ["Disease Control", "TREATMENT", 142, 157]]], ["We also dropped one single FIPS code for which there was some problem with data collection reported by Safegraph.", [["FIPS code", "DNA", 27, 36], ["data collection", "PROBLEM", 75, 90]]], ["Median distance traveled from home is measured in meter and excluded zero values.Variable construction ::: MATERIALS AND METHODSWe used the daily census block-level database to create daily county level data.", [["the daily census block", "TREATMENT", 136, 158]]], ["For the Completely_home_devicesit and Full_time_workit variables for the county i on day t, we took total sum of the variables by the county level.Variable construction ::: MATERIALS AND METHODSFor both Median_home_timeit and Median_distance_traveledit variables we calculated the median weighted total number of devices in the census block f for county i in t.", [["Completely_home_devicesit", "DNA", 8, 33], ["METHODSFor both Median_home_timeit and Median_distance_traveledit variables", "TREATMENT", 187, 262], ["the median weighted total number of devices", "TREATMENT", 277, 320]]], ["We used STATA function [aweight] in STATA16.", [["STATA16", "GENE_OR_GENE_PRODUCT", 36, 43], ["STATA16", "PROTEIN", 36, 43], ["STATA function", "TEST", 8, 22]]], ["Small geographical bias is possible as acknowledged by the data collectors.", [["Small geographical bias", "PROBLEM", 0, 23], ["geographical bias", "OBSERVATION", 6, 23]]], ["They tested the reporting bias and calculated it to be less than one percent and, therefore, the data is very accurate for this study.", [["this study", "TEST", 123, 133]]], ["The weighted measures control for the effect of more populous counties.Variable construction ::: MATERIALS AND METHODSCompletely_home_devicesit, Full_time_workit, Median_home_timeit and Median_distance_traveledit variables were our social distancing measures.", [["The weighted measures control", "TREATMENT", 0, 29], ["METHODSCompletely_home_devicesit", "TREATMENT", 111, 143], ["Full_time_workit", "TREATMENT", 145, 161], ["Median_home_timeit", "TREATMENT", 163, 181], ["Median_distance_traveledit variables", "TREATMENT", 186, 222]]], ["That is, social distancing in this study was measured by what proportion of a county\u2019s population is staying home completely; how much time they were spending indoors, versus outdoors, in public spaces like working full-time, which is critical for this analysis.", [["this study", "TEST", 30, 40], ["this analysis", "TEST", 248, 261]]], ["Further, we concentrated on social distancing measures at individual county level because we matched the above social distancing measures with county level COVID-19 infections data and NPIs data.Analysis design ::: MATERIALS AND METHODSThe complete data is detailed enough to help us to measure each consumer\u2019s physical movement between counties and to different places of work.", [["infections", "DISEASE", 165, 175], ["social distancing measures", "TREATMENT", 28, 54], ["NPIs data", "TEST", 185, 194], ["METHODSThe complete data", "TEST", 229, 253]]], ["This allowed us to create a panel measure of social distancing by each county and enabled to design a difference-in-difference analysis of the impact of the lockdowns on the rate of spread of COVID-19 after controlling for all county, time and county-time fixed effects.", [["a panel", "TEST", 26, 33], ["COVID", "TEST", 192, 197]]], ["Difference-in-difference analysis estimates the effect of NPIs through social distancing for the counties where NPIs were enacted compared to non-NPIs enacted counties.", [["NPIs", "TREATMENT", 58, 62]]], ["Thus we were able to filter out many unknown factors present, such as the numbers of tests done, availability of local test centers, general difference in demographic, and political and public health infrastructures across these counties, among others.Analysis design ::: MATERIALS AND METHODSAll the counties with NPIs enacted between February 1 and March 31, 2020 served as our treatment counties.", [["tests", "TEST", 85, 90], ["local test centers", "TEST", 113, 131]]], ["If a county did not have any NPI then we considered that as a sample in the control group.", [["a sample in the control group", "TREATMENT", 60, 89]]], ["We created a dummy variable, NPIs, which equals one if county i ordered NPIs on, or after day t (where day 1 starts February 1, 2020), and zero otherwise.", [["a dummy variable, NPIs", "PROBLEM", 11, 33]]], ["Our treatment counties were in states including New York and California, which have been extremely affected by COVID-19.Analysis design ::: MATERIALS AND METHODSTo analyze the effect of these social distancing measures on COVID-19 cases and how this effect is working on the treatment counties comparing to the control counties, we estimated the following difference-in-difference (DID) model:Analysis design ::: MATERIALS AND METHODSIn(cases)it = \u03b11NPIit + \u03bbXit + Ct + t + Ui + \u03b5it (1)Analysis design ::: MATERIALS AND METHODSwhere t represents the day starting from February 1, 2020 and i represents the county.", [["\u03b11NPIit + \u03bbXit + Ct + t + Ui", "CHEMICAL", 448, 476], ["\u03b11NPIit", "SIMPLE_CHEMICAL", 448, 455], ["COVID", "TEST", 111, 116], ["the treatment counties", "TREATMENT", 271, 293], ["it", "TEST", 443, 445], ["1NPIit", "TEST", 449, 455], ["Xit", "TEST", 459, 462], ["Ct", "TEST", 465, 467]]], ["The ln(cases) presents the natural logarithm of the number of confirmed COVID-19 cases.", [["COVID", "TEST", 72, 77], ["ln", "ANATOMY", 4, 6]]], ["NPIit is our treatment variable.", [["NPIit", "TREATMENT", 0, 5], ["our treatment", "TREATMENT", 9, 22]]], ["The parameter a1 measures the average effect of NPIs for county i after it was imposed on date t.", [["NPIs", "TREATMENT", 48, 52]]], ["The parameter l measures the mean effect of NPIs as a result of the social distancing in county i comparing to control counties.", [["NPIs", "PROBLEM", 44, 48], ["mean effect", "OBSERVATION_MODIFIER", 29, 40]]], ["We also included separate county, county-time and state fixed effects in Ct, time fixed effect (t) and a binary factor variable Uit as the urban-rural dummy variable that is equal to one if the county is an urban county. \u03b5it is the county and time specific error term.Analysis design ::: MATERIALS AND METHODSTime invariant factors of a county or state, including geographical variables, political outlook, local public health and demographic differences, state infrastructure differences, etc., were controlled in our modelling design for by the county and state fixed effects.", [["Ct", "TEST", 73, 75], ["a binary factor", "TEST", 103, 118]]], ["More importantly, the county-time fixed effects were included to take account for any local county level time varying factors, such as local temperature variances as well as the number of test centers set up and the number of tests that were being administered, etc. As a further robustness measure, we clustered the standard errors at the county level.", [["local temperature variances", "PROBLEM", 135, 162], ["tests", "TEST", 226, 231]]], ["We re-estimated equation 1 with various lags.RESULTSWe present the daily change in the natural logarithm of the confirmed number of cases [ln(cases)], daily number of completely stay at home devices and daily median time spent at home (minutes) for each day during the duration of our study, in Figure 1 (A, B and C).", [["home devices", "TREATMENT", 186, 198], ["our study", "TEST", 281, 290]]], ["Figure 1A shows the highest affected states from the database, and it represents a sharp increase in the number of cases after March 4, 2020 with California and New York seeing the highest number of cases.", [["Figure 1A", "TEST", 0, 9], ["highest", "OBSERVATION_MODIFIER", 20, 27], ["sharp", "OBSERVATION_MODIFIER", 83, 88], ["increase", "OBSERVATION_MODIFIER", 89, 97]]], ["Figure 1B depicts that, in these highly affected states, there was a sharp increase in percentage of devices stationed completely at home after March 15, 2020 and people started spending more time indoors after March 17, 2020.", [["people", "ORGANISM", 163, 169], ["people", "SPECIES", 163, 169], ["a sharp increase in percentage of devices", "PROBLEM", 67, 108], ["sharp", "OBSERVATION_MODIFIER", 69, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["percentage", "OBSERVATION_MODIFIER", 87, 97]]], ["Together, figures 1B and 1C show that an increasing number of people started spending extended times at home after March 11.", [["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68], ["increasing", "OBSERVATION_MODIFIER", 41, 51], ["number", "OBSERVATION_MODIFIER", 52, 58]]], ["California observed the highest number of people staying at home till the 3rd week of March, but after that New Jersey was the state leading this measure.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["highest", "OBSERVATION_MODIFIER", 24, 31], ["number", "OBSERVATION_MODIFIER", 32, 38]]], ["Table 1 presents the summary statistics of all the variables for all counties and also by treated and control groups.RESULTSAs noted above, we estimated equation (1) with the right hand side treatment and interaction variables included at t, with a five days\u2019 and a fifteen days\u2019 lag.", [["right hand", "ANATOMY", 175, 185], ["RESULTSAs", "TEST", 117, 126], ["the right hand side treatment", "TREATMENT", 171, 200], ["interaction variables", "PROBLEM", 205, 226], ["right", "ANATOMY_MODIFIER", 175, 180]]], ["Column 1 of Table 2 shows that after controlling for county, state, time and county-time fixed effects, counties where NPIs were enacted, full time work and distance-travelled-from-home increased the COVID-19 cases by 54% (p-value 0.001) and 13% (p-value 0.001), respectively.", [["the COVID", "TREATMENT", 196, 205], ["p-value", "TEST", 223, 230]]], ["This might be because the first counties to have enacted an NPI are also those which were fast becoming the infection hot spots, combining with an artefact of the nature of the contagion that it can start an infection as early as within hours of contact.", [["infection", "DISEASE", 108, 117], ["infection", "DISEASE", 208, 217], ["the infection hot spots", "PROBLEM", 104, 127], ["an infection", "PROBLEM", 205, 217], ["infection", "OBSERVATION", 108, 117], ["infection", "OBSERVATION", 208, 217]]], ["Column 2 of Table 2 shows that at the five-day lag of the interaction variables, distance-travelled-from-home increased the COVID-19 cases by 16% (p-value 0.001).", [["the COVID", "TEST", 120, 129]]], ["Full-time-work variables after NPIs were imposed, were no longer significant.", [["NPIs", "TREATMENT", 31, 35], ["no longer", "UNCERTAINTY", 55, 64]]], ["This is an interesting finding, as it might indicate exposure to the risks from full-time work not being significant anymore, as awareness of the virus increases, and most people who are sick are staying at home or quarantining.", [["people", "ORGANISM", 172, 178], ["people", "SPECIES", 172, 178], ["the virus", "PROBLEM", 142, 151]]], ["On the other hand, distance travelled from home now might indicate visits to the stores and other points of interest where likely the virus was spreading through droplets found in the air, or the other forms of spread discussed in the introduction.RESULTSAfter running the regressions with more days of lags for the interaction variables, we found significant negative effects of Time-spent-at-home at the fifteen-day lag for the counties with NPIs, as well as significant positive effects of NPIdistance-travelled-from-home in the treatment counties compared to control counties.", [["NPIdistance", "CHEMICAL", 493, 504], ["the virus", "PROBLEM", 130, 139], ["NPIs", "TREATMENT", 444, 448], ["NPIdistance", "TREATMENT", 493, 504], ["the treatment counties", "TREATMENT", 528, 550], ["air", "OBSERVATION", 184, 187], ["significant", "OBSERVATION_MODIFIER", 348, 359], ["negative", "OBSERVATION", 360, 368]]], ["Time spent at home decreased COVID-19 cases by 49%, 15 days after NPIs were enacted compared to control counties (column 3).", [["COVID", "TEST", 29, 34], ["NPIs", "TREATMENT", 66, 70]]], ["After 15 days of enactment of the NPIs, the effects of full time work and distance travelled from home on COVID-19 infection increased to 84% and 25% (compared to 54% and 13% immediate effects).", [["infection", "DISEASE", 115, 124], ["COVID-19", "SPECIES", 106, 114], ["the NPIs", "TREATMENT", 30, 38], ["COVID", "TEST", 106, 111], ["infection", "PROBLEM", 115, 124]]], ["But given that much of the NPIs were enacted towards the end of our sample period, means we lose samples very quickly and the significance of the estimates disappears after the 17th day.RESULTSFigure 2 presents the effect on NPIs on the COVID-19 cases across two counties.", [["NPIs", "CANCER", 27, 31], ["NPIs", "TREATMENT", 225, 229], ["the COVID", "TREATMENT", 233, 242]]], ["The red line presents the change in cases for the county (e.g., LA county, CA) where NPI was enacted earlier and the blue line represents the change in COVID-19 cases for the county (e.g., Jefferson county, AL) where NPI was enacted later in the March.Author contributions. ::: Conclusion ::: DISCUSSIONTB received the original data.", [["The red line", "TREATMENT", 0, 12], ["NPI", "TREATMENT", 85, 88], ["the blue line", "TREATMENT", 113, 126], ["COVID", "TEST", 152, 157], ["NPI", "TREATMENT", 217, 220], ["the original data", "TEST", 315, 332], ["red line", "OBSERVATION", 4, 12], ["change", "OBSERVATION_MODIFIER", 26, 32], ["blue line", "OBSERVATION", 117, 126], ["change", "OBSERVATION_MODIFIER", 142, 148]]], ["TB and AN planned the analysis, analyzed the data and interpreted the results.", [["TB", "DISEASE", 0, 2], ["TB", "PROBLEM", 0, 2], ["the analysis", "TEST", 18, 30], ["the data", "TEST", 41, 49]]], ["TB and AN wrote the paper.", [["TB", "DISEASE", 0, 2], ["TB", "PROBLEM", 0, 2]]], ["The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.Acknowledgments. ::: Conclusion ::: DISCUSSIONWe thank Safegraph for generously providing the social distancing metrics database for this analysis, and Dr. Aditi Sengupta and Dr. Ayanangshu Nayak for their helpful comment on an earlier version of the manuscript.Disclaimer. ::: Conclusion ::: DISCUSSIONAuthors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH and/or the Pan American Health Organization (PAHO).", [["the current study", "TEST", 41, 58], ["this analysis", "TEST", 258, 271], ["the RPSP/PAJPH", "PROBLEM", 563, 577]]]], "fd31ade73c720f893a5ddb2370df90a84511ec4a": [["IntroductionSwine influenza virus (SIV) is the cause of an acute respiratory disease that affects swine worldwide.", [["respiratory", "ANATOMY", 65, 76], ["influenza virus (SIV)", "DISEASE", 18, 39], ["respiratory disease", "DISEASE", 65, 84], ["IntroductionSwine influenza virus", "ORGANISM", 0, 33], ["SIV", "ORGANISM", 35, 38], ["swine", "ORGANISM", 98, 103], ["IntroductionSwine influenza virus", "SPECIES", 0, 33], ["swine", "SPECIES", 98, 103], ["IntroductionSwine influenza virus", "SPECIES", 0, 33], ["SIV", "SPECIES", 35, 38], ["swine", "SPECIES", 98, 103], ["IntroductionSwine influenza virus", "PROBLEM", 0, 33], ["an acute respiratory disease", "PROBLEM", 56, 84], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["respiratory disease", "OBSERVATION", 65, 84]]], ["SIV infection is characterized by fever, inactivity, decreased food intake, respiratory distress, coughing, sneezing, conjunctivitis, and nasal discharge.", [["respiratory", "ANATOMY", 76, 87], ["nasal", "ANATOMY", 138, 143], ["SIV infection", "DISEASE", 0, 13], ["fever", "DISEASE", 34, 39], ["decreased food intake", "DISEASE", 53, 74], ["respiratory distress", "DISEASE", 76, 96], ["coughing", "DISEASE", 98, 106], ["sneezing", "DISEASE", 108, 116], ["conjunctivitis", "DISEASE", 118, 132], ["SIV", "ORGANISM", 0, 3], ["nasal", "ORGANISM_SUBDIVISION", 138, 143], ["SIV", "SPECIES", 0, 3], ["SIV infection", "PROBLEM", 0, 13], ["fever", "PROBLEM", 34, 39], ["inactivity", "PROBLEM", 41, 51], ["decreased food intake", "PROBLEM", 53, 74], ["respiratory distress", "PROBLEM", 76, 96], ["coughing", "PROBLEM", 98, 106], ["sneezing", "PROBLEM", 108, 116], ["conjunctivitis", "PROBLEM", 118, 132], ["nasal discharge", "PROBLEM", 138, 153], ["infection", "OBSERVATION", 4, 13], ["fever", "OBSERVATION", 34, 39], ["decreased", "OBSERVATION_MODIFIER", 53, 62], ["food intake", "OBSERVATION", 63, 74], ["respiratory distress", "OBSERVATION", 76, 96], ["conjunctivitis", "OBSERVATION", 118, 132], ["nasal", "ANATOMY", 138, 143]]], ["1, 2 Disease severity is affected by many factors, including the viral strain, but typically, the onset of disease is sudden.", [["2 Disease severity", "PROBLEM", 3, 21], ["the viral strain", "PROBLEM", 61, 77], ["disease", "PROBLEM", 107, 114], ["sudden", "PROBLEM", 118, 124], ["Disease", "OBSERVATION", 5, 12], ["severity", "OBSERVATION_MODIFIER", 13, 21], ["many", "OBSERVATION_MODIFIER", 37, 41], ["factors", "OBSERVATION", 42, 49], ["viral strain", "OBSERVATION", 65, 77], ["disease", "OBSERVATION", 107, 114]]], ["The disease is characterized by high morbidity and generally low mortality rates.", [["The disease", "PROBLEM", 0, 11], ["high morbidity", "PROBLEM", 32, 46], ["generally low mortality rates", "PROBLEM", 51, 80], ["disease", "OBSERVATION", 4, 11], ["high", "OBSERVATION_MODIFIER", 32, 36], ["morbidity", "OBSERVATION", 37, 46], ["low", "OBSERVATION_MODIFIER", 61, 64]]], ["3 Influenza A viruses are members of the Orthomyxoviridae family and are 80-120 nm enveloped viruses with segmented, single-stranded, negative-sense RNA genomes.", [["3", "ORGANISM", 0, 1], ["Influenza A viruses", "ORGANISM", 2, 21], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 41, 57], ["segmented, single-stranded, negative-sense RNA genomes", "DNA", 106, 160], ["Influenza A viruses", "SPECIES", 2, 21], ["Influenza", "PROBLEM", 2, 11]]], ["3 The segmented genome of influenza virus allows reassortment between different viruses, and once cells are infected with two or more different influenza viruses, the exchange of RNA segments between the viruses allows the generation of progeny containing a novel combination of genes.", [["cells", "ANATOMY", 98, 103], ["influenza viruses", "DISEASE", 144, 161], ["influenza virus", "ORGANISM", 26, 41], ["cells", "CELL", 98, 103], ["influenza viruses", "ORGANISM", 144, 161], ["RNA segments", "RNA", 179, 191], ["influenza virus", "SPECIES", 26, 41], ["influenza virus", "SPECIES", 26, 41], ["influenza virus", "PROBLEM", 26, 41], ["different viruses", "PROBLEM", 70, 87], ["different influenza viruses", "PROBLEM", 134, 161], ["the exchange of RNA segments", "TREATMENT", 163, 191], ["the viruses", "PROBLEM", 200, 211], ["influenza virus", "OBSERVATION", 26, 41], ["viruses", "OBSERVATION", 80, 87], ["influenza viruses", "OBSERVATION", 144, 161], ["viruses", "OBSERVATION", 204, 211]]], ["3 The viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) are the main targets of the host immune response, and they are important for host specificity and virulence.", [["hemagglutinin", "GENE_OR_GENE_PRODUCT", 34, 47], ["HA", "GENE_OR_GENE_PRODUCT", 49, 51], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 57, 70], ["viral surface glycoproteins", "PROTEIN", 6, 33], ["hemagglutinin", "PROTEIN", 34, 47], ["HA", "PROTEIN", 49, 51], ["neuraminidase", "PROTEIN", 57, 70], ["NA", "PROTEIN", 72, 74], ["The viral surface glycoproteins hemagglutinin (HA)", "TREATMENT", 2, 52], ["neuraminidase (NA)", "TREATMENT", 57, 75], ["virulence", "PROBLEM", 174, 183], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["surface", "OBSERVATION_MODIFIER", 12, 19], ["host immune response", "OBSERVATION", 104, 124]]], ["4 HA binds to the cell receptor N-acetylneuraminic acid-2,3-galactose linkage or to the N-acetylneuraminic acid-2,6-galactose linkage on sialyloligosaccharides of avian and mammalian viruses, respectively.", [["cell", "ANATOMY", 18, 22], ["N-acetylneuraminic acid-2,3-galactose", "CHEMICAL", 32, 69], ["N-acetylneuraminic acid-2,6-galactose", "CHEMICAL", 88, 125], ["N-acetylneuraminic acid-2,3-galactose", "CHEMICAL", 32, 69], ["N-acetylneuraminic acid-2,6-galactose", "CHEMICAL", 88, 125], ["cell", "CELL", 18, 22], ["N-acetylneuraminic acid-2,3-galactose", "SIMPLE_CHEMICAL", 32, 69], ["N-acetylneuraminic acid-2,6-galactose", "SIMPLE_CHEMICAL", 88, 125], ["sialyloligosaccharides", "SIMPLE_CHEMICAL", 137, 159], ["avian", "ORGANISM", 163, 168], ["mammalian viruses", "ORGANISM", 173, 190], ["4 HA binds", "PROBLEM", 0, 10], ["the cell receptor", "TEST", 14, 31], ["N-acetylneuraminic acid", "TEST", 32, 55], ["galactose linkage", "TEST", 60, 77], ["the N-acetylneuraminic acid", "TEST", 84, 111], ["sialyloligosaccharides of avian", "TREATMENT", 137, 168], ["mammalian viruses", "TREATMENT", 173, 190], ["mammalian viruses", "OBSERVATION", 173, 190]]], ["5 Swine have been considered to be a potential 'mixing vessel' because they have receptors for both avian and human influenza viruses.", [["vessel", "ANATOMY", 55, 61], ["influenza viruses", "DISEASE", 116, 133], ["vessel", "MULTI-TISSUE_STRUCTURE", 55, 61], ["avian", "ORGANISM", 100, 105], ["human influenza viruses", "ORGANISM", 110, 133], ["human", "SPECIES", 110, 115], ["human influenza viruses", "SPECIES", 110, 133], ["a potential 'mixing vessel'", "TREATMENT", 35, 62], ["human influenza viruses", "PROBLEM", 110, 133], ["influenza viruses", "OBSERVATION", 116, 133]]], ["6 In 2009, a new influenza virus emerged in the human population of North America.", [["influenza virus", "DISEASE", 17, 32], ["human", "ORGANISM", 48, 53], ["influenza virus", "SPECIES", 17, 32], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["a new influenza virus", "PROBLEM", 11, 32], ["new", "OBSERVATION_MODIFIER", 13, 16], ["influenza virus", "OBSERVATION", 17, 32]]], ["Pandemic H1N1 (H1N1pdm09), which has a unique genome with six gene segments (PB1, PB2, PA, HA, NP, and NS) from the triple reassortant swine lineage of the North American virus and the M and NA gene derived from the Eurasian lineage of the swine influenza virus, 7 had never before been recognized in swine.", [["influenza virus", "DISEASE", 246, 261], ["Pandemic H1N1", "ORGANISM", 0, 13], ["PA", "GENE_OR_GENE_PRODUCT", 87, 89], ["HA", "GENE_OR_GENE_PRODUCT", 91, 93], ["North American virus", "ORGANISM", 156, 176], ["swine influenza virus", "ORGANISM", 240, 261], ["swine", "ORGANISM", 301, 306], ["PB1", "DNA", 77, 80], ["PB2", "DNA", 82, 85], ["HA", "DNA", 91, 93], ["NP", "DNA", 95, 97], ["M and NA gene", "DNA", 185, 198], ["Pandemic H1N1", "SPECIES", 0, 13], ["swine", "SPECIES", 135, 140], ["swine influenza virus", "SPECIES", 240, 261], ["swine", "SPECIES", 301, 306], ["North American virus", "SPECIES", 156, 176], ["swine influenza virus", "SPECIES", 240, 261], ["swine", "SPECIES", 301, 306], ["Pandemic H1N1 (H1N1pdm09", "PROBLEM", 0, 24], ["PB1", "TEST", 77, 80], ["PB2", "TEST", 82, 85], ["PA", "TEST", 87, 89], ["HA", "PROBLEM", 91, 93], ["NP", "TEST", 95, 97], ["NS", "TREATMENT", 103, 105], ["the swine influenza virus", "PROBLEM", 236, 261], ["H1N1", "OBSERVATION", 9, 13], ["Eurasian lineage", "OBSERVATION", 216, 232], ["influenza virus", "OBSERVATION", 246, 261]]], ["Immediately after the spread of H1N1pdm09 in human populations, outbreaks in pigs were reported in many countries worldwide.", [["H1N1pdm09", "CHEMICAL", 32, 41], ["human", "ORGANISM", 45, 50], ["pigs", "ORGANISM", 77, 81], ["H1N1pdm09", "DNA", 32, 41], ["human", "SPECIES", 45, 50], ["pigs", "SPECIES", 77, 81], ["human", "SPECIES", 45, 50], ["pigs", "SPECIES", 77, 81]]], ["8 Brazil is the fifth leading global pork producer and the fourth largest pork exporter, and swine production is economically important.", [["pork", "ORGANISM_SUBDIVISION", 74, 78], ["swine", "SPECIES", 93, 98], ["pork", "SPECIES", 74, 78], ["swine", "SPECIES", 93, 98], ["global", "OBSERVATION_MODIFIER", 30, 36], ["pork producer", "OBSERVATION", 37, 50], ["fourth", "OBSERVATION_MODIFIER", 59, 65], ["largest", "OBSERVATION_MODIFIER", 66, 73]]], ["However, few studies have investigated the presence of SIV antibodies or virus isolates in Brazilian pigs.", [["SIV", "ORGANISM", 55, 58], ["pigs", "ORGANISM", 101, 105], ["SIV antibodies", "PROTEIN", 55, 69], ["pigs", "SPECIES", 101, 105], ["SIV", "SPECIES", 55, 58], ["pigs", "SPECIES", 101, 105], ["few studies", "TEST", 9, 20], ["SIV antibodies", "PROBLEM", 55, 69], ["virus isolates", "TREATMENT", 73, 87], ["SIV antibodies", "OBSERVATION", 55, 69]]], ["In Brazil, SIV was first isolated in 1978 in a pig from Minas Gerais state.", [["SIV", "ORGANISM", 11, 14], ["pig", "ORGANISM", 47, 50], ["pig", "SPECIES", 47, 50], ["SIV", "SPECIES", 11, 14], ["pig", "SPECIES", 47, 50], ["SIV", "OBSERVATION", 11, 14]]], ["9 One study reported a low prevalence of antibodies against H1N1 and H3N2 subtypes in pigs from 10 Brazilian states between 1996 and 1999.", [["H3N2 subtypes", "ORGANISM", 69, 82], ["pigs", "ORGANISM", 86, 90], ["antibodies", "PROTEIN", 41, 51], ["H3N2", "SPECIES", 69, 73], ["pigs", "SPECIES", 86, 90], ["pigs", "SPECIES", 86, 90], ["One study", "TEST", 2, 11], ["antibodies", "PROBLEM", 41, 51], ["H1N1", "PROBLEM", 60, 64], ["H3N2 subtypes", "PROBLEM", 69, 82], ["low prevalence", "OBSERVATION_MODIFIER", 23, 37], ["H3N2", "OBSERVATION", 69, 73]]], ["10 Further studies demonstrated the prevalence of anti-influenza antibodies against human 11 and swine viruses 12 in southeastern Brazil.", [["human", "ORGANISM", 84, 89], ["swine viruses", "ORGANISM", 97, 110], ["anti-influenza antibodies", "PROTEIN", 50, 75], ["human", "SPECIES", 84, 89], ["swine", "SPECIES", 97, 102], ["human", "SPECIES", 84, 89], ["Further studies", "TEST", 3, 18], ["anti-influenza antibodies", "TREATMENT", 50, 75]]], ["In a seroprevalence study in Paran a (southern Brazil), the authors reported that 46% of the sampled farms were positive for anti-H3N2 antibodies, and the prevalence of antibodies against human H3N2 in those pigs was 20%.", [["H3N2", "DISEASE", 194, 198], ["human", "ORGANISM", 188, 193], ["H3N2", "ORGANISM", 194, 198], ["pigs", "ORGANISM", 208, 212], ["anti-H3N2 antibodies", "PROTEIN", 125, 145], ["antibodies", "PROTEIN", 169, 179], ["human", "SPECIES", 188, 193], ["pigs", "SPECIES", 208, 212], ["anti-H3N2", "SPECIES", 125, 134], ["human", "SPECIES", 188, 193], ["a seroprevalence study", "TEST", 3, 25], ["the sampled farms", "TEST", 89, 106], ["anti-H3N2 antibodies", "PROBLEM", 125, 145], ["antibodies", "TREATMENT", 169, 179], ["human H3N2", "TREATMENT", 188, 198]]], ["13 After the H1N1pdm09 outbreak, few studies reported the presence of influenza virus in Brazilian herds.", [["influenza virus", "DISEASE", 70, 85], ["influenza virus", "ORGANISM", 70, 85], ["the H1N1pdm09 outbreak", "PROBLEM", 9, 31], ["few studies", "TEST", 33, 44], ["influenza virus", "PROBLEM", 70, 85], ["influenza virus", "OBSERVATION", 70, 85]]], ["14, 15 However, no data are available concerning the prevalence of antibodies against swine influenza virus in Brazilian herds after 2009.", [["swine influenza virus", "DISEASE", 86, 107], ["swine influenza virus", "ORGANISM", 86, 107], ["antibodies", "PROTEIN", 67, 77], ["swine influenza virus", "SPECIES", 86, 107], ["swine influenza virus", "SPECIES", 86, 107], ["antibodies", "PROBLEM", 67, 77], ["swine influenza virus", "PROBLEM", 86, 107]]], ["In Brazil, a vaccine protecting swine against influenza virus was licensed on May 2014.", [["influenza virus", "DISEASE", 46, 61], ["swine", "ORGANISM", 32, 37], ["influenza virus", "ORGANISM", 46, 61], ["swine", "SPECIES", 32, 37], ["influenza virus", "SPECIES", 46, 61], ["swine", "SPECIES", 32, 37], ["a vaccine protecting swine", "TREATMENT", 11, 37], ["influenza virus", "PROBLEM", 46, 61]]], ["Prior to that vaccine, the presence of anti-influenza antibodies in pigs was attributed to natural infection.", [["infection", "DISEASE", 99, 108], ["pigs", "ORGANISM", 68, 72], ["anti-influenza antibodies", "PROTEIN", 39, 64], ["pigs", "SPECIES", 68, 72], ["pigs", "SPECIES", 68, 72], ["that vaccine", "TREATMENT", 9, 21], ["anti-influenza antibodies", "TREATMENT", 39, 64], ["natural infection", "PROBLEM", 91, 108], ["anti-influenza antibodies", "OBSERVATION", 39, 64], ["natural", "OBSERVATION_MODIFIER", 91, 98], ["infection", "OBSERVATION", 99, 108]]], ["Recently, there were many reports regarding respiratory outbreaks in farms around the country 16 and producers and veterinarians began vaccinating against swine influenza to reduce economic losses.IntroductionAn analysis of the serological profile may provide information regarding viral circulation and might be useful in implementing vaccination strategies and effective control measures based on the characteristics of individual herds.", [["respiratory outbreaks", "DISEASE", 44, 65], ["swine influenza", "DISEASE", 155, 170], ["swine", "SPECIES", 155, 160], ["swine", "SPECIES", 155, 160], ["respiratory outbreaks", "PROBLEM", 44, 65], ["swine influenza", "PROBLEM", 155, 170], ["economic losses", "PROBLEM", 181, 196], ["IntroductionAn analysis", "TEST", 197, 220], ["the serological profile", "TEST", 224, 247], ["viral circulation", "PROBLEM", 282, 299], ["vaccination strategies", "TREATMENT", 336, 358], ["effective control measures", "TREATMENT", 363, 389], ["respiratory", "ANATOMY", 44, 55], ["outbreaks", "OBSERVATION", 56, 65]]], ["Thus, the objective of this study was to evaluate the serological profile for influenza virus in pigs from farrowto-finish farms in Minas Gerais state, Brazil.Sample collectionSerum samples, which were collected from May to August 2012 by jugular puncture, were centrifuged after clot formation, and the serum was stored at \u00c020\u00b0C. Thirty farms (F1 to F30) from the four larger pig production areas in Minas Gerais state (Zona da Mata, Tri\u00e2ngulo Mineiro/Alto Parana \u0131ba, South/Southwest and the Belo Horizonte metropolitan area) were selected for this study ( Figure 1 ); these farms represented approximately 2\u00c14% of all herds in the state.", [["collectionSerum samples", "ANATOMY", 166, 189], ["jugular", "ANATOMY", 239, 246], ["clot", "ANATOMY", 280, 284], ["serum", "ANATOMY", 304, 309], ["influenza virus", "DISEASE", 78, 93], ["influenza virus", "ORGANISM", 78, 93], ["pigs", "ORGANISM", 97, 101], ["collectionSerum samples", "CANCER", 166, 189], ["jugular puncture", "MULTI-TISSUE_STRUCTURE", 239, 255], ["clot", "ORGANISM_SUBSTANCE", 280, 284], ["serum", "ORGANISM_SUBSTANCE", 304, 309], ["pig", "ORGANISM", 377, 380], ["influenza virus", "SPECIES", 78, 93], ["pigs", "SPECIES", 97, 101], ["pig", "SPECIES", 377, 380], ["influenza virus", "SPECIES", 78, 93], ["pigs", "SPECIES", 97, 101], ["pig", "SPECIES", 377, 380], ["this study", "TEST", 23, 33], ["the serological profile", "TEST", 50, 73], ["influenza virus", "PROBLEM", 78, 93], ["Sample collectionSerum samples", "TEST", 159, 189], ["jugular puncture", "TEST", 239, 255], ["clot formation", "PROBLEM", 280, 294], ["the serum", "TEST", 300, 309], ["this study", "TEST", 546, 556], ["jugular", "ANATOMY", 239, 246], ["clot", "OBSERVATION", 280, 284]]], ["The number of farms was calculated based on the premise that each repetition has a maximum weight of 3\u00c133% in the sample, 17 and the response was expressed as a percentage.", [["a maximum weight", "TEST", 81, 97]]], ["At each farm, blood samples were randomly collected from 20 animals in each production cycle category: breeding animals (sows and gilts), farrowing crate (2-3 weeks), nursery (4-7 weeks), grower pigs (8-14 weeks), and finisher pigs (15-16 weeks) .", [["blood samples", "ANATOMY", 14, 27], ["blood samples", "ORGANISM_SUBSTANCE", 14, 27], ["sows", "ORGANISM_SUBDIVISION", 121, 125], ["gilts", "ORGANISM_SUBDIVISION", 130, 135], ["pigs", "ORGANISM", 195, 199], ["pigs", "ORGANISM", 227, 231], ["pigs", "SPECIES", 195, 199], ["pigs", "SPECIES", 227, 231], ["pigs", "SPECIES", 195, 199], ["pigs", "SPECIES", 227, 231], ["blood samples", "TEST", 14, 27]]], ["In total, there were 100 samples per farm and 3000 animals in the study.", [["the study", "TEST", 62, 71]]], ["All farms were farrow-to-finishing operations, with no SIV vaccination history, and most farms utilized allin-all-out production systems.", [["SIV", "ORGANISM", 55, 58], ["SIV", "SPECIES", 55, 58], ["no", "UNCERTAINTY", 52, 54]]], ["The farms had between 160 and 1950 sows, and three farms had experienced respiratory disease outbreaks with swine influenza diagnostic confirmed between 3 and 6 months prior to the sample collection.", [["respiratory", "ANATOMY", 73, 84], ["sample", "ANATOMY", 181, 187], ["respiratory disease", "DISEASE", 73, 92], ["influenza", "DISEASE", 114, 123], ["swine", "SPECIES", 108, 113], ["swine", "SPECIES", 108, 113], ["respiratory disease outbreaks", "PROBLEM", 73, 102], ["swine influenza diagnostic", "PROBLEM", 108, 134], ["the sample collection", "PROBLEM", 177, 198], ["respiratory", "ANATOMY", 73, 84], ["disease", "OBSERVATION", 85, 92]]], ["This study was conducted under the approval of the Universidade Federal de Minas Gerais ethics committee.", [["This study", "TEST", 0, 10]]], ["All herd owners provided consent for the use of the sera.Virus and controlThe samples were tested for hemagglutination inhibition (HI) activity against the H1N1 pandemic strain (A/swine/ Brazil/11/2009) and the H3N2 IAV (A/swine/Iowa/8548-2/ 98) reference strain.", [["sera", "ANATOMY", 52, 56], ["samples", "ANATOMY", 78, 85], ["sera", "ORGANISM_SUBSTANCE", 52, 56], ["Virus", "ORGANISM", 57, 62], ["A/swine", "ORGANISM", 178, 185], ["H3N2 IAV", "ORGANISM", 211, 219], ["swine", "ORGANISM", 223, 228], ["H1N1 pandemic", "SPECIES", 156, 169], ["swine", "SPECIES", 180, 185], ["H3N2 IAV", "SPECIES", 211, 219], ["swine", "SPECIES", 223, 228], ["A/swine/ Brazil/11/2009", "SPECIES", 178, 201], ["H3N2 IAV (A/swine/Iowa/8548-2/ 98", "SPECIES", 211, 244], ["Virus", "TREATMENT", 57, 62], ["The samples", "TEST", 74, 85], ["hemagglutination inhibition", "TEST", 102, 129], ["the H1N1 pandemic strain", "PROBLEM", 152, 176]]], ["The same viruses were used in the back titration in each plate for the HI assay, and phosphatebuffered saline (PBS; pH 7\u00c14) was used as a negative control.Hemagglutination inhibitionThe HI test was performed as previously described, 18 with some modifications.", [["phosphatebuffered saline", "SIMPLE_CHEMICAL", 85, 109], ["The same viruses", "PROBLEM", 0, 16], ["the back titration", "TREATMENT", 30, 48], ["the HI assay", "TEST", 67, 79], ["phosphatebuffered saline (PBS", "TREATMENT", 85, 114], ["pH", "TEST", 116, 118], ["Hemagglutination inhibition", "TEST", 155, 182], ["The HI test", "TEST", 182, 193], ["viruses", "OBSERVATION", 9, 16]]], ["The sera were treated with 20% kaolin suspension and 0\u00c15% rooster red blood cell (RBC) suspension to remove non-specific inhibitors and natural serum agglutinins.", [["sera", "ANATOMY", 4, 8], ["red blood cell", "ANATOMY", 66, 80], ["RBC", "ANATOMY", 82, 85], ["serum", "ANATOMY", 144, 149], ["kaolin", "CHEMICAL", 31, 37], ["kaolin", "CHEMICAL", 31, 37], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["kaolin", "SIMPLE_CHEMICAL", 31, 37], ["rooster", "ORGANISM", 58, 65], ["red blood cell", "CELL", 66, 80], ["RBC", "CELL", 82, 85], ["serum", "ORGANISM_SUBSTANCE", 144, 149], ["rooster red blood cell", "CELL_TYPE", 58, 80], ["RBC", "CELL_TYPE", 82, 85], ["20% kaolin suspension", "TREATMENT", 27, 48], ["0\u00c15% rooster red blood cell (RBC) suspension", "TREATMENT", 53, 97], ["non-specific inhibitors", "TREATMENT", 108, 131], ["natural serum agglutinins", "TEST", 136, 161]]], ["The initial serum dilution was 1:20 using PBS; then, each sample was diluted twofold to a final dilution of 1:640 in 96-well V-bottom plates.", [["serum", "ANATOMY", 12, 17], ["sample", "ANATOMY", 58, 64], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["The initial serum dilution", "TEST", 0, 26], ["PBS", "TREATMENT", 42, 45], ["a final dilution", "TEST", 88, 104]]], ["The HI antibody titer of each sample was determined as the reciprocal of the highest dilution in which no hemagglutination was observed.", [["sample", "ANATOMY", 30, 36], ["HI antibody", "GENE_OR_GENE_PRODUCT", 4, 15], ["The HI antibody titer", "TEST", 0, 21], ["hemagglutination", "PROBLEM", 106, 122], ["highest dilution", "OBSERVATION", 77, 93], ["no", "UNCERTAINTY", 103, 105], ["hemagglutination", "OBSERVATION", 106, 122]]], ["Samples with an HI titer \u226540 were considered to be positive.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["an HI titer", "TEST", 13, 24], ["positive", "OBSERVATION", 51, 59]]], ["Titers were classified as follows: \u226420, negative; 40-80, low; 160-320, medium; and \u2265640, high.", [["Titers", "TEST", 0, 6]]], ["Values were expressed by mean log 2 antibody titers.", [["Values", "TEST", 0, 6], ["mean log 2 antibody titers", "TEST", 25, 51]]], ["Means log 2 antibody titers are equivalent to HI titers: 4\u00c132 = 20; 5\u00c132 = 40; 6\u00c132 = 80; 7\u00c132 = 160; 8\u00c132 = 320; and 9\u00c132 = 640.", [["Means log 2 antibody titers", "TEST", 0, 27], ["HI titers", "TEST", 46, 55]]], ["A herd was considered positive when at least one of the animals was seropositive.ResultsIn this study, the percentages of animals with antibodies against H1N1pdm09 and H3N2 SIV were 26\u00c123% and 1\u00c157%, respectively, considering the 3000 samples tested.", [["animals", "ORGANISM", 56, 63], ["animals", "ORGANISM", 122, 129], ["H3N2 SIV", "ORGANISM", 168, 176], ["antibodies", "PROTEIN", 135, 145], ["H3N2 SIV", "SPECIES", 168, 176], ["H3N2 SIV", "SPECIES", 168, 176], ["positive", "PROBLEM", 22, 30], ["seropositive", "PROBLEM", 68, 80], ["this study", "TEST", 91, 101], ["antibodies", "TEST", 135, 145], ["H1N1pdm09", "TEST", 154, 163], ["H3N2 SIV", "TEST", 168, 176]]], ["The percentages of seropositive herds for both viruses were 96\u00c16% and 13\u00c12%, respectively.", [["seropositive herds", "TREATMENT", 19, 37], ["both viruses", "TEST", 42, 54], ["seropositive herds", "OBSERVATION", 19, 37]]], ["The HI results per area and virus are summarized in Table 1 .ResultsThe number of pigs with anti-H1N1pdm09 antibodies varied between the farms.", [["pigs", "ORGANISM", 82, 86], ["anti-H1N1pdm09 antibodies", "GENE_OR_GENE_PRODUCT", 92, 117], ["anti-H1N1pdm09 antibodies", "PROTEIN", 92, 117], ["pigs", "SPECIES", 82, 86], ["pigs", "SPECIES", 82, 86], ["virus", "PROBLEM", 28, 33], ["pigs", "TREATMENT", 82, 86], ["anti-H1N1pdm09 antibodies", "TREATMENT", 92, 117]]], ["Serological profiles against this antigen in each studied area are shown in Figure 2 .", [["Serological profiles", "TEST", 0, 20], ["this antigen", "TEST", 29, 41]]], ["One farm (F16) from area 3 had a higher mean antibody titer in the farrowing crate group than in breeding animals (female group) ( Figure 2 ).", [["a higher mean antibody titer", "PROBLEM", 31, 59]]], ["The serological profiles from areas 1, 3, and 4 followed a characterized pattern of antibody profiles in which the antibody titers were higher in the female group and decreased through 8-14 weeks of age when seroconversion by natural infection normally occurs.", [["infection", "DISEASE", 234, 243], ["3", "GENE_OR_GENE_PRODUCT", 39, 40], ["The serological profiles", "TEST", 0, 24], ["antibody profiles", "PROBLEM", 84, 101], ["the antibody titers", "TEST", 111, 130], ["seroconversion", "TREATMENT", 208, 222], ["natural infection", "PROBLEM", 226, 243], ["antibody profiles", "OBSERVATION", 84, 101], ["decreased", "OBSERVATION_MODIFIER", 167, 176], ["infection", "OBSERVATION", 234, 243]]], ["In contrast, the serological profiles from area 2 varied greatly, and in some farms, seroconversion occurred earlier (4-7 weeks) in the production system ( Figure 2 ).", [["the serological profiles", "TEST", 13, 37], ["seroconversion", "PROBLEM", 85, 99], ["some", "OBSERVATION_MODIFIER", 73, 77], ["farms", "OBSERVATION_MODIFIER", 78, 83], ["seroconversion", "OBSERVATION", 85, 99]]], ["In addition, some farms had detectable antibody levels throughout all ages, and the means of the antibody titers did not reach negative values, suggesting that the virus had recently circulated in all groups at these farms.", [["detectable antibody levels", "PROBLEM", 28, 54], ["the antibody titers", "TEST", 93, 112], ["the virus", "PROBLEM", 160, 169], ["virus", "OBSERVATION", 164, 169]]], ["Furthermore, F10 showed relatively constant mean antibody titers throughout the production cycle, suggesting virus circulation in all categories.", [["relatively constant mean antibody titers", "PROBLEM", 24, 64], ["virus circulation in all categories", "PROBLEM", 109, 144], ["suggesting", "UNCERTAINTY", 98, 108], ["virus circulation", "OBSERVATION", 109, 126]]], ["Additionally, one farm (F8) had no anti-H1N1pdm09 antibodies at all ages, suggesting that the H1N1pdm09 virus was not circulating in the herd at that moment.ResultsThe percentage of antibodies in each category of the production cycle also varied between the farms and studied areas (Figure 3 ).", [["anti-H1N1pdm09 antibodies", "GENE_OR_GENE_PRODUCT", 35, 60], ["H1N1pdm09 virus", "ORGANISM", 94, 109], ["anti-H1N1pdm09 antibodies", "PROTEIN", 35, 60], ["antibodies", "PROTEIN", 182, 192], ["H1N1pdm09 virus", "SPECIES", 94, 109], ["anti-H1N1pdm09 antibodies", "PROBLEM", 35, 60], ["the H1N1pdm09 virus", "PROBLEM", 90, 109], ["antibodies", "PROBLEM", 182, 192], ["the production cycle", "PROBLEM", 213, 233]]], ["At one farm (F30), only the females demonstrated anti-H1N1pdm09 antibodies, and all other categories were seronegative for this virus.", [["anti-H1N1pdm09", "GENE_OR_GENE_PRODUCT", 49, 63], ["anti-H1N1pdm09 antibodies", "PROTEIN", 49, 74], ["anti-H1N1pdm09 antibodies", "PROBLEM", 49, 74], ["all other categories", "PROBLEM", 80, 100], ["this virus", "PROBLEM", 123, 133]]], ["Additionally, 28 of 30 farms (93\u00c13%) had at least one piglet from the farrowing crates cycle with at least low antibody titers against the pandemic virus.", [["pandemic", "DISEASE", 139, 147], ["piglet", "ORGANISM", 54, 60], ["low antibody titers", "PROBLEM", 107, 126], ["the pandemic virus", "PROBLEM", 135, 153], ["pandemic virus", "OBSERVATION", 139, 153]]], ["Grower and finisher pigs from 17 farms were all seronegative for H1N1pdm09.", [["pigs", "ORGANISM", 20, 24], ["pigs", "SPECIES", 20, 24], ["pigs", "SPECIES", 20, 24], ["H1N1pdm09", "PROBLEM", 65, 74]]], ["A total of 98\u00c133% of grower pigs in areas 1 and 3 were seronegative for H1N1pdm09 virus, and the percentage of seronegative animals in the finisher pig cycle was lower than that in the grower pig cycle for all studied areas.", [["pigs", "ORGANISM", 28, 32], ["H1N1pdm09 virus", "ORGANISM", 72, 87], ["pig", "ORGANISM", 148, 151], ["pig", "ORGANISM", 192, 195], ["pigs", "SPECIES", 28, 32], ["pig", "SPECIES", 148, 151], ["pig", "SPECIES", 192, 195], ["pigs", "SPECIES", 28, 32], ["H1N1pdm09 virus", "SPECIES", 72, 87], ["pig", "SPECIES", 148, 151], ["pig", "SPECIES", 192, 195], ["grower pigs in areas", "TEST", 21, 41], ["H1N1pdm09 virus", "PROBLEM", 72, 87], ["seronegative animals", "PROBLEM", 111, 131], ["the finisher pig cycle", "TREATMENT", 135, 157], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Overall, the percentage of pigs seronegative for H1N1pdm09 virus increased with age, and the highest values were observed in nursery pigs (areas 2 and 4) and grower pigs (areas 1 and 3) (Figure 3 ).", [["pigs", "ORGANISM", 27, 31], ["H1N1pdm09 virus", "ORGANISM", 49, 64], ["pigs", "ORGANISM", 133, 137], ["pigs", "ORGANISM", 165, 169], ["pigs", "SPECIES", 27, 31], ["pigs", "SPECIES", 133, 137], ["pigs", "SPECIES", 165, 169], ["pigs", "SPECIES", 27, 31], ["H1N1pdm09 virus", "SPECIES", 49, 64], ["H1N1pdm09 virus", "PROBLEM", 49, 64]]], ["Interestingly, one area 1 farm (F6) and two area 3 farms (F21 and F22) had respiratory outbreaks, with influenza virus confirmed as a primary causative agent, a few months prior to sample collection.", [["sample", "ANATOMY", 181, 187], ["respiratory outbreaks", "DISEASE", 75, 96], ["influenza virus", "DISEASE", 103, 118], ["influenza virus", "SPECIES", 103, 118], ["influenza virus", "SPECIES", 103, 118], ["respiratory outbreaks", "PROBLEM", 75, 96], ["influenza virus", "PROBLEM", 103, 118], ["sample collection", "PROBLEM", 181, 198], ["one", "OBSERVATION_MODIFIER", 15, 18], ["area", "OBSERVATION_MODIFIER", 19, 23], ["respiratory", "ANATOMY", 75, 86], ["outbreaks", "OBSERVATION", 87, 96], ["influenza virus", "OBSERVATION", 103, 118]]], ["At that time, clinical disease occurred mostly in nursery and grower pigs, thus corroborating our findings demonstrating susceptibility at these ages.", [["pigs", "ORGANISM", 69, 73], ["pigs", "SPECIES", 69, 73], ["clinical disease", "PROBLEM", 14, 30], ["disease", "OBSERVATION", 23, 30]]], ["Figure 4 shows the antibody distribution at all four farms with animals that were seropositive for H3N2 SIV virus.", [["H3N2 SIV virus", "ORGANISM", 99, 113], ["H3N2 SIV virus", "SPECIES", 99, 113], ["H3N2 SIV virus", "SPECIES", 99, 113], ["Figure", "TEST", 0, 6], ["the antibody distribution", "PROBLEM", 15, 40], ["H3N2 SIV virus", "PROBLEM", 99, 113], ["antibody distribution", "OBSERVATION", 19, 40]]], ["The most varied profile of antibodies against H3N2 SIV virus was observed at Farm 27 (area 4), at which the pigs showed low to medium antibody levels.", [["H3N2 SIV virus", "ORGANISM", 46, 60], ["pigs", "ORGANISM", 108, 112], ["antibodies", "PROTEIN", 27, 37], ["H3N2 SIV virus", "SPECIES", 46, 60], ["pigs", "SPECIES", 108, 112], ["H3N2 SIV virus", "SPECIES", 46, 60], ["pigs", "SPECIES", 108, 112], ["antibodies", "TREATMENT", 27, 37], ["H3N2 SIV virus", "PROBLEM", 46, 60], ["the pigs", "TEST", 104, 112], ["low to medium antibody levels", "PROBLEM", 120, 149], ["most varied", "OBSERVATION_MODIFIER", 4, 15], ["low", "OBSERVATION_MODIFIER", 120, 123], ["medium antibody levels", "OBSERVATION", 127, 149]]], ["Farms 7 (area 2) and 29 (area 4) had only two and one females, respectively, with anti-H3N2DiscussionInfluenza is a disease that is associated with economic losses in swine herds.", [["Influenza", "DISEASE", 101, 110], ["swine", "SPECIES", 167, 172], ["swine", "SPECIES", 167, 172], ["Influenza", "PROBLEM", 101, 110], ["a disease", "PROBLEM", 114, 123], ["economic losses in swine herds", "PROBLEM", 148, 178]]], ["SIV is widespread in swine worldwide, and many countries have described virus circulation and antibody prevalence in pig populations.", [["SIV", "ORGANISM", 0, 3], ["swine", "ORGANISM", 21, 26], ["pig", "ORGANISM", 117, 120], ["swine", "SPECIES", 21, 26], ["pig", "SPECIES", 117, 120], ["SIV", "SPECIES", 0, 3], ["swine", "SPECIES", 21, 26], ["pig", "SPECIES", 117, 120], ["SIV", "PROBLEM", 0, 3], ["virus circulation", "PROBLEM", 72, 89], ["widespread", "OBSERVATION_MODIFIER", 7, 17], ["pig populations", "OBSERVATION", 117, 132]]], ["In Brazil, few studies have shown the presence of influenza virus in the swine population.", [["influenza virus", "DISEASE", 50, 65], ["influenza virus", "ORGANISM", 50, 65], ["swine", "ORGANISM", 73, 78], ["swine", "SPECIES", 73, 78], ["influenza virus", "SPECIES", 50, 65], ["swine", "SPECIES", 73, 78], ["few studies", "TEST", 11, 22], ["influenza virus", "PROBLEM", 50, 65], ["influenza virus", "OBSERVATION", 50, 65]]], ["10, 11, [13] [14] [15] However, the anti-influenza antibody prevalence after the H1N1 pandemic and the susceptibility of pigs in farrow-to-finish farms has not been extensively studied in the country.", [["[13] [14] [15", "SIMPLE_CHEMICAL", 8, 21], ["pigs", "ORGANISM", 121, 125], ["pigs", "SPECIES", 121, 125], ["pigs", "SPECIES", 121, 125], ["the anti-influenza antibody", "TEST", 32, 59], ["the H1N1 pandemic", "PROBLEM", 77, 94]]], ["The detection of anti-influenza antibodies in most of the farms suggests virus circulation, once Brazil had no approved vaccination program against influenza while this experiment was being performed.", [["influenza", "DISEASE", 148, 157], ["anti-influenza antibodies", "PROTEIN", 17, 42], ["anti-influenza antibodies", "PROBLEM", 17, 42], ["virus circulation", "PROBLEM", 73, 90], ["vaccination program", "TREATMENT", 120, 139], ["influenza", "PROBLEM", 148, 157], ["anti-influenza antibodies", "OBSERVATION", 17, 42], ["virus circulation", "OBSERVATION", 73, 90]]], ["Virus circulation is also suggested in this study because of the variation of antibody titers between the farms and across the sampled categories, which may be caused by seroconversion at some farms.DiscussionIn this study, we found that 26\u00c12% and 1\u00c157% of sampled animals and 96\u00c16% and 13\u00c13% of herds were seropositive for H1N1pdm09 and H3N2 IAV, respectively.", [["Virus", "ORGANISM", 0, 5], ["herds", "ORGANISM", 296, 301], ["H3N2 IAV", "ORGANISM", 338, 346], ["H3N2 IAV", "SPECIES", 338, 346], ["H1N1pdm09", "SPECIES", 324, 333], ["H3N2 IAV", "SPECIES", 338, 346], ["Virus circulation", "PROBLEM", 0, 17], ["this study", "TEST", 39, 49], ["antibody titers", "PROBLEM", 78, 93], ["seroconversion", "PROBLEM", 170, 184], ["this study", "TEST", 212, 222], ["herds", "TEST", 296, 301], ["H1N1pdm09", "PROBLEM", 324, 333], ["H3N2 IAV", "PROBLEM", 338, 346], ["may be caused", "UNCERTAINTY", 153, 166], ["seroconversion", "OBSERVATION", 170, 184]]], ["The rates of animals with anti-influenza antibodies found in this study were lower than those previously reported for many countries.", [["animals", "ORGANISM", 13, 20], ["anti-influenza antibodies", "PROTEIN", 26, 51], ["anti-influenza antibodies", "TEST", 26, 51], ["this study", "TEST", 61, 71], ["anti-influenza antibodies", "OBSERVATION", 26, 51]]], ["One study reported that 66\u00c13% of the animals at swine farms in the United States had antibodies against subtype H1; a lower rate (33\u00c17%) was detected for antibodies against the H3 subtype.", [["animals", "ORGANISM", 37, 44], ["antibodies against subtype H1", "GENE_OR_GENE_PRODUCT", 85, 114], ["antibodies against the H3", "GENE_OR_GENE_PRODUCT", 154, 179], ["antibodies", "PROTEIN", 85, 95], ["subtype H1", "PROTEIN", 104, 114], ["antibodies", "PROTEIN", 154, 164], ["H3 subtype", "PROTEIN", 177, 187], ["swine", "SPECIES", 48, 53], ["swine", "SPECIES", 48, 53], ["One study", "TEST", 0, 9], ["subtype H1", "PROBLEM", 104, 114], ["a lower rate", "TEST", 116, 128], ["antibodies", "PROBLEM", 154, 164], ["the H3 subtype", "PROBLEM", 173, 187], ["H3 subtype", "OBSERVATION", 177, 187]]], ["19 Another study investigating the seroprevalence of antibodies against H1N1, H3N2, and H1N2 in sows from European herds detected seroprevalence rates that were >50% for H1N1 and H3N2 in Belgium (80\u00c18% and 53\u00c18%, respectively) and in Germany (70\u00c18% and 58\u00c16%, respectively).", [["H1N1", "DISEASE", 170, 174], ["H1N1, H3N2", "ORGANISM", 72, 82], ["sows", "ORGANISM", 96, 100], ["antibodies", "PROTEIN", 53, 63], ["H3N2", "SPECIES", 78, 82], ["H1N2", "SPECIES", 88, 92], ["Another study", "TEST", 3, 16], ["antibodies", "TREATMENT", 53, 63], ["H1N1", "PROBLEM", 72, 76], ["H3N2", "PROBLEM", 78, 82], ["H1N2", "PROBLEM", 88, 92], ["European herds", "TREATMENT", 106, 120], ["seroprevalence rates", "TEST", 130, 150], ["H1N1", "PROBLEM", 170, 174], ["H3N2", "PROBLEM", 179, 183], ["H3N2", "OBSERVATION", 179, 183]]], ["However, the prevalence rates were lower in Italy (46\u00c14% and 41\u00c17%, respectively) and Spain (38\u00c15% and 38\u00c10%, respectively).", [["the prevalence rates", "TEST", 9, 29], ["lower", "OBSERVATION_MODIFIER", 35, 40]]], ["20 The seroprevalence of H1 and H3 subtypes at farrow-to-finish and specialized finishing farms from Netherlands was investigated; at the farrow-to-finish farms, 44\u00c13% of the animals were seropositive for H1, and 6\u00c16% of the animals were seropositive for H3.", [["H3", "GENE_OR_GENE_PRODUCT", 32, 34], ["animals", "ORGANISM", 175, 182], ["animals", "ORGANISM", 225, 232], ["H3", "GENE_OR_GENE_PRODUCT", 255, 257], ["H3", "PROTEIN", 255, 257], ["H1", "SPECIES", 25, 27], ["H1", "SPECIES", 205, 207], ["H1 and H3 subtypes", "TREATMENT", 25, 43], ["H1", "PROBLEM", 205, 207], ["H3", "PROBLEM", 255, 257]]], ["21 Although the prevalence of anti-influenza antibodies against H1 viruses has been higher than that of H3 viruses in most countries, comparing these prevalences is challenging when analyzing vaccinated and non-vaccinated herds because the circulation of influenza viruses at these farms may assume different routes, depending on the type of production system.", [["influenza", "DISEASE", 255, 264], ["H1 viruses", "ORGANISM", 64, 74], ["H3 viruses", "ORGANISM", 104, 114], ["influenza viruses", "ORGANISM", 255, 272], ["anti-influenza antibodies", "PROTEIN", 30, 55], ["H1 viruses", "SPECIES", 64, 74], ["H3 viruses", "SPECIES", 104, 114], ["anti-influenza antibodies", "TREATMENT", 30, 55], ["H1 viruses", "PROBLEM", 64, 74], ["H3 viruses", "PROBLEM", 104, 114], ["influenza viruses", "PROBLEM", 255, 272], ["higher", "OBSERVATION_MODIFIER", 84, 90], ["H3 viruses", "OBSERVATION", 104, 114]]], ["21 Furthermore, although the H3N2 used in our study has been isolated in pigs from North America in 1998, there is a relative cross-protection between viruses with the same type of hemagglutinin.", [["pigs", "ORGANISM", 73, 77], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 181, 194], ["hemagglutinin", "PROTEIN", 181, 194], ["pigs", "SPECIES", 73, 77], ["pigs", "SPECIES", 73, 77], ["the H3N2", "PROBLEM", 25, 33], ["our study", "TEST", 42, 51], ["a relative cross-protection between viruses", "PROBLEM", 115, 158], ["hemagglutinin", "TREATMENT", 181, 194], ["viruses", "OBSERVATION", 151, 158]]], ["Using a H3N2 from different country might be one factor to explain the low prevalence for antibodies against H3N2 in our study.", [["H3N2", "DISEASE", 109, 113], ["antibodies", "PROTEIN", 90, 100], ["a H3N2", "TREATMENT", 6, 12], ["antibodies", "PROBLEM", 90, 100], ["H3N2", "PROBLEM", 109, 113], ["our study", "TEST", 117, 126]]], ["Despite of that, due the cross-protection, our results could be useful to show H3N2 general circulation in Brazil.DiscussionSome Brazilian studies have also detected anti-influenza antibodies at pig farms.", [["H3N2", "ORGANISM", 79, 83], ["pig", "ORGANISM", 195, 198], ["anti-influenza antibodies", "PROTEIN", 166, 191], ["pig", "SPECIES", 195, 198], ["pig", "SPECIES", 195, 198], ["Brazilian studies", "TEST", 129, 146], ["anti-influenza antibodies", "TREATMENT", 166, 191]]], ["A seroprevalence study of a farm in S\u00e3o Paulo found a prevalence of 85\u00c13% for both H1N1 and H3N2 viruses; 11 however, rates of 2\u00c12% and 16\u00c13%, respectively, were found for the same viruses in a study of several Brazilian states.", [["H1N1 and H3N2 viruses", "DISEASE", 83, 104], ["H3N2 viruses", "ORGANISM", 92, 104], ["H3N2", "SPECIES", 92, 96], ["H3N2 viruses", "SPECIES", 92, 104], ["A seroprevalence study", "TEST", 0, 22], ["both H1N1 and H3N2 viruses", "PROBLEM", 78, 104], ["rates", "TEST", 118, 123], ["the same viruses", "PROBLEM", 172, 188], ["a study", "TEST", 192, 199], ["H1N1", "OBSERVATION", 83, 87], ["H3N2 viruses", "OBSERVATION", 92, 104]]], ["10 In another study, a prevalence of 20\u00c11% was reported for the H3N2 virus in a herd in Paran a state.", [["H3N2 virus", "ORGANISM", 64, 74], ["H3N2 virus", "SPECIES", 64, 74], ["H3N2 virus", "SPECIES", 64, 74], ["another study", "TEST", 6, 19], ["the H3N2 virus", "PROBLEM", 60, 74]]], ["13 Although the prevalences in these Brazilian studies were related to human viruses, our rates were not similar.", [["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human viruses", "SPECIES", 71, 84], ["these Brazilian studies", "TEST", 31, 54], ["human viruses", "PROBLEM", 71, 84], ["our rates", "TEST", 86, 95]]], ["In 2009, a seroprevalence study investigated the prevalence of anti-swine influenza virus antibodies in sows from 17 farrow-to-finish farms in Minas Gerais state and found rates of 44\u00c15% and 10\u00c11% for swine H1N1 and H3N2 viruses, respectively.", [["swine H1N1 and H3N2 viruses", "DISEASE", 201, 228], ["anti-swine influenza virus", "ORGANISM", 63, 89], ["sows", "ORGANISM", 104, 108], ["swine H1N1", "ORGANISM", 201, 211], ["H3N2 viruses", "ORGANISM", 216, 228], ["anti-swine influenza virus antibodies", "PROTEIN", 63, 100], ["anti-swine influenza virus", "SPECIES", 63, 89], ["swine H1N1 and H3N2", "SPECIES", 201, 220], ["anti-swine influenza virus", "SPECIES", 63, 89], ["swine H1N1", "SPECIES", 201, 211], ["H3N2 viruses", "SPECIES", 216, 228], ["a seroprevalence study", "TEST", 9, 31], ["anti-swine influenza virus antibodies", "PROBLEM", 63, 100], ["rates", "TEST", 172, 177], ["swine H1N1", "PROBLEM", 201, 211], ["H3N2 viruses", "PROBLEM", 216, 228]]], ["12 In this case, although the prevalence was higher than that found in our study, it aligns more closely than those found in other Brazilian states.", [["our study", "TEST", 71, 80]]], ["In contrast, a higher prevalence of antibodies against H3N2 virus was found in a herd from southern Brazil, 13 suggesting that there may be differences in the circulating serotypes of influenza virus in different regions of Brazil.DiscussionVaccination against influenza virus was not regulated in Brazil for the duration of this study; therefore, the presence of anti-influenza antibodies in Brazilian pigs detected herein suggests natural infection.", [["influenza virus", "DISEASE", 184, 199], ["influenza virus", "DISEASE", 261, 276], ["infection", "DISEASE", 441, 450], ["H3N2 virus", "ORGANISM", 55, 65], ["influenza virus", "ORGANISM", 184, 199], ["influenza virus", "ORGANISM", 261, 276], ["pigs", "ORGANISM", 403, 407], ["antibodies", "PROTEIN", 36, 46], ["anti-influenza antibodies", "PROTEIN", 364, 389], ["H3N2 virus", "SPECIES", 55, 65], ["influenza virus", "SPECIES", 184, 199], ["pigs", "SPECIES", 403, 407], ["H3N2 virus", "SPECIES", 55, 65], ["influenza virus", "SPECIES", 184, 199], ["pigs", "SPECIES", 403, 407], ["a higher prevalence of antibodies", "PROBLEM", 13, 46], ["H3N2 virus", "PROBLEM", 55, 65], ["influenza virus", "PROBLEM", 184, 199], ["influenza virus", "PROBLEM", 261, 276], ["this study", "TEST", 325, 335], ["anti-influenza antibodies", "TREATMENT", 364, 389], ["natural infection", "PROBLEM", 433, 450], ["may be", "UNCERTAINTY", 133, 139], ["influenza virus", "OBSERVATION", 184, 199], ["anti-influenza antibodies", "OBSERVATION", 364, 389], ["natural", "OBSERVATION_MODIFIER", 433, 440], ["infection", "OBSERVATION", 441, 450]]], ["Despite viral circulation, we found that one and 26 farms were seronegative for H1N1pdm09 and H3N2 viruses, respectively.", [["H3N2 viruses", "ORGANISM", 94, 106], ["H1N1pdm09", "SPECIES", 80, 89], ["viral circulation", "PROBLEM", 8, 25], ["H1N1pdm09", "PROBLEM", 80, 89], ["H3N2 viruses", "PROBLEM", 94, 106], ["viral circulation", "OBSERVATION", 8, 25], ["H3N2 viruses", "OBSERVATION", 94, 106]]], ["At these farms, as well as at farms with low antibody levels, the pigs were still susceptible to influenza virus infection and clinical disease because of their lack of immunity against the virus.", [["influenza virus infection", "DISEASE", 97, 122], ["pigs", "ORGANISM", 66, 70], ["influenza virus", "ORGANISM", 97, 112], ["pigs", "SPECIES", 66, 70], ["influenza virus", "SPECIES", 97, 112], ["pigs", "SPECIES", 66, 70], ["influenza virus", "SPECIES", 97, 112], ["low antibody levels", "PROBLEM", 41, 60], ["the pigs", "TREATMENT", 62, 70], ["influenza virus infection", "PROBLEM", 97, 122], ["clinical disease", "PROBLEM", 127, 143], ["the virus", "PROBLEM", 186, 195]]], ["The introduction of influenza virus into a herd is usually associated with moving and the introduction of new animals.", [["influenza virus", "DISEASE", 20, 35], ["influenza virus", "ORGANISM", 20, 35], ["influenza virus", "SPECIES", 20, 35], ["influenza virus", "SPECIES", 20, 35], ["influenza virus", "PROBLEM", 20, 35], ["influenza virus", "OBSERVATION", 20, 35]]], ["22 Moreover, a higher seroprevalence of anti-influenza antibodies has been associated with a greater density of pigs, which may lead to increased contact and also facilitate airborne transmission between herds.", [["pigs", "ORGANISM", 112, 116], ["anti-influenza antibodies", "PROTEIN", 40, 65], ["pigs", "SPECIES", 112, 116], ["pigs", "SPECIES", 112, 116], ["anti-influenza antibodies", "TREATMENT", 40, 65], ["anti-influenza antibodies", "OBSERVATION", 40, 65], ["greater", "OBSERVATION_MODIFIER", 93, 100], ["density", "OBSERVATION", 101, 108]]], ["23 Minas Gerais is the fourth largest pork producing state in Brazil, and 22\u00c16% of its commercial farms have \u2265100 sows, 24 which suggests that a high pig density in the state may be associated with risk factors for influenza virus infection, particularly in negative herds, in which pigs are more vulnerable.DiscussionIn this study, the female and farrowing crate groups had the highest percentages of seropositive animals.", [["influenza virus infection", "DISEASE", 215, 240], ["pork", "ORGANISM_SUBDIVISION", 38, 42], ["pig", "ORGANISM", 150, 153], ["influenza virus", "ORGANISM", 215, 230], ["pigs", "ORGANISM", 283, 287], ["influenza virus", "SPECIES", 215, 230], ["pigs", "SPECIES", 283, 287], ["pig", "SPECIES", 150, 153], ["influenza virus", "SPECIES", 215, 230], ["pigs", "SPECIES", 283, 287], ["a high pig density", "PROBLEM", 143, 161], ["risk factors", "PROBLEM", 198, 210], ["influenza virus infection", "PROBLEM", 215, 240], ["this study", "TEST", 321, 331], ["high", "OBSERVATION_MODIFIER", 145, 149], ["pig density", "OBSERVATION", 150, 161], ["may be associated with", "UNCERTAINTY", 175, 197]]], ["Females more frequently had the greatest mean antibody titers and the highest number of animals with low and medium titers, followed by the farrowing crate group.", [["the greatest mean antibody titers", "TEST", 28, 61], ["low and medium titers", "PROBLEM", 101, 122]]], ["For females, these results may indicate frequent exposure to influenza virus and continuous viral circulation because they remain in the production system longer.", [["influenza", "DISEASE", 61, 70], ["influenza virus", "ORGANISM", 61, 76], ["influenza virus", "SPECIES", 61, 76], ["influenza virus", "PROBLEM", 61, 76], ["continuous viral circulation", "TREATMENT", 81, 109], ["influenza virus", "OBSERVATION", 61, 76]]], ["The occurrence of high levels of antibodies against influenza virus in farrowing piglets, in association with the decrease of antibody levels over time, is similar to that in a study of serological profiles in farrow-to- finish farms in Taiwan.", [["influenza virus", "DISEASE", 52, 67], ["influenza virus", "ORGANISM", 52, 67], ["piglets", "ORGANISM", 81, 88], ["antibodies", "PROTEIN", 33, 43], ["influenza virus", "SPECIES", 52, 67], ["piglets", "SPECIES", 81, 88], ["high levels of antibodies", "PROBLEM", 18, 43], ["influenza virus", "PROBLEM", 52, 67], ["the decrease of antibody levels", "PROBLEM", 110, 141], ["a study", "TEST", 175, 182], ["serological profiles", "TEST", 186, 206], ["high levels", "OBSERVATION_MODIFIER", 18, 29], ["decrease", "OBSERVATION_MODIFIER", 114, 122]]], ["25 In that study, the lowest maternally derived antibodies against influenza virus were observed at 3-9 weeks of age, suggesting that animals are more susceptible later in the production cycle.", [["influenza virus", "DISEASE", 67, 82], ["influenza virus", "ORGANISM", 67, 82], ["influenza virus", "SPECIES", 67, 82], ["influenza virus", "SPECIES", 67, 82], ["that study", "TEST", 6, 16], ["the lowest maternally derived antibodies", "PROBLEM", 18, 58], ["influenza virus", "PROBLEM", 67, 82]]], ["Maternally derived antibodies are able to partially protect piglets against clinical disease, but not against infection, 26 and suckling piglets may become infected and shed virus in their secretions even in the presence of passive antibodies.", [["secretions", "ANATOMY", 189, 199], ["infection", "DISEASE", 110, 119], ["piglets", "ORGANISM", 60, 67], ["piglets", "ORGANISM", 137, 144], ["Maternally derived antibodies", "PROTEIN", 0, 29], ["passive antibodies", "PROTEIN", 224, 242], ["piglets", "SPECIES", 60, 67], ["piglets", "SPECIES", 137, 144], ["piglets", "SPECIES", 60, 67], ["piglets", "SPECIES", 137, 144], ["Maternally derived antibodies", "PROBLEM", 0, 29], ["clinical disease", "PROBLEM", 76, 92], ["infection", "PROBLEM", 110, 119], ["infected", "PROBLEM", 156, 164], ["shed virus in their secretions", "PROBLEM", 169, 199], ["passive antibodies", "PROBLEM", 224, 242], ["not against", "UNCERTAINTY", 98, 109], ["infection", "OBSERVATION", 110, 119], ["infected", "OBSERVATION", 156, 164], ["passive antibodies", "OBSERVATION", 224, 242]]], ["3 In such cases, piglets with maternally derived antibodies could play an important role in viral spread in the herd.DiscussionIn this study, most grower and finisher pigs were seronegative for H1N1pdm09 and H3N2 viruses.", [["piglets", "ORGANISM", 17, 24], ["herd", "ORGANISM_SUBDIVISION", 112, 116], ["pigs", "ORGANISM", 167, 171], ["H3N2 viruses", "ORGANISM", 208, 220], ["piglets", "SPECIES", 17, 24], ["pigs", "SPECIES", 167, 171], ["H3N2", "SPECIES", 208, 212], ["piglets", "SPECIES", 17, 24], ["pigs", "SPECIES", 167, 171], ["H1N1pdm09", "SPECIES", 194, 203], ["maternally derived antibodies", "PROBLEM", 30, 59], ["this study", "TEST", 130, 140], ["finisher pigs", "TREATMENT", 158, 171], ["H1N1pdm09", "PROBLEM", 194, 203], ["H3N2 viruses", "PROBLEM", 208, 220]]], ["The levels of anti-influenza antibodies decrease over time, and in some studies, maternally derived antibody levels were undetectable in animals between nine and 10 weeks of age.", [["anti-influenza antibodies", "PROTEIN", 14, 39], ["anti-influenza antibodies decrease", "PROBLEM", 14, 48], ["some studies", "TEST", 67, 79], ["maternally derived antibody levels", "TEST", 81, 115], ["anti-influenza antibodies", "OBSERVATION", 14, 39], ["decrease", "OBSERVATION_MODIFIER", 40, 48]]], ["25, 27 These results may explain why pigs later in the nursery age and early in the growing period are more vulnerable to influenza virus infection.", [["influenza virus infection", "DISEASE", 122, 147], ["pigs", "ORGANISM", 37, 41], ["influenza virus", "ORGANISM", 122, 137], ["pigs", "SPECIES", 37, 41], ["influenza virus", "SPECIES", 122, 137], ["pigs", "SPECIES", 37, 41], ["influenza virus", "SPECIES", 122, 137], ["influenza virus infection", "PROBLEM", 122, 147], ["may explain", "UNCERTAINTY", 21, 32], ["influenza virus infection", "OBSERVATION", 122, 147]]], ["Moreover, the timing of influenza infection may vary based on the type of production system.", [["influenza infection", "DISEASE", 24, 43], ["influenza infection", "PROBLEM", 24, 43], ["infection", "OBSERVATION", 34, 43]]], ["21 A study comparing the timing of infection in finisher pigs in nonvaccinated farrow-to-finish herds and specialized finishing herds showed that infection was highest at the beginning of the finishing period in farrow-to-finish herds, while in finishing herds, the incidence of influenza infections was highest in the end of the same period.", [["infection", "DISEASE", 35, 44], ["infection", "DISEASE", 146, 155], ["influenza infections", "DISEASE", 279, 299], ["pigs", "ORGANISM", 57, 61], ["pigs", "SPECIES", 57, 61], ["pigs", "SPECIES", 57, 61], ["A study", "TEST", 3, 10], ["infection", "PROBLEM", 35, 44], ["infection", "PROBLEM", 146, 155], ["influenza infections", "PROBLEM", 279, 299], ["infection", "OBSERVATION", 35, 44], ["infection", "OBSERVATION", 146, 155], ["influenza", "OBSERVATION_MODIFIER", 279, 288], ["infections", "OBSERVATION", 289, 299]]], ["21 Differences in the time of influenza infection occurrence may require different preventive measures, and because passive antibodies may interfere in the immune response to vaccination or infection, vaccination strategies must be analyzed to improve protection against influenza infection.", [["influenza infection", "DISEASE", 30, 49], ["infection", "DISEASE", 190, 199], ["influenza infection", "DISEASE", 271, 290], ["passive antibodies", "PROTEIN", 116, 134], ["influenza infection", "PROBLEM", 30, 49], ["different preventive measures", "TREATMENT", 73, 102], ["passive antibodies", "PROBLEM", 116, 134], ["vaccination", "TREATMENT", 175, 186], ["infection", "PROBLEM", 190, 199], ["vaccination strategies", "TREATMENT", 201, 223], ["influenza infection", "PROBLEM", 271, 290], ["infection", "OBSERVATION", 40, 49]]], ["Based on our results, it is not possible to suggest a single vaccination program against influenza virus because susceptible animals were generally detected in all categories of the production system.", [["influenza virus", "DISEASE", 89, 104], ["influenza virus", "ORGANISM", 89, 104], ["animals", "ORGANISM", 125, 132], ["influenza virus", "SPECIES", 89, 104], ["a single vaccination program", "TREATMENT", 52, 80], ["influenza virus", "PROBLEM", 89, 104], ["susceptible animals", "PROBLEM", 113, 132]]], ["Thus, some strategies, such as female-only vaccination or female vaccination followed by vaccination of pigs at 7-8 weeks, could be helpful, depending on the immunity of the herd.DiscussionA few months prior to the sample collection, some farms had outbreaks of respiratory disease in nursery and grower pigs due to influenza virus infection.", [["respiratory", "ANATOMY", 262, 273], ["respiratory disease", "DISEASE", 262, 281], ["influenza virus infection", "DISEASE", 316, 341], ["pigs", "ORGANISM", 104, 108], ["herd", "ORGANISM_SUBDIVISION", 174, 178], ["pigs", "ORGANISM", 304, 308], ["influenza virus", "ORGANISM", 316, 331], ["pigs", "SPECIES", 104, 108], ["pigs", "SPECIES", 304, 308], ["influenza virus", "SPECIES", 316, 331], ["pigs", "SPECIES", 104, 108], ["influenza virus", "SPECIES", 316, 331], ["vaccination", "TREATMENT", 43, 54], ["female vaccination", "TREATMENT", 58, 76], ["vaccination of pigs", "TREATMENT", 89, 108], ["the sample collection", "PROBLEM", 211, 232], ["respiratory disease", "PROBLEM", 262, 281], ["influenza virus infection", "PROBLEM", 316, 341], ["respiratory disease", "OBSERVATION", 262, 281], ["influenza virus", "OBSERVATION", 316, 331]]], ["According to our results, the percentage of seronegative pigs for H1N1pdm09 virus increased with age, and the highest values were observed in nursery and grower pigs.", [["pigs", "ORGANISM", 57, 61], ["H1N1pdm09 virus", "ORGANISM", 66, 81], ["pigs", "ORGANISM", 161, 165], ["pigs", "SPECIES", 57, 61], ["pigs", "SPECIES", 161, 165], ["H1N1pdm09 virus", "SPECIES", 66, 81], ["pigs", "SPECIES", 161, 165], ["seronegative pigs", "TREATMENT", 44, 61], ["H1N1pdm09 virus", "PROBLEM", 66, 81], ["seronegative pigs", "OBSERVATION", 44, 61]]], ["Overall, influenza virus circulates in the herds and may cause disease in susceptible pigs 21 regardless of age.", [["influenza virus", "DISEASE", 9, 24], ["influenza virus", "ORGANISM", 9, 24], ["pigs", "ORGANISM", 86, 90], ["influenza virus", "SPECIES", 9, 24], ["pigs", "SPECIES", 86, 90], ["influenza virus", "SPECIES", 9, 24], ["influenza virus circulates", "PROBLEM", 9, 35], ["disease", "PROBLEM", 63, 70], ["influenza virus", "OBSERVATION", 9, 24], ["may cause", "UNCERTAINTY", 53, 62]]], ["The presence of seronegative animals in the nursery and grower phases (after reported outbreaks in these ages) suggests that influenza virus was circulating in the farms but that during the sampling, the virus was not circulating in the nursery and grower pig categories.DiscussionThe percentages of seropositive pigs for H1N1pdm09 and H3N2 SIV found in this study differed between them, and H1N1pdm09 showed higher circulation in herds in Minas Gerais state.", [["influenza virus", "DISEASE", 125, 140], ["influenza virus", "ORGANISM", 125, 140], ["pig", "ORGANISM", 256, 259], ["pigs", "ORGANISM", 313, 317], ["H3N2 SIV", "ORGANISM", 336, 344], ["pigs", "SPECIES", 313, 317], ["H3N2 SIV", "SPECIES", 336, 344], ["influenza virus", "SPECIES", 125, 140], ["pig", "SPECIES", 256, 259], ["pigs", "SPECIES", 313, 317], ["H1N1pdm09", "SPECIES", 322, 331], ["H3N2 SIV", "SPECIES", 336, 344], ["seronegative animals", "PROBLEM", 16, 36], ["influenza virus", "PROBLEM", 125, 140], ["the sampling", "TEST", 186, 198], ["the virus", "PROBLEM", 200, 209], ["seropositive pigs", "TREATMENT", 300, 317], ["H1N1pdm09", "PROBLEM", 322, 331], ["H3N2 SIV", "PROBLEM", 336, 344], ["this study", "TEST", 354, 364], ["seronegative animals", "OBSERVATION", 16, 36], ["influenza virus", "OBSERVATION", 125, 140], ["pig categories", "OBSERVATION", 256, 270], ["higher", "OBSERVATION_MODIFIER", 409, 415], ["circulation", "OBSERVATION_MODIFIER", 416, 427]]], ["The serological profiles differed for both viruses and among geographical areas, suggesting a high variety of viral circulation across the state and resulting in seronegative animals that were susceptible to influenza infection and respiratory disease outbreaks.", [["respiratory", "ANATOMY", 232, 243], ["influenza infection", "DISEASE", 208, 227], ["respiratory disease", "DISEASE", 232, 251], ["The serological profiles", "TEST", 0, 24], ["both viruses", "PROBLEM", 38, 50], ["viral circulation", "PROBLEM", 110, 127], ["seronegative animals", "PROBLEM", 162, 182], ["influenza infection", "PROBLEM", 208, 227], ["respiratory disease outbreaks", "PROBLEM", 232, 261], ["viruses", "OBSERVATION", 43, 50], ["high", "OBSERVATION_MODIFIER", 94, 98], ["variety", "OBSERVATION_MODIFIER", 99, 106], ["viral circulation", "OBSERVATION", 110, 127], ["seronegative animals", "OBSERVATION", 162, 182], ["respiratory disease", "OBSERVATION", 232, 251]]], ["Little information is available regarding the influenza subtypes circulating in swine in the country, and because the lack of cross-protection between different subtypes is one of the obstacles preventing the development of efficacious vaccines and prevention of influenza infection in swine, more studies are needed to improve the knowledge of viral circulation and to determine the best strategies for preventing economic losses related to influenza virus infection in Brazil.", [["influenza infection", "DISEASE", 263, 282], ["influenza virus infection", "DISEASE", 442, 467], ["influenza virus", "ORGANISM", 442, 457], ["swine", "SPECIES", 80, 85], ["swine", "SPECIES", 286, 291], ["influenza virus", "SPECIES", 442, 457], ["swine", "SPECIES", 80, 85], ["swine", "SPECIES", 286, 291], ["influenza virus", "SPECIES", 442, 457], ["the influenza subtypes", "PROBLEM", 42, 64], ["efficacious vaccines", "TREATMENT", 224, 244], ["influenza infection", "PROBLEM", 263, 282], ["viral circulation", "PROBLEM", 345, 362], ["economic losses", "PROBLEM", 415, 430], ["influenza virus infection", "PROBLEM", 442, 467], ["influenza", "OBSERVATION", 263, 272]]], ["Studies involving serological surveillance for the influenza virus in other regions in Brazil, detection of endemic viruses circulating in swine herds and monitoring the genetic evolution of these samples by sequencing could be useful to provide information about molecular epidemiology of SIV and provide data for vaccine production and control of influenza virus in Brazil.", [["samples", "ANATOMY", 197, 204], ["influenza virus", "DISEASE", 51, 66], ["influenza virus", "DISEASE", 349, 364], ["influenza virus", "ORGANISM", 51, 66], ["samples", "CANCER", 197, 204], ["SIV", "ORGANISM", 290, 293], ["influenza virus", "ORGANISM", 349, 364], ["influenza virus", "SPECIES", 51, 66], ["swine", "SPECIES", 139, 144], ["influenza virus", "SPECIES", 51, 66], ["swine", "SPECIES", 139, 144], ["SIV", "SPECIES", 290, 293], ["influenza virus", "SPECIES", 349, 364], ["Studies", "TEST", 0, 7], ["serological surveillance", "TEST", 18, 42], ["the influenza virus", "PROBLEM", 47, 66], ["endemic viruses", "PROBLEM", 108, 123], ["vaccine production", "TREATMENT", 315, 333], ["influenza virus", "PROBLEM", 349, 364], ["endemic viruses", "OBSERVATION", 108, 123]]]]}